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Abstract
Oral splints for patients with temporomandibular disorders or
bruxism: a systematic review and economic evaluation
Philip Rileyo ,1 Anne-Marie Glennyo ,1 Helen V Worthingtono ,1*
Elisabet Jacobseno ,2 Clare Robertsono ,3 Justin Durhamo ,4
Stephen Davieso ,5 Helen Peterseno 6 and Dwayne Boyerso 2
1Cochrane Oral Health, Division of Dentistry, School of Medical Sciences, Faculty of Biology,
Medicine and Health, University of Manchester, Manchester, UK
2Health Economics Research Unit, University of Aberdeen, Aberdeen, UK
3Health Services Research Unit, University of Aberdeen, Aberdeen, UK
4Centre for Oral Health Research and School of Dental Sciences, Newcastle University,
Newcastle upon Tyne, UK
5TMD Unit, University Dental Hospital of Manchester, Manchester, UK
6University Dental Hospital of Manchester, Manchester, UK
*Corresponding author helen.worthington@manchester.ac.uk
Background: Splints are a non-invasive, reversible management option for temporomandibular
disorders or bruxism. The clinical effectiveness and cost-effectiveness of splints remain uncertain.
Objectives: The objectives were to evaluate the clinical effectiveness and cost-effectiveness of splints
for patients with temporomandibular disorders or bruxism. This evidence synthesis compared (1) all
types of splint versus no/minimal treatment/control splints and (2) prefabricated versus custom-made
splints, for the primary outcomes, which were pain (temporomandibular disorders) and tooth wear
(bruxism).
Review methods: Four databases, including MEDLINE and EMBASE, were searched from inception
until 1 October 2018 for randomised clinical trials. The searches were conducted on 1 October 2018.
Cochrane review methods (including risk of bias) were used for the systematic review. Standardised
mean differences were pooled for the primary outcome of pain, using random-effects models in
temporomandibular disorder patients. A Markov cohort, state-transition model, populated using
current pain and Characteristic Pain Intensity data, was used to estimate the incremental cost-
effectiveness ratio for splints compared with no splint, from an NHS perspective over a lifetime
horizon. A value-of-information analysis identified future research priorities.
Results: Fifty-two trials were included in the systematic review. The evidence identified was of very
low quality with unclear reporting by temporomandibular disorder subtype. When all subtypes were
pooled into one global temporomandibular disorder group, there was no evidence that splints reduced
pain [standardised mean difference (at up to 3 months) –0.18, 95% confidence interval –0.42 to 0.06;
substantial heterogeneity] when compared with no splints or a minimal intervention. There was no
evidence that other outcomes, including temporomandibular joint noises, decreased mouth-opening,
and quality of life, improved when using splints. Adverse events were generally not reported, but
seemed infrequent when reported. The most plausible base-case incremental cost-effectiveness
ratio was uncertain and driven by the lack of clinical effectiveness evidence. The cost-effectiveness
acceptability curve showed splints becoming more cost-effective at a willingness-to-pay threshold of
≈£6000, but the probability never exceeded 60% at higher levels of willingness to pay. Results were
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sensitive to longer-term extrapolation assumptions. A value-of-information analysis indicated that
further research is required. There were no studies measuring tooth wear in patients with bruxism.
One small study looked at pain and found a reduction in the splint group [mean difference (0–10 scale)
–2.01, 95% CI –1.40 to –2.62; very low-quality evidence]. As there was no evidence of a difference
between splints and no splints, the second objective became irrelevant.
Limitations: There was a large variation in the diagnostic criteria, splint types and outcome measures
used and reported. Sensitivity analyses based on these limitations did not indicate a reduction in pain.
Conclusions: The very low-quality evidence identified did not demonstrate that splints reduced pain in
temporomandibular disorders as a group of conditions. There is insufficient evidence to determine
whether or not splints reduce tooth wear in patients with bruxism. There remains substantial
uncertainty surrounding the most plausible incremental cost-effectiveness ratio.
Future work: There is a need for well-conducted trials to determine the clinical effectiveness and
cost-effectiveness of splints in patients with carefully diagnosed and subtyped temporomandibular
disorders, and patients with bruxism, using agreed measures of pain and tooth wear.
Study registration: This study is registered as PROSPERO CRD42017068512.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 24, No. 7. See the NIHR Journals Library website for further project information.
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Plain English summary
Treatment options for people experiencing temporomandibular disorders (pain and/or restrictedmovement in and around the jaw joint) include splints, which are removable appliances, often
similar to a mouthguard. They are provided to patients to help ease pain in the mouth, face or jaws.
They are also used to manage the symptoms of temporomandibular disorders, such as frequent
headaches/migraines, clicking jaws, restricted mouth-opening or tooth wear from the grinding of teeth
(bruxism). There are many types of splints.
This research looked at the evidence addressing the primary question of whether or not splints work
(regardless of type of splint) in reducing the pain associated with temporomandibular disorders and/or
tooth wear, and if they offered value for money. Patients were involved in the research to ensure that
the question and the outcomes that were measured were appropriate.
A systematic review of the literature was undertaken to find all randomised controlled trials including
patients with temporomandibular disorders or bruxism. Online databases of research publications
were searched, and these searches were checked, to identify relevant trials. All stages of the review
process were undertaken to the highest standards by two people, independently and in duplicate, using
well-respected and recognised Cochrane methods. We conducted a value-for-money assessment,
comparing the trial data with the costs of splints to see if splints are a cost-effective use of NHS funding.
There was no evidence that splints reduced pain when compared with not wearing a splint or
when compared with a minimal treatment (like jaw exercises, advice or education) in patients with
temporomandibular disorders. The evidence was assessed as being of very low quality; therefore,
it remains unclear whether or not splints are good value for money, or if they should be paid for by
the NHS.
This research showed that more well-conducted trials on temporomandibular disorder patients
are needed.
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Scientific summary
Background
Splints have long been used as a non-invasive, reversible management option for patients presenting
with certain orofacial signs and symptoms including orofacial pain, joint clicking, limited mouth-opening
and tooth wear. Typically they have been used with patients presenting with temporomandibular
disorders or bruxism. The clinical effectiveness and cost-effectiveness of splints remain uncertain.
Objectives
The objectives were to evaluate the clinical effectiveness and cost-effectiveness of splints for patients
with temporomandibular disorders or bruxism. The comprehensive evidence synthesis compared (1) all
types of splint versus no/placebo splints and (2) prefabricated splints versus custom-made splints, for
the primary outcomes orofacial pain for temporomandibular disorder patients and tooth wear for
bruxism patients.
Methods
In the systematic review, we included randomised controlled trials that included children (aged > 11 years)
and adults with either temporomandibular disorders or bruxism, for whom the dental or other health-care
worker was considering treatment with an oral splint, in either primary or secondary care.We excluded
studies in which the majority of patients were undergoing fixed or removable orthodontic treatment. The
no splint/control splint group also included watchful waiting or minimal treatment or self-management.
The primary outcome for the review was pain, which was measured in a variety of ways. For bruxism patients,
we also considered tooth wear as a primary outcome. Harms were also a primary outcome, which included
any problems such as soreness of the oral cavity caused by the splint. Secondary outcomes included clicking
of the temporomandibular joint, change in restricted mouth-opening, frequency of headaches (secondary to
pain-related temporomandibular disorders) and quality-of-life data (including physical and emotional function).
Patient satisfaction and adherence to treatment data were collected whenever possible. For bruxism,
the index and frequency of bruxism activity was recorded. Follow-up periods for the outcome data were
divided into short-term follow-up (0–3 months), medium-term follow-up (3–6 months) or long-term
follow-up (6–12 months). After discussion with the clinicians during the data extraction period, it was
decided to present the results for the 0- to 3-month time period for the primary analysis. A systematic
literature search was also undertaken to identify any cost-effectiveness evidence.
Four databases were searched on 1 October 2018: (1) Cochrane Central Register of Controlled Trials
in The Cochrane Library, (2) MEDLINE via OvidSP (from 1946 onwards), (3) EMBASE via OvidSP (from
1980 onwards) and (4) Cumulative Index to Nursing and Allied Health Literature from EBSCOhost (from
1937 onwards). When appropriate, the searches of these databases were linked to study design search
filters developed by Cochrane for identifying reports of randomised and controlled clinical trials. They
were undertaken without restrictions on language or date of publication.
We undertook the systematic review using Cochrane methods. All data extraction was undertaken
independently in duplicate. The following domains were assessed for the risk-of-bias assessment for
each included trial: sequence generation (selection bias), allocation concealment (selection bias), blinding
of participants and personnel (performance bias), blinding of outcome assessors (detection bias),
incomplete outcome data (attrition bias), selective outcome reporting (reporting bias) and other bias.
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Pain was frequently measured by a visual analogue scale and we had planned to use the mean and
standard deviation of this as the treatment effect, using standardised mean difference if different
scales were used (e.g. pain could be measured as pain experienced now or the worst pain experienced
over the previous month). We used risk ratios with 95% confidence intervals for the effect estimates
of the dichotomous data. We contacted authors, when feasible, for missing outcome data.
Heterogeneity was assessed by the chi-squared test and quantified by I2. We undertook data
syntheses, when appropriate, using random-effects models. We planned to undertake subgroup
analyses for different splint types.
Summary of findings tables were used to summarise the results, and the quality of the body of evidence
was assessed using the Grading of Recommendations Assessment, Development and Evaluation methods.
A Markov cohort state-transition decision-analysis model was developed to assess the cost-effectiveness
of splints compared with no splints for temporomandibular disorders from an NHS perspective.
A separate model was structured for bruxism but could not be populated owing to a lack of cost, utility,
transition probability or clinical effectiveness data.
The temporomandibular disorder model was structured to estimate cost-effectiveness based on three
pain tertile health states (low, moderate or high) based on current pain or Characteristic Pain Intensity
definitions. In each 3-monthly model cycle, the cohort had a probability of transiting between health states
(or remaining in the current health state) based on a reanalysis of the Developing Effective and Efficient
care pathways in chronic Pain (DEEP) UK cohort study (Durham J, Breckons M, Araujo-Soares V, Exley C,
Steele J, Vale L. Developing Effective and Efficient care pathways in chronic Pain: DEEP study protocol.
BMC Oral Health 2014;14:6) data conducted for this project. There was no additional risk of mortality,
and the whole cohort, regardless of treatment arm, was exposed to general population all-cause
mortality risks. The model was run over a lifetime horizon, with costs and quality-adjusted life-years
occurring in the future being discounted at a rate of 3.5% per annum.
When possible, meta-analysis of clinical effectiveness studies was used to obtain mean differences
(splints vs. no splints) in the alternative pain measures. Mean differences were translated into assumed
relative risks in pain tertiles and applied to the transition probability data obtained from the DEEP
study. DEEP study data were also used to inform the costs and utilities of different pain states in the
model. All model input data were sampled probabilistically from respective sampling distributions for
transition probabilities, mean differences in pain, costs and utilities.
The model was, therefore, fully probabilistic. Expected values of costs and quality-adjusted life-years
were obtained using Monte Carlo simulation (1000 repetitions) and used to calculate incremental
cost-effectiveness ratios. Results were reported using scatterplots of the cost-effectiveness plane, and
cost-effectiveness acceptability curves were used to illustrate the decision uncertainty regarding the
optimal strategy. It was assumed that the threshold value of willingness to pay for a quality-adjusted
life-year gained was £20,000. Expected value of perfect information and expected value of perfect
parameter information analyses were used to determine whether or not further research was worthwhile,
and, if so, what model parameters should be researched to reduce future decision uncertainty.
Results
Fifty-two trials were included in the systematic review. Fifty trials were assessed as being at high risk
of bias and the remaining two trials had an unclear risk of bias. Therefore, no studies were deemed to
have a low risk of bias in this review.
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Comparing splints with no splints/control or placebo splints/minimal intervention in patients
with temporomandibular disorders (all subtypes of temporomandibular disorder pooled into
one group)
From 35 studies comparing splints with no splints or a minimal intervention, there was no evidence
that providing splints reduced pain (measured on continuous/discrete graded scales) in patients with
temporomandibular disorders when all subtypes of temporomandibular disorder were pooled into one
group [standardised mean difference (up to 3 months) –0.18, 95% confidence interval –0.42 to 0.06;
substantial heterogeneity I2 = 70%; very low-quality evidence; 13 studies; 1076 participants]. There were
fewer studies and patients contributing to the standardised mean difference estimates at the other time
points and, similarly, no evidence that splints reduced pain. The standardised mean difference effect size
at up to 3 months was considered to be small and we undertook an analysis for current pain measured
on a visual analogue scale or numerical rating scale (scored from 0 to 100) to look at the effect size in
standard units. Eleven studies and 874 patients were included and the mean difference during the 0- to
3-month time period was –4.48 (95% confidence interval –11.59 to 2.64; I2 = 94%), with insufficient
evidence of any difference at the other time points. Data for the secondary outcomes of the review also
failed to provide any evidence that splints improved these outcomes. There was no evidence of adverse
events associated with splints, but reporting was poor regarding this outcome.
The literature review did not identify any studies evaluating the cost-effectiveness of splints for
temporomandibular disorder; therefore, the results of the decision-analysis model are reported to address
the clear gap in the evidence base. There was substantial uncertainty regarding the optimal treatment
strategy. The base-case incremental cost-effectiveness ratios for splints versus no splints were £39,216
and dominated (i.e. splints were, on average, more costly and generated fewer quality-adjusted life-years)
for the current pain and Characteristic Pain Intensity configurations, respectively. However, these
incremental cost-effectiveness ratios were surrounded by considerable uncertainty and it is most
informative to consider the decision uncertainty as reported for the probabilistic analysis. Assuming
that society is willing to pay a maximum of £20,000 to achieve a one-unit quality-adjusted life-year gain,
there was only a 58% and 29% chance that splints are the optimal (i.e. most cost-effective) treatment
strategy using the current pain and Characteristic Pain Intensity configurations, respectively. Deterministic
sensitivity and scenario analyses indicate that the cost-effectiveness results are most sensitive to
assumptions made about (1) the long-term benefits of splints (mean differences in pain intensity),
(2) long-term transition probabilities and (3) the frequency of splint replacement.
Comparing splints with no splints/control or placebo splints/minimal intervention in patients
with bruxism
There were no studies measuring tooth wear in patients with bruxism. One small study looked at pain and
found a reduction in the splint group (mean difference –2.01, 95% confidence interval –2.62 to –1.40; very
low-quality evidence). There was no cost-effectiveness evidence in the literature. Furthermore, it was not
possible to populate a decision-analysis model to determine cost-effectiveness because of a paucity of data
regarding transition probabilities between tooth wear states, utilities or costs.
Comparing prefabricated and custom-made splints
As there was no evidence that splints reduced pain or improved other outcomes in the clinical
effectiveness review, this comparison between different splint types became irrelevant. However,
exploratory cost-effectiveness analyses were conducted to identify the main drivers of cost-effectiveness
in a three-way comparison of custom-made versus prefabricated versus no splints. Results were highly
uncertain and the model indicated an approximately equal chance of custom-made, prefabricated and none
being the most cost-effective strategy, further emphasising the need for future research.
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Limitations
There are a number of substantial limitations in this evidence synthesis due to the large variation
in the diagnostic criteria, splint types and methods of outcome measurement and reporting.
We performed sensitivity analyses based on these limitations, but did not demonstrate a reduction
in pain.
Owing to a lack of relative risk data from the clinical effectiveness review to match the economic
model structured around pain tertiles, assumptions were required to map mean differences to
tertile-specific relative risks. This process was based on assumptions about the feasible changes in
tertile for each possible mean difference. This assumption raises uncertainties in the model, as the
results are not based on true relative risks. Furthermore, there were no data available to inform
the long-term effectiveness of splints and assumptions were required about the impact of splints
beyond 6–12 months. An advantage of the modelling approach taken is that, for the base-case
analysis, different assumptions were incorporated probabilistically, meaning that each assumption
had an equal chance of being applied in each Monte Carlo simulation.
Conclusions
The very low-quality evidence identified did not demonstrate that splints reduced pain in
temporomandibular disorder as a group of conditions; data were poorly reported for different
temporomandibular disorder subtypes. There is insufficient evidence to determine whether or not
splints reduce tooth wear in patients with bruxism. It remains unclear whether or not splints offer
value for money to the NHS.
Future work
There is a need for well-conducted trials to determine the clinical effectiveness and cost-effectiveness
of splints in patients with carefully diagnosed and subtyped temporomandibular disorder, and patients
with bruxism, using agreed measures of pain and tooth wear.
The value-of-information analysis revealed a very high expected value of perfect information, indicating
that future research to resolve decision uncertainty regarding the optimal, most cost-effective strategy
(splints or no splints) is beneficial. The expected value of perfect parameter information analysis identified
future research priorities and indicated that further research regarding the clinical effectiveness of splints
(in the short and longer term) is particularly worthwhile. In addition, the expected value of perfect
parameter information analysis indicated that further research should be carried out to determine the
long-term impact of temporomandibular disorders on pain states (beyond 2 years), as well as the
frequency of splint replacement.
Study registration
The study is registered as PROSPERO CRD42017068512.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 7.
See the NIHR Journals Library website for further project information.
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Chapter 1 Objective
Our objective was to evaluate the clinical effectiveness and cost-effectiveness of oral splints forpatients with temporomandibular disorder (TMD) or bruxism.
We met our aim by undertaking a comprehensive evidence synthesis, utilising Cochrane methodology,
evaluating:
l all oral splints provided by dentists or other health-care workers versus no splints for patients with
TMD or bruxism
l prefabricated splints versus custom-made splints provided by dentists or other health-care workers
for patients with TMD or bruxism.
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Chapter 2 Background
Parts of this chapter have been adapted from Riley et al.1 This article is licensed under a CreativeCommons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution
and reproduction in any medium or format, as long as you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons licence and your intended use is not permitted by statutory regulation or
exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view
a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. This includes minor additions
and formatting changes to the original text.
Description of the condition
Temporomandibular disorders are the second most common cause (after dental pain) of orofacial pain,
characterised by pain in the temporomandibular joint area and in the facial muscles. Apart from pain,
patients may experience other signs and symptoms, such as clicking of the joint and restricted mouth-
opening. It is estimated that around 5–12% of the population have TMD symptoms to some degree,
varying by age group and sex.2 There are many ways of managing TMD (e.g. pharmacological, psychological,
physiotherapy and surgical interventions); one of the most common ways that dentists, particularly in
primary care, manage symptomatic TMD is the provision of oral splints.3
Splints are also provided to help manage tooth wear caused by bruxism. Bruxism is the repetitive
jaw-muscle activity characterised by clenching or grinding of the teeth and/or bracing or thrusting of
the mandible. Bruxism has two distinct circadian manifestations: it can occur during sleep (indicated
as sleep bruxism) or during wakefulness (indicated as awake bruxism).4 The prevalence of bruxism
ranges from 8% to 31% in the general population,5 and it is estimated that sleep bruxism affects 16%,
and awake bruxism 24%, of the adult population globally.6
In the UK it has been estimated that bruxism affects more than six million people. The severity of the
symptoms and the frequency of grinding vary. Bruxism can occur in both children and adults, although
it is most common in adults between the ages of 25 and 44 years. Although many patients are unaware
of their bruxism habit, there can be an associated tooth wear, which can cause pathological damage and
require treatment in the longer term. This is often diagnosed by the general dental practitioner when the
patient is attending for a check-up or dental treatment. It is important that tooth wear alone is not taken
as a sign that the patient is an active bruxist, as opposed to being a legacy of a previous bruxism habit.7
Description of the intervention
Oral splints are removable appliances that can cover all or some of the teeth in either the maxillary
or the mandibular arches. The term ‘oral splint’ is used colloquially in (UK) dentistry and is really a
misnomer, as oral splints do not actually splint (i.e. immobilise) anything. Splints can also be known
variously throughout the literature and the world as oral appliances, devices, orthotics or biteplates.
Oral splints can resemble a device similar to a mouthguard used in contact sports, overlaying the biting
surface of the teeth with some type of material. Numerous types of oral splints are available, varying in
design, material, coverage and application. Splints cover either the upper teeth (upper splints) or the
lower teeth (lower splints) and can be classified by the type of material they are made from: hard (hard
acrylics), soft (soft polymers or plastics), or composite amalgams of the two aforementioned materials.8
They can then be subdivided into whether they cover all the surfaces of the teeth in one jaw (full coverage)
or only some of the teeth surfaces (partial coverage, e.g. covering only the front six to eight teeth, or
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two to four of the anterior incisor teeth), and whether or not they provide an adjusted biting surface to
equalise the way the teeth meet the splint (‘occlusally adjusted’ surface).9,10 Finally, they may be made from
impressions of a patient’s teeth (custom made) or adapted directly onto the teeth from a non-specific blank
(prefabricated or non-custom made).
It should be noted that there are multiple names for different types of splints, and many variations on
a design theme. For example, an upper hard stabilisation splint is also known as a Michigan splint, and
a Lucia jig is similar in design to the proprietary Nociceptive Trigeminal Inhibition Tension Suppression
System (NTI-tss)™ (National Dentex LLC, Palm Beach Gardens, FL, USA) splint.
Traditionally, oral splints recommended by dentists have been custom made, often in dental laboratories,
sometimes requiring a number of appointments. More recently, a vast array of prefabricated splints have
become available, either for provision by the dentist or health-care worker at a single appointment, or
as over-the-counter purchases for patients who wish to self-manage their symptoms.11 Prefabricated
splints include soft, rubber splints (which function by separating the teeth); hydrostatic splints, which are
cushioned with fluid to redistribute occlusal force; and the NTI-tss device (semi-customisable).
The aims, duration of treatment, need for adjustments, perceived mode of action and the costs of the
splints vary across splint types.
How the intervention might work
There is continuing debate about the exact mechanism of action of oral splints. However, mechanisms
include:
l muscle relaxation/habit-breaking for patients with increased parafunctional or muscle-tightening habits
l protection of teeth and jaws, particularly when teeth clenching and grinding may lead to damage
of teeth, resulting in the need for restorative treatment
l normalising periodontal ligament proprioception, by utilising a splint to spread the forces placed on
individual teeth
l repositioning of the jaws and condyles into centric relation
l central effects that are yet to be fully understood.12
The mode of action varies according to the type of splint used, with some splints (permissive) allowing
the teeth/jaw to move or glide over the biting surfaces unimpeded (permissive splints) and others
having indentations that hold the jaw in a fixed position (directive or non-permissive).
Why it was important to do this review
This systematic review arose from a National Institute for Health Research Health Technology
Assessment programme call addressing the research question: ‘what is the clinical effectiveness and
cost-effectiveness of prefabricated oral splints and custom-made splints for the treatment of orofacial
symptoms?’. Our application was successful and we received funding to conduct this systematic review
and economic evaluation, so the objectives of this review have been driven by this.
It should be noted that the original call focused on treatment for orofacial symptoms. The causes of
orofacial pain are varied, but splint therapy for orofacial pain is primarily limited to pain resulting from
TMD. Splint therapy is also used for non-painful TMD and bruxism. In order to reflect the use of oral
splints in dental practice in the UK, the review will focus on TMD (pain related and non-pain related)
and bruxism.
Although we used Cochrane methods, this was not undertaken as a Cochrane review; however, we will
share all data from the screening of studies, data extraction forms and correspondence with authors of
any future Cochrane reviews, or review updates that overlap with the scope of this review.
BACKGROUND
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Dentists in the NHS in both primary and secondary care are currently providing oral splints for patients
who have orofacial signs (such as tooth wear in patients with bruxism) or symptoms (primarily pain). In
Scotland alone, the number of splints provided in NHS primary care is increasing from 1985 custom-made
hard splints in 2005/06 to 3521 custom-made hard splints in 2015/16. Dentists in Scotland have also
recently been allowed to provide custom-made soft splints on the NHS; 16,888 were provided in 2015/16.
Oral splints are also provided privately and directly to patients, with a growing industry reported.11
Despite the frequent use of splints for the management of orofacial sign and symptoms, their clinical
effectiveness and cost-effectiveness remain uncertain. This research proposal will inform the NHS,
dentists and patients as to whether or not oral splints provided by dentists or other health-care
workers are effective in reducing orofacial symptoms (primarily pain) and when they are indicated to
prevent tooth wear. If oral splints are found to be effective, then the effectiveness of prefabricated
splints compared with custom-made splints (laboratory made, requiring more than one visit to the
health-care worker to fit) will be evaluated to help inform care pathways for the target population.
If prefabricated splints are found to be at least as effective as custom-made splints, then there is the
potential for a cost saving to both the NHS and directly to patients. Currently, in primary care, the
provision of custom-made oral splints for these patients is a band 3 charge to the patient under
the 2016 NHS dental fee scale (£256.50). Prefabricated splits are a much cheaper alternative to
custom-made splints as they require only one visit for fitting rather than two, do not require laboratory
costs and are a band 2 charge in the NHS (£59.10 in 2016 values). Over-the-counter splints can be
purchased for < £10.
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Chapter 3 Assessment of clinical effectiveness
Parts of this chapter have been adapted from Riley et al.1 This article is licensed under a CreativeCommons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution
and reproduction in any medium or format, as long as you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons licence and your intended use is not permitted by statutory regulation or
exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view
a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. This includes minor additions
and formatting changes to the original text.
Review methods
Types of studies
We included randomised controlled trials (RCTs) but did not include crossover studies as we do not
feel that this is an appropriate design owing to the transient nature of the TMD symptoms, or bruxism
in patients (which may be due to external factors such as stress).
Types of participants
Inclusion criteria: children (aged > 11 years) and adults who have either TMD or bruxism, and the
dentist or other health-care worker is considering treating the patient with an oral splint, in either
primary or secondary care.
Exclusion criteria: studies in which the majority of participants were undergoing fixed or removable
orthodontic treatment.
Types of interventions
Two comparisons are made:
1. Splints versus no splints, which included any type of splint provided for patients, as described in
Types of participants. The no-splint group also included a control splint, which is used in some trials,
watchful waiting or minimal treatment. Minimal treatment included advice/counselling, education or
self-performed exercises (but could not involve multiple visits/appointments).
2. Prefabricated splints versus custom-made splints. No other head-to-head comparisons were included
between different splint types.
For clarity, we refer to a splint according to the jaw in which it is used (upper/lower), its material
(hard/soft/composite), its degree of coverage of teeth (full/partial) and then its most generic name,
unless the proprietary name is particularly pertinent.
Types of outcome measures
Primary outcomes
The primary outcome for the review was pain. This was measured in a number of ways, including
changes in the pain intensity from baseline, end-score pain measures or frequency of episodes of pain.
Harms were a primary outcome, which included any problems such as soreness of the oral cavity
caused by the splint.
For bruxism patients, tooth wear was also considered a primary outcome.
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Secondary outcomes
Secondary outcomes included clicking of the temporomandibular joint, change in restricted mouth-opening,
frequency of headaches (secondary to pain-related TMD) and quality-of-life data (including physical and
emotional function). Patient satisfaction and adherence to treatment were collected whenever possible.
For bruxism, the index and frequency of bruxism activity were also to be recorded.
Follow-up periods for the outcome data were divided into short-term follow-up (0–3 months), medium-term
follow-up (3–6 months) or long-term follow-up (6–12 months). By consensus, the clinicians in the review
team decided that the 0- to 3-month follow-up was the best time point to use for primary data analysis.
Search methods for identification of studies
An information specialist developed a search strategy (see Appendix 1) and conducted the literature
searches. The searches were originally undertaken on 24 August 2017, and were updated on
1 October 2018 to ensure that more recent studies were considered for inclusion prior to publication.
Electronic searches
The following databases were searched:
l Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library
(to issue 9, 2018, searched on 1 October 2018)
l MEDLINE via OvidSP (from 1946 to 1 October 2018)
l EMBASE via OvidSP (from 1980 to 1 October 2018)
l Cumulative Index to Nursing and Allied Health Literature (CINAHL) via EBSCOhost (1937 to
1 October 2018).
When appropriate, the searches of these databases were linked to study design search filters
developed by Cochrane for identifying reports of randomised and controlled clinical trials. They were
undertaken without restrictions on language or date of publication.
Searching other resources
Unpublished data on clinical trials was sought via searches of the US National Institutes of Health trials
register (ClinicalTrials.gov) and theWorld Health Organization International Clinical Trials Registry
Platform, which includes trials data from the European Union, the UK, Australia, China, the Netherlands,
Brazil, India and Republic of Korea (South Korea). Conference proceedings were searched via EMBASE in
the main literature search, and theWeb of Science. Abstracts of dissertations and theses were searched
via the ProQuest database. Searches of these databases were also undertaken on 1 October 2018,
without any restrictions on date of publication or language.
Additional grey literature was sourced through the American Academy of Dental Sleep Medicine
website.13 The International Association of Dental Research (IADR) annual conference abstracts were
searched via the IADR website14 on 1 October 2018. The protocol stated that we planned to search
the conference proceedings of the American Academy of Orofacial Pain and the European Academy of
Craniomandibular Disorders; however, these were not available to us.
Data collection and analysis
Selection of studies
Two review authors independently assessed the abstracts of retrieved studies. We obtained full-text
copies of studies deemed to be relevant or potentially relevant, or for which there was insufficient
information in the title and abstract to make a clear decision. Two review authors independently
assessed the full-text papers and any disagreements on the eligibility of studies were resolved through
discussion and consensus. If necessary, a third review author was consulted.
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Data extraction and management
Two review authors independently extracted the following data from the included trials:
l location/setting, type of provider, number of centres, recruitment period, trials registry identifier
l inclusion/exclusion criteria, age and sex of participants, number randomised/analysed, any other
important prognostic factors (i.e. comorbidities, concomitant prescription medicines/co-interventions)
l population characteristics – age, sex, presenting condition [bruxism, TMD (plus subtype) or mixed]
and severity, duration since presenting condition began, comorbidities
l intervention – primary purpose of splint (e.g. pain reduction, bruxist motor activity reduction, to aid
functional rehabilitation, to decrease tooth damage, jaw repositioning); type of splint in terms of
jaw worn in (upper/lower), material (hard/soft/composite), teeth coverage (full/partial), design
(prefabricated/custom made); duration of splint use
l detailed description of comparator
l details of the outcomes reported, including method of assessment and time(s) assessed
l details of sample size calculations, funding sources, declarations/conflicts of interest.
Assessment of risk of bias in included studies
The assessment of risk of bias was done independently and in duplicate, using the Cochrane Risk of
Bias tool.15 The following domains were assessed: sequence generation (selection bias), allocation
concealment (selection bias), blinding of participants and personnel (performance bias), blinding of
outcome assessors (detection bias), incomplete outcome data (attrition bias), selective outcome reporting
(reporting bias) and other bias.We realised that it would be difficult or impossible to blind participants and
personnel to whether or not a participant had been randomised to receiving a splint. This could potentially
introduce performance bias, and, in the case of subjective outcomes, detection bias.
The overall risk of bias of individual studies was categorised as being low, high or unclear according to
the following:
l low risk of bias (plausible bias unlikely to seriously alter the results) if all domains had a low risk
of bias
l unclear risk of bias (plausible bias that raises some doubt about the results) if one or more domains
had an unclear risk of bias
l high risk if one or more domains had a high risk of bias.
Measures of treatment effect
For continuous outcomes [e.g. pain on a visual analogue scale (VAS)], we used the means and standard
deviations (SDs) reported in the trials to express the estimate of effect as mean difference (MD) with a
95% confidence interval (CI). In the event that different scales were used, we expressed the treatment
effect as a standardised mean difference (SMD).
For dichotomous outcomes (e.g. jaw clicking/no jaw clicking), we expressed the estimate of effect as a
risk ratio (RR) with a 95% CI.
Unit-of-analysis issues
The patient was the unit of analysis for all included studies.
Dealing with missing data
We attempted to contact the author(s) of all included studies, if feasible, in the event of missing data.
Missing SDs were estimated according to the methods for estimating missing SDs described in section
7.7.3 of the Cochrane Handbook for Systematic Reviews of Interventions.15
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Assessment of heterogeneity
If a sufficient number of studies were included in any meta-analyses, we planned to assess any clinical
heterogeneity by examining the following characteristics of the studies: the similarity between the
types of participants [TMD, bruxism; age (< 18 and ≥ 18 years)], the type of health-care worker providing
the splints, the type of splint, the control intervention and the outcomes.
We assessed heterogeneity statistically by using a chi-squared test, in which a p-value of < 0.1 indicates
statistically significant heterogeneity. We quantified heterogeneity by using the I2 statistic. A guide to
the interpretation of the I2 statistic, as given in the Cochrane Handbook,15 is as follows:
l 0–40% – might not be important
l 30–60% – may represent moderate heterogeneity
l 50–90% – may represent substantial heterogeneity
l 75–100% – considerable heterogeneity.
Assessment of reporting biases
If a sufficient number of studies had been included in any meta-analyses, publication bias would have
been assessed in accordance with the recommendations on testing for funnel plot asymmetry,16 as
described in section 10.4.3.1 of the Cochrane Handbook for Systematic Reviews of Interventions.15
If asymmetry had been identified, other possible causes of asymmetry would have been assessed, as
outlined in table 10.4.a of the Cochrane Handbook.15 We were unable to undertake funnel plot analysis
on the main primary outcome because the effect estimate was reported as SMD.
Data synthesis
We carried out meta-analyses only if there were studies of similar comparisons reporting the same
outcomes. We performed meta-analyses using Cochrane’s Review Manager software (RevMan version
5.3, The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark) and exported
the forest plots into this document to graphically display the results. We combined MDs (or SMDs
when different scales were used) for continuous data, and RRs for dichotomous data. Our general
approach was to use a random-effects model. With this approach, the CIs for the average intervention
effect are wider than those that would have been obtained using a fixed-effect approach, leading to a
more conservative interpretation.
We used additional tables (see Appendix 2, Tables 26–29) to report the results from studies not suitable
for meta-analysis.
For the meta-analysis of splints versus no splints, we planned to include prefabricated and custom-made
splints as subgroups; however, there was an insufficient number of studies including prefabricated
splints. Pooling across subgroups depended on the degree of heterogeneity/subgroup differences.
As an additional analysis, if we had determined that there was evidence that the prefabricated splits,
when placed by any health-care professional, are effective for the primary outcomes, then we planned
to look at any head-to-head RCTs comparing the delivery of prefabricated splints by different types of
health-care workers. There was insufficient evidence to undertake this.
We planned to consider undertaking a network meta-analysis for different splint types; however, there
were insufficient data to undertake this.
Subgroup analysis and investigation of heterogeneity
For the meta-analysis of splints versus no splints, we planned to include the following subgroups:
l prefabricated
l hard custom-made splints that alter occlusion (jaw relationship)
l hard custom-made splints that do not alter occlusion (jaw relationship)
l soft custom-made splints that do not alter occlusion (jaw relationship).
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There were insufficient data to undertake this.
Sensitivity analysis
For TMD patients, we undertook a sensitivity analysis restricted to trials in which the inclusion criteria
were based on, or could be clearly mapped to, one of the following sets of diagnostic criteria:
l Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) guidelines17
l Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) guidelines18
l American Association of Orofacial Pain (AAOP) guidelines.19
Similarly, for bruxism patients, we planned to undertake a sensitivity analysis restricted to trials for
which there was a clear diagnosis of bruxism.4 The study should have used polysomnography to
diagnose the bruxism. There were insufficient trials to do this.
We planned to test the robustness of our results by performing sensitivity analyses based on excluding
studies deemed to be at high and unclear risks of bias from the analyses. However, we knew this was
unlikely to be possible for the splint versus no splint comparison if we judged that there was a high
risk of performance bias or detection bias or both.
If any meta-analyses had included several small studies and a single very large study, we planned to
undertake sensitivity analyses comparing the effect estimates from both random-effects and fixed-
effects models. If these were different, we intended to report on both analyses as part of the results
section, and consider possible interpretation.
Presentation of main results
We developed a summary of findings table for each comparison and for the main outcomes of this review
following Grading of Recommendations Assessment, Development and Evaluation (GRADE) methods,20 and
using the GRADEPro online tool.21 The quality of the body of evidence was assessed with reference to the
overall risk of bias of the included studies, the directness of the evidence, the inconsistency of the results, the
precision of the estimates and the risk of publication bias.We categorised the quality of the body of evidence
for each of the main outcomes for each comparison as being high, moderate, low or very low.
Patient and public involvement
We established a patient advisory group during the development of the application.We asked members of
the patient advisory group to help devise the final list of outcomes to be included in the review protocol.
The patient advisory group worked with the Cochrane Oral Health Consumer Co-ordinator (Ruth Floate),
who has experience of consulting the public and patients to ensure full and honest input into the production
of systematic reviews and their relevant outputs (particularly the production of plain language summaries).
At least one member of the patient advisory group attended each of the face-to-face meetings of the
research team held in Manchester, and took part in most of the monthly teleconferences.
Studies included in the review
A flow chart of included studies is shown in Figure 1. Fifty-two studies were included in the review.
The full details of the characteristics and reference for each study are given in Appendix 3.
Characteristics of the studies
Study design
All included studies were of parallel design. In one of these studies, non-responders from the control
group were allowed to cross over after 6 weeks, but we report data up to 6 weeks, thus treating the
study as parallel (Wassell et al.22).
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Number of arms
Many studies had more than two arms as they assessed more than one splint type or more than one
control type or both. Twenty-four studies had two arms, 19 had three arms, eight had four arms and
one had five arms.
Setting
Fifty-one studies were conducted in universities or public hospitals/clinics. The remaining study was
carried out at the Mexican Institute for Clinical Research (Tavera et al.23).
Eleven studies were carried out in Brazil,24–34 10 in Sweden,35–44 seven in the USA,45–51 three in Turkey,52–54
two in India,55,56 two in Egypt,57,58 two in China,59,60 two in Germany,61,62 two in the UK,22,63 two in Italy,64,65
two in Japan,66,67 one in Canada,68 one in the Netherlands,69 one in Mexico,23 one in Poland70 and one in
Finland.71 The remaining two studies72,73 were carried out in both Sweden and Finland.
Forty-seven studies were conducted at a single centre. One study was conducted at 11 general dental
practices in the UK (Wassell et al.22), one study was conducted at two locations in Sweden (Lundh et al.40),
one study was conducted at two locations in the USA (DeVocht et al.45), one study was conducted at two
locations (Sweden and Finland; Nilner et al.73) and one study was conducted at three locations (two in
Sweden and one in Finland; Christidis et al.72).
Records screened
(n = 915)
Records after duplicates removed
(n = 915)
Records identified
through database
searching
(n = 1492)
Additional records
identified through
other sources
(n = 195)
Full-text articles
assessed for
eligibility
(n = 58)
Records excluded
(n = 857)
Full-text articles
excluded
(n = 6)
Studies included
in qualitative
synthesis
(n = 52)
Studies included
in quantitative
analysis
(n = 43)
FIGURE 1 Flow of studies through the review process. Adapted from Riley et al.1 This article is licensed under a Creative
Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in
any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article
are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If
material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view
a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. This includes minor additions and formatting
changes to the original text.
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Sample size calculation
Ten studies reported sample size calculations that were met, although one of studies was not powered
on a relevant outcome (Gomes et al.32), one sample size was met at 10 weeks but not at 6 and 12 months
(Nilsson et al.43) and one stated only that a sample size calculation had been done and that it had been
met (Zhang et al.60). A further study reported a sample size calculation but it was unclear if it was met
(Costa et al.29). Four studies50,66,71,72 reported sample size calculations that were not met. Three studies
reported only post hoc sample size calculations (Giannakopoulos et al.,62 Michelotti et al.64 and Sharma49).
One study did not perform an a priori sample size calculation as it was a feasibility study, so it was not
powered to detect differences between groups (DeVocht et al.45). In the remaining 33 studies, sample
size calculations were not mentioned so it was unclear whether or not they were done.
Funding and conflicts of interest
Twenty-three studies22,24–27,29,31,35,36,38,43,44,46,47,50,53,66,68–73 declared what appeared to be public funding. Five
studies39–41,45,63 reported both public and industry funding. One study declared only industry funding
(Ficnar et al.61). Five studies32,52,54,55,67 declared that they received no funding. One study reported the
funding source but it was unclear whether this represented public or industry funding (Yu and Qian59).
The remaining 17 studies did not mention funding.
Sixteen studies27,29,32,52,54,55,57,61,62,64,65,67,70–73 declared that the authors had no conflicts of interest.
However, in one of those studies, one of the authors had designed and patented the splint used in the
study (Rampello et al.65). In a further study (DeVocht et al.45), one author declared instructing for the
manufacturers of one of the interventions. However, that intervention was excluded from the review
because it was ineligible. The remaining 35 studies did not mention conflicts of interest.
Characteristics of the participants
Number randomised/analysed
The studies randomised 3229 participants to the arms we included in this review (i.e. some trial arms
were not eligible or were not used; therefore, those participants are not included in this number). The
number of participants included in analyses varied by the time at which the outcomes were assessed,
and sometimes it was unclear how many were analysed.
Age and sex
The reported age range of the participants was 10–76 years. In the majority of studies (31 studies), the
participants’ mean or median age range was 30–39 years. The vast majority of participants were female.
Diagnosis
Fifty-two studies were included in this evidence synthesis. The majority of studies [47/52 (90%)]
focused on people with TMD, with only four studies recruiting people with bruxism (8%). One study
evaluated the use of splints in people with bruxism with comorbid TMD.
For the studies evaluating the effectiveness of splints for people with TMD, the diagnostic criteria for TMD
varied. However, the predominantly used criteria were the RDC/TMD, used in 26 studies. Two studies
used the DC/TMD criteria (Sharma49 and Tatli et al.54) and an additional five studies used criteria that
approximated to the RDC/TMD (either by citing the instrument and/or their description matched a similar
process) (Conti et al.,25 de Felício et al.,30 Ekberg et al.,35 Wassell et al.22 and Wright et al.51). One study used
the AAOP criteria (Alencar and Becker24).
The remaining studies used criteria that we had not prespecified in our protocol (RDC/TMD, DC/TMD
or AAOP)17–19 or were undefined/unclear:
l Three had used the Helkimo index74 (Daif,57 Johansson et al.37 and List et al.38).
l Two used arthrography (Lundh et al.41 and Lundh et al.40).
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l One used MRI (Haketa et al.66).
l One had defined myofascial pain dysfunction syndrome (Rubinoff et al.48).
l Six used diagnostic systems that it was not possible to classify (Elsharkawy and Ali,58 Leeson,63
Lundh et al.,39 Magnusson and Syrén,42 Rampello et al.65 and Zuim et al.34).
If studies had not clearly used the prespecified criteria (RDC/TMD, DC/TMD or AAOP),17–19 an expert
reviewer examined the information available in the paper, alongside any correspondence from authors,
to identify the probable subgroup of TMD included in the study. When possible, a ‘probable’ RDC/TMD
(sub)group diagnosis was assigned. If a (sub)group diagnosis was not possible, then the sample was
regarded as ‘painful TMD’ (Conti et al.,25 de Felício et al.,30 Elsharkawy and Ali,58 Johansson et al.,37
Katyayan et al.,56 Leeson,63 Lundh et al.39 and Rampello et al.65).
Table 1 provides an overview of the number of studies, including participants for each probable
RDC/TMD subgroup diagnoses.
All studies that did not use the prespecified diagnostic criteria were excluded from the sensitivity
analyses.
The four studies (Gomes et al.,33 Karakis et al.,53 Pierce and Gale46 and van der Zaag et al.69) examining
the effects of splints on bruxism all used the Lobbezoo et al.4 criteria for likelihood of a bruxism
diagnosis: ‘possible’ self-report of bruxism, ‘probable’ clinical evidence of bruxism with or without
self-report, and ‘definite’ defined by polsomnography. On this basis, one study examined ‘definite’ sleep
bruxism and all the other studies examined ‘probable’ sleep bruxism.
TABLE 1 Probable RDC/TMD subgroup diagnoses for included studies examining TMD
RDC/TMD group RDC/TMD subgroup
Number of studies with
people in specified subgroup
Group I: muscle disorders Ia 12
Ib 12
Subgroup not specifieda 18
Total 42
Group II: disc disorders IIa 10
IIb 4
IIc 1
Subgroup not specifieda 8
Total 23
Group III: arthralgia and arthritides IIIa 10
IIIb 2
IIIc 3
Subgroup not specifieda 5
Total 20
Painful TMDb 8
Total 93
a Participants were categorisable only at the highest group level (e.g. examined Group I), but it was impossible to
identify if this was Group Ia or Ib.
b When it was not possible to categorise under the RDC/TMD from the information provided in the paper or
information received from the research team, the sample was defined as ‘painful TMD’.
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The study that examined bruxism with comorbid TMD used the Fonseca index75 for TMD and
examined ‘probable’ bruxism (Gomes et al.32). This study was classified as examining ‘painful TMD’ and
excluded from the sensitivity analyses.
Characteristics of the interventions and comparisons
Most of the studies included one comparison eligible for inclusion in this review. There were four
studies that included two different eligible comparisons (Ficnar et al.,61 Giannakopoulos et al.,62
Gomes et al.32 and Truelove et al.50).
Splint versus no splint for temporomandibular disorder
Comparison type
Thirty-five studies compared splints with no splints for TMD patients.
Ten of these studies used a no-treatment control group (Conti et al.,25 Daif,57 de Felício et al.,31
Johansson et al.,37 List et al.,38 Lundh et al.,39 Lundh et al.,41 Nitecka-Buchta et al.,70 Rampello et al.65 and
Wright et al.51).
Twenty had a co-intervention in each arm (e.g. splint + co-intervention vs. co-intervention alone).
Of these 20 studies, 13 had a co-intervention of usual treatment, counselling, information or exercise
(Conti et al.,27 Conti et al.,28 Costa et al.,29 DeVocht et al.,45 Ficnar et al.,61 Giannakopoulos et al.,62
Hasanoglu et al.,52 Katyayan et al.,56 Lundh et al.,40 Nagata et al.,67 Niemelä et al.,71 Truelove et al.50
and Wahlund et al.44), whereas seven had a co-intervention of ‘acuhealth’, manipulative and physical
therapy, massage, fluoxetine (Prozac®, Eli Lilly and Company, Indianapolis, IN, USA) microcurrent electrical
nerve stimulation, physical therapy with vapocoolant spray, arthrocentesis and sodium hyaluronate
{Elsharkawy and Ali,58 Gomes et al.,32 Leeson,63 Sharma,49 Tatli et al.,54 Yu and Qian59 [this study had
four arms with which we made two separate pairwise comparisons: (1) splint + co-intervention vs.
co-intervention alone and (2) splint vs. minimal treatment] and Zuim et al.34}.
The remaining six studies had minimal treatment controls: three were self-exercises (Haketa et al.,66
Magnusson and Syrén42 and Tavera et al.23), and three were information-based {de Felício et al.,30
Michelotti et al.64 and Yu and Qian59 [this study had four arms with which we made two separate
pairwise comparisons: (1) splint + co-intervention vs. co-intervention alone and (2) splint vs. minimal
treatment]}.
Splint type
Seven studies compared more than one splint against no splint:
1. Conti et al.25 – (1) stabilisation splint compared with (2) anterior repositioning splint for 3 or 4 months
and then converted into stabilisation splints for the remainder of the treatment period.
2. Conti et al.27 – (1) stabilisation splint compared with (2) nociceptive trigeminal inhibition splint.
3. Conti et al.28 – (1) anterior repositioning splint compared with (2) NTI-tss splint.
4. Ficnar et al.61 – (1) stabilisation splint compared with (2) prefabricated, semi-finished occlusal splint
(SOLUBrux®; W3 Solutions SÀRL, Crassier Switzerland).
5. Giannakopoulos et al.62 – (1) vacuum-formed splint compared with (2) prefabricated oral splint with
water-filled elastic pads.
6. Lundh et al.39 – (1) anterior repositioning splint compared with (2) flat occlusal splint.
7. Truelove et al.50 – (1) flat-plane splint compared with (2) prefabricated soft thermoplastic athletic
mouthguard splint.
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Fifteen studies used a stabilisation splint, 12 of which were in the upper jaw (Michigan-style splints)
(Costa et al.,29 de Felício et al.,31 Gomes et al.,32 Haketa et al.,66 Katyayan et al.,56 Leeson,63 List et al.,38
Magnusson and Syrén,42 Michelotti et al.,64 Nagata et al.,67 Wahlund et al.44 and Yu and Qian59).
The remaining three studies did not clearly report whether the splint was in the upper or lower jaw
(Niemelä et al.,71 Tatli et al.54 and Tavera et al.23).
The splint used in two studies was described as a flat-plane splint (Daif57 and Sharma49).
The splint used in two studies was described as a flat occlusal splint (Lundh et al.40 and Lundh et al.41).
The splint used in five studies was described only as an occlusal splint (de Felício et al.,30 Elsharkawy
and Ali,58 Johansson et al.,37 Nitecka-Buchta et al.70 and Zuim et al.34).
The splint used in one study was described only as a soft splint (Wright et al.51).
The splint used in one study was described as a reversible interocclusal splint (DeVocht et al.45).
One study used a NTI-tss splint (Hasanoglu et al.52).
One study used a Universal Neuromuscular Immediate Relaxing Appliance (UNIRA) splint, designed
and patented by the study author (Rampello et al.65).
Custom-made splint versus prefabricated splint for temporomandibular disorders
Six studies compared custom-made splints with prefabricated splints for TMD patients:
1. Amin et al.55 – (1) prefabricated readily available liquid occlusal splint (Aqualizer®; Bainbridge Island,
WA, USA), (2) hard occlusal splint and (3) soft occlusal splint.
2. Christidis et al.72 – (1) prefabricated occlusal splint (Relax; Unident AB, Falkenberg, Sweden) and
(2) stabilisation splint.
3. Ficnar et al.61 – (1) prefabricated, semi-finished occlusal splint (SOLUBrux) and (2) stabilisation splint.
4. Giannakopoulos et al.62 – (1) prefabricated oral splint with water-filled elastic pads (Aqualizer) and
(2) vacuum-formed splint.
5. Nilner et al.73 – (1) prefabricated occlusal splint (Relax) and (2) stabilisation splint.
6. Truelove et al.50 – (1) prefabricated soft thermoplastic athletic mouthguard splint and (2) flat-plane
hard splint.
Splint versus control splint for temporomandibular disorders
Ten studies compared control splints that did not alter the occlusion with active splints for TMD
patients. In six of the studies, the active splint was described as a stabilisation splint (Dao et al.,68
Ekberg et al.,35 Ekberg et al.,36 Rubinoff et al.,48 Wassell et al.22 and Zhang et al.60). In one study it was
described as a flat-plane splint (Raphael and Marbach47) and in another only as an occlusal splint
(Nilsson et al.43). The remaining studies compared two active splints against the control splint:
l Alencar and Becker24 – (1) hard occlusal splint and (2) soft occlusal splint.
l Conti et al.26 – (1) modified stabilisation splint and (2) conventional stabilisation splint.
Splint versus no splint for bruxism
Three studies compared splints with no splints for bruxism patients:
1. Gomes et al.32 – Michigan splint +massage versus massage.
2. Gomes et al.33 – (1) Michigan splint versus no treatment and (2) Michigan splint +massage versus
massage (i.e. two pairwise comparisons).
3. Pierce and Gale46 – flat-plane splint versus no treatment.
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Custom-made splint versus prefabricated splint for bruxism
One study compared custom-made stabilisation splints with prefabricated splints (Bruxogard™;
Myofunctional Research Europe B.V., Waalwijk, the Netherlands) for bruxism patients (Karakis et al.53).
Splint versus control splint for bruxism
One study compared stabilisation splints with control splints for bruxism patients (van der Zaag et al.69).
Characteristics of the outcomes
Nine of the 52 studies did not contribute any outcome data to this review, either in the meta-analyses
or the data analysis presented in the additional tables (Conti et al.,25 Conti et al.,26 Dao et al.,68 Ficnar
et al.,61 Gomes et al.,32 Karakis et al.,53 Pierce and Gale,46 Rampello et al.65 and Zuim et al.34).
Primary outcomes
Pain
Only five studies did not report some form of pain outcome (Daif,57 Gomes et al.,32 Karakis et al.,53
Pierce and Gale46 and van der Zaag et al.69). Four of those were bruxism studies; therefore, this was to
be expected.
Table 2 demonstrates how pain was reported in the studies and that a lot of studies reported pain in
multiple ways.
The most commonly used measures of pain in the included studies were VAS/numerical rating scales (NRS)
and pain on palpation/pressure. In this review, we prioritised VAS/NRS for the main meta-analysis, also
including Characteristic Pain Intensity (CPI) (which was reported as a composite measure encompassing
current, worst and average pain over a specified period of time). Despite the majority of studies reporting
one of the three pain measures, many studies did not report the data sufficiently for us to include them in
the meta-analysis. Furthermore, some measured current pain intensity, whereas others measured average
pain over a specified period of time or worst pain experienced. Pain at rest was favoured over pain while
chewing or during any other movement.
Harms/adverse effects
Nine studies reported on harms (Christidis et al.,72 Haketa et al.,66 Nilner et al.,73 Nitecka-Buchta et al.,70
Tatli et al.,54 Tavera et al.,23 Truelove et al.,50 Wahlund et al.44 and Wright et al.51). Eight of these were
reported narratively, with one study reporting raw data for occlusal contact changes (Wright et al.51).
Tooth wear (bruxism only)
None of the five bruxism studies reported on tooth wear.
Secondary outcomes
Temporomandibular joint clicking
Fourteen studies reported this outcome (Conti et al.,25 Conti et al.,26 Conti et al.,28 de Felício et al.,30
de Felício et al.,31 Ekberg et al.,35 Ekberg et al.,36 Lundh et al.,39 Lundh et al.,40 Magnusson and Syrén,42
Nagata et al.,67 Rubinoff et al.,48 Truelove et al.50 and Wassell et al.22). One further study measured this
outcome but did not report it (Wahlund et al.44). Some studies reported on joint sounds and did not
specify clicking. The majority of studies reported this outcome dichotomously.
Change in restricted mouth-opening
Twenty-seven studies reported on this outcome (Christidis et al.,72 Conti et al.,25 Conti et al.,28 de Felício
et al.,30 de Felício et al.,31 Ekberg et al.,35 Ekberg et al.,36 Ficnar et al.,61 Giannakopoulos et al.,62 Haketa et al.,66
Hasanoglu et al.,52 Katyayan et al.,56 Leeson,63 Magnusson and Syrén,42 Michelotti et al.,64 Nagata et al.,67
Niemelä et al.,71 Nilner et al.,73 Rampello et al.,65 Rubinoff et al.,48 Sharma,49 Tatli et al.,54 Truelove et al.,50
Wahlund et al.,44 Wassell et al.,22 Wright et al.51 and Yu and Qian59).
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TABLE 2 Pain outcomes reported in the included studies
Study
VAS
50%
reduction
in VAS NRS CPI
Mod-SSI
(0.035 to 1)
Pain on
palpation/
pressure
(measured in
various ways) GCPS
Overall
improvement
(0–5)
Catastrophising
Thoughts
Subscale
(0–4)
Pain
(various
yes/no)
Pain
intensity
(various
ordinal
scales)
Frequency
(various ordinal
and continuous
scales)
Duration
(ordinal
0–4)
Pain during
mandibular
movements
(number of
movements)
Impaired/
unchanged/
improved/
symptom free
Pain index
(VAS ×
frequency)
Aggregate
joint
tenderness
First author
and year
Alencar 200924 ✗ ✗
Amin 201655 ✗ ✗
Castroflorio
201876
Christidis
201472
✗ ✗ ✗
Conti 200525 ✗ ✗
Conti 200626 ✗ ✗
Conti 201227 ✗ ✗ ✗
Conti 201528 ✗ ✗
Costa 201529 ✗
Daif 201257
Dao 199468 ✗
de Felício
200630
✗ ✗
de Felício
201031
?
DeVocht 201345 ✗
Ekberg 199835 ✗ ✗ ✗ ✗ ✗ ✗ ✗
Ekberg 200336 ✗ ✗ ✗ ✗ ✗ ✗
Elsharkawy
199558
✗ ✗ ✗
Ficnar 201361 ✗
Giannakopoulos
201662
✗
Gomes 201432
Gomes 201533 ✗
Haketa 201066 ✗
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Study
VAS
50%
reduction
in VAS NRS CPI
Mod-SSI
(0.035 to 1)
Pain on
palpation/
pressure
(measured in
various ways) GCPS
Overall
improvement
(0–5)
Catastrophising
Thoughts
Subscale
(0–4)
Pain
(various
yes/no)
Pain
intensity
(various
ordinal
scales)
Frequency
(various ordinal
and continuous
scales)
Duration
(ordinal
0–4)
Pain during
mandibular
movements
(number of
movements)
Impaired/
unchanged/
improved/
symptom free
Pain index
(VAS ×
frequency)
Aggregate
joint
tenderness
First author
and year
Hasanoglu
201752
✗
Johansson
199137
✗ ✗ ✗
Karakis 201453
Katyayan
201456
✗ ✗
Leeson 200763 ✗ ✗ ✗ ✗ ✗
List 199238 ✗ ✗
Lundh 198539 ✗ ✗
Lundh 198840 ✗ ✗
Lundh 199241 ✗ ✗
Magnusson
199942
✗ ✗
Michelotti
201264
✗
Nagata 201567 ✗
Niemelä 201271 ✗ ✗
Nilner 200873 ✗ ✗ ✗ ✗
Nilsson 200943 ✗ ✗ ✗
Nitecka-Buchta
201470
✗
Pierce 198846
Rampello
201365
✗ ✗
Raphael 200147 ✗ ✗
Rubinoff 198748 ✗ ✗
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TABLE 2 Pain outcomes reported in the included studies (continued )
Study
VAS
50%
reduction
in VAS NRS CPI
Mod-SSI
(0.035 to 1)
Pain on
palpation/
pressure
(measured in
various ways) GCPS
Overall
improvement
(0–5)
Catastrophising
Thoughts
Subscale
(0–4)
Pain
(various
yes/no)
Pain
intensity
(various
ordinal
scales)
Frequency
(various ordinal
and continuous
scales)
Duration
(ordinal
0–4)
Pain during
mandibular
movements
(number of
movements)
Impaired/
unchanged/
improved/
symptom free
Pain index
(VAS ×
frequency)
Aggregate
joint
tenderness
First author
and year
Sharma 201649 ✗
Tatli 201754 ✗ ✗
Tavera 201223 ✗
Truelove 200650 ✗ ✗ ✗
van der Zaag
200569
Wahlund
200344
✗ ✗ ✗ ✗ ✗
Wassell 200422 ✗ ✗ ✗
Wright 199551 ✗
Yu 201659 ✗
Zhang 201360 ✗
Zuim 200634 ✗
CPI, Characteristic Pain Intensity; GCPS, Graded Chronic Pain Scale; Mod-SSI, Modified Symptom Severity Index; NRS, numerical rating scale.
Note
‘?’ means ‘unclear’, as it could not be determined from the paper if it used VAS or not.
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Two studies reported the incidence of participants with a mouth-opening capacity of < 40 mm (Ekberg
et al.35 and Ekberg et al.36). One study reported this outcome as difficulty when opening the mouth (yes/no)
(de Felício et al.30). One study reported a self-assessment of functional limitation of the jaw using a
0–100 mm VAS (Hasanoglu et al.52). One study reported only on the splint group and not on the control
group, and only for those who started with restricted mouth-opening (Rampello et al.65). The remaining
studies all reported maximum mouth-opening in various ways, namely without pain/with pain/until pain,
and assisted/unassisted. One of them also reported the incidence of having difficulty opening the mouth
wide (yes/no) (Magnusson and Syrén42).
Frequency of headaches (secondary to pain-related temporomandibular disorder)
Four studies reported this outcome. Three were reported categorically (Costa et al.,29 Nilner et al.73 and
Nilsson et al.43) and one as number per week (Wassell et al.22).
Quality of life
Thirteen studies reported on this outcome. Four used the Modified Symptom Checklist-90-Revised
(SCL-90-R) (Christidis et al.,72 Nilner et al.,73 Nilsson et al.43 and Raphael and Marbach47). One of those
also assessed average mood using a 0–10 scale (Raphael and Marbach47). Two studies used the 14-item
Oral Health Impact Profile (OHIP-14) (DeVocht et al.45 and Niemelä et al.71). One study used the Hospital
Anxiety and Depression scale (Costa et al.29). One study used the Short Form questionnaire-36 items
(SF-36) (Gomes et al.33). One study used the Limitation of Daily Functions for TMD Questionnaire
(Haketa et al.66). One study used the RDC/TMD Axis II biobehavioural questionnaire (Tatli et al.54).
One study used an unnamed scale (Dao et al.68) and the remaining two studies used multiple scales:
Leeson63 used the following: (1) Multidimensional Pain Inventory severity; (2) McGill Short Pain
Questionnaire; (3) Kellner Illness Attitude Scale; and (4) Beck Depression Inventory scores, whereas
Sharma49 used the following: (1) Patient Health Questionnaire-9 items; (2) Patient Health Questionnaire-15
items; and (3) Generalised Anxiety Disorder-7.
Patient satisfaction
Four studies reported on patient satisfaction. In one study, this was assessed using a 0–10 scale
(DeVocht et al.45); in another, it was reported dichotomously as satisfied or not (Ekberg et al.36).
The data were not usable in the remaining two studies (Conti et al.28 and Tavera et al.23).
Adherence to treatment
Nine studies reported on compliance (Christidis et al.,72 Daif,57 Ekberg et al.,36 Nilner et al.,73 Nilsson et al.,43
Raphael and Marbach,47 Tavera et al.,23 Truelove et al.50 and Wahlund et al.44).
Bruxism severity
Of the five bruxism studies, two reported on bruxism severity. One reported the duration of bruxing
per hour (Pierce and Gale46) and the other used a bruxism time index, which was the percentage of
total sleep time spent bruxing (van der Zaag et al.69).
Bruxism frequency
Of the five bruxism studies, two reported bruxism episodes per hour (Pierce and Gale46 and
van der Zaag et al.69).
Risk of bias in included studies
A summary of the risk-of-bias assessments for the seven domains is given in Figure 2.
Allocation (selection bias)
Random sequence generation
Twenty-nine studies22,26,29–33,35,36,43,45,49–51,54–57,60,62–64,66,67,69–73 were judged to be at a low risk of bias for the
domain of random sequence generation. The remaining 23 studies23–25,27,28,34,37–42,44,46–48,52,53,58,59,61,65,68
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?Zuim 200634 ? – – + + +
Zhang 201360 ? ? ? –++ +
?Yu 201659 ? – – + + +
Wright 199551 ? – – ++ + +
Wassell 200422 – – –+ ++ +
?Wahlund 200344 ? – – – – +
van der Zaag 200569 ? – +++ + +
Truelove 200650 – – – + ++ +
?Tavera 201223 ? – – – – +
Tatli 201754 ? – – + + ++
Sharma 201649 ? ?– – + ++
?Rubinoff 198748 ? ? ++ + +
?Raphael 200147 ? ? ? + + +
?Rampello 201365 ? – – –+ +
?Pierce 198846 ? ?– –+ +
Nitecka-Buchta 201470 – –– + ++ +
Nilsson 200943 ? ? – + ++ +
Nilner 200873 – – – – ++ +
Niemelä 201271 ? – – + + ++
? – – + + ++
? – – + + ++
Nagata 201567
Michelotti 201264
?Magnusson 199942 ? – – + + +
?Lundh 199241 ? – – –+ +
? ? – – –+ +
? ? – – –+ +
Lundh 198840
Lundh 198539
?List 199238 ? – – – –+
Leeson 200763 – – + + +
Katyayan 201456 – – + + +
+ +
+ +
?Karakis 201453 ? ?– –+ +
?Johansson 199137 ? – – + + –
?Hasanoglu 201752 ? – – + + +
Haketa 201066 – – + + ++ +
Gomes 201533 – – – – ++ +
Gomes 201432 – –++ +
Giannakopoulos 201662 – – + + +
+ +
+ +
?Ficnar 201361 ? – – + + +
?Elsharkawy 199558 ? – – – – +
Ekberg 200336 – + +
Ekberg 199835 –
–
–+ +
DeVocht 201345 – – + + +
+ +
+ +
+ +
de Felício 201031 ? ?– – + +
de Felício 200630 ?
?
?
– – –+ +
+
+
?Dao 199468 ? – –+ ++
Daif 201257 ? – – –+ ++
Costa 201529 – – – – ++ +
?Conti 201528 ? ?– – – –
? ? ?– – – –Conti 201227
Conti 200626 ? ?– – –++
?Conti 200525 ? ? ?– – –
Christidis 201472 – – – + ++ +
Amin 201655 ? ?– – + ++
?Alencar 200924 ? – – + + +
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FIGURE 2 Summary of risk-of-bias assessments for each study. Adapted from Riley et al.1 This article is licensed under
a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and
reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the
copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. This includes minor
additions and formatting changes to the original text.
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reported that participants were randomly allocated to interventions, but were judged to be at an
unclear risk of bias owing to an inadequate description of the methods used.
Allocation concealment
Sixteen studies22,29,32,33,35,36,43,45,50,56,62,63,66,70,72,73 described an adequate method of allocation concealment and
we judged them to be at a low risk of bias for this domain. The remaining 36 studies23–28,30,31,34,37–42,44,46–49,51–55,
57–61,64,65,67–69,71 did not provide a description of the methods used to conceal the allocation sequence.
Overall, sixteen studies22,29,32,33,35,36,43,45,50,56,62,63,66,70,72,73 were deemed to be at a low risk of selection bias
as they were rated as being at a low risk for both of the above domains. The remaining 36 studies23–28,
30,31,34,37–42,44,46–49,51–55,57–61,64,65,67–69,71 had an unclear risk of selection bias as they had an unclear rating for
one or both of the above domains.
Blinding of participants and personnel (performance bias)
Forty-eight studies22–42,44–46,49–59,61–73 were rated as having a high risk of performance bias because of the
inability to blind patients and personnel to splint/no splint or splint type. Four studies43,47,48,60 were rated as
having an unclear risk of bias. These studies all compared splints against control splints, and attempts were
made to blind the personnel and/or patients; however, it was not clear if both were blinded.
Blinding of outcome assessment (detection bias)
Forty-one studies22–31,33,34,37–42,44,45,49–52,54–59,61–67,70–73 were rated as having a high risk of detection bias
based on the primary outcome of pain. This was because the patients were aware of their assigned
group in the studies and would then subjectively rate their own pain.
Six studies were rated as being at a low risk of detection bias. In two of these studies, comparing
splints with control splints, the patients were blinded (Dao et al.68 and Rubinoff et al.48). Two studies
used objective assessment of bruxism while the participants slept (Pierce and Gale46 and van der Zaag
et al.69). Two studies did not assess any outcomes of this review; therefore, detection bias was irrelevant
(Gomes et al.32 and Karakis et al.53).
The remaining five studies were rated as having an unclear risk of bias. These all compared splints with
control splints and it was not clear whether or not the patients were blinded (Ekberg et al.,35 Ekberg
et al.,36 Nilsson et al.,43 Raphael and Marbach47 and Zhang et al.60).
Incomplete outcome data (attrition bias)
Thirty-four studies22,24,26,30,32,34–42,45,47,48,51,52,54,56,57,59–69,71 had limited or no attrition and were rated as being
at a low risk of attrition bias. Twelve studies23,27–29,33,43,44,50,58,70,72,73 were rated as being at a high risk of
attrition bias because of high attrition rates, substantial differences between groups in attrition rate, or
both. The remaining six studies25,31,46,49,53,55 were rated as having an unclear risk of attrition bias owing
to poor reporting of numbers randomised or analysed.
Selective reporting (reporting bias)
Twenty-eight studies24,31,34,37,42,43,45,47–52,54–56,59,61–67,69–72 reported outcome data adequately and were assessed as
being at a low risk of reporting bias. The remaining 24 studies22,23,25–30,32,33,35,36,38–41,44,46,53,57,58,60,68,73 had problems
with the way in which the data were reported and were rated as being at a high risk of reporting bias.
Other bias
For 45 studies,22–24,29–36,39–64,66–73 we did not identify any other potential source of bias and rated them
as being at a low risk of bias. Three studies were rated as having a high risk of bias because outcomes
were followed up at different times for the two groups (Johansson et al.,37 List et al.38 and Rampello et al.65).
For one of those studies, there was also a substantial sex imbalance between groups, potentially indicating
that the randomisation process was inadequate or did not work (List et al.38). The remaining four studies
were rated as having an unclear risk of bias because the reporting was poor and we were unable to properly
assess them (Conti et al.,25 Conti et al.,26 Conti et al.27 and Conti et al.28).
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Overall risk of bias
Fifty studies22–46,49–73 were rated as having a high risk of bias overall because they received at least one
high risk-of-bias rating for the above domains. The remaining two studies47,48 were rated as having an
unclear risk of bias because they did not receive any high risk-of-bias ratings for the above domains,
but received at least one unclear risk-of-bias rating. Therefore, no study included in this review was
considered to be at a low risk of bias.
Studies excluded from the review
Six studies were excluded from the review for the following reasons: not random allocation (Al Quran
and Kamal,77 Alpaslan et al.78 and Gavish et al.79), inappropriate study design [4-month difference in
timing of outcomes between the groups (Madani and Mirmortazavi80)], the counselling group had
multiple reinforcement sessions and therefore not considered minimal treatment (Manfredini et al.81)
and we were unable to obtain a full-text copy (Castroflorio et al.76).
Results of the systematic review
The results and presented for the two comparisons specified in Chapter 1.
Comparison 1: splints versus no splints/minimal intervention/control splints
The results for the two conditions, TMD (pain-related and non-pain-related) and bruxism, are
considered separately, as trials included only TMD patients or only bruxism patients because they are
considered discrete groups of patients.
Patients with temporomandibular disorder
One of the main questions posed in this investigation is whether or not there is evidence that splints
are effective for reducing pain when compared with no splints. We undertook two analyses. One was for
the splint group compared with no/minimal intervention, such as watchful waiting or minimal treatment
or self-management. A second analysis was conducted for comparisons with a placebo/control splint,
which was used in some trials. There was consensus among clinicians and methodologists that 0–3 months
was an appropriate time point to use for the primary analysis of the data. The primary pain outcome was
any continuous scale that was sensible to combine (e.g. VAS, NRS, CPI). VAS was the most frequently
reported outcome, and 0–3 months was the most frequently reported time point. Other time points,
3–6 months and 6–12 months, were also analysed and reported.
Pain (splint versus no splint/minimal intervention)
Thirteen trials of 16 pairwise comparisons (three of the studies assessed more than one type of splint),
all rated as having a high risk of bias, with 1076 patients contributed to the results for the no/minimal
interventions at 3 months (Figure 3). There was considerable heterogeneity and the overall SMD
was –0.18 (95% CI –0.42 to 0.06). Using a rule of thumb for SMD effect estimates, 0.18 would be
considered a small effect15 and, as this was not statistically significant, there is insufficient evidence,
which is of very low quality,20 to show that oral splints reduce pain (Table 3). Owing to differences in
splint type, the control group no/minimal interventions and different types of TMD diagnoses between
the individual studies, we were unable to investigate the heterogeneity any further. There were fewer
studies and patients for the other time periods (3–6 months: two trials, 160 patients; and 6–12 months:
two trials, three pairwise comparisons, 246 patients), and the effect sizes were SMD –0.31 (95% CI
–1.31 to 0.68) and 0.11 (95% CI –0.16 to 0.38) for the 3- to 6-month and 6- to 12-month time periods,
respectively, which also fail to demonstrate that oral splints reduced pain (Table 4) (see also Appendix 4,
Figures 15 and 16).
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aConti 201528
bde Felício 201031
cGiannakopoulos 201662
dGiannakopoulos 201662
eHaketa 201066
fHasanoglu 201752
gLeeson 200763
hList 199238
iNagata 201567
jNiemelä 201271
kNitecka-Buchta 201470
lTatli 201754
mTruelove 200650
nTruelove 200650
oYu 201659
pYu 201659
Total (95% CI)
Heterogeneity: τ2 = 0.15; χ2 = 50.22, df = 15 (p < 0.0001); I 2 = 70%
Test for overall effect: Z = 1.50 (p = 0.13)
SMD IV, random (95% CI)Weight (%)
Splint
Study or subgroup
– 1.21 (– 2.17 to – 0.26)
0.10 (– 0.77 to 0.98)
– 0.39 (– 1.38 to 0.60)
– 1.13 (– 2.19 to – 0.06)
0.54 (– 0.07 to 1.15)
– 0.02 (– 0.64 to 0.60)
0.11 (– 0.24 to 0.46)
– 0.57 (– 1.11 to – 0.02)
0.18 (– 0.11 to 0.47)
– 0.20 (– 0.65 to 0.25)
– 1.54 (– 2.10 to – 0.98)
0.27 (– 0.17 to 0.72)
0.01 (– 0.45 to 0.47)
– 0.12 (– 0.59 to 0.34)
– 0.05 (– 0.48 to 0.38)
– 0.05 (– 0.48 to 0.37)
– 0.18 (– 0.42 to 0.06)
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FIGURE 3 Forest plot of comparison: TMD, splint vs. no/minimal treatment; outcome – pain: any combinable scale (higher =more pain), 0–3 months. Risk of bias: A, random sequence
generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment (detection bias);
E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias. a, Current pain intensity 0 to 100 mm VAS (custom anterior repositioning); b, muscle
pain 0 to 10 for when (1) waking, (2) chewing, (3) speaking, (4) at rest (score summed = 0 to 40 scale); c, current pain intensity 0 to 10 NRS converted to a 0 to 100 scale (prefabricated
splint); d, current pain intensity 0 to 10 NRS converted to a 0 to 100 scale (custom splint); e, current maximum daily pain intensity 0 to 100 mm VAS; f, current pain intensity 0 to 100 mm
VAS; g, current pain intensity 0 to 10 cm VAS converted to 0 to 100 mm; h, 0 to 100 mm VAS, recorded three times daily with average calculated on weekly basis (appears to be reported
in cm – we converted this to mm); i, current orofacial pain 0 to 10 NRS converted to a 0 to 100 scale; j, current facial pain intensity 0 to 10 cm VAS (we converted this to mm); k, current
pain intensity – 0 to 10 cm VAS (we converted this to mm); l, current pain intensity – 0 to 10 cm VAS (we converted to mm); m, CPI 0 to 10 converted to 0 to 100 scale – SD is median
value from range of SDs reported in the paper; n, CPI 0 to 10 converted to 0 to 100 scale – SD is median value from range of SDs reported in the paper (custom-made splint vs. control);
o, current pain intensity 0 to 10 VAS – we converted to 0 to 100 (splint vs. control); p, current pain intensity 0 to 10 VAS – we converted to 0 to 100 (splint + manipulative and physical
therapies vs. manipulative and physical therapies). Adapted from Riley et al.1 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use,
sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. This includes minor
additions and formatting changes to the original text.
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TABLE 3 Summary of findings for oral splints provided for TMD vs. no/minimal intervention/control splintsa
Outcomes
Illustrative comparative risks
(95% CI)
Relative effect
(95% CI)
Number of
participants
(n studies)
Quality of the
evidence (GRADE) Comments
Assumed risk Corresponding risk
No splint Oral splint
Pain SD units:
l Pain measured on
combinable scale
l 0–3 months
l (unable to use MD due to
differences in the way pain
was measured in the studies)
The pain score in the oral splint group was, on
average, 0.18 SDs lower (0.06 higher to 0.42
lower) than the no/minimal intervention group
1076 (13 RCTs;
16 pairwise
comparisons)
⊕⊝⊝⊝ very lowb l No evidence that splints
reduced pain
l As rule of thumb, 0.2 SD
represents a small difference,
0.5 a moderate difference and
0.8 a large difference
l Similar effect sizes at other
time points
l Comparisons between splint and
control splint indicated a
reduction in pain for the splint
group at 0–3 months [SMD –0.67
(95% CI –1.16 to –0.17)] but not
at other time points
l Current pain intensity
measured on VAS
(0–100mm)
or NRS (0 to 100)
l 0–3 months
The mean pain
intensity in the
control groups
ranged from
9.23 to 41.1 mm,c
median= 20
The mean pain intensity
in the splint groups was
4.48 mm lower (11.59
lower to 2.64 higher)
874 (11 RCTs;
13 pairwise
comparisons)
⊕⊝⊝⊝ very lowb Results similar at other time points
Clicking of joint at 0–3 months
(yes/no)
500d per 1000 425 per 1000
(255 to 715)
RR 0.85
(0.51 to 1.43)
252 (3 RCTs;
5 pairwise
comparisons)
⊕⊝⊝⊝ very lowb l No evidence of a difference in
joint clicking
l Results similar at other
time points
l No evidence of a difference
between splint and control splint
at 0–3 months: RR 0.95 (95% CI
0.68 to 1.31). No data at other
time points
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Outcomes
Illustrative comparative risks
(95% CI)
Relative effect
(95% CI)
Number of
participants
(n studies)
Quality of the
evidence (GRADE) Comments
Assumed risk Corresponding risk
No splint Oral splint
Maximum mouth-opening (mm)
at 0–3 months
The mean maximum
mouth-opening in
the control groups
rangedc from 33.08
to 47.1 mm; median
40mm
The mean maximum
mouth-opening in the
splint groups was
1.17 mm higher (0.68
lower to 3.03 higher)
913 (13 RCTs;
16 pairwise
comparisons)
⊕⊝⊝⊝ very lowb l No evidence of a difference in
maximum mouth opening
l The results from the 3- to
6-month time period: MD
0.29 mm (95% CI –0.63 to
1.20 mm). No data for the
6- to 12-month time period
l No evidence of a difference in
incidence of mouth-opening
< 40mm between splint and
control splint in the 0- to
3-month time period: RR 0.40
(95% CI 0.05 to 3.41). No data
at other time points
Quality of life using OHIP-14
(0 to 56, worsening scale) at
0–3 months
The meane score in
the control groups
was 14.84
The mean score in the
splint groups was
1.43 lower (5.11 lower
to 2.24 higher)
80 (2 RCTs) ⊕⊝⊝⊝ very lowb l No evidence of a difference in
quality of life
l Similar results at other time points
l Insufficient evidence for splint
vs. control splint
Adverse events None of the studies reported any adverse events
a The evidence in this table is based purely on the data in the forest plots and not the data in the additional tables.
b Downgraded as all studies were rated as being at a high risk of bias, there was substantial heterogeneity between studies and there was a lack of precision in the pooled estimate.
c The range does not include two studies that reported change scores.
d Median event rate for no/minimal intervention group.
e This is the mean in the study that reported an end score, as the other study reported a change score.
Notes
Oral splints for patients with orofacial signs or symptoms to reduce orofacial pain.
Patient or population: patients provided with oral splints for TMD.
Setting: primary or secondary care.
Intervention: oral splint.
Comparison: no splint/minimal intervention/placebo splint.
Adapted from Riley et al.1 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any
medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.The images
or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright
holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. This includes minor additions and formatting changes to the original text.
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The results for the other pain outcomes are shown as forest plots (see Appendix 4, Figure 17) and
summarised in Table 4. There was no convincing evidence that the oral splints reduced pain (apart from
a single study rated as having a high risk of bias that showed a statistically significant difference in
incidence of 50% reduction in VAS pain, in favour of the control group, between 6 and 12 months),
although the quality of the evidence was assessed as being very low.
Pain was also measured and reported in other ways that were not possible to meta-analyse, with
mixed and inconclusive results (see Appendix 2, Table 26).
Pain (splints versus control splints)
Three trials (159 patients) were included in the comparison between splints and control splints for the
0- to 3-month time period (Figure 4). The SMD effect size was –0.67 (95% CI –1.16 to –0.17), which
indicated a possible benefit for the oral splint compared with a control splint in reducing pain (very
low-quality evidence). This result was not confirmed at the two longer-term time points, although the
same single study was included in both (Nilsson et al.43) (see Appendix 4, Figures 21 and 22) (Table 5).
Pain was also measured and reported in other ways that were either not possible to meta-analyse or
were not VAS/NRS/CPI, with mixed and inconclusive results (see Appendix 2, Table 28).
Other outcomes (splint versus no intervention/minimal intervention/control splint)
Several other outcomes were measured for these comparisons; these are summarised in Tables 6 and 7.
When comparing splints with no/minimal interventions or with control splints, there was no evidence that
they reduced TMD clicking or increased mouth-opening at any of the time points measured. There was no
evidence that splints improved quality of life at any time point when compared with no/minimal interventions.
There was also no evidence of a difference in compliance between the splints and the control splints at any
time point. The quality of the evidence for all these other outcomes was assessed as being very low.
TABLE 4 Summary of effect estimates for TMD pain: splint vs. no/minimal treatment
Outcome
Number of studies
(n participants)
Effect estimate (95% CI)
(random effects)
p-value
for effect
estimate
Heterogeneity
χ2 p-value I2 (%)
Pain: any combinable scale (higher =more pain)
0–3 months (see Figure 3) 13 (1076); 16 pairwise
comparisons
SMD –0.18 (–0.42 to 0.06) 0.13 < 0.0001 70
3–6 months (see Appendix 4,
Figure 15)
2 (160) SMD –0.31 (–1.31 to 0.68) 0.54 0.002 90
6–12 months (see Appendix 4,
Figure 16)
2 (246); 3 pairwise
comparisons
SMD 0.11 (–0.16 to 0.38) 0.43 0.45 0
Pain: 50% reduction in VAS pain
0–3 months (see Appendix 4,
Figure 17)
2 (164); 3 pairwise
comparisons
RR 1.38 (0.69 to 2.73) 0.36 0.19 39
6–12 months (see Appendix 4,
Figure 18)
1 (51) RR 0.49 (0.26 to 0.92) 0.03 N/A N/A
CPI (0–100 worsening scale)
0–3 months (see Appendix 4,
Figure 19)
2 (93) MD –0.24 (–7.55 to 7.08) 0.95 0.70 0
3–6 months (see Appendix 4,
Figure 20)
1 (80) MD 5.20 (–0.62 to 11.02) 0.08 N/A N/A
N/A, not applicable.
ASSESSMENT OF CLINICAL EFFECTIVENESS
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– 2 – 1 0
SMD IV, random (95% CI)Weight (%)
Splint
Study or subgroup
– 0.50 (– 1.02 to 0.01)
– 0.38 (– 0.88 to 0.12)
– 1.31 (– 2.04 to – 0.58)
– 0.67 (– 1.16 to – 0.17)
36.5
37.4
26.2
100.0
aEkberg 200336
bRaphael 200147
cZhang 201360
Total (95% CI)
Heterogeneity: τ2 = 0.11; χ2 = 4.52, df = 2 (p = 0.10); I 2 = 56%
Test for overall effect: Z = 2.65 (p = 0.008) 1 2
Favours splint Favours control splint
Control splint
SD TotalMean
30.1
21.3245
16.4
30
31
18
79
56
34.19
30.3
28.7
20.1384
10.2
30
32
18
80
41
26.16
12
SD TotalMean
FIGURE 4 Forest plot of comparison: TMD, splint vs. control splint; outcome – pain: any combinable scale (higher =more pain), 0–3 months. a, Worst pain experienced 0 to 100 mm
VAS; b, mean daily pain in the 2 weeks prior to follow-up – 0 to 10 scale (we converted to 0 to 100); c, current pain intensity 0 to 100 mm.
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TABLE 5 Summary of effect estimates for TMD pain: splint vs. control splint
Outcome
Number of studies
(n participants)
Effect estimate (95% CI)
(random effects)
p-value
for effect
estimate
Heterogeneity
χ2 p-value I2 (%)
Pain: any combinable scale (higher =more pain)
0–3 months (see Figure 4) 3 (159) SMD –0.67 (–1.16 to -0.17) 0.008 0.10 56
3–6 months (see Appendix 4,
Figure 21)
1 (57) MD –12.00 (–27.76 to 3.76) 0.14 N/A N/A
6–12 months (see Appendix 4,
Figure 22)
1 (51) MD 3.00 (–14.31 to 20.31) 0.73 N/A N/A
N/A, not applicable.
TABLE 6 Summary effect estimates for TMD outcomes other than pain for splints vs. no/minimal intervention
Outcome
Number of studies
(n participants)
Effect estimate (95% CI)
(random effects)
p-value
for effect
estimate
Heterogeneity
χ2 p-value I2 (%)
TMJ clicking: presence of joint noises (detected during TMJ palpation/opening/closing)
0–3 months (see Appendix 4,
Figure 23)
3 (252); 5 pairwise
comparisons
RR 0.85 (0.51 to 1.43) 0.55 0.001 77
3–6 months (see Appendix 4,
Figure 24)
3 (131); 4 pairwise
comparisons
RR 0.90 (0.79 to 1.03) 0.13 0.76 0
6–12 months (see Appendix 4,
Figure 25)
2 (238); 4 pairwise
comparisons
RR 0.90 (0.74 to 1.10) 0.30 0.15 43
Change in restricted mouth-opening: maximum mouth-opening (mm)
0–3 months (see Appendix 4,
Figure 26)
13 (913); 16 pairwise
comparisons
MD 1.17 (–0.68 to 3.03) 0.22 < 0.00001 83
3–6 months (see Appendix 4,
Figure 27)
3 (236) MD 0.29 (–0.63 to 1.20) 0.54 0.30 18
Quality of life: OHIP-14 (0–56, worsening scale)
0–3 months (see Appendix 4,
Figure 28)
2 (80) MD –1.43 (–5.11 to 2.24) 0.44 0.62 0
3–6 months (see Appendix 4,
Figure 29)
2 (76) MD 0.90 (–3.94 to 5.74) 0.72 0.21 36
6–12 months (see Appendix 4,
Figure 30)
1 (43) MD 1.31 (–5.11 to 7.73) 0.69 N/A N/A
N/A, not applicable; TMJ, temporomandibular joint.
Adapted from Riley et al.1 This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and
indicate if changes were made. The images or other third party material in this article are included in the article’s
Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in
the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence,
visit http://creativecommons.org/licenses/by/4.0/. This includes minor additions and formatting changes to the
original text.
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Analysis of the robustness of the results (sensitivity analyses)
For TMD patients, we planned to undertake a sensitivity analysis restricted to trials for which the
inclusion criteria were based on, or could be clearly mapped to, one of the following sets of diagnostic
criteria: RDC/TMD guidelines,17 TMD (DC/TMD) guidelines18 or AAOP guidelines.19 For the primary
analysis of splints versus no/minimal intervention in the 0- to 3-month time period (see Figure 3), there
was no difference in the result when removing those trials that did not use the above diagnostic
criteria: SMD –0.24 (95% CI –0.52 to 0.04; p = 0.09, I2 = 71%; 851 participants) (Figure 5).
We also carried out a sensitivity analysis restricting the meta-analysis in Figure 3 to studies using
stabilisation splints. Again, this did not change the result: SMD 0.04 (95% CI –0.13 to 0.22; p = 0.62,
I2 = 27%; 750 participants) (Figure 6). This removed much of the heterogeneity seen in the other analyses.
We had also planned to test the robustness of the results by performing sensitivity analyses based
on excluding studies deemed to be at high and unclear risks of bias from the analyses. This was not
possible as all the studies in this comparison were assessed as being at a high risk of bias.
Current pain intensity on visual analogue scale/numerical rating scale
For the purposes of the economic modelling, the main pain results as SMDs needed to be presented as
MDs. To do this, we undertook further sensitivity analyses including only studies that measured pain at
the time of assessment (current pain), measured on a 0–100 VAS or NRS. Two studies (DeVocht et al.45
and Michelotti et al.64) that reported the results as change scores, and therefore were not possible
to include in the main SMD analysis, were added to this analysis for the 0- to 3-month time period
because they reported current pain intensity on a VAS or NRS. The results were consistent with the
main SMD results, as the point estimate represented a very small, clinically unimportant, reduction in
pain for splints, with imprecision in the CI that included a benefit for both using splints and not using
splints: MD –4.48 (95% CI –11.59 to 2.64; p = 0.22, I2 = 94%; 874 participants) (Figure 7). However,
the extremely high heterogeneity means that the results should be interpreted with caution.
For the 3- to 6-month time period, DeVocht et al.45 was again added to the analysis and the result was again
consistent with the SMD analysis: MD –3.43 (95% CI –11.77 to 4.90; p= 0.42, I2= 82%; 202 participants).
TABLE 7 Summary effect estimates for TMD outcomes other than pain for splints vs. control splints
Outcome
Number of studies
(n participants)
Effect estimate (95% CI)
(random effects)
p-value
for effect
estimate
Heterogeneity
χ2 p-value I2 (%)
TMJ clicking: presence of joint noises (detected during TMJ palpation/opening/closing)
0–3 months (see Appendix 4,
Figure 31)
4 (218) RR 0.95 (0.68 to 1.31) 0.74 0.87 0
Change in restricted mouth-opening
Maximum mouth-opening of
< 40mm (see Appendix 4,
Figure 32)
2 (120) RR 0.40 (0.05 to 3.41) 0.40 0.12 59
Compliance: splint worn every night or most nights
0–3 months (see Appendix 4,
Figure 33)
3 (191) RR 1.03 (0.94 to 1.12) 0.51 0.53 0
3–6 months (see Appendix 4,
Figure 34)
1 (57) RR 1.06 (0.68 to 1.66) 0.80 N/A N/A
6–12 months (see Appendix 4,
Figure 35)
1 (51) RR 1.07 (0.58 to 1.97) 0.83 N/A N/A
N/A, not applicable; TMJ, temporomandibular joint.
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lYu 201659
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FIGURE 5 Forest plot of comparison: TMD, splint vs. no/minimal treatment; outcome – pain: any combinable scale (higher =more pain); sensitivity analysis of studies using the
recommended diagnostic criteria, 0–3 months. Risk of bias: A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and
personnel (performance bias); D, blinding of outcome assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias.
a, Current pain intensity 0 to 100 mm VAS (custom anterior repositioning); b, muscle pain 0 to 10 for when (1) waking, (2) chewing, (3) speaking, (4) at rest, score summed = 0 to
40 scale; c, current pain intensity 0 to 10 NRS converted to a 0 to 100 scale (custom splint); d, current pain intensity 0 to 10 NRS converted to a 0 to 100 scale (prefabricated splint);
e, current pain intensity 0 to 100 mm VAS; f, current orofacial pain 0 to 10 NRS converted to a 0 to 100 scale; g, current facial pain intensity 0 to 10 cm VAS (we converted this to
mm); h, current pain intensity – 0 to 10 cm VAS (we converted this to mm); i, current pain intensity 0 to 10 cm VAS (we converted this to mm); j, CPI 0 to 10 converted to 0 to
100 scale – SD is median value from range of SDs reported in the paper; k, CPI 0 to 10 converted to 0 to 100 scale – SD is median value from range of SDs reported in the paper
(custom-made splint vs. control); l, current pain intensity 0 to 10 VAS – we converted to 0 to 100 (splint + manipulative and physical therapies vs. manipulative and physical therapies);
m, current pain intensity 0 to 10 VAS – we converted to 0 to 100 (splint vs. control).
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Heterogeneity:  τ2 = 0.02; χ2 = 10.92, df = 8 (p = 0.21); I 2 = 27%
Test for overall effect: Z = 0.50 (p = 0.62)
SMD IV, random (95% CI)Weight (%)
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Study or subgroup
0.10 (– 0.77 to 0.98)
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– 0.57 (– 1.11 to – 0.02)
0.18 (– 0.11 to 0.47)
– 0.20 (– 0.65 to 0.25)
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– 0.05 (– 0.48 to 0.37)
– 0.05 (– 0.48 to 0.38)
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FIGURE 6 Forest plot of comparison: TMD, splint vs. no/minimal treatment; outcome – pain: any combinable scale (higher =more pain); sensitivity analysis of studies using only
stabilisation splints, 0–3 months. Risk of bias: A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel
(performance bias); D, blinding of outcome assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias. a, Muscle
pain 0 to 10 for when (1) waking, (2) chewing, (3) speaking, (4) at rest, score summed = 0 to 40 scale; b, current maximum daily pain intensity 0 to 100 mm VAS; c, current pain
intensity 0 to 10 cm VAS converted to 0 to 100 mm; d, 0 to 100 mm VAS, recorded three times daily with average calculated on weekly basis (appears to be in cm – we converted this
to mm); e, current orofacial pain 0 to 10 NRS converted to a 0 to 100 scale; f, current facial pain intensity 0 to 10 cm VAS (we converted this to mm); g, current pain intensity 0 to
10 cm VAS (we converted to mm); h, current pain intensity 0 to 10 VAS – we converted to 0 to 100 (splint + manipulative and physical therapies vs. manipulative and physical
therapies); i, current pain intensity 0 to 10 VAS – we converted to 0 to 100 (splint vs. control).
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Conti 201529
aDeVocht 201345
Giannakopoulos 201662
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Heterogeneity: τ2 = 133.99; χ2 = 190.50, df = 12 (p < 0.00001); I 2 = 94%
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SD TotalMean
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FIGURE 7 Forest plot of comparison: TMD, splint vs. no/minimal treatment; outcome – pain: sensitivity analysis of studies reporting current pain intensity on a 0–100 VAS/NRS
(higher =more pain), 0–3 months. Risk of bias: A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel
(performance bias); D, blinding of outcome assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias. a, Change
score reported.
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For the 6- to 12-month time period, when considering only studies that measured pain at the time of
assessment (current pain) measured on a 0–100 VAS or NRS, this reduced the analysis to a single study.
There was, again, insufficient evidence of a difference: MD 8.70 (95% CI –4.30 to 21.70; p = 0.19;
78 participants).
Patients with bruxism
An overview of the findings for bruxism is given in Table 8.
Two trials that focused on patients with bruxism provided usable outcome data for the 0- to 3-month
time period; however, neither study looked at the primary outcome of tooth wear. The results for
the other outcomes are presented in Table 9 (compared with minimal intervention) and Table 10
(compared with control splints). There is some very low-quality evidence that splints, when compared
with minimal intervention, reduced pain intensity (see Table 9); however, there was insufficient
evidence to determine whether or not the splints led to shorter bruxism times, or fewer episodes than
control splints (see Table 10).
TABLE 8 Summary of findings table for oral splints provided for patients with bruxism vs. no/minimal
intervention/control splints
Outcome
Illustrative comparative risks (95% CI)
Number of
participants
(n studies)
Quality of the
evidence
(GRADE) Comments
Assumed risk Corresponding risk
No splint (control
splint where
indicated) Oral splint
Tooth wear No studies reported our primary bruxism outcome of tooth wear
Pain intensity
measured on
(0–10) NRS
(0–3 months)
The mean pain
intensity in the
two control
groups was 6.7
The mean reduction in
the splint groups was
2.01 (1.40 to 2.62)
78 (1 study;
2 pairwise
comparisons)
⊕⊝⊝⊝a very low Reduction in pain
intensity for the
splint group
Bruxism time
index (% of time
spent bruxing)
The mean time in
the control splint
group was 1.9%
The mean in the splint
group was 0.18 higher
(1.76 lower to
2.12 higher)
21 (1 study) ⊕⊝⊝⊝a very low Insufficient evidence
to determine if there
is a difference in
bruxism time or not
Episodes of
bruxism per hour
(0–3 months)
The mean number
of episodes in the
control splint
group was 10.6
The mean in the splint
group was 0.54 higher
(10.95 lower to
12.03 higher)
21 (1 studies) ⊕⊝⊝⊝a very low Insufficient evidence
to determine if there
is a difference in
episodes of bruxism
or not
Quality of life No studies reported quality of life
Adverse events No studies reported adverse events
a Downgraded by three levels as a single, small study at a high risk of bias with lack of precision.
TABLE 9 Bruxism: splint vs. no/minimal treatment (other outcomes)
Outcome: pain
Number of studies
(n participants)
Effect estimatea (95% CI)
(random effects)
p-value for effect
estimate
Current pain intensity [0 (no pain) to
10 (worst pain) NRS] (0–3 months)
1 (78) MD –2.01 (–2.62 to –1.40)
favours splint
p < 0.00001
a Pooling the effects with and without massage.
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Comparison 2: prefabricated splints versus custom-made splints
Once again, we undertook separate analyses for patients with TMD and patients with bruxism.
Patients with temporomandibular disorder
Pain
Table 11 indicates that three trials (178 patients) were included in the meta-analysis comparing custom-
made with prefabricated splints for pain on a combinable scale (0–100) for the 0- to 3-month time period.
There was no evidence of any heterogeneity and the pooled SMD was –0.14 (95% CI –0.44 to 0.15)
(Figure 8). The evidence was assessed as being of very low quality (Table 12) and there was insufficient
evidence to determine whether or not there were any differences between custom-made and
prefabricated splints with respect to pain measured on a combinable scale.
Very low-quality data for pain on a combinable scale at the other time points also failed to determine
whether or not there were any differences between custom-made and prefabricated splints (see
Appendix 4, Figures 36 and 37).
A summary of all the pain outcome data comparing custom and prefabricated splints is shown in Table 13,
with the forest plots shown in Figure 8 and in Appendix 4, Figures 36–40.
Pain was also measured and reported in other ways that were not possible to meta-analyse, with
mixed and inconclusive results (see Appendix 2, Table 27).
Other outcomes
Several other outcomes were measured for this comparison; these are summarised in Table 13. When
comparing custom-made splints with prefabricated splints, there was no evidence that either improved
maximum mouth-opening, quality of life or adherence to treatment at any of the time points measured.
Some outcomes were measured for which data were reported that were not possible to meta-analyse in the
forest plots; these are reported in Appendix 2, Table 27. There was no evidence of a benefit for either type of
splint for any of these additional analyses, and the quality of the evidence was assessed as being very low.
Patients with bruxism
One study including patients with bruxism compared prefabricated splints with custom-made splints,
but provided no data for this review (Table 14).
Harms
Harms/adverse events are reported for all comparisons in Appendix 2, Table 29. These were generally
poorly reported and minor in nature.
TABLE 10 Bruxism: splint vs. control splint (other outcomes)
Outcome: bruxism severity
Number of studies
(n participants)
Effect estimate (95% CI)
(random effects)
p-value for effect
estimate
Bruxism time index (% of total sleep
time spent bruxing) (0–3 months)
1 (21) MD 0.18 (–1.76 to 2.12) 0.86 favours neither
Episodes per hour (0–3 months) 1 (21) MD 0.54 (–10.95 to 12.03) 0.93 favours neither
ASSESSMENT OF CLINICAL EFFECTIVENESS
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TABLE 11 Oral splints provided for TMD: custom-made vs. prefabricated splints
Outcomes
Illustrative comparative risks (95% CI)
Relative effect
(95% CI)
Number of
participants
(n studies)
Quality
of the
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Custom-made splints Prefabricated splints
l Pain SD units:
l Pain measured on
combinable scale
l 0–3 months
The pain score in the custom-made oral splint group was,
on average, 0.14 SDs lower (0.15 higher to 0.44 lower)
than that of the prefabricated splint group
178 (3 studies) ⊕⊝⊝⊝
very lowa
l Insufficient evidence to
determine if either splint type
leads to less pain, at this and
other time points, and also for
pain measured on the GCPS,
and pain on palpation
l As rule of thumb, 0.2 SD
represents a small difference,
0.5 a moderate difference and
0.8 a large difference
Clicking of joint at 0–3 months
(yes/no)
500b per 1000 500 per 1000 (350 to 720) RR 1.00
(0.70 to 1.44)
110 (1 study) ⊕⊝⊝⊝
very lowc
Insufficient evidence to determine
if either splint type leads to a
reduction in joint clicking, at
0–3 months and at 6–12 months
Maximum mouth-opening at
0–3 months (mm)
The mean maximum
mouth-opening in the
custom-made splint group
was 41mm
The mean maximum
mouth-opening in the
prefabricated splint group
was 4.47 mm higher than
for the custom-made splint
group (6.13 lower to 15.07
higher)
68 (2 studies) ⊕⊝⊝⊝
very lowd
Insufficient evidence to determine if
either splint type leads to an increase
in maximum mouth-opening at any
time point
continued
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TABLE 11 Oral splints provided for TMD: custom-made vs. prefabricated splints (continued )
Outcomes
Illustrative comparative risks (95% CI)
Relative effect
(95% CI)
Number of
participants
(n studies)
Quality
of the
evidence
(GRADE) Comments
Assumed risk Corresponding risk
Custom-made splints Prefabricated splints
Quality of life: SCL-90-R –
depression 0–4 (higher=worse)
at 0–3 months
The mean quality-of-life
score in the custom-made
splint group was 0.743
The mean quality-of-life
score in the prefabricated
splint group was 0.03 higher
(0.46 lower to 0.53 higher)
44 (1 study) ⊕⊝⊝⊝
very lowc
Insufficient evidence to determine
if either splint type leads to an
increase in quality of life at any
time point
Quality of life: SCL-90-R –
non-specific physical symptoms
0–4 (higher =worse) at
0–3 months
The mean quality-of-life
score in the custom-made
splint group was 0.685
The mean quality-of-life
score in the prefabricated
splint group was 0.02 higher
(0.46 lower to 0.5 higher)
44 (1 study) ⊕⊝⊝⊝
very lowc
Insufficient evidence to determine
if either splint type leads to an
increase in quality of life at any
time point
Adverse events Two studies reported that there had been no adverse events. A further study reported on an increased overbite in one patient in the prefabricated
splint group, which was treated and not present at 12 months
GCPS, Graded Chronic Pain Scale.
a Downgraded as all three studies were rated as having a high risk of bias and a lack of precision in the pooled estimate.
b Event rate for custom-made splint group.
c Downgraded as a single study was rated as having a high risk of bias, with lack of precision.
d Downgraded as two small studies were rated as having high risks of bias, substantial heterogeneity, with lack of precision.
Notes
Oral splints for patients with orofacial signs or symptoms to reduce orofacial pain.
Patient or population: patients provided with oral splints for TMD.
Setting: primary or secondary care.
Intervention: prefabricated oral splint.
Comparison: custom-made oral splint.
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aChristidis 201472
bGiannakopoulus 201662
cTruelove 200650
Total (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 1.51, df = 2 (p = 0.47); I 2 = 0%
Test for overall effect: Z = 0.93 (p = 0.35)
SMD IV, random (95% CI)Weight (%)
Custom splint
Study or subgroup
0.07 (– 0.52 to 0.66)
– 0.56 (– 1.38 to 0.26)
– 0.14 (– 0.51 to 0.24)
– 0.14 (– 0.44 to 0.15)
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Favours custom splint Favours prefabricated splint
FIGURE 8 Custom splint vs. prefabricated splint: pain – any combinable scale (higher =more pain), 0–3 months. Risk of bias: A, random sequence generation (selection bias);
B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment (detection bias); E, incomplete outcome data
(attrition bias); F, selective reporting (reporting bias); and G, other bias. a, Assessed daily in a 1-week pain diary for the week prior to each assessment point using 0 to 100 (pain at rest);
b, current pain intensity 0 to 10 NRS converted to a 0 to 100 scale; c, CPI 0 to 10 converted to 0 to 100 scale – SD is median value from range of SDs reported in the paper.
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TABLE 12 Effect estimates for TMD pain: prefabricated splint vs. custom-made splint
Outcome
Number of studies
(n participants)
Effect estimate (95% CI)
(random effects)
p-value
for effect
estimate
Heterogeneity
χ2 p-value I2 (%)
Pain: any combinable scale (higher =more pain)
0–3 months (see Figure 8) 3 (178) SMD –0.14 (–0.44 to 0.15) 0.35; favours
custom splint
0.47 0
3–6 months (see Appendix 4,
Figure 36)
1 (37) SMD 0.71 (–9.12 to 10.55) 0.89; favours
prefabricated
N/A N/A
6–12 months (see Appendix 4,
Figure 37)
2 (153) SMD –0.18 (–0.50 to 0.14) 0.26; favours
custom splint
0.43 0
Pain: GCPS (incidence of grade III or IV)
0–3 months (see Appendix 4,
Figure 38)
1 (44) RR 1.64 (0.30 to 8.89) 0.56; favours
prefabricated
N/A N/A
3–6 months (see Appendix 4,
Figure 39)
2 (85) RR 1.48 (0.29 to 7.41) 0.64; favours
prefabricated
0.63 0
6–12 months (see Appendix 4,
Figure 40)
2 (82) RR 1.00 (0.03 to 33.30) 1.00 0.09 65
GCPS, Graded Chronic Pain Scale; N/A, not applicable.
TABLE 13 Effect estimates for TMD outcomes other than pain for custom-made splints vs. prefabricated splints
Outcome
Number of studies
(n participants)
Effect estimate (95% CI)
(random effects)
p-value
for effect
estimate
Heterogeneity
χ2 p-value I2 (%)
Change in restricted mouth-opening: maximum mouth-opening (mm)
0–3 months (see Appendix 4,
Figure 41)
2 (68) MD (mm) –4.47 (–15.07 to 6.13) 0.41 0.07 70
3–6 months (see Appendix 4,
Figure 42)
1 (37) MD (mm) –1.00 (–6.74 to 4.74) 0.73 N/A N/A
6–12 months (see Appendix 4,
Figure 43)
1 (33) MD (mm) –1.00 (–7.82 to 5.82) 0.77 N/A N/A
Quality of life: SCL-90-R – depression, 0–4 (higher =worse)
0–3 months (see Appendix 4,
Figure 44)
1 (44) MD –0.03 (–0.53 to 0.46) 0.89 N/A N/A
3–6 months (see Appendix 4,
Figure 45)
2 (89) MD 0.04 (–0.31 to 0.39) 0.83 0.22 35
6–12 months (see Appendix 4,
Figure 46)
2 (82) MD 0.11 (–0.54 to 0.75) 0.75 0.95 0
Quality of life: SCL-90-R – non-specific physical symptoms, 0–4 (higher =worse)
0–3 months (see Appendix 4,
Figure 47)
1 (44) MD –0.02 (–0.50 to 0.46) 0.93 N/A N/A
3–6 months (see Appendix 4,
Figure 48)
2 (89) MD –0.07 (–0.47 to 0.33) 0.73 0.17 48
6–12 months (see Appendix 4,
Figure 49)
2 (82) MD 0.17 (–0.14 to 0.49) 0.29 0.34 0
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Patient and public involvement
Three people (Mrs Coldrick, Mrs Lear and Mrs Palmer) who wear oral splints for TMD and/or bruxism
agreed to be involved in our research to provide a patient perspective. At the stage of writing the protocol
for the effectiveness review, we wanted to find out what questions and outcomes were important to them.
Two patients identified pain relief as the most important outcome and found relief within 7–10 days of
wearing the first splint. However, there was a discrepancy with regard to the ease of using the splint.
These comments helped to assure us that the outcomes to be measured in the review and how they were
measured were appropriate and that we had not missed specifying any important outcomes in the protocol.
Members of the patient advisory group provided feedback on the Plain English summary that had been
written by Ruth Floate, and agreed the final version.
TABLE 13 Effect estimates for TMD outcomes other than pain for custom-made splints vs. prefabricated splints
(continued )
Outcome
Number of studies
(n participants)
Effect estimate (95% CI)
(random effects)
p-value
for effect
estimate
Heterogeneity
χ2 p-value I2 (%)
Adherence to treatment: use of appliance for several nights per week or more
0–3 months (see Appendix 4,
Figure 50)
2 (109) RR 0.99 (0.91 to 1.08) 0.84 0.38 0
3–6 months (see Appendix 4,
Figure 51)
1 (37) RR 1.02 (0.71 to 1.47) 0.92 N/A N/A
6–12 months (see Appendix 4,
Figure 52)
1 (33) RR 1.09 (0.65 to 1.82) 0.74 N/A N/A
N/A, not applicable.
TABLE 14 Prefabricated splints provided to patients with bruxism vs. custom-made splints
Outcomes
Illustrative comparative risks
(95% CI)
Number of
participants
(n studies)
Quality of the
evidence (GRADE) Comments
Assumed
risk
Corresponding
risk
No splint Oral splint
Tooth wear No studies looked at tooth wear
Pain No studies looked at pain
Bruxism time index (% of time
spent bruxing)
No studies looked at bruxism time
Episodes of bruxism per hour No studies looked at episodes of bruxism
Quality of life No studies reported quality of life
Adverse events No studies reported adverse events
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Chapter 4 Assessment of cost-effectiveness
Overview of the principles of economic evaluations
Highly constrained public funding for health means that health-care resources are scarce. Economic
evaluation is a useful tool that compares the relative costs and benefits of different health-care
interventions. It is widely used by health-care decision-makers to assess whether or not new
interventions generate value for money.
The most common framework of economic evaluation is cost–utility analysis (CUA). In a CUA, health-care
benefits are measured in terms of quality-adjusted life-years (QALYs). QALYs combine an individual’s
length of life with the quality (utility) of those life-years. The additional costs of an intervention are
compared with the additional QALYs gained to generate an incremental cost-effectiveness ratio (ICER).
In the UK, an intervention is typically considered cost-effective if the ICER is < £20,000 to £30,000 per
QALY gained. Interventions that are more costly and less effective than the comparator are dominated,
whereas interventions that are cost-saving and also more effective are dominant. Decision modelling is
often used to extrapolate trial results over the longer term to ensure that the economic evaluation
captures all the costs and consequences of importance.
Systematic review of economic evaluations
This section reports the findings of cost-effectiveness studies comparing (1) splints versus no splints or
(2) prefabricated splints versus custom-made splints for patients with orofacial signs or symptoms,
presenting with either TMD or bruxism (tooth grinding).
Review methods
This section provides detailed methods used for the search strategy, inclusion criteria and exclusion
criteria.
Search strategy
Literature searches were conducted in four databases: MEDLINE via OvidSP (including Epub Ahead Of
Print, pre-indexed, etc.), EMBASE via OvidSP, NHS Economic Evaluation Database (NHS EED) and CINAHL
via EBSCOhost. The initial search was conducted in October 2017. The detailed search strategy is provided
in Appendix 1. Table 15 includes a summary of the studies retrieved from each database. The searches
TABLE 15 Economic evaluation search strategy results
Database Version/issue Date of search Records retrieved (n)
MEDLINE via OvidSP (including Epub
Ahead Of Print, pre-indexed, etc.)
1946 to 1 October 2018 1 October 2018 19 (with filter)
EMBASE via OvidSP 1980 to 1 October 2018 1 October 2018 13 (with filter)
NHS EED To issue 1, 2016 (database
discontinued after this date)
1 October 2018 0
CINAHL via EBSCOhost 1937 to 1 October 2018 1 October 2018 14
Notes
Total references retrieved from electronic searches for this review: n = 46.
Total references left after deduplication for this review: n = 38.
Total sent to authors for this search: n= 38.
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were updated on 1 October 2018, to ensure that more recent studies were considered for inclusion prior
to publication. The update search did not identify any additional cost-effectiveness records.
Inclusion and exclusion criteria
Study inclusion and exclusion criteria regarding types of participants and types of interventions
were identical to those specified for the clinical effectiveness review (see Chapter 3, Review methods).
Studies were included only if they could be classified as full economic evaluations with a comparative
analysis of costs and outcomes using any of the following frameworks: cost-effectiveness, cost–utility,
cost–benefit or cost minimisation. Economic evaluations of any design, including evaluations alongside
single effectiveness studies and decision-analysis models, were all deemed eligible for inclusion. Partial
economic evaluations (i.e. studies that did not explicitly compare costs and outcomes of two or more
treatments), review articles, cost-of-illness studies and methodological studies were all excluded.
Data extraction strategy
All titles and abstracts identified from the literature search were assessed against the inclusion and
exclusion criteria by one health economist (EJ). All full texts were also assessed against the inclusion and
exclusion criteria, with a second health economist (DB) checking the inclusion of each study. Disagreements
were addressed through mutual consensus. The plan for data extraction was for one health economist (EJ)
to conduct the data extraction and quality assess the studies against standardised checklists for economic
evaluations alongside trials (using the Drummond checklist82) and for economic models (using the Philips
checklist83).
Review results
The number of studies identified from the database searches is provided in Figure 9.
Duplicates excluded
(n = 8)
Excluded
(n = 29)
Included
(n = 0)
Selected for full-text
screening
(n = 9)
Excluded
(n = 9)
Total studies
identified from
primary search
(n = 38)
References retrieved
from electronic
searches
(n = 46)
• Not a full economic evaluation, n = 7
• Not evaluating splints as treatment for TMD/bruxism, n = 2
FIGURE 9 Flow diagram for the identification of studies (cost-effectiveness).
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A total of 38 studies were identified from the literature searches. After screening titles and abstracts,
29 studies (76%) were excluded as they did not include an economic evaluation. Full-text versions
were obtained for 9 studies (24%),11,84–91 but none were included in the review because (1) they did
not conduct a formal economic evaluation (n = 7 studies) or (2) they did not evaluate splints for the
treatment of orofacial signs or symptoms (n = 2).
Economic analysis methods
Introduction
As there was no evidence available from the systematic review to inform the cost-effectiveness of
splints, or different types of splints for patients with orofacial signs and symptoms with TMD or bruxism,
it was decided to develop a de novo decision-analysis model to answer the research question.
The overall project aim was to assess the cost-effectiveness of splints for orofacial signs and symptoms.
From the outset, TMD and bruxism were considered as distinct entities that required different economic
models to evaluate. However, as highlighted in Chapter 3, there is insufficient evidence regarding the
effects of splints to populate a meaningfully structured model for bruxism, and the limited data that do
exist cannot readily be translated into meaningful, patient-relevant health states. However, in consultation
with clinical expert opinion, we propose an outline structure of a Markov cohort state-transition decision-
analysis model that might be used in the future if more data become available. The suggested structure,
provided in Appendix 5, might be used to guide the data collection in future research studies that could be
used to help inform the cost-effectiveness of splints for treating bruxism.
Given the lack of data, this chapter focuses solely on the model developed to determine the
cost-effectiveness of splints for treating TMD. The economic analysis first seeks to determine the
cost-effectiveness of all splints compared with none (as defined in Chapter 3) for treating TMD and to
determine if sufficient data exist to determine the most cost-effective form of splints by comparing
custom-made with prefabricated splints. It is important to note from the outset that the clinical
effectiveness evidence base is limited and these uncertainties inevitably translate into the economic
model. The cost-effectiveness results should, therefore, be considered as exploratory in nature. The model
is, however, informative in determining the key parameters that drive the cost-effectiveness results, and
importantly, value-of-information (VOI) analysis is conducted to steer the future research agenda to
minimise decision uncertainty.
Model structure
A Markov cohort state-transition model was developed in TreeAge Pro (TreeAge Software Inc.,
Williamstown, MA, USA) to evaluate the cost-effectiveness of splints in patients with TMD. The
comparator was no splints. The model population was the adult population with TMD, with a starting
age of 25 years, which is a common age for symptoms of TMD to start, as the 18–35 years age group
are significantly more likely to experience first-onset persistent orofacial pain.92,93 The proportion of
the cohort that are male is taken from the Developing Effective and Efficient care pathways in chronic
Pain (DEEP) study (19.1% male).94 Figure 10 outlines the model structure.
The model simulated a cohort through the health states depicted in Figure 10. The health states include
pain tertiles, ‘low pain’, ‘moderate pain’ and ‘high pain’, and ‘death’. The health states defined using a NRS
of pain intensity (from 0 to 10) in which low-intensity pain was definied as a NRS score of 0–3, moderate
pain was defined as a NRS score of 4–6 and high-intensity pain was defined as a NRS score of 7–10.
The preferred instrument to measure the impact of TMD is the Graded Chronic Pain Scale (GCPS),
of which the CPI scale is a subcomponent. GCPS is preferable because it incorporates both the pain
intensity and disability associated with TMD.95 However, there was insufficient evidence comparing the
use of splints with no splints in relation to the GCPS; therefore, it was not possible to parameterise the
model using the preferred measure of treatment effect. In the absence of sufficient clinical effectiveness
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data to structure a model around GCPS, it was felt that pain tertiles provided the most feasible and
practical balance between a meaningful structure to capture the potential impact of treatment on
outcomes (pain) that could be populated using clinical effectiveness data, as well as cost and utility
data from the DEEP cohort study. The state classification was chosen for practicality, but future
research should aim to collect sufficient data to populate a TMD model structured around GCPS.
The economic model has therefore been designed to allow population of the health states (transition
probabilities, effect sizes, costs and utilities) using two alternative definitions of pain (CPI and current
pain intensity). CPI is a combination of three factors measuring current pain, average pain (in the
previous 6 months) and worst pain intensity (in the previous 6 months) using a NRS, with the final
score based on an average of the three domains. Current pain intensity asks patients to report their
present pain state, on, for example, a NRS or VAS.
The proportion of the cohort entering the model in each of the pain states is determined by the
corresponding proportions from the DEEP study cohort. Using a pain definition of ‘current pain’, 34%,
34% and 32% enter the cohort in low, moderate and high states, respectively. For pain defined as CPI,
the corresponding proportions are 41%, 27% and 31%, respectively.
At the end of each 3-monthly model cycle, a proportion of the cohort move between pain states. A
proportion of the cohort are also assumed to die in the model following age- and sex-adjusted general
population all-cause mortality rates.96 The cycle length defines the fixed period of time, at which point
the cohort is introduced to a new set of transition probabilities, costs and utilities. The model estimates
the accumulated costs and QALYs using a UK NHS perspective, over an 85-year time horizon in the
base case, running for 340 (3-monthly) cycles in the base case up until a maximum of age 110 years
to reflect all the costs and outcomes associated with pain states over a lifetime horizon. Half-cycle
corrections were applied to the costs and outcomes, to reflect that, on average, events occur in the
middle of a cycle rather than at the start or end of a cycle. Costs and QALYs occurring into the future
are discounted at a rate of 3.5% per annum, as recommended by the National Institute for Health and
Care Excellence (NICE) in England and Wales.97
Death
4
Moderate pain
2
Low pain
1
High pain
3
Pain scale
ModerateLow High
100
FIGURE 10 State-transition diagram and pain NRS.
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Model parameters
The model was populated using best-available data on transition probabilities, costs, utilities and clinical
treatment effects. Clinical treatment effects were estimated as MDs using random-effects meta-analysis
of studies included in the clinical effectiveness review (see Chapter 3) to obtain MDs between splints
and no splints at 3, 6 and 12 months. Longer-term effect size estimates were unavailable, or insufficient
for populating the model. The transition probabilities, costs and utilities were sourced from a reanalysis
of the DEEP study data. The DEEP study was an observational study in the UK, including 35 dental and
medical practices, with a total of 198 patients.94,98,99 The cohort was followed up over a 2-year period.
The reanalysis, performed and provided by the DEEP study chief investigator (Professor Durham) was
tailored to provide model parameter estimates (transition probabilities, costs and utilities) applicable
for a population of the desired model health states. DEEP study data are the most appropriate source of
model parameter estimates, being the largest available cohort, with the longest follow-up and from a
UK perspective.
Transition probabilities
Table 16 illustrates the transition probabilities used to populate the model, obtained from the DEEP
study for tertiles (low, moderate and high) of both current pain and CPI. Transition probabilities are
incorporated probabilistically in the model using beta distributions, with alpha and beta distribution
parameters obtained using the method of moments approach.100 Alpha is the number of individuals that
transition between states in the DEEP study in a given 6-monthly time frame (0–6 months, 6–12 months,
12–18 months and 18–24 months) and beta is given as the total sample minus alpha. For example,
the total number of individuals starting in the lowest tertile for the 0- to 6-month time period was 26
(and 26 individuals started with moderate pain and 24 with high pain). Six-monthly probabilities were
converted to 3-monthly cycle-specific probabilities using Equation 1:101
1− exp − −
LN(1−6-monthly transition probability)
Time to be converted from
Time to be converted to
0
B@
1
CA
2
64
3
75, (1)
where the time to be converted from is 6 months (0.5 years) and the time to be converted to is 3 months
(0.25 years). The approach was implemented in TreeAge, using the inbuilt ‘probtoprob’ function.
Transition probabilities for TMD patients beyond 24 months are unknown; therefore, assumptions
must be made about how the cohort will progress through pain states in the longer term. Two options
were considered and discussed with clinical experts. The first assumes that, for the duration of the
model, the distribution of the cohort across pain states does not change further over time, with the
cohort remaining in the modelled health state at 2 years for the duration of the model until death
(all-cause mortality rates). The second assumption is that the transitions observed between 18 and
24 months from the DEEP study continue until the whole cohort transits to a single pain health state
or dies. Both assumptions are surrounded by considerable uncertainty, and both are considered equally
plausible. To incorporate this structural uncertainty in the model-based cost-effectiveness outputs,
a switch is incorporated in the model, which is sampled probabilistically from a uniform distribution,
where switch = 1 means the cohort remain in their current state and switch = 2 means the cohort
transition according to the DEEP study data. The switch is sampled at the start of each model stage
following cycle 8 (2 years). The approach taken means that, in each model stage, either approach to
estimating long-term state transitions is equally probable.
Treatment effects
Existing evidence identified from the clinical effectiveness review was used to inform the relative
treatment effects of splints compared with no splints. Relative treatment effects are incorporated in
the model as MDs on the VAS/NRS scale. MDs are estimated at 3 and 6 months for current pain and
at 3, 6 and 12 months for CPI, using random-effects meta-analysis of studies included in the systematic
DOI: 10.3310/hta24070 Health Technology Assessment 2020 Vol. 24 No. 7
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Riley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
47
review of clinical effectiveness. Further details regarding the studies included in these meta-analyses
are provided in the sensitivity analysis section of the clinical effectiveness review (see Chapter 3). MDs
are sampled probabilistically in the economic model from a normal distribution with standard error
(SD of the sampling distribution) calculated as [(CI high – CI low) ÷ 2 × 1.96]. MD data used to populate
each of the model effect sizes are summarised in Table 17.
TABLE 16 Transition probabilities used in the model
Transition probabilities
Current pain intensity CPI
Probability at
3 months (%) Alpha Beta
Probability at
3 months (%) Alpha Beta
0–6 months
Low to high 4 2 24 7 4 25
Low to moderate 24 11 15 7 4 25
Moderate to high 10 5 21 15 5 17
Moderate to low 6 3 23 15 6 16
High to moderate 13 6 18 15 7 18
High to low 2 1 23 4 2 23
6–12 months
Low to high 0 0 17 0 0 29
Low to moderate 31 9 8 19 10 19
Moderate to high 8 5 29 14 5 14
Moderate to low 16 10 24 8 3 16
High to moderate 14 5 14 15 6 16
High to low 3 1 18 2 1 21
12–18 months
Low to high 3 1 15 0 0 20
Low to moderate 17 5 11 13 5 15
Moderate to high 13 7 22 19 8 15
Moderate to low 11 6 23 9 4 19
High to moderate 18 6 12 13 5 15
High to low 0 0 18 0 0 20
18–24 months
Low to high 3 1 14 0 0 17
Low to moderate 7 2 13 3 1 16
Moderate to high 17 8 18 7 3 18
Moderate to low 17 8 18 18 7 14
High to moderate 14 5 14 23 9 13
High to low 11 4 15 2 1 21
Note
Low, moderate and high refers to the health states ‘low pain’, ‘moderate pain’ and ‘high pain’, respectively.
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The long-term effect size of splints versus no splints beyond 6 months is highly uncertain. A number
of assumptions are thus required to populate the model over the longer term. The first assumption is
that the MD in current pain at 12 months equals the MD at 6 months, namely there is no difference
between the MD score at 6 months and 12 months. This assumption reflects the lack of adequate-
quality data from the systematic review to populate the model. No data exist to inform the long-term
impact of splints on any pain measure beyond 12 months; therefore, further assumptions are required.
Two possible scenarios are considered: (1) the MD beyond 12 months is zero and (2) the MD in the
longer term is the same as the MD at 6 months. These assumptions represent lower (pessimistic) and
upper (optimistic) bounds on the long-term effect of splints on pain. To incorporate this structural
uncertainty, the model includes a switch, sampled probabilistically at each model stage, from a uniform
distribution, to allow an equal chance of either assumption being applied in the model.
Mean difference data cannot be incorporated directly in the model structure when health states are
defined as pain tertiles. An algorithm was therefore developed to infer an approximated relative risk of
each possible transition (low to moderate, low to high, moderate to low, moderate to high, high to low
and high to moderate) based on the sampled MD data. First, transition probability data (by tertile) from
the DEEP study were summarised for each possible state transition. Second, all possible MDs (ranging
from –10 to 10) were converted to plausible transitions. For example, a MD of 0 had a 0% probability
of changing state, whereas a MD of –10 had a 100% chance of moving to the low-pain state, regardless
of the starting point. This process was repeated for the impact of each MD (ranging from –10 to 10)
on all possible transitions between tertiles, accounting for the ceiling and floor effects of the scale.
All possible transitions, by MD, are reported in Table 18.
To obtain an assumption of the relative risk, these inferred transitions were divided through by the
transition probabilities from the DEEP study cohort to obtain an approximation of the relative risk by
MD. For example, using our approach, with a MD in pain of –3, the splints cohort is more likely to
move to a better health state than the comparator group (represented by the DEEP study cohort).
Those that are already in the ‘low pain’ health state will remain in that health state, accounting for the
floor effects of the scale. Those in the ‘moderate pain’ health state are more likely to move to a better
health state (‘low pain’) than remain in the moderate pain health state. Those in the ‘high pain’ health
state are more likely to move to a better health state (‘moderate pain’) than remain in the high-pain
health state.
The approach taken should be interpreted with caution, as it does not directly incorporate relative risk
estimates. Future research is required to obtain effect size estimates (i.e. relative risks) that are more
amenable for use in populating decision-analysis models structured around different pain states in TMD.
Mortality parameters
General population all-cause mortality risks (adjusted for age and sex) were applied in the model,
obtained from UK lifetables.96 There is no evidence to suggest an added mortality risk to those with
TMD; therefore, no excess mortality is applied to either arm of the model.
TABLE 17 Mean differences in current pain and CPI used to populate the economic model
Time point (months) Current pain, MD (95% CI) CPI, MD (95% CI)
3 –0.448 (–1.159 to 0.264) –0.074 (–1.176 to 0.672)
6 –0.343 (–1.177 to 0.490) 0.520 (–0.062 to 1.102)
12 N/A 0.006 (–0.664 to 0.676)
NA, not available.
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TABLE 18 Plausible state transitions (splints) for alternative MD values
MD p (low to low)
p (low to
moderate) p (low to high)
p (moderate
to low)
p (moderate to
moderate)
p (moderate
to high) p (high to low)
p (high to
moderate) p (high to high)
–10 1 0 0 1 0 0 1 0 0
–9 1 0 0 1 0 0 1 0 0
–8 1 0 0 1 0 0 1 0 0
–7 1 0 0 1 0 0 1 0 0
–6 1 0 0 1 0 0 0.60 0.40 0
–5 1 0 0 1 0 0 0.33 0.67 0
–4 1 0 0 1 0 0 0.14 0.86 0
–3 1 0 0 0.75 0.25 0 0 0.75 0.25
–2 1 0 0 0.44 0.56 0 0 0.44 0.56
–1 1 0 0 0.20 0.80 0 0 0.2 0.80
0 1 0 0 0 1 0 0 0 1
1 0.80 0.20 0 0 0.80 0.20 0 0 1
2 0.56 0.44 0 0 0.56 0.44 0 0 1
3 0.25 0.75 0 0 0.25 0.75 0 0 1
4 0 0.86 0.14 0 0 1 0 0 1
5 0 0.67 0.33 0 0 1 0 0 1
6 0 0.40 0.60 0 0 1 0 0 1
7 0 0 1 0 0 1 0 0 1
8 0 0 1 0 0 1 0 0 1
9 0 0 1 0 0 1 0 0 1
10 0 0 1 0 0 1 0 0 1
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Utilities and quality-adjusted life-years
Health-state utilities, by pain tertile, for both CPI and current pain definitions, were obtained from
a reanalysis of the DEEP study,94 conducted specifically for this project. An average utility value for
each pain tertile was calculated using the generalised estimating equation approach, using Stata®
version 13.1 software (StataCorp LP, College Station, TX, USA).
Those in the low-pain state had the highest utility value, and those in the high-pain state had the
lowest utility value. Utilities are incorporated in the model probabilistically, using beta distributions.
The mean and SD (of the sampling distribution) of utilities by health state are listed in Table 19,
rounded to the nearest two decimals.
The utility values obtained from the DEEP study were based on a generic EuroQol-5 Dimensions,
five-level version, (EQ-5D-5L) quality-of-life measurement, with corresponding utility values obtained
using an interim scoring approach to map between the EQ-5D-5L and the EuroQol-5 Dimensions,
three-level version (EQ-5D-3L).102 The EQ-5D-5L questionnaire includes five dimensions of quality of
life (mobility, self-care, usual activities, anxiety/depression and pain/discomfort), each with five levels of
impact (ranging from no problems to extreme problems). All utilities used in the model were age- and
sex-adjusted for UK general population norms.103
Intervention costs
All model costs are reported in 2016 Great British pounds. Intervention costs are calculated using the
payment system for dentistry used in England and Wales. Every treatment in primary care dentistry is
categorised into one of three treatment bands. Each treatment band is associated with a predefined
number of units of dental activity (UDAs), where more UDAs reflect more complex treatments. UDAs
are assigned to treatment bands as follows: band 1 (1 UDA), band 2 (3 UDAs) and band 3 (12 UDAs).
Each UDA is associated with a value, with the values of each UDA varying across dental practices.
Currently, the average UDA value in England is approximately £25.104,105 An alternative estimate of the
UDA value can be obtained from data published by the NHS Business Services Authority for general
dental services contracts across dental practices with contracts to provide services on behalf of NHS
England. Using this approach, the mean UDA value was £26.74, with a SD across practices of £18.94.106
Using this alternative approach, it is possible to include the value of a UDA probabilistically in the model.
In the UK, patients pay a proportion of the UDA value (approximately 80% of the treatment value),
unless they are exempt from payment charges (e.g. low income), in which case the full treatment
value is paid for by the NHS. The cost to the NHS of each treatment band therefore depends on the
proportion of patients exempt from charges. The following formula was used to calculate the average
cost to the NHS of a band 1, 2 or 3 course of treatment:
NHS cost = ½((treatment value−patient charge) × proportion eligible to pay)
+ (treatment value × (1−proportion eligible to pay)). (2)
Table 20 includes the inputs to the formula for the calculation of the band 1 to 3 courses of treatment.
TABLE 19 Health-state utilities
Health state (pain tertile)
Current pain CPI
Mean (SD)a Alpha Beta Mean (SD)a Alpha Beta
Low 0.782 (0.004) 8737 2439 0.770 (0.005) 6241 1863
Moderate 0.682 (0.004) 7591 3535 0.709 (0.004) 8294 3397
High 0.596 (0.005) 6747 4565 0.601 (0.005) 6285 4181
a SD of the sampling distribution, equivalent to the standard error of the source data.
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Splints can be custom made or prefabricated. Custom-made splints are typically provided as a band 3
treatment charge on the NHS in England, while prefabricated splints are likely to be charged as a band
2 service because less resources are required to make the splints. The cost of splints included in the
model is an average of the two types, weighted by the proportion of patients receiving each splint type
in the clinical effectiveness review.
Of those studies that used current pain as their primary outcome, 91% reported using custom-made
splints. Of those studies that used CPI as their primary outcome, 75% reported using custom-made
splints. The weighted average approach taken ensures that the distribution of splint type used for the
costing is congruent with that used to generate the treatment effect estimates used in the model.
A sensitivity analysis explores the impact of alternative assumptions on the results.
The cost of replacing a splint was assumed to be the same as the cost of providing an initial splint.
However, there was substantial uncertainty among the clinical expert advisors as to the most probable
frequency of splint replacement, and whether or not this would differ by custom-made or prefabricated
splint. Expert opinion suggested that splints would be replaced, on average, every 2–5 years, but in
some cases patients may use a splint for up to 20 years. To incorporate this uncertainty in the model,
three alternative values were considered based on expert opinion: every 2 years, every 5 years and
every 20 years. These values were sampled from a log-normal distribution with mean = replacement
every 9 years, and median = replacement every 5 years. It is clear that clinical expert opinion regarding
the frequency of replacement varied widely among the project advisory group. Therefore, further
deterministic analyses are considered in sensitivity analyses to explore the impact of the following
alternative assumptions on the cost-effectiveness results: (1) no replacement, (2) 2-yearly replacement,
(3) 5-yearly replacement and (4) 20-yearly replacement.
Health-state costs
Health-state costs were obtained from the DEEP study and include the cost of resources consumed in
both the dental and general health-care budgets. Costs include contact with all health professionals
(dental and general) for dental-related problems. Drug costs are also incorporated. Full details of the
costing methodology are reported in the DEEP study.98,99 For the purposes of this economic analysis,
the cost of splints was excluded from the analysis to avoid a risk of double-counting. To estimate
the health-care costs by health state (‘low pain’, ‘moderate pain’ and ‘high pain’), a regression analysis
was conducted using Stata. As was done with the utilities, an average cost for each pain tertile was
estimated using the generalised estimating equation approach separately for tertile of current pain and
CPI. All costs from the DEEP study are reported in 2012 values, and have therefore been updated to
2016/17 values using the Cochrane and Campbell online tool.108 The estimated means and SDs of the
sampling distribution for health-care costs are provided in Table 21. Cost data provided reflect total
costs (excluding splint provision costs) by health state of the 2-year follow-up period of the DEEP
study. These costs are converted to 3-monthly cycle-specific costs and are sampled probabilistically
from gamma distributions for inclusion in the model.
TABLE 20 Payment for dental care in England and Wales
NHS band
treatment UDA
Treatment
value (£)
Patient charge
(2016) (£)
Paying
adults (%) Sources
1 1 25 19.70 82 NHS Dental Statistics for England –
2016–17107
2 3 75 53.90 69
3 12 300 233.70 49
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Assessment of cost-effectiveness
A CUA was conducted using QALYs as the measure of benefits. The results presented are over the
lifetime of the simulated cohort (with a starting age of 25 years in the base case). The model is fully
probabilistic, with model outputs calculated using Monte Carlo simulation with 1000 repetitions,
sampling from distributions for transition probabilities, MDs, utilities and costs as described in
Tables 16, 17, 19 and 21, respectively. The probabilistic analysis is advantageous because it varies
all parameters simultaneously. Model results are reported as expected values of costs and QALYs
over the modelled time horizon. An incremental comparison of costs and QALYs between splints
and no splints is reported and ICERs are calculated as the MD in costs divided by the MD in QALYs.
The ICER is then compared with a commonly used cost per QALY threshold recommended by NICE.97
If the ICER is within the desired range (£20,000–30,000, or below), an intervention would generally
be considered cost-effective. However, in all cases, determination of cost-effectiveness must also
consider the variability around the point estimates of incremental costs, incremental QALYs and, hence,
the ICER. Consideration of such uncertainty is important to determine if current evidence is sufficient
for decision-making, and if decision-makers can be confident that the ICER is likely to fall below
commonly accepted threshold values.
As all models are run probabilistically, it is possible to determine the probability of cost-effectiveness
at threshold values of willingness to pay (WTP) for a QALY gained (e.g. £20,000 per QALY) for each
scenario analysis. Uncertainty in the base-case results is also illustrated using scatterplots of the
cost-effectiveness plan and cost-effectiveness acceptability curves (CEACs). Scatterplots and CEACs
are particularly informative as they demonstrate the uncertainty arising due to the combined statistical
variability in all the models’ parameter inputs. The CEAC shows the probability that splints or no splints
are the most efficient use of resources at difference threshold values of society’s WTP for a QALY gain.
A range of scenario analyses were also conducted to account for structural and methodological
uncertainty as well as heterogeneity. In economic models, some structural assumptions are made that
come with some uncertainty. An example of this would be to vary the time horizon or vary the frequency
at which individuals are assumed to replace their splints. There is also uncertainty surrounding the
methods that could be used in the model. For example, there are uncertainties regarding the discount
rates that should be applied to costs and benefits. The results from the analysis might be subject to
heterogeneity. To account for heterogeneity, conducting the analysis in, for example, different age groups
would be beneficial. All sensitivity and scenario analyses are listed in Table 22. It should be noted that
all analyses, including the base-case and scenario analyses, are reported for different definitions of pain
(current and CPI).
Value-of-information analysis
Value-of-information analysis is a useful tool for identifying what contributes to the decision uncertainty
in the model. The expected value of perfect information (EVPI) is the difference between the expected
value with perfect information and the expected value with current information, and can be used to
determine whether or not future research to resolve current decision uncertainty is a worthwhile
TABLE 21 Health-state costs
Health state
Current pain CPI
Mean (SD)a (£) Alpha Lambdab Mean (SD)a (£) Alpha Lambdab
Low pain 345.43 (10.10) 1303 3.57 332.70 (11.20) 983 2.80
Moderate pain 519.17 (12.27) 1995 3.64 479.80 (11.40) 1974 3.90
High pain 675.41 (13.45) 2810 3.94 697.63 (13.19) 3117 4.23
a SD of the sampling distribution, equivalent to the standard error of the source data.
b Note that TreeAge Pro software parameterises the gamma distribution using lambda, equivalent to 1/beta.
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TABLE 22 Scenario and sensitivity analyses conducted
Assumption/model
parameter Base-case assumption
Alternative assumption in
scenario analysis Justification
Definition of pain Current pain and CPI definitions considered as a joint
base-case analysis
A joint base case is provided
for current pain and CPI.
Although CPI is the preferred
measure (as part of the GCPS),
data to populate effect sizes
are more complete for current
pain, and based on a greater
number of studies
Cohort starting age 25 years Alternative starting ages of
40 and 56 years
Age varied to reflect alternative
ages at TMD onset and
presentation for treatment with
splints (informed by the project
advisory group)
Discount rate for
costs and QALYs
3.5% Vary between 0% and 6% Recommended variation of
discount rate according to
NICE methods for technology
appraisal97
Modelled time
horizon
85 years 2, 10, 20 and 30 years The base case reflects
best-practice methods to
incorporate all the possible
costs and benefits over a
lifetime. However, long-term
uncertainty is extensive;
therefore, shorter time
horizons could be expected
to yield better estimates of
cost-effectiveness
Splint replacement Frequency of splint
replacement based on wide
variation in expert opinion
(0, 2, 5 and 20 years),
sampled probabilistically
Scenarios include no
replacement, replacement
every 2, 5 and 20 years
There is likely to be substantial
heterogeneity across the TMD
population with regards to how
often splints are replaced. This
sensitivity analysis explores a
range of assumptions, discussed
with the project advisory board,
and is based on clinical and
patient expert opinion
Cost of splints Weighted average of
custom-made and
prefabricated splints using
current estimated banding
Assuming all splints are
(1) band 1, (2) band 2 and
(3) band 3 treatment
Reflects uncertainty in the
current banding system for
payment that is not necessarily
based on the opportunity cost
of time and resource use
required for different splint
treatments
Long-term MD
(beyond 12 months)
Assumes equal likelihood of
(1) long-term MD of 0 and
(2) long-term MD=MD at
12 months
Varies the assumption
between long-term MD = 0
and long-term MD =MD at
12 months
Long-term MD data do not
exist, but are an important
driver of cost-effectiveness.
Clinical expert opinion
considered each scenario
equally probable
Long-term
transition
probabilities
Assumes equal likelihood
that transition probabilities
beyond the DEEP study
cohort time horizon
(2 years) are (1) zero and
(2) equal to the transitions
between 18 and 24 months
Varies the assumption
between long-term
probabilities equal to zero
and equal to transitions
between 18 and 24 months
Long-term transition probability
data do not exist beyond the
2-year follow-up of the DEEP
study cohort. However, they
are an important driver of
cost-effectiveness. Clinical
expert opinion considered each
scenario equally probable
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investment. The EVPI is calculated using the net monetary benefit (NMB). The NMB is calculated from
the results of the probabilistic analysis. The intervention with the highest NMB is the most cost-effective
intervention. The EVPI is the maximum NMB of each iteration from the Probabilistic Sensitivity Analysis,
averaged:109
NMB(i, θ) = λ × Effect(i, θ)−Cost(i, θ), (3)
where λ = threshold, and
EVPI = Expectedθ MaximumiNMB(i, θ)−MaximumiExpectedθNMB(i, θ). (4)
The population EVPI is the value of doing further research in the population of interest, namely
those who would benefit from the intervention, for example the value of conducting further research
on the relative effectiveness of splints compared with no splints in the TMD population in the UK.
The expected value of perfect parameter information (EVPPI) estimates which parameters contribute to
the decision uncertainty. The EVPPI is conducted by taking an iteration from the Monte Carlo simulation
of a parameter in the outer loop and running the model for a defined number of simulations (e.g. 1000
runs), and repeating this exercise for all the parameter iterations from the probabilistic analysis.
To calculate the population EVPI, a number of assumptions were made both regarding the population
likely to benefit from the intervention and the lifetime of the health technology evaluated. The
population likely to benefit each year was assumed to be 2,311,407 (based on an annual prevalence
of examiner-verified TMD of 3.5% obtained from Slade,110 and a UK-wide population of approximately
66 million111). The expected lifetime of the technology was assumed to be 10 years, in line with typical
practice for the conduct of a VOI analysis, and the threshold value of WTP for a QALY gained was
assumed to be £20,000, in line with typical UK decision-making processes.97
The VOI analysis was conducted on the Sheffield Accelerated Value of Information (SAVI) application.112
If the EVPI is positive, further research might be worthwhile. If this is the case, EVPPIs would be
calculated to identify the source(s) of uncertainty in the results and the value of future research to
resolve decision uncertainty surrounding the most important drivers of cost-effectiveness results.
Cost-effectiveness results
Base-case results
The base-case analyses used either current pain as the measurement of pain intensity or CPI, because
the majority of included RCTs focused on current pain or CPI (see Chapter 3 for further details). Table 23
reports the base-case analysis for both current pain and CPI specifications of the model.
TABLE 23 Base-case cost-effectiveness results for splints vs. no splints
Intervention
Total
costs (£)
Incremental
costs (£)
Total
QALYs
Incremental
QALYs ICER (£)
Probability of cost-effectiveness
at different WTP thresholds (%)
£0 £20,000 £30,000
Current pain
No splints 6375 17.999 93.3 42.5 41.0
Splints 7463 1088 18.027 0.028 39,216 6.7 57.5 59.0
CPI
No splints 5681 18.575 97.3 70.9 66.8
Splints 6660 980 18.557 –0.018 Dominated 2.7 29.1 33.2
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The point estimate of the ICER indicates that splints are not cost-effective using a model structured
around current pain. Splints are less likely to be cost-effective using the CPI specification of the model,
in which, on average, splints appear to be more costly and less beneficial in terms of QALYs gained.
The unfavourable results for splints are driven by the point estimate of the MD for CPI at 6 months,
which non-significantly favours the no-splint group. However, these results should be interpreted with
caution and must be considered in the light of the very poor quality of the trials used to generate the
effect size estimates used in the model. The optimal strategy is highly uncertain and estimates of the
ICER should be considered as exploratory in nature.
For all analyses, considering the point estimates of the ICER in isolation may be misleading regarding
the true cost-effectiveness of splints using either definition of pain. It may be more appropriate to
consider the illustrations of cost-effectiveness provided by scatterplots of the cost-effectiveness plane
and CEACs, which more adequately characterise the substantial uncertainty surrounding the results.
Figures 11 and 12 illustrate the scatterplot of the cost-effectiveness plane and the CEACs, illustrating
the probability that each strategy (splints/no splints) is the most efficient use of resources at
alternative threshold values of society’s WTP for a QALY gained.
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FIGURE 11 Cost-effectiveness plane for splints vs. no splints (current pain specification).
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FIGURE 12 Cost-effectiveness acceptability curve for current pain specification.
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The scatterplot indicates a high level of uncertainty surrounding the incremental QALYs gained, driven by
uncertainty in the effect size for pain MDs identified in the review of clinical effectiveness (see Chapter 3).
The CEAC indicates substantial uncertainty regarding the optimal strategy, with probabilities of the
cost-effectiveness of splints never increasing above 60% at WTP threshold values of between £10,000
and £40,000 per QALY.
Figures 13 and 14 report similar data for the CPI specification of the model.
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FIGURE 13 Cost-effectiveness plane for splints vs. no splints (CPI specification).
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FIGURE 14 Cost-effectiveness acceptability curve for CPI specification.
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The scatterplot for CPI also indicates a high level of uncertainty surrounding the incremental QALYs
gained, again driven by uncertainty in the effect size from poor-quality studies regarding the MDs in
CPI between splints and no splints used to populate the model (see Chapter 3). Although the results
indicate a lower likelihood of splints being cost-effective using the CPI specification, it should be noted
that this is driven by the MD favouring no splints at 6 months. However, as discussed in Chapter 3,
Results of the systematic review, this finding should be interpreted with caution and in the light of the
poor methodological quality of the included studies in the clinical effectiveness review.
Scenario and sensitivity analyses
The base-case analysis should be interpreted with caution. A range of scenario and sensitivity analyses
have also been undertaken, the results of which are presented in Table 24 and serve to illustrate the wider
variation in the ICER depending on the assumptions applied in the model. All scenario and sensitivity
analyses were conducted probabilistically and report results for both current pain and CPI. These analyses
are informative in determining the key assumptions that drive the cost-effectiveness results.
TABLE 24 Sensitivity and scenario analyses
Intervention
Total
costs (£)
Incremental
costs (£)
Total
QALYs
Incremental
QALYs ICER (£)
Probability of cost-effectiveness at
difference WTP thresholds (%)
£0 £20,000 £30,000
Base case
Current pain
No splints 6375 17.999 93.3 42.5 41.0
Splints 7463 1088 18.027 0.028 39,216 6.7 57.5 59.0
CPI
No splints 5681 18.575 97.3 70.9 66.8
Splints 6660 980 18.557 –0.018 Dominated 2.7 29.1 33.2
Assume long-term MD beyond 12 months = 0 and long-term transition probabilities continue as per DEEP study
Current pain
No splints 6088 18.310 100.0 100.0 100.0
Splints 7849 1761 17.614 –0.697 Dominated 0.0 0.0 0.0
CPI
No splints 5054 19.115 100.0 76.1 70.4
Splints 6014 960 19.115 0.000 9,502,983 0.0 23.9 29.6
Assume long-term MD beyond 12 months =MD at 12 months and long-term transition probabilities continue as per
DEEP study
Current pain
No splints 6088 18.310 93.3 1.1 0.3
Splints 6893 805 18.645 0.334 2407 6.7 98.9 99.7
CPI
No splints 5054 19.115 100.0 85.3 80.2
Splints 6040 986 19.092 –0.023 Dominated 0.0 14.7 19.8
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TABLE 24 Sensitivity and scenario analyses (continued )
Intervention
Total
costs (£)
Incremental
costs (£)
Total
QALYs
Incremental
QALYs ICER (£)
Probability of cost-effectiveness at
difference WTP thresholds (%)
£0 £20,000 £30,000
Assume long-term MD beyond 12 months =MD at 12 months and long-term transition probabilities = 0
Current pain
No splints 6626 17.728 83.4 17.5 16.1
Splints 7394 768 18.102 0.374 2054 16.6 82.5 83.9
CPI
No splints 6243 18.092 95.4 61.8 59.4
Splints 7252 1009 18.047 –0.045 Dominated 4.6 38.2 40.6
Assume long-term MD beyond 12 months = 0 and long-term transition probabilities = 0
Current pain
No splints 6626 17.728 96.8 58.0 55.3
Splints 7730 1104 17.739 0.011 98,645 3.2 42.0 44.7
CPI
No splints 6243 18.092 96.7 59.6 56.9
Splints 7214 971 18.081 –0.011 Dominated 3.3 40.4 43.1
Starting age of cohort set to 40 years
Current pain
No splints 5670 15.247 94.4 42.5 41.0
Splints 6655 985 15.275 0.027 35,988 5.6 57.5 59.0
CPI
No splints 5059 15.731 98.0 70.6 66.6
Splints 5948 889 15.716 –0.016 Dominated 2.0 29.4 33.4
Starting age of cohort set to 56 years
Current pain
No splints 4524 11.394 95.5 42.4 41.4
Splints 5343 819 11.420 0.026 31,032 4.5 57.6 58.6
CPI
No splints 4049 11.749 98.4 70.4 67.1
Splints 4792 743 11.737 –0.012 Dominated 1.6 29.6 32.9
Discount rate of 0%
Current pain
No splints 14,658 39.733 86.4 42.8 41.6
Splints 16,953 2296 39.754 0.021 107,798 13.6 57.2 58.4
CPI
No splints 12,982 41.048 96.0 72.4 68.4
Splints 15,023 2040 41.010 –0.038 Dominated 4.0 27.6 31.6
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TABLE 24 Sensitivity and scenario analyses (continued )
Intervention
Total
costs (£)
Incremental
costs (£)
Total
QALYs
Incremental
QALYs ICER (£)
Probability of cost-effectiveness at
difference WTP thresholds (%)
£0 £20,000 £30,000
Discount rate of 6%
Current pain
No splints 4289 12.291 96.0 42.3 40.9
Splints 5077 788 12.320 0.029 27,437 4.0 57.7 59.1
CPI
No splints 3840 12.675 98.7 69.4 66.5
Splints 4555 715 12.662 –0.013 Dominated 1.3 30.6 33.5
Time horizon of 2 years
Current pain
No splints 539 1.459 100.0 38.2 31.4
Splints 825 285 1.482 0.022 12,787 0.0 61.8 68.6
CPI
No splints 513 1.490 100.0 74.1 67.7
Splints 778 264 1.489 –0.001 Dominated 0.0 25.9 32.3
Time horizon of 10 years
Current pain
No splints 2222 6.482 98.7 44.2 42.5
Splints 2708 486 6.509 0.027 18,275 1.3 55.8 57.5
CPI
No splints 2021 6.665 100.0 64.7 61.3
Splints 2463 442 6.662 –0.003 Dominated 0.0 35.3 38.7
Time horizon of 20 years
Current pain
No splints 3748 10.963 95.7 43.4 41.5
Splints 4451 703 10.989 0.026 26,700 4.3 56.6 58.5
CPI
No splints 3366 11.299 99.3 69.3 65.4
Splints 4005 640 11.288 –0.011 Dominated 0.7 30.7 34.6
Time horizon of 30 years
Current pain
No splints 4813 13.979 95.0 43.3 41.9
Splints 5674 861 14.004 0.026 33,212 5.0 56.7 58.1
CPI
No splints 4304 14.418 98.5 67.2 63.2
Splints 5078 774 14.407 –0.011 Dominated 1.5 32.8 36.8
Cost of splints and replacement set at band 3 charge
Current pain
No splints 6375 17.999 94.8 42.7 41.2
Splints 7548 1173 18.027 0.028 42,289 5.2 57.3 58.8
ASSESSMENT OF COST-EFFECTIVENESS
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TABLE 24 Sensitivity and scenario analyses (continued )
Intervention
Total
costs (£)
Incremental
costs (£)
Total
QALYs
Incremental
QALYs ICER (£)
Probability of cost-effectiveness at
difference WTP thresholds (%)
£0 £20,000 £30,000
CPI
No splints 5681 18.575 98.5 73.9 68.9
Splints 6897 1216 18.557 –0.018 Dominated 1.5 26.1 31.1
Cost of splints and replacement set at band 2 charge
Current pain
No splints 6375 17.999 56.9 40.1 40.0
Splints 6601 226 18.027 0.028 8139 43.1 59.9 60.0
CPI
No splints 5681 18.575 87.1 61.4 60.3
Splints 5950 269 18.557 –0.018 Dominated 12.9 38.6 39.7
Cost of splints and replacement set at band 1 charge
Current pain
No splints 6375 17.999 43.4 39.6 39.6
Splints 6413 38 18.027 0.028 1352 56.6 60.4 60.4
CPI
No splints 5681 18.575 73.4 57.9 57.4
Splints 5761 81 18.557 –0.018 Dominated 26.6 42.1 42.6
Replacing splints every 2 years
Current pain
No splints 6375 17.999 100.0 45.7 43.4
Splints 8903 2528 18.027 0.028 91,119 0.0 54.3 56.6
CPI
No splints 5681 18.575 100.0 83.0 78.1
Splints 7904 2223 18.557 –0.018 Dominated 0.0 17.0 21.9
Replacing splints every 5 years
Current pain
No splints 6375 17.999 99.5 42.0 41.3
Splints 7489 1114 18.027 0.028 40,156 0.5 58.0 58.7
CPI
No splints 5681 18.575 100.0 74.5 69.1
Splints 6683 1002 18.557 –0.018 Dominated 0.0 25.5 30.9
Replacing splints every 20 years
Current pain
No splints 6375 17.999 88.6 40.5 40.0
Splints 6790 415 18.027 0.028 14,951 11.4 59.5 60.0
continued
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The model results for the current pain configuration were most sensitive to varying structural assumptions
about the long-term MD and long-term transition probabilities. Assuming a long-term MD of zero, namely
that splints have no additional effectiveness beyond 1 year of usage, generates additional costs to the NHS
with mean QALY losses, and thus a very low probability of cost-effectiveness. However, assuming that the
MD observed at 6 months continues over a patient’s lifetime, splints would be a highly cost-effective use
of resources, with an ICER of just over £2000 per QALY gained. These analyses serve to illustrate the
sensitivity of the model to long-term assumptions about differences in pain, and highlight the need for
further research to adequately determine the appropriate long-term trajectory of the effectiveness of
splints. The CPI-configured model is also sensitive to this assumption, but less so given that the distribution
of the MD in CPI at 12 months is centred closer to zero. It should also be noted that extrapolation of MD
data to the longer term are based on poor-quality shorter-term MDs (at 3, 6 or 12 months), adding a
further layer of uncertainty to the results. It is imperative that high-quality data are obtained for MD in
pain related to TMD to generate more robust estimates of cost-effectiveness from the modelling analysis.
The model is also somewhat sensitive to assumptions around the costs of splints and the frequency of
splint replacement. There is substantial uncertainty over the actual banded change that might be applied
to splints, particularly for prefabricated splints, which could feasibly incur a band 1 or 2 charge, with
custom-made splints more likely to incur a band 2 or 3 charge. As anticipated, lower banding improves
the cost-effectiveness case for splints. Similarly, there was much uncertainty among the project’s clinical
advisors regarding the most probable frequency of splint replacement. This is an important driver of
incremental costs in the model, with more frequent replacement generating lower likelihoods of cost-
effectiveness. For the current pain configuration, the probability of cost-effectiveness (at £20,000 per
QALY) drops from 60% when never replaced to 54% when replaced every 2 years. The CPI results are
more sensitive to this assumption, decreasing from 40% to only 17% for the same replacement frequencies.
The scenario indicates that the model results were not particularly sensitive to the discount rate or
time horizon chosen.
Value-of-information results
This section reports the results of the VOI analysis. Given the high level of uncertainty described in
the previous section, it is important to determine the value of additional research to determine the
cost-effectiveness of splints. The EVPI results in Table 25 indicate that future research is worthwhile.
TABLE 24 Sensitivity and scenario analyses (continued )
Intervention
Total
costs (£)
Incremental
costs (£)
Total
QALYs
Incremental
QALYs ICER (£)
Probability of cost-effectiveness at
difference WTP thresholds (%)
£0 £20,000 £30,000
CPI
No splints 5681 18.575 96.0 63.8 61.6
Splints 6079 398 18.557 –0.018 Dominated 4.0 36.2 38.4
Cost of replacing splints set to £0
Current pain
No splints 6375 17.999 51.0 39.8 39.7
Splints 6543 168 18.027 0.028 6041 49.0 60.2 60.3
CPI
No splints 5681 18.575 87.2 59.9 59.0
Splints 5865 185 18.557 –0.018 Dominated 12.8 40.1 41.0
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The EVPPI results build on this to identify the parameters in the model for which further research is
most valuable to reduce uncertainty regarding the optimal treatment decision (splints or no splints).
The VOI analysis further emphasises the decision uncertainty, and identified the key drivers of the
cost-effectiveness results. The large positive values of EVPI indicate that further research would be a
good investment. EVPPI helps to indicate the parameters in the model that contribute most to decision
uncertainty. Large EVPPI values (for current pain in particular) indicate that further research should be
prioritised to resolve decision uncertainty about the impact of splints on pain (i.e. the MDs used in the
model). This should also encompass an assessment of the long-term effectiveness to more accurately
guide extrapolation in the model. In addition, further research regarding the long-run trajectory of
disease would be worthwhile, to determine transition probabilities over the full life course. Research
on the costs of splints and, in particular, the replacement cost of splints over time is also worthy of
further research, although EVPPIs are lower than for the clinical effectiveness data. Although generating
positive values of EVPPI, further research with regard to health-state utilities is less valuable, and
should be considered only after decision uncertainty in clinical effectiveness and costs of splints has
been resolved.
It is noted that parameter EVPPI is positive, but remains consistently lower in models parameterised
around CPI than in those parameterised around current pain. This finding must be considered in the
light of the other findings in the report, and, in particular, the poor methodological quality of the
underlying effect size studies. VOI is a useful tool in prioritising future research, but is driven solely by
sampling uncertainty around the input parameters. It does not consider the methodological quality of
the clinical effectiveness studies. Details of the economic evaluation results, including VOI results,
comparing custom-made and prefabricated splints with no splints can be found online.113
TABLE 25 Value-of-information (EVPI and EVPPI) results
VOI Current pain (£) CPI (£)
EVPI
Per person 3961 867
Population (10 years) 91.57B 20.04B
EVPPI
Transition probabilities
Per person 2318 404
Population (10 years) 53.59B 9.34B
Mean difference
Per person 2847 15
Population (10 years) 65.80B 0.35B
Costs
Per person 201 26
Population (10 years) 4.64B 0.59B
Utilities
Per person 40 2
Population (10 years) 0.93B 0.06B
DOI: 10.3310/hta24070 Health Technology Assessment 2020 Vol. 24 No. 7
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Riley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
63

Chapter 5 Discussion
Parts of this chapter have been adapted from Riley et al.1 This article is licensed under a CreativeCommons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution
and reproduction in any medium or format, as long as you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The
images or other third party material in this article are included in the article’s Creative Commons licence,
unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative
Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence,
visit http://creativecommons.org/licenses/by/4.0/. This includes minor additions and formatting changes
to the original text.
Summary of main results
Despite the inclusion of 35 studies comparing oral splints with no splints or a minimal intervention in
patients with TMD, the body of evidence was assessed as being of very low quality. There was no
evidence that oral splints reduced pain, reduced clicking of the temporomandibular joint or increased
mouth-opening, when TMD is considered as a group of conditions. When comparing oral splints with
control splints, there was some very low-quality evidence from three studies36,47,60 that oral splints
reduced pain when compared with control splints for a time period of 0–3 months; however, this was
not supported at the other time periods (3–6 months and 6–12 months). In the light of the absence of
any evidence showing that splints reduce pain against no/a minimal control, the benefit for splints,
when compared with control splints, seen at 3 months may indicate that such control splints are
actually detrimental. It is therefore unclear if the provision of control splints is an appropriate control
to use in RCTs of this type.
The economic analysis was configured to report cost-effectiveness based on differences in pain
measured as current pain or CPI. The modelling for TMD is based on poor-quality clinical effectiveness
data and estimates of cost-effectiveness should be considered exploratory in nature. The base-case
results showed that there was substantial uncertainty regarding the most cost-effective treatment
strategy. The scatterplots of the cost-effectiveness plane depict the high uncertainty in the results.
For the current pain configuration, about half the point estimates of the ICER favour splints and the
other half favour the no-splint group, meaning that there is an equal chance that either strategy may
be cost-effective. The results were slightly less uncertain for the CPI configuration, with a ≈29% chance
that splints are cost-effective and a 71% chance that no splints offers the best value for money. However,
as described by the scenario analyses undertaken, substantial variability exists in incremental costs
and incremental QALYs, depending on the assumptions applied, meaning that the most cost-effective
treatment strategy cannot be determined. The estimates of cost-effectiveness should be interpreted
with caution. It is probably more informative to consider the substantial impact of plausible variations in
important assumptions on the ICER and to thus use the modelling results to identify the key parameters
that drive the cost-effectiveness results, on which further research would be informative.
For patients with bruxism, there was insufficient evidence to conclude whether or not the provision
of oral splints reduced tooth wear, as no studies reported this. Although a small number of studies
reported pain and other outcomes, there was also insufficient evidence to conclude whether or not
oral splints were beneficial. With regard to cost-effectiveness, there was no evidence to support or
refute the use of splints for bruxism and there was no evidence available to populate a decision model.
Six studies50,55,61,62,72,73 compared prefabricated splints with custom-made splints in patients with varying
subtypes of TMD.There was insufficient evidence to determine whether or not there was a difference
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between the splint types for any outcomes included in this review. This evidence was assessed as being of
very low quality, and insufficient to draw any robust conclusions regarding either clinical effectiveness or
cost-effectiveness. It should be noted that many types of prefabricated splints exist, some of which are
readily available to patients via the internet, without the need for dental consultation/fitting. Such splints
were not evaluated in the trials identified for this review.
Overall completeness and applicability of evidence
For TMD, we undertook a sensitivity analysis restricted to trials for which the inclusion criteria were
based on, or could be clearly mapped to, one of the following sets of diagnostic criteria: RDC/TMD
guidelines,17 TMD (DC/TMD) guidelines18 or AAOP guidelines.19 There was no difference in the results
when removing studies that did not use these diagnostic criteria.
Similarly, for bruxism patients, we planned to undertake a sensitivity analysis restricted to trials for
which there was a clear diagnosis of bruxism.4 We were unable to do this for the five bruxism trials
included in the systematic review owing to the lack of outcome data reported in these studies.
For both patients with TMD and with bruxism, owing to differences in the diagnoses of the included
trial participants and differences in the types of splints and control groups used, the applicability
of the evidence is questionable, and certainly incomplete for patients with bruxism. We suspect
that this same variability and lack of diagnostic criteria is mirrored in primary care when splints are
being prescribed.
Pain was reported in numerous different ways, at different times, and this reduced the number of
studies that could be combined in a meta-analysis to produce a pooled estimate. The use of an agreed
measure for pain and how and when this is measured would enable the pain data from all the studies
to contribute to one single pooled estimate. It is also important to consider what would be a clinically
important reduction in pain. It is suggested that around a 20% reduction represents a minimally
important decrease, 30% a moderately important decrease and 50% a substantial decrease.114
Several of the studies reported study outcomes but we were unable to use the data. The main reason for
this was missing SDs. Once again, this compromised the completeness of the results of the meta-analyses.
Numerous studies reported on some of our outcomes but did not report the data in a suitable format
for inclusion in our meta-analyses. This can mean that meta-analyses are biased by missing information.
However, the Cochrane Risk of Bias tool15 and meta-analyses do not currently address this issue
adequately. A study may be assessed as having a high risk of selective outcome reporting, but if that
study is not included in a meta-analysis because it has no data, then this is not reflected or accounted for.
This highlights the need for standardisation in both ‘what to measure’ and ‘how to measure it’ in clinical
trials in this area of research. Otherwise, there will continue to be research waste, with data that are not
able to be pooled in data syntheses. There are initiatives such as Initiative on Methods, Measurement
and Pain Assessment in Clinical Trials (IMMPACT),114,115 Core Outcome Measures in Effectiveness Trials
(COMET)116 and COnsensus-based Standards for the selection of health Measurement Instruments
(COSMIN)117 that can help with these issues, and future research in these areas would be beneficial.
The use of a control/placebo splint is also questionable in trials conducted on patients with TMD or
bruxism. It is unclear what effect the control splint may have on the outcomes measured, and this may
explain why the comparisons of splints versus minimal interventions, and splints versus control splints,
led to different findings.
Meta-analysis is the key tool for facilitating progress in science by quantifying what is known and
identifying what is not known.118 The most consequential effect of introducing formal research synthesis
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methodology has been a profound change in the way scientists think about the outcomes of scientific
research. An individual primary study may now be seen as a contribution towards the accumulation of
evidence, rather than revealing the conclusive answer to a scientific problem.118,119 In the field of TMD,
it could be considered that each new trial be designed with the current evidence in mind (as part of a
funding application). This could help to ensure that the trial is asking an important question, on the right
population using the right methodology, especially the measurement of pain using consistent methods.
Unless research in this area does not address these issues, then there may continue to be a mismatch
of poor-quality trials on different interventions, in different groups of patients, with different diagnoses,
and using different ways of measuring pain or other TMD outcomes. So, rather than there being a call
for a reduction in evidence synthesis in this area,120 it is vital that there is a methodologically sound
evidence base that is kept up to date in order for the science in this area to progress.
Quality of the evidence
The quality of the evidence for comparing splints with no splints/minimal interventions/control splints
in patients with all subtypes of TMD was downgraded to ‘very low’ owing to the studies being at a high
risk of bias, heterogeneity and a lack of precision in the estimates. Most studies were assessed as being
at a high risk of bias because of the inability of researchers to blind patients to wearing a splint or not,
or wearing different types of splint. As the primary outcome for the TMD patients was pain assessed
by the patients, this meant that this outcome measurement was also assessed as being at a high risk
of bias. It is difficult to design trials to overcome this problem. We were unable to investigate the
heterogeneity of the effect estimates because of the different splint types used, different patient
diagnoses and the different minimal interventions being used as control groups.
There were no studies looking at tooth wear, and very few studies and a lack of useable other data for
patients with bruxism, so we were unable to determine whether or not splints are effective in these
patients. The quality of the evidence was therefore deemed to be very low for the reported outcomes.
The risk of bias of 5022–46,49–73 of the 52 studies was high. Although patient blinding is not possible
when comparing oral splints with no splints or a minimal intervention, there were also problems with
selective reporting bias and incomplete outcome data. The majority of the studies were assessed as
having an unclear risk for selection bias, with researchers not reporting the trial methodology and data
according to the Consolidated Standards of Reporting Trials (CONSORT).121
Patient and public involvement
The project benefited from the establishment of a patient advisory group during the development of
the application. At least one member of the patient advisory group attended each of the face-to-face
meetings of the research team held in Manchester, and took part in most of the monthly teleconferences.
On reflection, involving patients in discussions about the questions and outcomes for the protocol,
and in the readability of the Plain English summary was helpful. It is more difficult to involve patients in
the more detailed work of the effectiveness review, as this is a specialist methodological exercise with
clinical involvement.
Economic modelling
A decision-analysis model was developed to fill a gap in the literature regarding the cost-effectiveness
of splints. Although the project intended to evaluate cost-effectiveness separately for bruxism and TMD,
it was possible to build a model for TMD only. There were insufficient data available to populate a model
focused around degrees of tooth wear resulting from bruxism activity. A suggested model structure is
provided in Appendix 5, and further research is required to refine the structure and populate the model.
Further research will be required to determine the long-term care pathway for bruxism patients, the
long-term impact of bruxing on tooth wear and treatment need, the effectiveness of splints, and the
costs and utilities of different bruxism health states.
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The TMD model was populated using the best-available evidence from a UK decision-making perspective.
A systematic approach was taken to search for the clinical effectiveness data. Costs, utilities and transition
probabilities were based on detailed cohort data from the DEEP study, a UK cohort study on people
with TMD.
There was a lack of available long-term data to inform the economic model, particularly with regards
to the long-run transition probabilities beyond 2 years. The effects of splints on pain are a particular
area of uncertainty, especially over longer time periods beyond 3 months. This uncertainty is evident in
the model results, with VOI analysis being used to inform further research priorities
One important limitation of the economic analysis is that there was no RR data available from the clinical
effectiveness review to inform the economic model. To populate the model, structured around tertiles of
pain, it was necessary to make assumptions about the probable RR obtained from a range of plausible MDs
observed in the clinical effectiveness review. The approach taken adds substantial additional uncertainty
to the results. Although the resulting data behave in a manner that is encouraging for face validity,
further work is required to determine the true RR of health-state occupation. The results provided by the
economic analysis are subject to the same limitations of the clinical effectiveness data described previously.
This project initially set out to also compare custom-made with prefabricated splints. However, the
majority of studies in the clinical effectiveness review used custom-made splints in their comparison,
meaning that a robust assessment of the cost-effectiveness of custom-made versus prefabricated
splints was not possible.
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Chapter 6 Conclusions
Parts of this chapter have been adapted from Riley et al.1 This article is licensed under a CreativeCommons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution
and reproduction in any medium or format, as long as you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The
images or other third party material in this article are included in the article’s Creative Commons licence,
unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative
Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence,
visit http://creativecommons.org/licenses/by/4.0/. This includes minor additions and formatting changes
to the original text.
Implications for health care
From this systematic review, there is no clear evidence to support the provision of splints for the
various subtypes of TMD or bruxism. However, the body of evidence that this conclusion is based on is
of very low quality. The studies included in this review differed in three important factors: (1) diagnoses,
(2) splint type and (3) outcome measurement/reporting. This made it difficult to draw clear and definitive
conclusions. We addressed these problems by performing sensitivity analyses to investigate the effects
of the three factors on the results, but this resulted in a decrease in the numbers of studies and patients
available with which to perform further analyses. We were still unable to demonstrate that splints
reduce pain in the study participants.
With regard to cost-effectiveness, there was no published evidence to determine the most efficient
allocation of resources. Our decision-analysis model identifies important drivers of cost-effectiveness
and highlights the need for future research, but definitive statements regarding cost-effectiveness
cannot be made as a result of the limited evidence on clinical effectiveness, identified in Chapter 3,
Results of the systematic review.
Recommendations for future research
Further research is urgently needed to determine whether or not the use of splints is clinically effective,
generates meaningful patient benefit and whether or not splints offer an efficient use of scarce NHS
resources for both bruxism and TMD. There is a need for well-conducted RCTs involving both TMD and
bruxism patients. These trials should compare oral splints with an agreed minimal intervention such as
advice/counselling, education or self-performed exercises (applied to both the intervention and control
groups). Multiple trials will be required to answer questions about patients with different subtypes of
TMD. The selection of patients for inclusion in these studies should, ideally, conform to the DC/TMD
diagnostic guidelines to ensure that patients have well-defined conditions and are a homogeneous
group. Trials should be conducted in those settings that reflect the current provision of splints provided
in the NHS. Triallists should carefully report the data for the patients included in each TMD subgroup
separately, to ensure that the data can be pooled for each subgroup in future meta-analyses.
The results of the EVPI analysis indicate that there is substantial decision uncertainty and that future
research is worthwhile. The EVPPI analysis identified two important areas of future research to reduce
decision uncertainty with regards to cost-effectiveness, as well as two areas of research in which
further research is unlikely to reduce decision uncertainty. The priority areas for further research are:
1. The treatment effectiveness of splints and, consequently, that of custom-made versus prefabricated
splints. Future economic evaluations should also include provision for extended follow-up to resolve
longer-term decision uncertainty in pain trajectory and clinical effectiveness.
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2. Further data are required to determine the long-term costs to the NHS of different types of splint
provision. This includes generating evidence regarding the appropriate banding for different splint
types on the NHS in England, as well as determining the frequency at which splints will require
replacement if rolled out to TMD patients.
The VOI analysis indicated that further research to determine the costs or utilities associated with pain
states would not be worthwhile, as current evidence obtained from the DEEP study94 is sufficient to
aid decision-making.
CONCLUSIONS
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Appendix 1 Literature search strategies
Reproduced from Riley et al.1 This article is licensed under a Creative Commons Attribution 4.0International License, which permits use, sharing, adaptation, distribution and reproduction in any
medium or format, as long as you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes were made. The images or
other third party material in this article are included in the article’s Creative Commons licence, unless
indicated otherwise in a credit line to the material. If material is not included in the article’s Creative
Commons licence and your intended use is not permitted by statutory regulation or exceeds the
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy
of this licence, visit http://creativecommons.org/licenses/by/4.0/. This includes minor additions and
formatting changes to the original text.
Clinical effectiveness
Cochrane Central Register of Controlled Trials
Date range searched: inception to issue 9 2018.
Date searched: 1 October 2018.
Search strategy
#1 [mh ^’Occlusal adjustment’]
#2 [mh ^’Occlusal splints’]
#3 [mh ^’Orthodontic appliances’]
#4 ((occlusal or oral or temporomandibular or jaw* or mandib* or mouth* or bite* or TMJ or dental)
near/5 splint*)
#5 ((dental or mouth or gum) next (guard* or shield*))
#6 (mouthguard* or gumguard* or nightguard* or gumshield* or ‘bite plane*’ or toothprotector*or
‘tooth protector*’)
#7 ‘splint therapy’
#8 ((oral or TMJ or orofacial) next appliance*)
#9 {or #1-#8}
#10 [mh ‘craniomandibular disorders’]
#11 [mh ^’facial pain’]
#12 [mh ^’facial neuralgia’]
#13 [mh ^’trigeminal neuralgia’]
#14 [mh ^arthralgia]
#15 [mh ^’temporomandibular joint’]
#16 #14 and #15
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#17 [mh bruxism]
#18 (bruxism or (teeth near/5 grind*) or (teeth near/5 clench) or (jaw* near/5 clench) or (jaw* near/5
grind*))
#19 ((craniofacial or myofacial or myofascial or facial or orofacial) near/5 (pain* or syndrome*))
#20 (‘trigeminal neuralgia’ or ‘sphenopalatine neuralgia’ or ‘Costen* syndrome*’)
#21 ((‘temporomandibular joint’ or craniomandibular or jaw* or mandib*) near/5 (pain* or disorder* or
dysfunction* or arthralgia or syndrome*))
#22 (TMD or TMJD or (TMJ near/3 (disorder* or dysfunction* or syndrome* or pain*))):ti,ab
#23 ((temporomandibular or jaw* or mandib*) near/5 (disk or disc) next displac*)
#24 #10 or #11 or #12 or #13 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23
#25 #9 and #24
MEDLINE (via OvidSP)
Date range searched: 1946 to 1 October 2018.
Date searched: 1 October 2018.
Search strategy
1. Occlusal adjustment/
2. Occlusal splints/
3. Orthodontic appliances/
4. ((occlusal or oral or temporomandibular or jaw$ or mandib$ or mouth$ or bite$ or TMJ or dental)
adj5 splint$).mp.
5. ((dental or mouth or gum) adj (guard$ or shield$)).mp.
6. (mouthguard$ or gumguard$ or nightguard$ or gumshield$ or ‘bite plane$’ or toothprotector$ or
‘tooth protector$’).mp.
7. ‘splint therapy’.mp.
8. ((oral or TMJ or orofacial) adj appliance$).mp.
9. or/1-8
10. exp Craniomandibular disorders/
11. Facial pain/
12. Facial neuralgia/
13. Trigeminal neuralgia/
14. Arthralgia/ and temporomandibular joint/
15. exp bruxism/
16. (bruxism or (teeth adj5 grind$) or (teeth adj5 clench) or (jaw$ adj5 clench) or (jaw$ adj5
grind$)).mp.
17. ((craniofacial or myofacial or myofascial or facial or orofacial) adj5 (pain$ or syndrome$)).mp.
18. (‘trigeminal neuralgia’ or ‘sphenopalatine neuralgia’ or ‘Costen$ syndrome$’).mp.
19. ((‘temporomandibular joint’ or craniomandibular or jaw$ or mandib$) adj5 (pain$ or disorder$ or
dysfunction$ or arthralgia or syndrome$)).mp.
20. (TMD or TMJD or (TMJ adj3 (disorder$ or dysfunction$ or syndrome$ or pain$))).ti,ab.
21. ((temporomandibular or jaw$ or mandib$) adj5 (disk or disc) adj displac$).mp. 22. or/10-21
22. 9 and 22
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Cochrane search filter for MEDLINE Ovid
Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomized trials in MEDLINE:
sensitivity maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box
6.4.c of The Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated
March 2011].
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. or/1-8
10. exp animals/ not humans.sh.
11. 9 not 10
EMBASE
Date range searched: 1980 to 1 October 2018.
Date searched: 1 October 2018.
Search strategy
1. Occlusal splint/
2. Orthodontic device/
3. ((occlusal or oral or temporomandibular or jaw$ or mandib$ or mouth$ or bite$ or TMJ or
dental) adj5 splint$).mp.
4. ((dental or mouth or gum) adj (guard$ or shield$)).mp.
5. (mouthguard$ or gumguard$ or nightguard$ or gumshield$ or ‘bite plane$’ or toothprotector$ or
‘tooth protector$’).mp.
6. ‘splint therapy’.mp.
7. ((oral or TMJ or orofacial) adj appliance$).mp.
8. or/1-7
9. Temporomandibular joint disorder/
10. Face pain/
11. Trigeminus neuralgia/
12. Arthralgia/ and temporomandibular joint/
13. exp bruxism/
14. (bruxism or (teeth adj5 grind$) or (teeth adj5 clench) or (jaw$ adj5 clench) or (jaw$ adj5
grind$)).mp.
15. ((craniofacial or myofacial or myofascial or facial or orofacial) adj5 (pain$ or syndrome$)).mp.
16. (‘trigeminal neuralgia’ or ‘sphenopalatine neuralgia’ or ‘Costen$ syndrome$’).mp.
17. ((‘temporomandibular joint’ or craniomandibular or jaw$ or mandib$) adj5 (pain$ or disorder$ or
dysfunction$ or arthralgia or syndrome$)).mp.
18. (TMD or TMJD or (TMJ adj3 (disorder$ or dysfunction$ or syndrome$ or pain$))).ti,ab.
19. ((temporomandibular or jaw$ or mandib$) adj5 (disk or disc) adj displac$).mp. or/9-19
20. 8 and 20
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The above subject search was linked to adapted version of the Cochrane EMBASE Project filter for
identifying RCTs in EMBASE Ovid (see online122 for information):
1. Randomized controlled trial/
2. Controlled clinical study/
3. Random$.ti,ab.
4. randomization/
5. intermethod comparison/
6. placebo.ti,ab.
7. (compare or compared or comparison).ti.
8. ((evaluated or evaluate or evaluating or assessed or assess) and (compare or compared or
comparing or comparison)).ab.
9. (open adj label).ti,ab.
10. ((double or single or doubly or singly) adj (blind or blinded or blindly)).ti,ab.
11. double blind procedure/
12. parallel group$1.ti,ab.
13. (crossover or cross over).ti,ab.
14. ((assign$ or match or matched or allocation) adj5 (alternate or group$1 or intervention$1
orpatient$1 or subject$1 or participant$1)).ti,ab.
15. (assigned or allocated).ti,ab.
16. (controlled adj7 (study or design or trial)).ti,ab.
17. (volunteer or volunteers).ti,ab.
18. trial.ti.
19. or/1-18
20. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human
or humans).ti.)
21. 19 not 20
Cumulative Index to Nursing and Allied Health Literature (via EBSCOhost)
Date range searched: 1937 to 1 October 2018.
Date searched: 1 October 2018.
Search strategy
S22 S8 and S21
S21 S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20
S20 ((temporomandibular or jaw* or mandib*) N5 (disk or disc))
S19 (TMD or TMJD or (TMJ N3 (disorder* or dysfunction* or syndrome* or pain*)))
S18 ((‘temporomandibular joint’ or craniomandibular or jaw* or mandib*) N5 (pain* or disorder* or
dysfunction* or arthralgia or syndrome*))
S17 (‘trigeminal neuralgia’ or ‘sphenopalatine neuralgia’ or ‘Costen* syndrome*’)
S16 ((craniofacial or myofacial or myofascial or facial or orofacial) N5 (pain* or syndrome*))
S15 (bruxism or (teeth N5 grind*) or (teeth N5 clench) or (jaw* N5 clench) or (jaw* N5 grind*))
S14 (MH bruxism+)
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S13 (MH arthralgia) AND (MH ‘temporomandibular joint’)
S12 (MH ‘trigeminal neuralgia’)
S11 (MH ‘facial neuralgia’)
S10 (MH ‘facial pain’)
S9 (MH ‘craniomandibular disorders+’)
S8 S1 or S2 or S3 or S4 or S5 or S6 or S7
S7 ((oral or TMJ or orofacial) N1 appliance*)
S6 ‘splint therapy’
S5 ((dental or mouth or gum) N1 (mouthguard* or gumguard* or nightguard* or gumshield* or ‘bite
plane*’ or toothprotector* or ‘tooth protector*’) guard* or shield*))
S4 ((dental or mouth or gum) N1 (guard* or shield*))
S3 ((occlusal or oral or temporomandibular or jaw* or mandib* or mouth* or bite* or TMJ or dental)
N5 splint*)
S2 (MH ‘Orthodontic appliances’)
S1 (MH ‘Splints’)
The above subject search was linked to Cochrane Oral Health’s filter for identifying RCTs in CINAHL
EBSCOhost:
S1 MH Random Assignment or MH Single-blind Studies or MH Double-blind Studies or MH
Triple-blind Studies or MH Crossover design or MH Factorial Design
S2 TI (‘multicentre study’ or ‘multicenter study’ or ‘multi-centre study’ or ‘multi-center study’) or
AB (‘multicentre study’ or ‘multicenter study’ or ‘multi-centre study’ or ‘multi-center study’) or SU
(‘multicentre study’ or ‘multicenter study’ or ‘multi-centre study’ or ‘multi-center study’)
S3 TI random* or AB random*
S4 AB ‘latin square’ or TI ‘latin square’
S5 TI (crossover or cross-over) or AB (crossover or cross-over) or SU (crossover or cross-over)
S6 MH Placebos
S7 AB (singl* or doubl* or trebl* or tripl*) or TI (singl* or doubl* or trebl* or tripl*)
S8 TI blind* or AB mask* or AB blind* or TI mask*
S9 S7 and S8
S10 TI Placebo* or AB Placebo* or SU Placebo*
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S11 MH Clinical Trials
S12 TI (Clinical AND Trial) or AB (Clinical AND Trial) or SU (Clinical AND Trial)
S13 S1 or S2 or S3 or S4 or S5 or S6 or S9 or S10 or S11 or S12
ProQuest Dissertations & Theses
Date range searched: no restriction.
Date searched: 1 October 2018.
Search strategy
all((splint or guard or shield or mouthguard or gumguard or gumshield or mouthshield or ‘tooth
protector’ or orthodontic)) AND all((‘temporomandibular joint’ or TMD or TMJD or ‘facial pain’ or
(face and pain) or bruxism))
Conference Proceedings Citation Index (via Web of Science)
Date range searched: no restriction.
Date searched: 1 October 2018.
Search strategy
# 15 #6 and #14
# 14 #7 or #8 or #9 or #10 or #11 or #12 or #13
# 13 TS=((temporomandibular or jaw* or mandib*) AND (disk or disc))
# 12 TS=(TMJ AND (disorder* or dysfunction* or syndrome* or pain*))
# 11 TS=(TMD or TMJD)
# 10 TS=((‘temporomandibular joint’ or craniomandibular or jaw* or mandib*) AND (pain* or disorder*
or dysfunction* or arthralgia or syndrome*))
# 9 TS=(‘trigeminal neuralgia’ or ‘sphenopalatine neuralgia’ or ‘Costen* syndrome*’)
# 8 TS=((craniofacial or myofacial or myofascial or facial or orofacial) AND (pain* or syndrome*))
# 7 TS=(bruxism or (teeth and grind*) or (teeth and clench) or (jaw* and clench) or (jaw* and grind*))
# 6 #1 or #2 or #3 or #4 or #5
# 5 TS=((oral or TMJ or orofacial) AND appliance*)
# 4 TS=‘splint therapy’
# 3 TS=((dental or mouth or gum) and (guard* or shield*))
# 2 TS=(mouthguard* or gumguard* or nightguard* or gumshield* or ‘bite plane*’ or toothprotector or
‘tooth protector*)
# 1 TS=((occlusal or oral or temporomandibular or jaw* or mandib* or mouth* or bite* or TMJ or
dental) AND splint*)
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US National Institutes of Health trials registry (ClinicalTrials.gov)
Date range searched: no restriction.
Date searched: 1 October 2018.
Search strategy
Condition: temporomandibular joint disorder
Other terms: splint*
Condition: Facial pain
Other terms: splint*
World Health Organization International Clinical Trials Registry Platform
Date range searched: no restriction.
Date searched: 1 October 2018.
Search strategy
Condition: temporomandibular joint disorder
Intervention: splint*
Condition: face AND pain
Intervention: splint*
American Academy of Dental Sleep Medicine website
Date range searched: no restriction.
Date searched: 1 October 2018.
Search strategy
temporomandibular and splint
International Association of Dental Research conference abstracts
Date range searched: no restriction.
Date searched: 1 October 2018.
Search strategy
occlusal splint and temporomandibular
occlusal splint and pain
occlusal splint and bruxism
Cost-effectiveness
MEDLINE (via OvidSP)
Date range searched: 1946 to 1 October 2018.
Date searched: 1 October 2018.
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Search strategy
1. Occlusal adjustment/
2. Occlusal splints/
3. Orthodontic appliances/
4. ((occlusal or oral or temporomandibular or jaw$ or mandib$ or mouth$ or bite$ or TMJ or dental
or ‘vacuum form$’) adj5 splint$).mp.
5. ((dental or mouth or gum) adj (guard$ or shield$)).mp.
6. (mouthguard$ or gumguard$ or nightguard$ or gumshield$ or ‘bite plane$’ or toothprotector$ or
‘tooth protector$’).mp.
7. ‘splint therapy’.mp.
8. ((oral or TMJ or orofacial) adj appliance$).mp.
9. (‘bite rais$’ adj appliance$).mp.
10. or/1-9
11. exp Craniomandibular disorders/
12. Facial pain/
13. Facial neuralgia/
14. Trigeminal neuralgia/
15. Arthralgia/ and temporomandibular joint/
16. exp bruxism/
17. (bruxism or (teeth adj5 grind$) or (teeth adj5 clench) or (jaw$ adj5 clench) or (jaw$ adj5
grind$)).mp.
18. ((craniofacial or myofacial or myofascial or facial or orofacial) adj5 (pain$ or syndrome$)).mp.
19. (‘trigeminal neuralgia’ or ‘sphenopalatine neuralgia’ or ‘Costen$ syndrome$’).mp.
20. ((‘temporomandibular joint’ or craniomandibular or jaw$ or mandib$) adj5 (pain$ or disorder$ or
dysfunction$ or arthralgia or syndrome$)).mp.
21. (TMD or TMJD or (TMJ adj3 (disorder$ or dysfunction$ or syndrome$ or pain$))).ti,ab.
22. ((temporomandibular or jaw$ or mandib$) adj5 (disk or disc) adj displac$).mp.
23. or/11-22
24. 10 and 23
The above search was linked to the economic studies filter used by the Scottish Intercollegiate
Guidelines Network123 (an adaptation of the strategy designed by the NHS Centre for Reviews and
Dissemination at the University of York).
1. Economics/
2. ‘costs and cost analysis’/
3. Cost allocation/
4. Cost-benefit analysis/
5. Cost control/
6. Cost savings/
7. Cost of illness/
8. Cost sharing/
9. ‘deductibles and coinsurance’/
10. Medical savings accounts/
11. Health care costs/
12. Direct service costs/
13. Drug costs/
14. Employer health costs/
15. Hospital costs/
16. Health expenditures/
17. Capital expenditures/
18. Value of life/
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19. Exp economics, hospital/
20. Exp economics, medical/
21. Economics, nursing/
22. Economics, pharmaceutical/
23. Exp ‘fees and charges’/
24. Exp budgets/
25. (low adj cost).mp.
26. (high adj cost).mp.
27. (health?care adj cost$).mp.
28. (fiscal or funding or financial or finance).tw.
29. (cost adj estimate$).mp.
30. (cost adj variable).mp.
31. (unit adj cost$).mp.
32. (economic$ or pharmacoeconomic$ or price$ or pricing).tw.
33. Or/1-32
EMBASE (via OvidSP)
Date range searched: 1980 to 1 October 2018.
Date searched: 1 October 2018.
Search strategy
1. Occlusal splint/Orthodontic device/((occlusal or oral or temporomandibular or jaw$ or mandib$ or
mouth$ or bite$ or TMJ or dental or ‘vacuum form$’) adj5 splint$).mp.
2. ((dental or mouth or gum) adj (guard$ or shield$)).mp.
3. (mouthguard$ or gumguard$ or nightguard$ or gumshield$ or ‘bite plane$’ or toothprotector$ or
‘tooth protector$’).mp.
4. ‘splint therapy’.mp.
5. ((oral or TMJ or orofacial) adj appliance$).mp.
6. (‘bite rais$’ adj appliance$).mp.
7. or/1-8
8. Temporomandibular joint disorder/
9. Face pain/
10. Trigeminus neuralgia/
11. Arthralgia/ and temporomandibular joint/
12. exp bruxism/
13. (bruxism or (teeth adj5 grind$) or (teeth adj5 clench) or (jaw$ adj5 clench) or (jaw$ adj5
grind$)).mp.
14. ((craniofacial or myofacial or myofascial or facial or orofacial) adj5 (pain$ or syndrome$)).mp.
15. (‘trigeminal neuralgia’ or ‘sphenopalatine neuralgia’ or ‘Costen$ syndrome$’).mp.
16. ((‘temporomandibular joint’ or craniomandibular or jaw$ or mandib$) adj5 (pain$ or disorder$ or
dysfunction$ or arthralgia or syndrome$)).mp.
17. (TMD or TMJD or (TMJ adj3 (disorder$ or dysfunction$ or syndrome$ or pain$))).ti,ab.
18. ((temporomandibular or jaw$ or mandib$) adj5 (disk or disc) adj displac$).mp
19. or/10-20
20. 9 and 21
The above search was linked to the economic studies filter used by the Scottish Intercollegiate
Guidelines Network123 (an adaptation of the strategy designed by the NHS Centre for Reviews and
Dissemination at the University of York).
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1. Socioeconomics/
2. Cost benefit analysis/
3. Cost effectiveness analysis/
4. Cost of illness/
5. Cost control/
6. Economic aspect/
7. Financial management/
8. Health care cost/
9. Health care financing/
10. Health economics/
11. Hospital cost/
12. (fiscal or financial or finance or funding).tw.
13. Cost minimization analysis/
14. (cost adj estimate$).mp.
15. (cost adj variable$).mp.
16. (unit adj cost$).mp.
17. Or/1-16
NHS EED Database (via OvidSP)
Date range searched: inception to issue 1 2016.
Date searched: 1 October 2018.
Search strategy
1. Splints/
2. (splint$ or guard$ or shield$ or mouthguard$ or gumguard$ or nightguard$ or gumshield$ or
plane$ or ‘tooth protector$’ or toothprotector$ or ‘oral appliance$’ or ‘orofacial appliance$’ or ‘bite
rais$ appliance$’).mp.
3. 1 or 2
4. Temporomandibular Joint Disorders/
5. Facial pain/
6. (TMD or TMJD).mp.
7. (bruxism or (teeth and grind$) or (teeth and clench$) or (jaw and clench$) or (jaw and
grind$)).mp.
8. ((temporomandibular$ or (craniofacial or myofacial or myofascial or facial or orofacial or face))
adj5 (pain$ or syndrome$)).mp.
9. or/4-8
10. 3 and 9
Cumulative Index to Nursing and Allied Health Literature (via EBSCOhost)
Date range searched: 1937 to 1 October 2018.
Date searched: 1 October 2018.
Search strategy
S22 S8 and S21
S21 S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20
S20 ((temporomandibular or jaw* or mandib*) N5 (disk or disc))
S19 (TMD or TMJD or (TMJ N3 (disorder* or dysfunction* or syndrome* or pain*)))
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S18 ((‘temporomandibular joint’ or craniomandibular or jaw* or mandib*) N5 (pain* or disorder* or
dysfunction* or arthralgia or syndrome*))
S17 (‘trigeminal neuralgia’ or ‘sphenopalatine neuralgia’ or ‘Costen* syndrome*’)
S16 ((craniofacial or myofacial or myofascial or facial or orofacial) N5 (pain* or syndrome*))
S15 (bruxism or (teeth N5 grind*) or (teeth N5 clench) or (jaw* N5 clench) or (jaw* N5 grind*))
S14 (MH bruxism+)
S13 (MH arthralgia) AND (MH ‘temporomandibular joint’)
S12 (MH ‘trigeminal neuralgia’)
S11 (MH ‘facial neuralgia’)
S10 (MH ‘facial pain’)
S9 (MH ‘craniomandibular disorders+’)
S8 S1 or S2 or S3 or S4 or S5 or S6 or S7
S7 ((oral or TMJ or orofacial or ‘bite rais*’) N1 appliance*)
S6 ‘splint therapy’
S5 ((dental or mouth or gum) N1 (mouthguard* or gumguard* or nightguard* or gumshield* or ‘bite
plane*’ or toothprotector* or ‘tooth protector*’) guard* or shield*))
S4 ((dental or mouth or gum) N1 (guard* or shield*))
S3 ((occlusal or oral or temporomandibular or jaw* or mandib* or mouth* or bite* or TMJ or dental or
‘vacuum form’) N5 splint*)
S2 (MH ‘Orthodontic appliances’)
S1 (MH ‘Splints’)
The above search was linked to the economic studies filter used by the Scottish Intercollegiate
Guidelines Network123 (an adaptation of the strategy designed by the NHS Centre for Reviews and
Dissemination at the University of York).
S23 S20 NOT (S21 or S22)
S22 AU Anonymous
S21 SO Cochrane
S20 S18 NOT S19
S19 (MH ‘Animal Studies’)
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S18 S13 NOT S17
S17 S14 or S15 or S16
S16 PT News
S15 PT Letter
S14 PT Editorial
S13 S11 or S12
S12 (cost or costs or economic* or pharmacoeconomic* or price* or pricing*)
S11 S7 or S10
S10 S8 OR S9
S9 SU health resource utilization
S8 SU health resource allocation
S7 S1 NOT S6
S6 S2 or S3 or S4 or S5
S5 (MH ‘Business+’)
S4 (MH ‘Financing, Organized+’)
S3 (MH ‘Financial Support+’)
S2 (MH ‘Financial Management+’)
S1 (MH ‘Economics+’)
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Appendix 2 Additional data tables
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TABLE 26 TMD: Splint vs. no/minimal treatment – other data
Outcome: pain
Assessment
point (months) Study
Splint, mean (SD);
number of events, or
number of events/
total number analysed
No/minimal
treatment, mean
(SD); number of
events Result: MD/RR (95% CI)
Pain
Catastrophizing Thoughts subscale of the Pain Related
Self-Statement Scale. Self-reported questionnaire consisting
of nine statements related to catastrophising thoughts
involved in pain perception. Respondent asked to answer
each statement indicating the frequency of thinking about
pain during a pain crisis, on a 0–4 scale. The sum of all
frequencies was divided by the total number of questions.
Higher values demonstrate higher levels of pain
catastrophising
3–6 Costa 201529 0.76 (0.82); n= 24 1.14 (1.28); n= 17 MD –0.38 (–1.07 to 0.31);
p = 0.28; favours splint
Presence of muscular pain (yes/no) 0–3 de Felício 200630 22/42 41/42 RR 0.54 (0.40 to 0.72);
p < 0.0001; favours splint
Current pain intensity using a 0 (no pain) to 10 (worst pain)
NRS; reported as change from baseline score (unable to
combine change score in primary meta-analysis using SMD;
used in sensitivity analyses of studies reporting current pain
intensity on VAS/NRS at 0–3 months and at 3–6 months)
0–3 DeVocht 201345 1.4 (2.3504); n = 20 0.7 (1.7575); n = 21 MD 0.70 (–0.58 to 1.98);
p = 0.28; favours splint
3–6 DeVocht 201345 2 (1.923); n = 20 1.7 (1.7575); n = 21 MD 0.30 (–0.83 to 1.43);
p = 0.6; favours splint
Changes in pain assessed according to the following
scale: impaired, unchanged, improved, symptom free
(we dichotomised this as incidence of improved and
symptom free)
0–3 Elsharkawy 199558 21/23 20/23 RR 1.05 (0.86 to 1.29);
p = 0.64; favours splint
Changes in facial pain and headache: reported as
incidence of impaired, unchanged, improved, symptom free
(we dichotomised the data to report the incidence of
improved and symptom free)
0–3 Johansson 199137 13/15 2/15 RR 6.50 (1.76 to 23.98);
p = 0.005; favours splint
Number of painful muscle sites on palpation (out of 20
sites); 2 lb of pressure for extraoral muscles, 1 lb of
pressure on the joints and intraoral muscles
3–6 Katyayan 201456 8.725 (3.088); n = 40 7.375 (3.2); n= 40 MD 1.35 (–0.03 to 2.73);
p = 0.05; favours control
TMJ pain as part of clinical dysfunction index Di
(Helkimo74) categorised as none, mild and severe –
we dichotomised as incidence of being pain free
0–3 Magnusson 199942 7/9 9/9 RR 0.79 (0.54 to 1.16);
p = 0.23; favours control
3–6 Magnusson 199942 8/9 9/9 RR 0.89 (0.67 to 1.20);
p = 0.46; favours control
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Outcome: pain
Assessment
point (months) Study
Splint, mean (SD);
number of events, or
number of events/
total number analysed
No/minimal
treatment, mean
(SD); number of
events Result: MD/RR (95% CI)
Muscle pain as part of clinical dysfunction index Di
(Helkimo74) categorised as none, mild and severe –
we dichotomised as incidence of being pain free
0–3 Magnusson 199942 4/9 5/9 RR 0.80 (0.31 to 2.04);
p = 0.64; favours control
3–6 Magnusson 199942 6/9 9/9 RR 0.68 (0.42 to 1.10);
p = 0.12; favours control
Pain on movement as part of clinical dysfunction index Di
(Helkimo74) categorised as none, mild and severe – we
dichotomised as incidence of being pain free
0–3 Magnusson 199942 8/9 8/9 RR 1.00 (0.72 to 1.39);
p = 1; favours neither
3–6 Magnusson 199942 9/9 9/9 RR 1.00 (0.82 to 1.22);
p = 1; favours neither
Spontaneous muscle pain and pain on chewing (chew
bilaterally for 60 seconds on a stick of chewing gum)
assessed separately using 0 mm (no pain) to 100mm (worst
pain) VAS; reported as change from baseline score (unable
to combine change score in primary meta-analysis using
SMD; used in sensitivity analyses of studies reporting
current pain intensity on VAS/NRS at 0–3 months)
0–3 Michelotti 201264 2.798 (2.012); n = 18 –11.289 (2.79);
n= 23
MD 14.09 (12.62 to
15.56); p = < 0.00001;
favours control
Pain on palpation: number of extraoral muscle sites (0–16) 0–3 Truelove 200650 Arm 1: custom splint
l 5.6 (5.4); n= 54
Arm 2: prefabricated
splint
l 4.7 (4.1); n= 56
4.3 (4); n= 54 MD 0.80 (–0.59 to 2.18);
p = 0.26; favours control
6–12 Truelove 200650 Arm 1: custom splint
l 3.6 (4.1); n= 65
Arm 2: prefabricated
splint
l 4.1 (4.4); n= 55
4.5 (4.5); n= 48 MD –0.66 (–2.14 to 0.82);
p = 0.38; favours splint
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TABLE 26 TMD: Splint vs. no/minimal treatment – other data (continued )
Outcome: pain
Assessment
point (months) Study
Splint, mean (SD);
number of events, or
number of events/
total number analysed
No/minimal
treatment, mean
(SD); number of
events Result: MD/RR (95% CI)
Pain on palpation: number of intraoral muscle sites (0–4) 0–3 Truelove 200650 Arm 1: custom splint
l 3 (1.4); n= 54
Arm 2: prefabricated
splint
l 2.8 (1.6); n= 56
2.5 (1.6); n= 54 MD 0.40 (–0.11 to 0.91);
p = 0.12; favours control
6–12 Truelove 200650 Arm 1: custom splint
l 2.6 (1.6); n= 65
Arm 2: prefabricated
splint
l 3 (1.4); n= 55
2.6 (1.4); n= 48 MD 0.20 (–0.28 to 0.68);
p = 0.41; favours control
Pain on palpation: number of TMJ sites (0–4) 0–3 Truelove 200650 Arm 1: custom splint
l 1.3 (1.5); n= 54
Arm 2: prefabricated
splint
l 1.1 (1.4); n= 56
1.1 (1.3); n= 54 MD 0.10 (–0.34 to 0.54);
p = 0.67; favours control
6–12 Truelove 200650 Arm 1: custom splint
l 0.9 (1.1); n= 65
Arm 2: prefabricated
splint
l 1 (1); n= 55
0.8 (0.9); n= 48 MD 0.15 (–0.17 to 0.47);
p = 0.35; favours control
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Outcome: pain
Assessment
point (months) Study
Splint, mean (SD);
number of events, or
number of events/
total number analysed
No/minimal
treatment, mean
(SD); number of
events Result: MD/RR (95% CI)
Pressure pain threshold measured using a pressure
algometer that applied pressure on the skin surface
(scale/units of measurement not stated but higher
score = better outcome): TMJ
0–3 Wahlund 200344 164.7 (51.5); n = 37 148.3 (53.8); n = 39 MD 16.40 (–7.27 to 40.07);
p= 0.17; favours splint
3–6 Wahlund 200344 158.4 (39.3); n = 37 161.3 (61.1); n = 39 MD –2.90 (–25.88 to
20.08); p = 0.8; favours
control
Pressure pain threshold measured using a pressure
algometer that applied pressure on the skin surface
(scale/units of measurement not stated but higher
score = better outcome): masticatory muscles
0–3 Wahlund 200344 334 (100.3); n = 37 295 (99.3); n = 39 MD 39.00 (–5.90 to
83.90); p = 0.09; favours
splint
3–6 Wahlund 200344 344.5 (100.7); n = 37 335 (94.3); n = 39 MD 9.50 (–34.42 to
53.42); p = 0.67; favours
splint
Muscle pain threshold assessed with a pressure algometer
on the anterior temporal muscle and on the superior and
inferior areas of the masseter muscle (psi: higher
score = better outcome)
0–3 Wright 199551 45.3 (12.7); n= 10 38.1 (22.8); n= 10 MD 7.20 (–8.98 to 23.38);
p = 0.38; favours splint
TMJ clicking
Articular noise (yes/no) – ‘The predominant type of
articular noise was a click (83.33% of cases)’
0–3 de Felício 200630 25/42 37/42 RR 0.68 (0.51 to 0.89);
p = 0.005; favours splint
Assessed using printed 0 (absence of symptom) to
10 (worst severity) for the following four situations:
(1) when waking up, (2) during chewing, (3) when speaking
and (4) at rest. The score was then summed and is
therefore a 0–40 scale
0–3 de Felício 201031 10.22 (8.11); n = 10 10.8 (6.68); n= 10 MD –0.58 (–7.09 to 5.93);
p = 0.86; favours splint
Measured using a 0–10 worsening NRS 0–3 Nagata 201567 1.856 (2.211); n = 96 1.5 (1.9565); n = 85 0.36 (–0.25 to 0.96);
p = 0.25; favours control
Change in restricted mouth-opening
Difficulty opening mouth (yes/no) 0–3 de Felício 200630 17/42 31/42 RR 0.55 (0.36 to 0.83);
p = 0.004; favours splint
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TABLE 26 TMD: Splint vs. no/minimal treatment – other data (continued )
Outcome: pain
Assessment
point (months) Study
Splint, mean (SD);
number of events, or
number of events/
total number analysed
No/minimal
treatment, mean
(SD); number of
events Result: MD/RR (95% CI)
Self-assessment of functional limitation of jaw using
0 (no limitation) to 100 (severe limitation) mm VAS
0–3 Hasanoglu 201752 12.1 (18); n = 20 19.2 (19.2); n= 20 MD –7.10 (–18.63 to 4.43);
p= 0.23; favours splint
Incidence of having difficulty in opening the mouth wide 0–3 Magnusson 199942 1/9 1/9 RR 1.00 (0.07 to 13.64);
p = 1; favours neither
3–6 Magnusson 199942 0/9 0/9 Not estimable
Frequency of headaches (secondary to pain-related TMD)
Categorised as number having either infrequent/absent
headache (< 1 day/month), frequent headache (1–14 days/
month) or chronic headache (> 14 days/month) – we
dichotomised the data as incidence of frequent or chronic
headache
3–6 Costa 201529 18/24 11/17 RR 1.16 (0.76 to 1.76);
p = 0.49; favours control
Quality of life (including physical and emotional function)
Pain-related disability (0–100 worsening scale) assessed
using RDC/TMD Axis II biobehavioural questionnaire
0–3 Tatli 201754 14.9 (12.7); n= 40 17.7 (9.3); n= 40 MD –2.80 (–7.68 to 2.08);
p = 0.26; favours splint
3–6 Tatli 201754 4.9 (6.4); n= 40 4.1 (6.6); n= 40 MD 0.80 (–2.05 to 3.65);
p = 0.58; favours control
Psychological status (0–4 worsening scale) assessed using
RDC/TMD Axis II biobehavioural questionnaire
0–3 Tatli 201754 0.7 (0.4); n= 40 0.8 (0.4); n= 40 MD –0.10 (–0.28 to 0.08);
p = 0.26; favours splint
3–6 Tatli 201754 0.5 (0.3); n= 40 0.6 (0.3); n= 40 MD –0.10 (–0.23 to 0.03);
p = 0.26; favours splint
Patient satisfaction
0 (not at all satisfied) to 10 (extremely satisfied) NRS 0–3 DeVocht 201345 7.2 (1.4); n= 20 4.9 (2.3); n= 21 2.30 (1.14 to 3.46);
p = 0.0001; favours splint
Adherence to treatment
Incidence of those not totally complying with postoperative
instructions
3–6 Daif 201257 5/20 Not applicable Not applicable
TMJ, temporomandibular joint.
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TABLE 27 TMD: custom splint vs. prefabricated splint – other data
Outcome
Assessment
point (months) Study
Custom splint: mean
(SD); number of
events
Prefabricated
splint: mean (SD);
number of events Result: MD/RR (95% CI)
Pain
Modified Symptom Severity Index (Mod-SSI) –
28 characters for each of three variables: intensity,
frequency and pain duration. Average of the three
variables obtained and final scores ranged from
0.035 to 1 (higher =worse)
0–3 Amin 201655 Arm 1: hard splint
l 0.02 (0.14); n= 15
Arm 2: soft splint
l 0.03 (0.13); n= 15
0.02 (0.13); n= 15 MD 0.00 (–0.08 to 0.09); p= 0.91;
favours neither
Muscular palpation (masseter, temporalis and
pterygoid muscles) performed bilaterally with
tight and constant pressure of 1500 g, classified
on 0–3 scale (0, no pain; 1, verbally reported pain;
2, pain or discomfort followed by facial musculature
contraction and 3, patient backed away or showed
lacrimation)
0–3 Amin 201655 Arm 1: hard splint
l 0 (0); n= 15
Arm 2: soft splint
l 0 (0); n= 15
0 (0); n= 15 Not estimable
Overall improvement in TMJ pain assessed by the
patient on a six-point rating scale: 0 = symptom free;
1 =much better; 2= better; 3 = unchanged;
4 =worse; 5 =much worse (we dichotomised as
incidence of unchanged or worse/much worse)
0–3 Christidis 201472 4/21 9/23 RR 0.49 (0.18 to 1.35); p = 0.17;
favours custom splint
3–6 Christidis 201472 2/17 6/20 RR 0.39 (0.09 to 1.70); p = 0.21;
favours custom splint
6–12 Christidis 201472 1/15 2/18 RR 0.60 (0.06 to 5.99); p = 0.66;
favours custom splint
Incidence of 30% reduction in worst reported
VAS pain
0–3 Nilner 200873 22/33 23/32 RR 0.93 (0.67 to 1.28); p = 0.65;
favours prefabricated splint
3–6 Nilner 200873 22/24 23/28 RR 1.12 (0.90 to 1.38); p = 0.31;
favours custom splint
6–12 Nilner 200873 21/22 26/27 RR 0.99 (0.88 to 1.11); p = 0.31;
favours neither
continued
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TABLE 27 TMD: custom splint vs. prefabricated splint – other data (continued )
Outcome
Assessment
point (months) Study
Custom splint: mean
(SD); number of
events
Prefabricated
splint: mean (SD);
number of events Result: MD/RR (95% CI)
Incidence of 50% reduction in worst reported
VAS pain
0–3 Nilner 200873 18/33 21/32 RR 0.83 (0.56 to 1.24); p = 0.36;
favours prefabricated splint
> 3–6 Nilner 200873 21/24 22/28 RR 1.11 (0.87 to 1.42); p = 0.39;
favours custom splint
> 6–12 Nilner 200873 17/22 24/27 RR 0.87 (0.67 to 1.13); p = 0.3;
favours prefabricated splint
Pain on palpation: number of extraoral muscle
sites (0–16)
0–3 Truelove 200650 5.6 (5.4); n= 54 4.7 (4.1); n= 56 MD 0.90 (–0.90 to 2.70); p= 0.33;
favours prefabricated splint
> 6–12 Truelove 200650 3.6 (4.1); n= 65 4.1 (4.4); n= 55 MD –0.50 (–2.03 to 1.03);
p = 0.52; favours custom splint
Pain on palpation: number of intraoral muscle
sites (0–4)
0–3 Truelove 200650 3 (1.4); n= 54 2.8 (1.6); n= 56 MD 0.20 (–0.36 to 0.76); p= 0.48;
favours prefabricated splint
> 6–12 Truelove 200650 2.6 (1.6); n= 65 3 (1.4); n= 55 MD –0.40 (–0.94 to 0.14);
p = 0.14; favours custom splint
Pain on palpation: number of TMJ sites (0–4) 0–3 Truelove 200650 1.3 (1.5); n= 54 1.1 (1.4); n= 56 MD 0.20 (–0.34 to 0.74); p= 0.47;
favours prefabricated splint
> 6–12 Truelove 200650 0.9 (1.1); n= 65 1 (1); n= 55 MD –0.10 (–0.48 to 0.28);
p = 0.6; favours custom splint
TMJ clicking
On opening, closing or both 0–3 Truelove 200650 28/54 29/56 RR 1.00 (0.70 to 1.44); p = 0.99;
favours neither
6–12 Truelove 200650 37/65 25/55 RR 1.25 (0.87 to 1.79); p = 0.22;
favours prefabricated splint
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Outcome
Assessment
point (months) Study
Custom splint: mean
(SD); number of
events
Prefabricated
splint: mean (SD);
number of events Result: MD/RR (95% CI)
Frequency of headaches (secondary to pain-related TMD)
During the preceding 6 months on a verbal scale,
as follows: no headache; rarely; once a month;
once a week; at least 15 times a month; continuous
(we dichotomised this as once per week or more)
0–3 Nilner 200873 7/32 12/32 RR 0.58 (0.26 to 1.29); p = 0.18;
favours custom splint
> 3–6 Nilner 200873 3/24 7/28 RR 0.50 (0.15 to 1.72); p = 0.27;
favours custom splint
> 6–12 Nilner 200873 2/22 7/27 RR 0.35 (0.08 to 1.52); p = 0.16;
favours custom splint
Adherence to treatment
Not clear what level of compliance (e.g. using splint
all the time/majority of the time, etc.)
0–3 Truelove 200650 48/54 42/56 RR 1.19 (0.99 to 1.42); p = 0.06;
favours custom splint
6–12 Truelove 200650 47/65 17/55 RR 2.34 (1.53 to 3.57); p< 0.0001;
favours custom splint
TMJ, temporomandibular joint.
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TABLE 28 TMD: splint vs. control splint – other data
Outcome
Assessment
point (months) Study
Splint: mean
(SD)/number of
events
Control splint:
mean (SD)/number
of events Result: MD/RR (95% CI)
Pain
Modified Symptom Severity Index (Mod-SSI) – 28
characters for each of three variables: intensity,
frequency and pain duration. Average of the three
variables obtained and final scores ranged from
0.035 to 1 (higher =worse)
0–3 Alencar 200924 Arm 1: hard splint
l 0.31 (0.2); n= 14
Arm 2: soft splint
l 0.3 (0.26); n= 14
0.24 (0.24); n= 14 MD 0.07 (–0.09 to 0.22); p = 0.4;
favours control splint
Muscular palpation (masseter, temporalis and
pterygoid muscles) performed bilaterally with
tight and constant pressure of 1500 g, classified
on 0–3 scale (0, no pain; 1, verbally reported pain;
2, pain or discomfort followed by facial musculature
contraction and 3, patient backed away or showed
lacrimation)
0–3 Alencar 200924 Arm 1: hard splint
l 0.3 (0.5); n= 14
Arm 2: soft splint
l 0.3 (0.6); n= 14
0.3 (0.7); n= 14 MD 0.00 (–0.42 to 0.42); p = 1;
favours neither
Incidence of > 30% reduction in current pain
intensity on VAS
0–3 Dao 199468 13/18 15/19 RR 0.91 (0.63 to 1.32); p = 0.64;
favours control splint
Incidence of 50% reduction of worst pain on VAS 0–3 Ekberg 199835 11/30 6/30 RR 1.83 (0.78 to 4.32); p = 0.17;
favours splint
Current pain intensity assessed using a five-point
verbal scale: 0= no pain, 1 = slight pain,
2 =moderate pain, 3 = severe pain, 4 = very severe
pain (we dichotomised as incidence of moderate to
very severe pain)
0–3 Ekberg 199835 19/30 26/30 RR 0.68 (0.53 to 0.88); p = 0.004;
favours splint
Ekberg 200336 13/30 22/30
Pain frequency assessed using a nine-point verbal
scale: 0 = never, 1= rarely, 2= once a month,
3 = once every second week, 4 = once a week,
5 = twice a week, 6 = 3 or 4 times a week, 7= daily,
8 = constantly (we dichotomised as incidence of
once a week or more)
0–3 Ekberg 199835 19/30 25/30 RR 0.68 (0.46 to 1.01); p = 0.06;
favours splint
Ekberg 200336 8/30 16/30
Decrease in pain at rest (yes/no) 0–3 Ekberg 199835 29/30 22/30 RR 1.32 (1.05 to 1.65); p = 0.02;
favours splint
A
P
P
E
N
D
IX
2
N
IH
R
Jo
u
rn
als
Lib
rary
w
w
w
.jo
u
rn
alslib
rary.n
ih
r.ac.u
k
1
0
2
Outcome
Assessment
point (months) Study
Splint: mean
(SD)/number of
events
Control splint:
mean (SD)/number
of events Result: MD/RR (95% CI)
Pain at rest (yes/no) 0–3 Ekberg 200336 7/30 13/30 RR 0.54 (0.25 to 1.16); p = 0.11;
favours splint
Decrease in pain during mandibular movements
(yes/no)
0–3 Ekberg 199835 15/30 22/30 RR 0.68 (0.45 to 1.04); p = 0.07;
favours control splint
Pain during mandibular movements (yes/no) 0–3 Ekberg 200336 12/30 21/30 RR 0.57 (0.35 to 0.94); p = 0.03;
favours splint
Pain during non-guided mandibular movements
(we dichotomised as incidence of pain during
2–4 movements)
0–3 Ekberg 199835 12/30 24/30 RR 0.52 (0.34 to 0.80); p = 0.003;
favours splint
Ekberg 200336 5/30 8/30
Number of painful masticatory muscles on palpation
(we dichotomised as incidence of ≥ 4 sites)
0–3 Ekberg 199835 20/30 24/30 RR 0.73 (0.52 to 1.03); p = 0.07;
favours splint
Ekberg 200336 13/30 22/30
Degree of tenderness of masticatory muscles
on palpation assessed using a four-point scale:
0 = no tenderness, 1 = tenderness reported by
the patient, 2= tenderness with a palpebral reflex,
3 = tenderness with a defence reaction (we
dichotomised as incidence of scores 2 or 3)
0–3 Ekberg 199835 26/30 28/30 RR 0.93 (0.82 to 1.05); p = 0.23;
favours splint
Ekberg 200336 26/30 28/30
Incidence of 30% reduction in worst pain VAS score 0–3 Nilsson 200943 22/40 17/40 RR 1.29 (0.82 to 2.04); p = 0.27;
favours splint
6–12 Nilsson 200943 19/40 14/40 RR 1.36 (0.80 to 2.31); p = 0.26;
favours splint
Characteristic pain intensity (0 to 100 worsening
scale: mean of three scales – current pain, worst and
average in previous 6 months)
3–6 Nilsson 200943 19 (18); n = 32 29 (23); n = 25 MD –10.00 (–20.96 to 0.96);
p = 0.07; favours splint
6–12 Nilsson 200943 23 (18); n = 28 24 (21); n = 23 MD –1.00 (–11.87 to 9.87);
p = 0.86; favours splint
Incidence of 30% reduction in characteristic pain
intensity (described above)
0–3 Nilsson 200943 24/35 20/33 RR 1.13 (0.79 to 1.61); p = 0.5;
favours splint
6–12 Nilsson 200943 20/40 17/40 RR 1.18 (0.73 to 1.89); p = 0.5;
favours splint
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TABLE 28 TMD: splint vs. control splint – other data (continued )
Outcome
Assessment
point (months) Study
Splint: mean
(SD)/number of
events
Control splint:
mean (SD)/number
of events Result: MD/RR (95% CI)
Frequency of pain reported categorically: we
dichotomised the data as incidence of recurrent or
persistent (vs. never/one-time experience)
0–3 Nilsson 200943 19/35 18/33 RR 1.00 (0.64 to 1.54); p = 0.98;
favours neither
3–6 Nilsson 200943 10/32 11/25 RR 0.71 (0.36 to 1.40); p = 0.32;
favours splint
6–12 Nilsson 200943 7/28 10/23 RR 0.57 (0.26 to 1.27); p = 0.17;
favours splint
Mean value of worst pain 0 (no pain) to 10
(worst pain) NRS (author informed us that pain was
probably recorded daily for 2 weeks prior to the
follow-up)
0–3 Raphael 200147 5.16 (2.5456); n = 32 6.13 (2.4498);
n= 31
MD –0.97 (–2.20 to 0.26);
p= 0.12; favours splint
Pain on palpation using 2 lb of pressure: mean
number of painful facial muscles (unclear how many
muscles were palpated)
0–3 Raphael 200147 9.97 (5.4871); n = 32 10.94 (5.5678);
n= 31
MD –0.97 (–3.70 to 1.76);
p = 0.49; favours splint
Tenderness on palpation scored 0 (no response)
to 3 (retreat of head in anticipation and report of
considerable pain on contact) on multiple regions
and scores summed to obtain a palpation score
(length of scale unclear) – change scores reported
(mean decrease in score)
0–3 Rubinoff 198748 4.1 (4.4); n= 15 1.82 (4.51); n= 11 MD 2.28 (–1.19 to 5.75); p = 0.2;
favours splint
Change in restricted mouth-opening
Maximal interincisal distance in mm – change scores
reported (mean increase in score)
0–3 Rubinoff 198748 2.0 (4.8); n= 15 0.55 (2.98); n= 11 MD 1.45 (–1.55 to 4.45);
p = 0.34; favours splint
Frequency of headaches (secondary to pain-related TMD)
Reported categorically at 6 and 12 months: we
dichotomised the data as incidence of recurrent or
persistent (vs. never/one-time experience)
3–6 Nilsson 200943 12/32 11/25 RR 0.85 (0.45 to 1.60); p = 0.62;
favours splint
6–12 Nilsson 200943 10/28 9/23 RR 0.91 (0.45 to 1.86); p = 0.8;
favours splint
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Outcome
Assessment
point (months) Study
Splint: mean
(SD)/number of
events
Control splint:
mean (SD)/number
of events Result: MD/RR (95% CI)
Quality of life (including physical and emotional function)
Depression (20 questions) from subscales of
the SCL-90-R – reported as incidence of normal,
moderate or severe (we dichotmised as incidence
of moderate to severe)
3–6 Nilsson 200943 11/32 7/25 RR 1.23 (0.56 to 2.71); p = 0.61;
favours control splint
6–12 Nilsson 200943 10/28 8/23 RR 1.03 (0.49 to 2.17); p = 0.94;
favours neither
Somatisation (12 questions) from subscales of
the SCL-90-R – reported as incidence of normal,
moderate or severe (we dichotmised as incidence
of moderate to severe)
3–6 Nilsson 200943 13/32 13/25 RR 0.78 (0.44 to 1.37); p = 0.39;
favours splint
6–12 Nilsson 200943 10/28 11/23 RR 0.75 (0.39 to 1.44); p = 0.38;
favours splint
Average mood assessed using a 0 (best possible
mood) to 10 (worst possible mood) scale
0–3 Raphael 200147 3.44 (2.2062); n = 32 4.23 (2.3941);
n= 31
MD –0.79 (–1.93 to 0.35);
p = 0.17; favours splint
Depression (13 items) from subscales of the SCL-90-R
(higher score=worse depression) (length of scale
not reported but is 0–4 in other included studies)
0–3 Raphael 200147 1.5 (0.6223); n= 32 1.66 (0.6681);
n= 31
MD –0.16 (–0.48 to 0.16);
p = 0.33; favours splint
Patient satisfaction
Satisfied with treatment (yes/no) 0–3 Ekberg 200336 26/30 13/30 RR 2.00 (1.30 to 3.08); p = 0.002;
favours splint
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TABLE 29 TMD: harms/adverse effects
Study Results
Custom splint vs. prefabricated splint
Christidis 201472 There were no reported adverse events
Nilner 200873 At the 6-month follow-up, one patient in the R group with a vertical overbite of –1 mm at
baseline had an overbite of –3 mm. The patient was given a stabilisation appliance, and
no further increase in vertical overbite could be registered at the 12-month follow-up
Truelove 200650 No subjects reported an adverse effect with any of the treatments
Splint vs. no splint
Haketa 201066 No significant adverse effect was reported resulting from either treatment
Nitecka-Buchta 201470 No complications or any unintended effects in either group
Tatli 201754 There were no adverse effects reported that were due to splint use. Both groups had
arthrocentesis and sodium hyaluronate, and the adverse events, which were mild transient
swelling of the TMJ area and transient hemifacial paralysis, were related to this
Group 1= arthrocentesis plus sodium hyaluronate (control); Group 2= splint + arthrocentesis
plus sodium hyaluronate
Comment: there were no adverse effects reported that were due to splint use
Tavera 201223 Treatment-related adverse events:
l Discomfort or pain – group A: 9.4% (6/64); group B: 7.1% (2/28)
l Diminished hearing acuity – group A: 1.6% (1/64); group B: 0% (0/28)
l Headache – group A: 4.7% (3/64); group B: 3.6% (1/28)
l Dizziness or nausea – group A: 3.1% (2/64); group B: 3.6% (1/28)
l Other – group A: 3.1% (2/64) – jaw muscle/gum-related; group B: 0% (0/28)
Truelove 200650 No subjects reported an adverse effect with any of the treatments
Wahlund 200344 None of the patients in any of the treatment modes reported any major adverse effects
Wright 199551 There was insufficient evidence of a difference in occlusal contact changes: MD –0.60
(95% CI –1.48 to 0.28; p = 0.18)
Splint: mean 1.3 (SD 1.1); n= 10
Control splint: mean 1.9 (SD 0.9); n= 10
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Appendix 3 Characteristics and risk of bias of
included studies
Parts of this appendix have been adapted from Riley et al.1 This article is licensed under a CreativeCommons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution
and reproduction in any medium or format, as long as you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The
images or other third party material in this article are included in the article’s Creative Commons licence,
unless indicated otherwise in a credit line to the material. If material is not included in the article’s
Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of
this licence, visit http://creativecommons.org/licenses/by/4.0/. This includes minor additions and
formatting changes to the original text.
Attribute Study details
Alencar 200924
Characteristics
Study details l Trial design: parallel (three arms)
l Location: Occlusion, TMD and Orofacial Pain Clinic, Araraquara School
of Dentistry, São Paulo State University, Brazil
l Number of centres: one
l Recruitment period: not reported
l Sample size calculation: not reported
l Funding: public (CAPES – Brazilian government, partial funding)
l Declarations/conflicts of interest: not reported
Participants l Diagnosis: myofascial pain based on a standardised and complete
clinical examination, based on the diagnostic criteria of the AAOP.
Patients were included if they received a diagnosis of myofascial pain
with reproduction of the chief complaint with palpation of a trigger
point in the masseter muscle
l Duration since presenting condition began: not reported, but patients
were excluded if they had previous experience with occlusal splint
l Age at baseline (years): group A – mean 39 (range 24–65); group B –
mean 33 (range 18–52); group C – mean 31 (range 18–51)
l Sex (% male): group A: 14; group B: 7; group C: 14
l Number randomised: 45 (group A: 15; group B: 15; group C: 15)
l Number evaluated: 42 (group A: 14; group B: 14; group C: 14)
Interventions Comparison: splint vs. control splint for TMD
Group A
l Splint type: custom hard occlusal splint
l Lower jaw
l Material: hard
l Teeth coverage: full
l Details of impression-taking: not reported
l Instructions to patients: patients were taught the resting postural
position of the mandible (teeth apart, lips slightly touching and tongue
not pushing against the teeth). They were also instructed to perform
simultaneous bilateral mastication, so as not to load any TMJ or
masticatory muscles, including the masseter. Patients were also
instructed not to take any pain medication, to wear the splint 24 hours
a day during the first 7 days and to take it out during meals. After the
first week, splint wear was restricted to bedtime
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Attribute Study details
l Monitoring of patients: evaluations at 7, 30, 60 and 90 days after splint
insert. Splint installation, adjustment and follow-up were carried out by
researcher
Group B
l Splint type: custom soft occlusal splint (using mouthguard material over
mandibular cast)
l Lower jaw
l Material: EVA soft rubber-like plate
l Teeth coverage: full
l Details of impression-taking: not reported
l Instructions to patients: same as for groups A and C
l Monitoring of patients: same as for groups A and C
Group C
l Splint type: custom non-occluding splint
l Lower jaw
l Material: chemically activated acrylic resin and stainless steel wires
l Teeth coverage: partial
l Details of impression-taking: not reported
l Instructions to patients: same as for groups A and B
l Monitoring of patients: same as for groups A and B
Duration of treatment: 90 days
Outcomes Assessed at 7, 30, 60 and 90 days; we used the 90-day data for our
0–3 month analysis
Primary:
l Pain –
¢ subjective pain: Mod-SSI – this scale has 28 characters for each
of the three variables: intensity, frequency and pain duration.
An average of the three variables was obtained and final scores
ranged from 0.035 to 1 (higher =worse)
¢ objective pain: muscular palpation (masseter, temporalis and
pterygoid muscles) was performed bilaterally with tight and
constant pressure of approximately 1500 g and was classified on a
scale from 0 to 3 (0, no pain; 1, verbally reported pain; 2, pain or
discomfort followed by facial musculature contraction; and 3, when
the patient backed away or showed lacrimation)
Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
l ‘Patients were randomly assigned’
l Comment: unclear how this was done
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Selection bias was considered through a defined and concealed
randomization process with rather [sic] and subject blind of
group assignment’
l Comment: unclear who the randomisation was concealed from and how
this was done
Blinding of participants and personnel
(performance bias):
l High risk of bias
Unable to blind patients to type of splint used
Blinding of outcome assessment
(detection bias):
l High risk of bias
Patient-assessed pain is subjective; unclear if objective assessment is
really objective (muscular palpation)
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Incomplete outcome data (attrition bias):
l Low risk of bias
l ‘We initially enroled 45 patients and ended up with 42. Three patients
dropped out (one from each group) and the main reason for this was
that they were feeling better, with no necessity to come back to
the University’
l Comment: as only one patient per group dropped out this is unlikely to
have caused any bias
Selective reporting (reporting bias):
l Low risk of bias
Outcomes fully reported
Other bias:
l Low risk of bias
No apparent other bias
Amin 201655
Characteristics
Study details Trial design: parallel (three arms)
Location: Department of Prosthodontics and Department of Oral
Medicine and Radiology, Sri Dharmasthala Manjunatheshwara (SDM)
College of Dental Sciences and Hospital, Karnataka, India
Number of centres: one
Recruitment period: not reported
Sample size calculation: not reported
Funding: ‘Nil’
Declarations/conflicts of interest: ‘There are no conflicts of interest’
Participants Diagnosis: diagnosed with myofascial pain based on a standardised and
complete clinical examination based on the RDC/TMD
Duration since presenting condition began: not reported
Age at baseline (years): not reported (inclusion was 18–65)
Sex: not reported
Number randomised: 45 (group A: 15; group B: 15; group C: 15)
Number evaluated: 45 (group A: 15; group B: 15; group C: 15) – assuming
no attrition but not clearly reported
Interventions Comparison: custom-made splint vs. prefabricated splint for TMD
Group A
l Splint type: custom-made hard occlusal splint
l Upper jaw
l Material: hard acrylic
l Teeth coverage: full
l Details of impression-taking: not reported
l Instructions to patients: not reported
l Monitoring of patients: seen at 7, 30, 60 and 90 days
Group B
l Splint type: custom-made soft occlusal splint
l Lower jaw
l Material: soft polyvinyl sheet
l Teeth coverage: full
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Attribute Study details
l Details of impression-taking: thermally controlled infrared heater over
the mandibular cast
l Instructions to patients: not reported
l Monitoring of patients: seen at 7, 30, 60 and 90 days
Group C
l Splint type: prefabricated readily available liquid occlusal splint (Aqualizer)
l Upper jaw
l Material: hard acrylic
l Teeth coverage: full
l Details of impression-taking: not done
l Instructions to patients: not reported
l Monitoring of patients: seen at 7, 30, 60 and 90 days
Duration of treatment: 90 days
Outcomes Assessed at 7, 30, 60 and 90 days: we used the 90-day data for our
0–3 months’ analysis
Primary:
l Pain –
¢ subjective pain: Mod-SSI – this scale has 28 characters for each of
the three variables: intensity, frequency and pain duration. An
average of the three variables was obtained and final scores ranged
from 0.035 to 1 (higher =worse)
¢ objective pain: muscular palpation (masseter, temporalis and
pterygoid muscles) was performed bilaterally with tight and
constant pressure of approximately 1500 g and was classified on a
scale from 0 to 3 (0, no pain; 1, verbally reported pain; 2, pain or
discomfort followed by facial musculature contraction and 3, when
the patient backed away or showed lacrimation)
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
‘Randomly assigned using randomization table’
Comment: appropriate method
Allocation concealment (selection bias):
l Unclear risk of bias
Not mentioned
Blinding of participants and personnel
(performance bias):
l High risk of bias
Unable to blind patients to type of splint used
Blinding of outcome assessment
(detection bias):
l High risk of bias
Patient-assessed pain is subjective; unclear if objective assessment is
really objective (muscular palpation)
Incomplete outcome data (attrition bias):
l Unclear risk of bias
Assuming no attrition but not entirely clear
Selective reporting (reporting bias):
l Low risk of bias
Outcomes fully reported
Other bias:
l Low risk of bias
No apparent other bias
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Christidis 201472
Characteristics
Study details Trial design: parallel (two arms)
Location: Department of Orofacial Pain and Jaw Function, Malmö
University, Sweden; Section of Orofacial Pain and Jaw Function,
Karolinska Institutet, Sweden; Department of Stomatognathic Physiology,
University of Turku, Finland
Number of centres: three
Recruitment period: not reported, but conducted from October 2008 to
December 2011
Sample size calculation: yes (not met)
Funding: public (supported by Finska Lakaresallskapet – scientific
organisation of Swedish-speaking physicians in Finland)
Declarations/conflicts of interest: ‘no conflicts of interest. None of the
authors have any commercial affiliation or financial interest in any of the
appliances used in this study’
Authors provided unpublished data
Participants Diagnosis: a diagnosis of arthralgia or osteoarthritis of the TMJ according
to RDC/TMD; self-assessed worst TMJ pain during the previous 6 months
of at least 4 on a 0–10 (higher =worse) graded NRS; and duration of pain
≥ 3 months
Duration since presenting condition began: group A: mean 57 weeks;
group B: mean 40 weeks
Age at baseline (years): group A (stabilisation appliance) – mean 41
(range 19–73); group B (prefabricated) – mean 40 (range 21–71)
Sex: group A: 8% male; group B: 4% male
Number randomised: 48 (group A: 24; group B: 24)
Number evaluated: 10 weeks – 44 (group A: 21; group B: 23); 6 months –
37 (group A: 17; group B: 20); 12 months – 33 (group A: 15; group B: 18)
Interventions Comparison: custom-made splint vs. prefabricated splint for TMD
Group A
l Splint type: custom occlusal stabilisation splint
l Upper/lower jaw: not reported
l Material: hard (methylmetacrylate)
l Teeth coverage: partial – canines and incisors
l Details of impression-taking: alginate impressions
l Instructions to patients: wear the appliance every night for the first
10 weeks and when needed thereafter
l Monitoring of patients: seen at 2 and 10 weeks and 6 and 12 months
Group B
l Splint type: prefabricated occlusal splint (Relax)
l Upper jaw
l Material: hard [‘The prefabricated appliance (polymethylmetacrylate)
was individually fitted with a self-curing silicone material
(polyvinyl siloxane)’]
l Teeth coverage: partial – covers the edges of the incisors and canines
with palatal extension of approximately 1 cm
l Details of impression-taking: not done
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l Instructions to patients: as above
l Monitoring of patients: as above
Duration of treatment: 12 months
Outcomes Assessed at 10 weeks, 6 months and 12 months: we used these in our
0–3 months’, 3–6 months’ and 6–12 months’ analyses
Primary:
l Pain –
¢ pain intensity, 0–100 VAS (higher =more pain), assessed each
evening in a 1-week pain diary in the week prior to each assessment
point (author provided unpublished means and SDs for pain at rest
and during movement – we used the pain-at-rest data)
¢ GCPS reported by incidence of grades 0–IV, which is included
in the RDC/TMD Axis II questionnaire. Divided into two parts:
(1) assessment of pain intensity (0–100 worsening scale) and
(2) assessment of pain-related disability/limitations in physical
functioning (0–6 worsening scale). GCPS grade 0: no TMD pain in
the previous 6 months; grade I: low disability (< 3) and low-intensity
pain (< 50); grade II: low disability (< 3) and high-intensity pain
(> 50); grade III: high disability that was moderately limiting (3 or 4
regardless of pain score); grade IV: high disability that was severely
limiting (5 or 6 regardless of pain score) (we dichotomised as
incidence of grade III or IV)
¢ overall improvement in TMJ pain as assessed by patients using a
six-point scale: 0 = no symptoms; 1=much better; 2 = better;
3= unchanged; 4=worse; 5=much worse; reported as incidence
(dichotomised as incidence of unchanged or worse/much worse)
l Harms/adverse effects – reported as number of tooth contacts in
centric occlusion, changes in tooth sensitivity and occlusal trauma
Secondary:
l Change in restricted mouth-opening: reported as maximum voluntary
mouth-opening capacity (mm)
l Quality of life (including physical and emotional function): SCL-90-R
instrument in the RDC/TMD Axis II questionnaire – 20 questions
for depression and 12 questions for non-specific physical symptoms.
Each used a 0–4 worsening scale. Depression was scored as normal
(< 0.535), moderate (1.105) or severe (> 1.105). Non-specific physical
symptoms were scored as: normal (< 0.5), moderate (0.5–1) or severe
(> 1) (author provided unpublished means and SDs)
l Adherence to treatment: reported as incidence of use of appliance for
several nights per week or more
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
‘For each center, 16 consecutively numbered, opaque, sealed envelopes
containing a note with the treatment (8 for each treatment) were made
and placed in a larger envelope. For each patient, an independent person
at each center randomly drew an envelope and handed it to Dentist B.
This was repeated until 16 patients at each center were included’
Comment: adequate method (lottery)
Allocation concealment (selection bias):
l Low risk of bias
‘For each center, 16 consecutively numbered, opaque, sealed envelopes
containing a note with the treatment (8 for each treatment) were made
and placed in a larger envelope. For each patient, an independent person
at each center randomly drew an envelope and handed it to Dentist B.
This was repeated until 16 patients at each center were included’
Comment: the next assignment was adequately concealed from the person
randomising patients
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Attribute Study details
Blinding of participants and personnel
(performance bias):
l High risk of bias
Unable to blind patients to type of splint used
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessment by patients (except for ‘change in
restricted mouth-opening’ which may be considered objective and was
measured by a blinded assessor)
Incomplete outcome data (attrition bias):
l High risk of bias
31% attrition at 12 months (group A: 38%; group B: 25%). This could
potentially bias the results
Selective reporting (reporting bias):
l Low risk of bias
No evidence of selective reporting
Other bias:
l Low risk of bias
No apparent other bias
Conti 200525
Characteristics
Study details Trial design: parallel (three arms)
Location: Orofacial Pain Clinic at Bauru Dental School, University of São
Paulo, Brazil
Number of centres: one
Recruitment period: not reported
Sample size calculation: not reported
Funding: public (CAPES – Brazilian Government)
Declarations/conflicts of interest: not reported
We emailed authors for data but none provided so far
Participants Diagnosis: presence of TMJ disc displacement with reduction and chief
complaint of pain in the joint followed by positive TMJ tenderness to
manual palpation, accompanied or not by muscle symptoms. The presence
of at least a clicking joint during opening, eliminated on opening in
protrusion, was also an inclusion criterion
Duration since presenting condition began: not reported
Age at baseline (years): group A (stabilisation splint) – mean 32.7; group B
(repositioning splint) – mean 31.4; group C (no treatment) – mean 31.1
Sex: not reported
Number randomised: 60
Number evaluated: 52
Interventions Comparison: splint vs. no splint for TMD
Group A
l Splint type: custom stabilisation splint
l Upper/lower jaw: not reported
l Material: not reported
l Teeth coverage: unclear
l Details of impression-taking: not reported
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l Instructions to patients: wear at night and when sleeping
l Monitoring of patients: only at planned visits (1 and 2 weeks, and 1, 3,
6 and 12 months)
Group B
l Splint type: custom anterior repositioning splint for 3 to 4 months and then
converted into stabilisation splints for the remainder of the treatment period
l Upper/lower jaw: not reported
l Material: not reported
l Teeth coverage: unclear
l Details of impression-taking: not reported
l Instructions to patients: wear at night and when sleeping for
repositioning splint (not reported for stabilisation splint)
l Monitoring of patients: only at planned visits (1 and 2 weeks, and 1, 3,
6 and 12 months)
Group C
l No treatment or initial counselling
Duration of treatment: 12 months
Outcomes Assessed at 1 and 2 weeks and at 1, 3, 6 and 12 months: we would have
used the the 3-, 6- and 12-month data in our 0–3 months’, 3–6 months’
and 6–12 months’ analyses, respectively
Primary:
l Pain –
¢ pain on a 0–100 VAS (higher =more pain) (no usable data –
no SD/SE/p-values)
¢ pain on TMJ and masticatory and cervical muscle palpation (digital
pressure of 1.5 kg) (no usable data – no mean + SD/SE/p-values or
incidence data)
Secondary:
l TMJ clicking – presence of joint noises (detected during TMJ palpation)
no usable data – no mean + SD/SE/p-values)
l Change in restricted mouth-opening: maximum mouth-opening (mm)
(no usable data – no mean + SD/SE/p-values)
Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
‘Subjects were randomly located into one of the following groups’
Comment: insufficient information
Allocation concealment (selection bias):
l Unclear risk of bias
‘Subjects were randomly located into one of the following groups’
Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Unable to blind patients
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessment by patients (except for ‘TMJ clicking’ and
‘change in restricted mouth-opening’, which may be considered objective
and were measured by a blinded assessor)
Incomplete outcome data (attrition bias):
l Unclear risk of bias
Numbers per group at randomisation and assessment points were not reported
Selective reporting (reporting bias): Results very poorly reported with very limited data for all outcomes
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l High risk of bias
Other bias:
l Unclear risk of bias
Level of reporting extremely poor so unable to assess this
Conti 200626
Characteristics
Study details Trial design: parallel (three arms)
Location: Orofacial Pain Centre, Bauru Dental School, University of São
Paulo, Brazil
Number of centres: one
Recruitment period: not reported
Sample size calculation: not reported
Funding: public [supported by Conselho Nacional de Desenvolvimento
Científico e Tecnológico (CNPq BRAZIL) grant number 14164312000–5]
Declarations/conflicts of interest: not reported
We emailed authors for data but none provided so far
Participants Diagnosis: RDC/TMD – subjects who met the diagnosis criteria for
group II (disk displacement) and group IIIa (arthralgia)
Duration since presenting condition began: TMJ pain for at least 3 months
Age at baseline (years): group A – mean 28.9; group B – mean 31.3;
group C – mean 29.5
Sex: 8% male (not reported by group)
Number randomised: 60 (not reported by group)
Number evaluated: 57 (not reported by group)
Interventions Comparison: splint versus control splint for TMD
Group A
l Splint type: custom modified occlusal stabilisation splint
l Upper jaw
l Material: hard (acrylic)
l Teeth coverage: full
l Details of impression-taking: not reported
l Instructions to patients: instructed to wear splints only at night,
while sleeping
l Monitoring of patients: monitored at 15 days, 1 month, 3 months and
6 months
Group B
l Splint type: custom conventional occlusal stabilisation splint
l Upper jaw
l Material: hard (acrylic)
l Teeth coverage: full
l Details of impression-taking: not reported
l Instructions to patients: as above
l Monitoring of patients: as above
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Group C
l Splint type: custom non-occluding splint
l Lower jaw
l Material: hard (acrylic)
l Teeth coverage: full
l Details of impression-taking: not reported
l Instructions to patients: as above
l Monitoring of patients: as above
Duration of treatment: 6 months
Outcomes Assessed at 1 and 2 weeks and at 1, 3 and 6 months: we would have used
the 3- and 6-month data in our 0–3 months’ and 3–6 months’ analyses,
respectively
Primary:
l Pain –
¢ pain on a 0–100mm VAS (higher =more pain) (no usable data –
no SD/SE/p-values)
¢ pain on TMJ and muscle palpation (temporal and masseter)
(no usable data – no means or incidence data)
Secondary:
l TMJ clicking: incidence of joint sounds detected at examination
(not possible to use data as the numbers of patients analysed at each
follow-up point were not reported)
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
‘We used a table generated by a computer to perform the randomization’
Comment: appropriate method
Allocation concealment (selection bias):
l Unclear risk of bias
‘We used a table generated by a computer to perform the randomization’
Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Unable to blind patients to type of splint used
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessment by patients (except for ‘TMJ clicking’,
which may be considered objective and was measured by a blinded
assessor)
Incomplete outcome data (attrition bias):
l Low risk of bias
Only three patients dropped out so unlikely to affect the results
Selective reporting (reporting bias):
l High risk of bias
Data not reported in full for any outcome
Other bias:
l Unclear risk of bias
Poorly reported so difficult to assess
Conti 201227
Characteristics
Study details Trial design: parallel (three arms)
Location: Bauru School of Dentistry, University of São Paulo, Brazil
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
116
Attribute Study details
Number of centres: one
Recruitment period: not reported
Sample size calculation: not reported
Funding: public [supported by Conselho Nacional de Desenvolvimento
Científico e Tecnológico (CNPq), Brazil]
Declarations/conflicts of interest: ‘The authors declare that they have no
conflicts of interest’
We emailed authors for data but none provided so far
Participants Diagnosis: RDC/TMD – myofascial pain with or without jaw opening
limitation (Ia and Ib)
Duration since presenting condition began: not reported
Age at baseline (years): group A – mean 38.1; group B – mean 35.3;
group C – mean 38.1
Sex: group A – 19% male; group B – 12% male; group C – 0% male
Number randomised: 51 (group A: 21; group B: 16; group C: 14)
Number evaluated: at 3 months= 39 (group A: 17; group B: 13; group C: 9)
Interventions Comparison: splint vs. no splint for TMD
All patients received counselling for habits and behavioural changes
(reinforced at each visit): instructed about beneficial behavioural
changes and received a printed version of the instructions, containing
information about relaxation techniques, sleep hygiene, diet modification,
thermotherapy and massage in the painful area, as well as avoidance of
caffeine and daytime clenching
Group A
l Splint type: custom occlusal stabilisation splint
l Upper jaw
l Material: hard (acrylic)
l Teeth coverage: full
l Details of impression-taking: not reported
l Instructions to patients: advised to wear the appliance only at night
while sleeping
l Monitoring of patients: seen at 2, 6 weeks and 3 months for
adjustments
Group B
l Splint type: custom occlusal nociceptive trigeminal inhibition
(NTI) splint
l Upper jaw
l Material: not reported
l Teeth coverage: partial
l Details of impression-taking: not reported
l Instructions to patients: as above
l Monitoring of patients: as above
Group C
l No other treatment
Duration of treatment: 3 months
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Outcomes Assessed at 2 and 6 weeks and at 3 months: we used the 3-month data
for our 0–3 months’ analysis
Primary:
l Pain –
¢ current pain 0 (no pain) to 100 (worst pain) mm VAS (no usable
data – no SD/SE/p-values)
¢ pressure pain threshold (PPT): digital algometer used to put
pressure on muscles (patient presses button when she/he feels
pain); reported as kgf/cm2 (higher score = less pain) (reported
separately for left and right side for five muscles – data not used)
¢ incidence of patients who halved their VAS scores
Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
‘The patients were randomly allocated into one of the following three
groups’
Comment: insufficient information
Allocation concealment (selection bias):
l Unclear risk of bias
‘The patients were randomly allocated into one of the following three
groups’
Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Unable to blind patients
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessment by patients
Incomplete outcome data (attrition bias):
l High risk of bias
Very high overall attrition (24%) and especially high in the control group
(group A: 19%; group B: 19%; group C: 36%)
Selective reporting (reporting bias):
l High risk of bias
Data not adequately reported for pain on 0–100 VAS
Other bias:
l Unclear risk of bias
Lacking in detail so unable to assess
Conti 201528
Characteristics
Study details Trial design: parallel (three arms)
Location: Orofacial Pain Clinic at Bauru Dental School, University of São
Paulo, Brazil
Number of centres: one
Recruitment period: not reported
Sample size calculation: not reported
Funding: not reported
Declarations/conflicts of interest: not reported
We emailed authors for data but none provided so far
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Participants Diagnosis: disc displacement with reduction (IIa) and arthralgia (IIIa)
according to RDC/TMD (myofascial pain, disc displacement without
reduction and osteoarthritis according to RDC/TMD were all excluded)
Duration since presenting condition began: not reported
Age at baseline (years): group A – mean 38.4; group B – mean 38.4;
group C – mean 46
Sex: 3% male (not reported by group)
Number randomised: 60 (group A: 20; group B: 20; group C: 20)
Number evaluated: 3 months – 33 (group A: 12; group B: 12; group C: 9
Interventions Comparison: splint vs. no splint for TMD
All patients received counselling: instructions containing information
about relaxation techniques, sleep hygiene, diet modification and hot
thermotherapy, as well as avoidance of caffeine and awaking clenching
Group A
l Splint type: custom anterior repositioning occlusal splint
l Upper jaw
l Material: hard (acrylic)
l Teeth coverage: unclear
l Details of impression-taking: not reported
l Instructions to patients: wear only while sleeping
l Monitoring of patients: visits at 2 and 6 weeks and at 3 months; at
each visit, a comprehensive assessment of splint adjustments was
performed and the counselling and behavioural changes information
was reinforced in all groups
Group B
l Splint type: custom NTI-tss occlusal splint
l Upper jaw
l Material: not reported
l Teeth coverage: partial
l Details of impression-taking: not reported
l Instructions to patients: as above
l Monitoring of patients: as above
Group C
l No other treatment
Duration of treatment: 3 months
Outcomes Assessed at 2 and 6 weeks and at 3 months: we used the 3-month data
for our 0–3 months’ analysis
Primary
l Pain:
¢ current pain intensity 0 (no pain) to 100 (worst pain) mm VAS
(reported by graph but no SDs – a p-value was presented for the
comparison of group A vs. group C, so we have used this in the
meta-analysis)
¢ pressure pain threshold of each TMJ, using a digital pressure
algometer, where patients press button when they feel pain,
reported at 3 months (data presented at 3 months as means and
SDs for each joint, described as VAS score – not used)
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Secondary
l TMJ clicking: presence of TMJ sounds according to RDC/TMD. Data
presented as bar charts with % joints on y-axis, so not used because of
clustering of data
l Change in restricted mouth-opening: unassisted maximum mouth-
opening in mm (between the top and bottom edges, taking the mid-line
as reference) until pain felt
l Patient satisfaction: comfort level reported at 2 weeks (more
comfortable or not) – data reported only for splint groups so not
usable in meta-analyses
Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
l ‘Randomly assigned’
l Comment: insufficient information
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Randomly assigned’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Unable to blind patients
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessment by patients (except for ‘TMJ clicking’ and
‘change in restricted mouth-opening’, which may be considered objective
and were measured by a blinded assessor)
Incomplete outcome data (attrition bias):
l High risk of bias
Overall attrition: 32% at 6 weeks and 45% at 3 months
Selective reporting (reporting bias):
l High risk of bias
Data not adequately reported (e.g. for VAS pain, no SD reported and
p-value reported only for comparison between groups A and C)
Other bias:
l Unclear risk of bias
Lacking in detail so unable to assess
Costa 201529
Characteristics
Study details Trial design: parallel (two arms)
Location: Orofacial Pain Clinic at Bauru Dental School, University of São
Paulo, Brazil
Number of centres: one
Recruitment period: August 2011 to November 2012
Sample size calculation: reported incompletely (unclear if met)
Funding: public (grant number 2011/04441–6 from FAPESP – São Paulo
Research Foundation)
Declarations/conflicts of interest: ‘The authors declare no conflicts of interest’
We emailed authors for data but none provided so far
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Participants Diagnosis: RDC/TMD – myofascial pain
Duration since presenting condition began: pain duration at least 3 months
Age at baseline (years) (inclusion was 18–50): group A – mean 27.7
(SD 6.7); group B – mean 36 (SD 6.6)
Sex: group A: 10% male; group B: 10% male
Number randomised: 60 (group A: 30; group B: 30)
Number evaluated: 5 months – 41 (group A: 24; group B: 17); unclear how
many participants were evaluated at 2 months
Interventions Comparison: splint vs. no splint for TMD
All patients received counselling: verbal and written information about
TMD aetiology and prognostics, diet modification in the sense of avoiding
hard foods, use of reminders to avoid parafunctional habits, relaxation
techniques of the jaw, application of a heating pad on painful muscles
followed by stretching and self-massage, as well as sleep hygiene and
encouragement to practise social and aerobic activities
Group A
l Splint type: custom occlusal stabilisation splint
l Upper jaw
l Material: hard (acrylic)
l Teeth coverage: full
l Details of impression-taking: not reported
l Instructions to patients: wear splints at night only while sleeping
l Monitoring of patients: adjustments during visits at 2 and 5 months
Group B
l No other treatment
Duration of treatment: 5 months
Outcomes Assessed at 2 and 5 months: we used the 5-month data for our
3–6 months’ analysis (we were unable to use the 2-month data as the
numbers analysed were not reported)
Primary
l Pain: Catastrophizing Thoughts subscale of the Pain Related
Self-Statement Scale. Self-reported questionnaire consisting of nine
statements related to catastrophising thoughts involved in pain
perception. Respondent asked to answer each statement indicating
the frequency of thinking about pain during a pain crisis, on a 0–4 scale.
The sum of all frequencies was divided by the total number of questions.
Higher values demonstrate higher levels of pain catastrophising
(reported in additional table – not used for SMD of pain)
Secondary
l Frequency of headaches (secondary to pain-related TMD): categorised
as number having either infrequent/absent headache (< 1 day per
month), frequent headache (1–14 days per month), or chronic headache
(> 14 days per month) – we dichotomised the data as incidence of
frequent or chronic headache
l Quality of life (including physical and emotional function): anxiety
and depression reported using HADS. Self-reported questionnaire
consisting of 14 multiple choice questions involving two interspersed
subscales: one for anxiety (seven questions) and the other for depression
(seven questions). The scores ranged from 0 to 21 points and were
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divided into four categories: 0–7 (no anxiety or depression), 8–10 (mild
anxiety or depression), 11–14 (moderate anxiety or depression) and
15–21 (severe anxiety or depression) – we dichotomised the data as
incidence of moderate or severe anxiety/depression (data not used –
some do not appear to add up to 100%)
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘Randomly assigned, by a computer-generated list’
l Comment: appropriate method
Allocation concealment (selection bias):
l Low risk of bias
l ‘The allocation of groups was concealed and designated according to
sequentially numbered, opaque, sealed envelopes given to a person
who did not know the allocation sequence’
l Comment: the next assignment was adequately concealed from the
person randomising patients
Blinding of participants and personnel
(performance bias):
l High risk of bias
Unable to blind patients
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessment by patients
Incomplete outcome data (attrition bias):
l High risk of bias
Overall attrition at 5 months was 32% and also differed by group
(group A: 20%; group B: 43%). This could potentially bias the results
Selective reporting (reporting bias):
l High risk of bias
We would have expected the authors to also report a more simple pain
intensity outcome in line with other RCTs in this field (e.g. 0–100mm VAS)
Other bias:
l Low risk of bias
No apparent other bias
Daif 201257
Characteristics
Study details Trial design: parallel (two arms)
Location: Department of Oral and Maxillofacial, Faculty of Oral & Dental
Medicine, Cairo University, Egypt
Number of centres: one
Recruitment period: not reported
Sample size calculation: not reported
Funding: not reported
Declarations/conflicts of interest: ‘The authors report no conflicts of interest’
Participants Diagnosis: TMD with myofascial pain by the presence of a non-teeth-related
chronic orofacial pain with localised areas of tenderness in the masticatory
muscles. Signs and symptoms were recorded according to the clinical
dysfunction index of Helkimo74
Duration since presenting condition began: not reported
Age at baseline (years): overall – mean 32 (range 22–46)
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Sex: overall – 42.5% male
Number randomised: 40 (group A: 20; group B: 20)
Number evaluated: 40 (group A: 20; group B: 20)
Interventions Comparison: splint vs. no splint for TMD
Group A
l Splint type: custom-made flat-plane occlusal splint
l Upper jaw
l Material: hard (acrylic resin)
l Teeth coverage: full
l Details of impression-taking: fabricated on articulated dental casts.
The vertical pin of the articulator was adjusted to create a 2- to 3-mm
space between the molars
l Instructions to patients: wear the splints during the whole night and as
much as possible during the daytime for 6 months
l Monitoring of patients: not reported
Group B
l No treatment
Duration of treatment: 6 months
Outcomes Assessed at 6 months: grouped under 3–6 months’ analysis
Secondary
l Adherence to treatment: incidence of those not totally complying with
postoperative instructions
l The other outcome assessed at 6 months (clinical dysfunction index of
Helkimo74) was not an outcome of this review
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘Randomization was performed using a computer-generated random
number list’
l Comment: appropriate method
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Randomization was performed using a computer-generated random
number list’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding not possible
Blinding of outcome assessment
(detection bias):
l High risk of bias
Patients were not blinded but self reported compliance
Incomplete outcome data (attrition bias):
l Low risk of bias
All randomised participants were included in analysis
Selective reporting (reporting bias):
l High risk of bias
The study focused on TMD with pain; therefore, we would have expected
pain to have been measured separately
Other bias:
l Low risk of bias
No apparent other bias
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Dao 199468
Characteristics
Study details Trial design: parallel (three arms)
Location: Faculty of Dentistry and Neuroscience Research Centre,
University of Montreal, Montreal, QC, Canada
Number of centres: one
Recruitment period: not reported
Sample size calculation: yes (met)
Funding: public (Medical Research Council of Canada and the Fonds de la
Recherche en Sante du Quebec)
Declarations/conflicts of interest: not reported
Participants Diagnosis: chief complaint of frequent pain (at least four times per week)
in the jaw muscles of at least 12 weeks duration; positive report of
tenderness to palpation of at least three sites in the masticatory muscles
Duration since presenting condition began: history of myofascial pain
varied from 3 months to 12 years, with a mean of 43.4 months
Age at baseline (years): group A – mean 29 (range 16–40); group B –
mean 28 (range 16–42)
Sex: group A – 18% male; group B – 20% male
Number randomised: 43 (group A: 22; group B: 21)
Number evaluated: 42 (group A: 22; group B: 20)
Interventions Comparison: splint vs. control splint for TMD
Group A
l Splint type: custom occlusal stabilising splint
l Upper jaw
l Material: not reported
l Teeth coverage: full
l Details of impression-taking: not reported
l Instructions to patients: wear day and night; remove only at meal times
l Monitoring of patients: adjustments made at 1, 3, 5 and 8 weeks
Group B
l Splint type: palatal U-shaped splint that did not interfere with occlusion
l Upper jaw
l Material: not reported
l Teeth coverage: partial (retained with clasps on maxillary teeth)
l Details of impression-taking: not reported
l Instructions to patients: as above
l Monitoring of patients: as above
Group C
l Wearing same splint as group A for 30 minutes at each appointment
(excluded from this review)
Duration of treatment: 8 weeks
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Outcomes Assessed at 1, 3, 5 and 8 weeks: we would have used the 8-week data for
our 0–3 month analysis
Primary:
l Pain –
¢ current pain intensity and pain unpleasantness assessed separately
on a 0 (no pain) to 100 (worst pain) mm VAS; both were assessed
separately at rest and after chewing for 3 minutes – we used only
current pain intensity at rest (unable to use the mean VAS scores –
no SD/SE/CI or p-values reported; we used data for incidence of
> 30% reduction in VAS pain)
Secondary:
l Quality of life (including physical and emotional function) –
¢ pain-related disability and psychosocial status assessed on a 0–4
worsening scale assessing how the pain affected six daily activities
or states: sleep, efficiency at work, social activities, depression,
anxiety and appetite – summed to obtain an overall score (no usable
data – means on a graph with no SD/SE/CI/p-value
Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
‘Patients were randomly allocated to 1 of the 3 experimental groups’
Comment: insufficient information
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Patients were randomly allocated to 1 of the 3 experimental groups’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
l ‘All patients were given the same description of the study. They were
told that the etiology of their pain remains unknown and that different
designs of splints and different methods of wearing these were being
tested, in order to find out which was the most practical and effective
therapy for their condition’
l Comment: although patients were probably effectively blinded,
personnel providing treatment were not
Blinding of outcome assessment
(detection bias):
l Low risk of bias
Subjective outcomes assessed by blinded patients
Incomplete outcome data (attrition bias):
l Low risk of bias
Only one participant was missing from the control group
Selective reporting (reporting bias):
l High risk of bias
It was not possible to use any VAS pain or quality-of-life data
Other bias:
l Low risk of bias
No apparent other bias
de Felício 200630
Characteristics
Study details Trial design: parallel (two arms)
Location: Dental School of Ribeirão Preto of the University of São Paulo,
Brazil
Number of centres: one
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Recruitment period: not reported
Sample size calculation: not reported
Funding: not reported
Declarations/conflicts of interest: not reported
Participants Diagnosis: presence of signs and symptoms characteristic of TMD: pain in
the masticatory muscles and/or in the TMJ during mandibular function and
palpation of the structures, limitation or deviation of mandibular movements,
noises in the TMJ, and abnormal static or dynamic occlusal relation
Duration since presenting condition began: not reported
Age at baseline (years): not reported
Sex: not reported
Number randomised: 84 (group A: 42; group B: 42)
Number evaluated: 84 (group A: 42; group B: 42)
Interventions Comparison: splint vs. minimal treatment for TMD
Group A
l Splint type: custom occlusal splint
l Upper jaw
l Material: hard (heat-polymerizable colourless acrylic resin)
l Teeth coverage: full
l Details of impression-taking: dental arches moulded with irreversible
hydrocolloid (alginate) and the plaster casts obtained were mounted
on a semi-adjustable articulator in the mandibular position of
centric relation
l Instructions to patients: use during the day and at night for the first
15 days, and only at night thereafter
l Monitoring of patients: not reported
Group B
Continued to attend occlusion outpatient clinic, receiving information
about TMD
Duration of treatment: 50 days
Outcomes Assessed at 50 days: grouped under 0–3 month analysis
Primary:
l Pain –
¢ presence of muscular pain (yes/no)
¢ severity of muscular pain and TMJ pain assessed separately using a
0–10 NRS – when waking up, during mastication, when speaking
and at rest all assessed separately for each type of pain and
summed (no usable data – no mean with SD/SE/CI or p-value)
Secondary:
l TMJ clicking –
¢ articular noise (yes/no) – ‘The predominant type of articular noise
was a click (83.33% of cases)’
¢ joint noise assessed using a 0–10 NRS – when waking up, during
mastication, when speaking and at rest all assessed separately and
summed (no usable data – no mean with SD/SE/CI or p-value)
l Change in restricted mouth-opening: difficulty opening mouth (yes/no)
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Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘Patients with TMD were randomly divided into two groups using
GraphPad software’ (GraphPad Software Inc., San Diego, CA, USA)
l Comment: author provided this information by e-mail
Allocation concealment (selection bias):
l Unclear risk of bias
Not mentioned
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding not possible
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessed by the patients
Incomplete outcome data (attrition bias):
l Low risk of bias
All randomised patients were included in the analyses
Selective reporting (reporting bias):
l High risk of bias
Poor reporting of NRS severity scores
Other bias:
l Low risk of bias
No apparent other bias
de Felício 201031
Characteristics
Study details Trial design: parallel (four arms)
Location: Faculty of Medicine of Ribeirão Preto of the University of São
Paulo, Brazil
Number of centres: one
Recruitment period: not reported
Sample size calculation: not reported
Funding: public (supported by Fundação de Amparo à Pesquisa do Estado
de São Paulo -FAPESP, Process N. 2004/08478–8 and Conselho Nacional
de Pesquisa – CNPq, Process N. 300950/2007–1)
Declarations/conflicts of interest: not reported
Participants Diagnosis: long-lasting associated articular and muscular TMD based on
RDC/TMD
Duration since presenting condition began: mean duration of TMD was
74.4 months (range 6–300 months)
Age at baseline (years): group A – mean 29 (range 17–64); group B –
mean 34 (range 14–63)
Sex: not reported
Number randomised: 20 (group A: 10; group B: 10)
Number evaluated: 20 (group A: 10; group B: 10) – this is assumed as
attrition was not mentioned
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Interventions Comparison: splint vs. no splint for TMD
l Group A
¢ Splint type: custom occlusal splint (Michigan)
¢ Upper/lower jaw not specified
¢ Material: not reported
¢ Teeth coverage: full
¢ Details of impression-taking: not reported
¢ Instructions to patients: continuous use recommended during first
15 days, except during eating and teeth cleaning, followed by only
nighttime use after this period
¢ Monitoring of patients: not reported
l Group B: no treatment
l Group C: orofacial myofunctional therapy (not eligible for inclusion in
this review)
l Group D: asymptomatic controls (not eligible for inclusion in this review)
Duration of treatment: 45 days
Outcomes Assessed at 45 days: grouped under 0–3 month analysis
Primary:
l Pain –
¢ muscle pain assessed on a printed 0 (absence of symptom) to 10
(worst severity) for the following four situations: (1) when waking
up, (2) during chewing, (3) when speaking and (4) at rest. The score
was then summed and is, therefore, a 0–40 scale
Secondary:
l TMJ clicking –
¢ assessed on a printed 0 (absence of symptom) to 10 (worst severity)
for the following four situations: (1) when waking up, (2) during
chewing, (3) when speaking and (4) at rest. The score was then
summed and is, therefore, a 0–40 scale
¢ Change in restricted mouth-opening: maximal mandibular opening in
mm (unclear if with/without/until pain or assisted/unassisted)
l Change in restricted mouth-opening: maximal mandibular opening in
mm (unclear if with/without/until pain or assisted/unassisted)
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘Randomly assigned to three groups using the GraphPad software’
l Comment: appropriate method
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Randomly assigned to three groups using the GraphPad software’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding not possible
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessment by patients (except for ‘change in
restricted mouth-opening’ and ‘TMJ clicking’ which were objective but
blinded assessor not mentioned)
Incomplete outcome data (attrition bias):
l Unclear risk of bias
Assuming no attrition but not entirely clear
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Selective reporting (reporting bias):
l Low risk of bias
Outcomes fully reported
Other bias:
l Low risk of bias
No other apparent bias
DeVocht 201345
Characteristics
Study details Trial design: parallel (four arms)
Location: Craniofacial Clinical Research Centre, University of Iowa,
Iowa City, IA, USA; Palmer College of Chiropractic, Davenport, IA, USA
Number of centres: two
Recruitment period: over 18 months, ending in July 2011
Sample size calculation: no (‘We chose the sample size to determine
feasibility and, therefore, the study was not powered to detect differences
between groups’)
Funding: public and industry (grants from National Institutes of Health;
ineligible interventions mentioned above were provided by the
manufacturer)
Declarations/conflicts of interest: one author declared instructing for
Activator Methods International, Phoenix (manufacturers of the ineligible
interventions mentioned above). None of the other authors reported any
disclosures
Participants Diagnosis: myofascial pain (RDC/TMD Axis I) with TMD pain over the
previous week of at least a 3 on a 0–10 NRS
Duration since presenting condition began: (inclusion criteria required
participants having had TMD symptoms for at least 6 months) – group A:
median 10 years (IQR 12.5); group B: median 10 years (IQR 11)
Age at baseline (years): group A – mean 31 (range 13–76); group B: mean
30 (range 15–72)
Sex: group A – 15% male; group B – 24% male
Number randomised: 41 (group A: 20; group B: 21)
Number evaluated: 41 (group A: 20; group B: 21) – ITT used (multiple
imputation for the missing outcomes)
Interventions Comparison: Splint versus no splint for TMD
All patients received TMD self-care programme: similar to usual
recommendations given to patients with TMD. Conservative and
reversible strategies requiring the dentist or dental care co-ordinator
to review TMD with the participant; explain to them the current
understanding of prognosis; and provide standardised treatment checklist
identifying recommendations for care (e.g. jaw relaxation, reduction of
parafunctional behaviours, use of thermal packs, use of over-the-counter
pain medications, passive jaw-opening stretches and suggestions about
stress reduction)
l Group A
¢ Splint type: custom-reversible interocclusal splint therapy (RIST)
¢ Upper jaw
¢ Material: hard (acrylic)
¢ Teeth coverage: full
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¢ Details of impression-taking: maxillary and mandibular vinyl
polysiloxane impressions made, then interocclusal records were
made using a fast-setting vinyl polysiloxane bite registration
material and an intraoral metal tray
¢ Instructions to patients: wear at night and for at least 2 hours
during the day
¢ Monitoring of patients: none
l Group B: no other treatment
l Group C: Activator Method Chiropractic Technique (not eligible for
inclusion in this review)
l Group D: sham Activator Method Chiropractic Technique (not eligible
for inclusion in this review)
Duration of treatment: 2 months
Outcomes Assessed at 2 and 6 months: we used these data in our 0–3 month and
3–6 month analyses, respectively
Primary:
l Pain –
¢ current pain intensity using a 0 (no pain) to 10 (worst pain) NRS;
reported as change score (unable to combine change score in
primary meta-analysis using SMD; used in sensitivity analyses of
studies reporting current pain intensity on VAS/NRS at 0–3 months
and 3–6 months)
Secondary:
l Quality of life (including physical and emotional function) – OHIP-14:
contains two questions about each of seven dimensions, indicating how
often the participant had experienced each difficulty in the previous
month; possible responses range from 0 (never) to 4 (very often). The
OHIP score is obtained by summing the 14 ratings; reported as change
score (unable to combine change score in primary meta-analysis using
SMD; used in sensitivity analyses of studies reporting current pain
intensity on VAS/NRS at 0–3 months)
l Patient satisfaction: using a 0 (not at all satisfied) to 10 (extremely
satisfied) NRS (no usable data at 6 months: no SD/SE/CI or p-value)
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘We allocated participants via a randomization algorithm stored in the
Web-based system, with future allocations concealed’
l Comment: appropriate method
Allocation concealment (selection bias):
l Low risk of bias
l ‘We allocated participants via a randomization algorithm stored in the
Web-based system, with future allocations concealed’
l Comment: probably done as a separate data co-ordinating centre was
used (The office of Data Management and Biostatistics at the Palmer
Centre for Chiropractic Research)
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding not possible
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessed by the patients
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Incomplete outcome data (attrition bias):
l Low risk of bias
ITT used (multiple imputation for the missing outcomes)
Selective reporting (reporting bias):
l Low risk of bias
No evidence of selective reporting
Other bias:
l Low risk of bias
No other apparent bias
Ekberg 199835
Characteristics
Study details Trial design: parallel (two arms)
Location: Department of Stomatognathic Physiology, Lund University, Sweden
Number of centres: one
Recruitment period: over 3 years
Sample size calculation: yes (met)
Funding: public (supported by the Faculty of Odontology at Lund
University and the Swedish Dental Society)
Declarations/conflicts of interest: not reported
Participants Diagnosis: TMD of arthrogeneous origin – pain localised to the TMJ
region and lateral and/or posterior tenderness to palpation of the TMJ
combined with self-assessed TMJ pain of ≥ 40mm on a 100mm VAS
Duration since presenting condition began: TMJ pain (months) – group A:
median 24 (range 3–360); group B: median 14 (range 2–120)
Age at baseline (years): group A – mean 31 (range 13–76); group B –
mean 30 (range 15–72)
Sex: group A – 13% male; group B – 3% male
Number randomised: 60 (group A: 30; group B: 30)
Number evaluated: 60 (group A: 30; group B: 30)
Interventions Comparison: splint vs. control splint for TMD
Group A
l Splint type: custom occlusal stabilisation splint
l Upper jaw
l Material: not reported
l Teeth coverage: full
l Details of impression-taking: not reported
l Instructions to patients: wear at night
l Monitoring of patients: a second adjustment was made after 2 weeks
but no further adjustment was performed during the following 8 weeks
except for single patients as a result of comfort
Group B
l Splint type: custom non-occlusal palatal splint
l Upper jaw
l Material: not reported
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l Teeth coverage: palatal coverage with clasps on the maxillary teeth
(did not interpose between the occluding teeth and therefore did not
alter the intermaxillary relationship)
l Details of impression-taking: not reported
l Instructions to patients: as above
l Monitoring of patients: as above
Duration of treatment: 10 weeks
Outcomes Assessed at 10 weeks: grouped under 0–3 month analysis
Primary:
l Pain –
¢ current pain intensity and worst pain experienced assessed
separately using a 0 (no pain) to 100 (worst pain) mm VAS (only
reported as incidence of 50% reduction of worst pain on VAS)
¢ current pain intensity assessed using a five-point verbal scale:
0= no pain, 1 = slight pain, 2 =moderate pain, 3 = severe pain,
4= very severe pain (we dichotomised as incidence of moderate to
very severe pain)
¢ pain frequency assessed using a nine-point verbal scale: 0= never,
1= rarely, 2 = once a month, 3= once every second week, 4= once
a week, 5 = twice a week, 6= three or four times a week, 7= daily,
8= constantly (we dichotomised as incidence of once a week
or more)
¢ pain duration assessed as follows: 0 = no pain, 1= a couple of
minutes, 2= some hours, 3= a full day, 4 = constant (not reported)
¢ reported pain both at rest and during mandibular movements (yes/no)
(only reported as incidence of a decrease)
¢ pain during non-guided mandibular movements (we dichotomised as
incidence of pain during 2–4 movements)
¢ number of painful masticatory muscles on palpation (we dichotomised
as incidence of ≥ 4 sites)
¢ degree of tenderness of masticatory muscles on palpation assessed
using a four-point scale: 0= no tenderness, 1= tenderness reported by
the patient, 2= tenderness with a palpebral reflex, 3= tenderness with
a defence reaction (we dichotomised as incidence of scores 2 or 3)
Secondary
l TMJ clicking – incidence of reciprocal clicking
l Change in restricted mouth-opening: reported as incidence of those
with opening < 40 mm
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘The randomization was carried out by one independent person, using
10 series of consecutively numbered sealed opaque envelopes’
l Comment: probably done
Allocation concealment (selection bias):
l Low risk of bias
l ‘The randomization was carried out by one independent person, using
10 series of consecutively numbered sealed opaque envelopes’
l Comment: the next assignment was adequately concealed from the
person randomising patients
Blinding of participants and personnel
(performance bias):
l High risk of bias
The person delivering and adjusting the splints was not blinded
Blinding of outcome assessment
(detection bias):
l Unclear risk of bias
Examiner was blinded. Many of the outcomes were patient-reported and
it was not clear if the patients were aware of their group assignment
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Incomplete outcome data (attrition bias):
l Low risk of bias
All randomised participants were included in analysis
Selective reporting (reporting bias):
l High risk of bias
Some outcomes measured but not reported fully (current pain VAS and
maximum mouth-opening mean and SD)
Other bias:
l Low risk of bias
No other apparent bias
Ekberg 200336
Characteristics
Study details Trial design: parallel (two arms)
Location: Department of Stomatognathic Physiology, Malmö University,
Sweden
Number of centres: one
Recruitment period: over approximately 2 years
Sample size calculation: not reported
Funding: public (grants from the Faculty of Odontology at Lund University
and the Swedish Dental Society)
Declarations/conflicts of interest: not reported
Participants Diagnosis: myofascial pain with or without limited opening according
to RDC/TMD; self-assessed myofascial pain of at least 40 mm on a
100mm VAS
Duration since presenting condition began: myofascial pain (months) –
group A: median 36 (range 4–420); group B: median 24 (range 1–120)
Age at baseline (years): group A – mean 31 (range 14–54); group B: mean
28 (range 14–56)
Sex: group A – 17% male; group B – 10% male
Number randomised: 60 (group A: 30; group B: 30)
Number evaluated: 60 (group A: 30; group B: 30)
Interventions Comparison: splint vs. control splint for TMD
Group A
l Splint type: custom occlusal stabilisation splint
l Upper jaw
l Material: not reported
l Teeth coverage: full
l Details of impression-taking: not reported
l Instructions to patients: wear at night
l Monitoring of patients: a second adjustment was made after 2 weeks
but no further adjustment was performed during the following 8 weeks
except for single patients as a result of comfort
Group B
l Splint type: custom non-occlusal palatal splint
l Upper jaw
l Material: not reported
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l Teeth coverage: palatal coverage with clasps to attach to one molar on
each side (appliance did not cover occlusal surfaces)
l Details of impression-taking: not reported
l Instructions to patients: as above
l Monitoring of patients: as above
Duration of treatment: 10 weeks
Outcomes Assessed at 10 weeks: grouped under 0–3 month analysis
Primary:
l Pain –
¢ current pain intensity and worst pain experienced assessed
separately using a 0 (no pain) to 100 (worst pain) mm VAS (only
worst pain means were reported with SD, so the current pain means
were not usable – we used worst pain in the meta-analysis)
¢ current pain intensity assessed using a five-point verbal scale:
0= no pain, 1 = slight pain, 2 =moderate pain, 3 = severe pain,
4= very severe pain (we dichotomised as incidence of moderate to
very severe pain)
¢ pain frequency assessed using a nine-point verbal scale: 0= never,
1= rarely, 2 = once a month, 3= once every second week, 4= once
a week, 5 = twice a week, 6= 3 or 4 times a week, 7= daily,
8= constantly (we dichotomised as incidence of once a week
or more)
¢ reported pain both at rest and during mandibular movements (yes/no)
¢ pain during non-guided mandibular movements (we dichotomised as
incidence of pain during 2–4 movements)
¢ number of painful masticatory muscles on palpation (we dichotomised
as incidence of ≥ 4 sites)
¢ degree of tenderness of masticatory muscles on palpation assessed
using a four-point scale: 0 = no tenderness, 1 = tenderness reported
by the patient, 2= tenderness with a palpebral reflex, 3= tenderness
with a defence reaction (we dichotomised as incidence of scores 2
or 3)
Secondary:
l TMJ clicking – incidence of reciprocal clicking
l Change in restricted mouth-opening – reported as incidence of those
with opening of < 40 mm
l Patient satisfaction – satisfied with their treatment (yes/no)
l Adherence to treatment – 0 = every night, 1= several nights a week,
2=when necessary, 3= not at all (we dichotomised as incidence of use
every night or several nights a week)
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘One independent person carried out the randomization by using
10 series of consecutively numbered, sealed, opaque envelopes’
l Comment: probably done
Allocation concealment (selection bias):
l Low risk of bias
l ‘One independent person carried out the randomization by using
10 series of consecutively numbered, sealed, opaque envelopes’
l Comment: the next assignment was adequately concealed from the
person randomising patients
Blinding of participants and personnel
(performance bias):
l High risk of bias
The person delivering and adjusting the splints was not blinded
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Blinding of outcome assessment
(detection bias):
l Unclear risk of bias
Examiner was blinded. Many of the outcomes were patient-reported and
it was not clear if the patients were aware of their group assignment
Incomplete outcome data (attrition bias):
l Low risk of bias
All randomised participants were included in analysis
Selective reporting (reporting bias):
l High risk of bias
Some outcomes measured but not reported fully (current pain VAS and
maximum mouth-opening mean and SD)
Other bias:
l Low risk of bias
No other apparent bias
Elsharkawy 199558
Characteristics
Study details Trial design: parallel (four arms)
Location: Oral Surgery Department, Cairo University, Egypt
Number of centres: one
Recruitment period: not reported
Sample size calculation: not reported
Funding: not reported
Declarations/conflicts of interest: not reported
Participants Diagnosis: based on presence of two or more of TMJ pain and tenderness
when palpated both laterally in the preauricular area and via the external
auditory meatus, masticatory muscle tenderness, clicking and jaw locking,
and trismus (patients with disc displacement were excluded)
Duration since presenting condition began: not reported
Age at baseline (years): not reported
Sex: not reported
Number randomised: 50 (group A: 25; group B: 25)
Number evaluated: 46 (group A: 23; group B: 23)
Interventions Comparison: splint vs. no splint for TMD
All patients in groups A and B received acuhealth therapy: acuhealth unit
detects energy acupucture points and performs stimulation/treatment
without penetrating the skin; weekly sessions for 8 weeks
l Group A
¢ Splint type: custom occlusal splint
¢ Lower jaw
¢ Material: soft (polyvinyl)
¢ Teeth coverage: full
¢ Details of impression-taking: not reported
¢ Instructions to patients: wear at night
¢ Monitoring of patients: not reported
DOI: 10.3310/hta24070 Health Technology Assessment 2020 Vol. 24 No. 7
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Riley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
135
Attribute Study details
l Group B: no other treatment
l Group C*: above-mentioned splint alone (no acuhealth therapy)
l Group D*: placebo acuhealth therapy (machine switched off)
*Groups C and D are excluded from this review as it was not possible to
make any eligible pairwise comparisons using them
Duration of treatment: 8 weeks
Outcomes Assessed at 3 months: grouped under 0–3 month analysis (also assessed
at 6 and 12 months but patients had crossed over and were no longer
analysed according to the group they were originally randomised to,
so the data were not eligible for inclusion)
Primary:
l Pain –
(a) current pain intensity 0 (no pain) to 100 (worst pain) mm VAS
(no data reported)
(b) subjective dysfunction score: 1= no pain, 2=mild pain,
3=moderate pain, 4 = severe pain, 5= very severe pain
(no data reported)
¢ the results for pain outcomes a and b above were individually
assessed according to the following scale: impaired, unchanged,
improved, symptom free (we dichotomised this as incidence of
improved and symptom free)
Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
l ‘Randomly divided’
l Comment: insufficient information
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Randomly divided’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding not possible
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective pain outcomes assessment by patients
Incomplete outcome data (attrition bias):
l High risk of bias
We were unable to use data at 6 and 12 months as some patients were no
longer analysed according to the group they were originally randomised to
Selective reporting (reporting bias):
l High risk of bias
Incomplete reporting of pain data
Other bias:
l Low risk of bias
No other apparent bias
Ficnar 201361
Characteristics
Study details Trial design: parallel (three arms)
Location: Department of Prosthetic Dentistry and Biomaterials
and the Department of Orthodontics of the Center for Dental, Oral
and Maxillofacial Diseases of Münster University Hospital, Germany
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
136
Attribute Study details
Number of centres: one
Recruitment period: 2009–10
Sample size calculation: not reported
Funding: industry (‘The expenses for this study were payed by Jaxeurope
[Taunusstein, Germany]’)
Declarations/conflicts of interest: ‘The authors declare that they have no
competing interests’
Participants Diagnosis: RDC/TMD Ia or Ib (myofascial pain) also in combination with
arthralgia (IIIa) and/or disk displacement with reduction (IIa) and a
maximum ‘von Korff’ pain grade of I (functional pain with low levels of
intensity) to II (functional pain with high levels of intensity)
Duration since presenting condition began: not reported
Age at baseline (years): median 35 (not reported by group)
Sex: 21% male (not reported by group)
Number randomised: 63 (group A: 21; group B: 21; group C: 21)
Number evaluated: 58 (group A: 18; group B: 21; group C: 19)
Interventions Comparison: splint vs. no splint for TMD – prefabricated splint vs.
custom-made splint for TMD
All patients received conservative therapy: self-exercises (muscle exercise
form according to Professor Schulte, self-massage techniques, mouth-
opening exercises), medication-based therapy using NSAID, muscle
relaxants as well as manual therapy
Group A
l Splint type: custom occlusal stabilisation splint
l Upper jaw/lower jaw: not reported
l Material: not reported
l Teeth coverage: full
l Details of impression-taking: a bite registration was taken using wax
l Instructions to patients: wear every night and for 2 hours during the day
l Monitoring of patients: not reported
Group B
l Splint type: prefabricated, semi-finished occlusal splint (SOLUBrux)
l Upper jaw
l Material: soft (malleable thermoplastic)
l Teeth coverage: full
l Details of impression-taking: no impression needed
l Instructions to patients: as above
l Monitoring of patients: not reported
Group C
l No other treatment
Duration of treatment: 2.5 months
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Outcomes Assessed at 2 weeks and 2.5 months: we would have used the 2.5 month
data for our 0–3 month analysis
Primary:
l Pain – reduction in the number of of pressure-sensitive areas on
palpation of (1) masticatory muscles and (2) TMJ (no usable data –
medians presented)
Secondary:
l Change in restricted mouth-opening – unassisted pain-free maximum
jaw opening – incisal edge distance in mm (no usable data –
medians presented)
Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
l ‘Randomisation’
l Comment: insufficient information
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Randomisation’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding not possible
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective pain outcome (‘change in restricted mouth-opening’ was more
objective but unclear whether or not it was measured by a blinded
assessor)
Incomplete outcome data (attrition bias):
l Low risk of bias
Low (8%) overall attrition and fairly equally distributed
Selective reporting (reporting bias):
l Low risk of bias
No evidence of selective reporting
Other bias:
l Low risk of bias
No other apparent bias
Giannakopoulos 201662
Characteristics
Study details Trial design: parallel (three arms)
Location: University clinic, Heidelberg, Germany
Number of centres: one
Recruitment period: 2009–11
Sample size calculation: no (only post hoc to estimate sample size required
for future trials)
Funding: not reported
Declarations/conflicts of interest: ‘The authors report no conflicts of
interest’
Authors provided unpublished data
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Participants Diagnosis: painful non-chronic (i.e. non-dysfunctional) TMD-related pain,
diagnosed by use of the RDC/TMD – patients with a GCPS value of 3 or 4,
indicative of disabling chronic pain, were not eligible for the study
Duration since presenting condition began: pain duration mean 42.98 weeks
(SD 51.33 weeks)
Age at baseline (years): overall mean 41.58 (SD 16.68) – not reported
by group
Sex: group A – 50% male; group B – 33.3% male; group C – 8.3% male
Number randomised: 36 (group A: 12; group B: 12; group C: 12)
Number evaluated: 36 (group A: 12; group B: 12; group C: 12)
Interventions Comparison: (1) splint vs. no splint for TMD; (2) custom-made splint vs.
prefabricated splint for TMD
All patients received counselling: their disease and its multifactorial
aetiology were explained, and they were given advice on how to reduce
stress on their masticatory system by avoiding extreme movements of the
jaw (e.g. yawning) and by avoiding chewing hard food or chewing gum. All
patients in extreme pain were allowed to use common over-the-counter
analgesics, the type, amount and frequency of which were to be reported
on recall
Group A
l Splint type: custom vacuum-formed oral splint fabricated on the
patient’s study casts in a dental laboratory
l Upper jaw/lower jaw: not reported
l Material: soft (1.5-mm-thick co-polyester film)
l Teeth coverage: full
l Details of impression-taking: ‘custom alginate impressions of both
dental arches and bite registrations were obtained from all patients’
l Instructions to patients: as above
l Monitoring of patients: as above
Group B
l Splint type: prefabricated oral splint with water-filled elastic
pads (Aqualizer)
l Upper jaw/lower jaw: not reported
l Material: soft (water-filled elastic pads)
l Teeth coverage: full
l Details of impression-taking: not used for this group
l Instructions to patients: wear splint during sleep and for at least
6 hours per day
l Monitoring of patients: none as intervention was used for only 2 weeks
Group C
l Waiting-list group, received normal counselling (described above)
followed by a Michigan-type hard acrylic oral splint after 2 weeks
(i.e. after the study finished)
Duration of treatment: 2 weeks
DOI: 10.3310/hta24070 Health Technology Assessment 2020 Vol. 24 No. 7
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Riley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
139
Attribute Study details
Outcomes Assessed at 2 weeks: grouped under 0 to 3 month analysis
Primary:
l Pain – current pain intensity using a 0 (no pain) to 10 (worst pain) NRS;
we converted this to a 0–100 scale as reported in the majority of other
studies
Secondary:
l Change in restricted mouth-opening – unassisted maximum jaw-opening
(mm) (only reported mean and SD for overall sample – author provided
data for opening with no pain, with pain and assisted opening; we used
opening with no pain)
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘A statistician not involved in the study had provided consecutively
numbered sealed envelopes with one random assignment in each’
l Comment: probably done considering allocation concealment was
done properly
Allocation concealment (selection bias):
l Low risk of bias
l ‘A statistician not involved in the study had provided consecutively
numbered sealed envelopes with one random assignment in each.
The envelopes were opened in sequence by the principal investigator
after an eligible patient had given his/her written informed consent to
participation in the study and had been examined’
l Comment: the next assignment was adequately concealed from the
person randomising patients
Blinding of participants and personnel
(performance bias):
l High risk of bias
Unable to blind patients
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective pain outcome assessment by patients (but ‘change in restricted
mouth-opening’ was objective and measured by a blinded assessor)
Incomplete outcome data (attrition bias):
l Low risk of bias
All randomised patients were included in the analyses
Selective reporting (reporting bias):
l Low risk of bias
Pain outcome fully reported and author provided mean and SD for each
group for the outcome of maximum mouth-opening
Other bias:
l Low risk of bias
No apparent other bias
Gomes 201432
Characteristics
Study details Trial design: parallel (four arms)
Location: Nove de Julho University, São Paulo, Brazil
Number of centres: one
Recruitment period: June 2011 to December 2012
Sample size calculation: yes (met – not powered on any of the relevant
outcomes from our review)
Funding: ‘This study had no financial support’
Declarations/conflicts of interest: ‘The authors declare that they have no
competing interests’
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Participants Diagnosis: severe TMD and sleep bruxism – (1) the Fonseca Patient
History Index was used to diagnose the presence and intensity of TMD;
(2) those with incisal and/or occlusal tooth wear and clinical signs in the
buccal mucosa and tongue of clenching or grinding were diagnosed with
bruxism based on the criteria of the American Academy of Sleep Medicine
and a positive self-report of awake bruxism
Duration since presenting condition began: at least 1 year
Age at baseline (years): (inclusion was 18–40 years) group A – mean 26
(SD 3); group B – mean 29 (SD 4)
Sex: group A – 7% male; group B – 13% male
Number randomised: 30 (group A: 15; group B: 15)
Number evaluated: 30 (group A: 15; group B: 15)
Interventions Comparison: splint vs. no splint for TMD and bruxism
All patients in groups A and B received massage: three weekly 30-minute
sessions of massage therapy performed by a physiotherapist who had
undergone a training exercise for the administration of sliding and
kneading manoeuvres of the masseter and anterior temporal muscles,
bilaterally, over 4 consecutive weeks (total: 12 sessions)
l Group A
¢ Splint type: custom Michigan-type occlusal splint
¢ Upper jaw
¢ Material: hard (acrylic)
¢ Teeth coverage: full
¢ Details of impression-taking: the upper arch of each volunteer was
moulded with irreversible hydrocolloid
¢ Instructions to patients: wear the splint while sleeping
¢ Monitoring of patients: adjustments made after 2 weeks by the
same dentist in charge of the evaluation and splint fabrication
l Group B: no other treatment
l Group C*: custom Michigan-type occlusal splint (not combined
with massage)
l Group D*: custom silicone occlusal splint (not combined with massage)
*Groups C and D are excluded from this review as it was not possible to
make any eligible pairwise comparisons using them
Duration of treatment: 4 weeks
Outcomes The outcomes measured at 4 weeks (electromyographic analysis of the
masseter and anterior temporal muscles, reported as median frequency,
and the Fonseca Patient History Index) were not outcomes of this review
and therefore there were no usable data in this study
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘Block randomization was employed and opaque envelopes were used
to conceal the allocation’
l Comment: probably done
Allocation concealment (selection bias):
l Low risk of bias
l ‘Block randomization was employed and opaque envelopes were used
to conceal the allocation’
l Comment: probably done
Blinding of participants and personnel
(performance bias):
l High risk of bias
Unable to blind patients
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Blinding of outcome assessment
(detection bias):
l Low risk of bias
Irrelevant as there are no outcomes of use for this review
Incomplete outcome data (attrition bias):
l Low risk of bias
All randomised patients appear to have been included in the analyses
(from correspondence with authors)
Selective reporting (reporting bias):
l High risk of bias
We would expect to see pain reported in the assessment of TMD patients
Other bias:
l Low risk of bias
No apparent other bias
Gomes 201533
Characteristics
Study details Trial design: parallel (four arms)
Location: Nove de Julho University, São Paulo, Brazil
Number of centres: one
Recruitment period: not reported
Sample size calculation: not reported
Funding: not reported
Declarations/conflicts of interest: not reported
Participants Diagnosis: sleep bruxism diagnosed by experienced dentist based on
criteria of the International Classification for Sleep Disorders of the
American Academy of Sleep Medicine, self-reported awake bruxism, and a
minimum pain intensity score of 3 on an 11-point NRS
Duration since presenting condition began (months): group A – mean
18.16 (SD 9.33); group B – mean 23.19 (SD 4.84); group C – mean 27.55
(SD 9.41); group D – mean 22.94 (SD 5.02)
Age at baseline (years): (inclusion was 18–40 years) group A – mean 24.40
(SD 4.10); group B – mean 25.72 (SD 6.20); group C – mean 28.60 (SD 4.20);
group D – mean 24.40 (SD 4.10)
Sex: all female
Number randomised: 100 (group A: 25; group B: 25; group C: 25; group D: 25)
Number evaluated: 78 (group A: 19; group B: 19; group C: 23; group D: 17)
Interventions Comparison: splint vs. no splint for bruxism
We split the four groups/arms into two pairwise comparisons of A vs. B
and C vs. D
Group A
l Splint type: custom Michigan-type occlusal splint
l Upper jaw
l Material: hard (acrylic)
l Teeth coverage: full
l Details of impression-taking: the upper arch of each volunteer was
moulded with irreversible hydrocolloid
l Instructions to patients: wear splint while sleeping
l Monitoring of patients: adjustments made after 2 weeks by the same
dentist in charge of the evaluation and splint fabrication
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Group B: no treatment
Group C: combined (splint + massage) – as groups A and D
Group D: massage – three weekly 30-minute sessions of massage of the
muscles of mastication over 4 consecutive weeks (total: 12 sessions).
Massage therapy performed by a physiotherapist who had undergone a
training exercise for the administration of the protocol, involving sliding
and kneading manoeuvres on the masseter and temporal muscles
Duration of treatment: 4 weeks
Outcomes Assessed at 4 weeks
Primary:
l Pain – current pain intensity using a 0 (no pain) to 10 (worst pain) NRS
Secondary:
l Quality of life (including physical and emotional function) – SF-36:
questionnaire with 36 items distributed across eight subscales: physical
functioning (10 items), role physical (4 items), bodily pain (2 items),
general health state (5 items), vitality (4 items), role social (2 items),
role emotional (3 items) and mental health (5 items) – each reported
separately apart from ‘bodily pain’, which was not assessed or reported
(0–100, higher = better health) (data not usable – no SD/SE/p-values)
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘Randomization was performed using opaque envelopes containing
information stipulating to which group each participant belonged’
l Comment: probably done
Allocation concealment (selection bias):
l Low risk of bias
l ‘Randomization was performed using opaque envelopes containing
information stipulating to which group each participant belonged’
l Comment: probably done
Blinding of participants and personnel
(performance bias):
l High risk of bias
Unable to blind patients
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessment by patients
Incomplete outcome data (attrition bias):
l High risk of bias
Overall attrition was 22% and also differed by group (group A: 24%; group B:
24%; group C: 8%; group D: 32%). High attrition for such a short-term study
Selective reporting (reporting bias):
l High risk of bias
No typical bruxism outcomes measured or reported
Other bias:
l Low risk of bias
No apparent other bias
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Haketa 201066
Characteristics
Study details Trial design: parallel (two arms)
Location: TMJ Clinic of the Tokyo Medical and Dental University, Japan
Number of centres: one
Recruitment period: January to December 2006
Trials registry ID: NCT00936338
Sample size calculation: yes (not met)
Funding: public (supported by the Dental Hospital and the Department of
Temporomandibular joint and Occlusion of Tokyo Medical and Dental
University)
Declarations/conflicts of interest: not reported
We emailed authors for data but none provided so far
Participants Diagnosis: anterior disc displacement without reduction – confirmed by
MRI; must have mouth-opening pain on TMJ-affected side and maximum
mouth-opening of < 40mm
Duration since presenting condition began: > 2 weeks
Age at baseline (years): group A – mean 38.6 (SD 13.8); group B – mean
38.8 (SD 15.2)
Sex: group A – 16% male; group B – 0% male
Number randomised: 52 (group A: 28; group B: 24)
Number evaluated: 44 (group A: 25; group B: 19)
Interventions Comparison: splint vs. minimal treatment (exercise) for TMD
Instructions to all participants in both groups: all participants received a verbal
explanation of the pathological conditions based on X-ray and MRI findings,
and a general self-care protocol such as good posture, soft diet, teeth apart,
etc. All participants were prescribed a NSAID three times every day
l Group A
¢ Splint type: custom occlusal stabilisation splint
¢ Upper jaw
¢ Material: hard (1.5-mm-thick, hard clear acrylic sheet)
¢ Teeth coverage: full
¢ Details of impression-taking: vacuum-adapted to the maxillary cast
¢ Instructions to patients: information as above; splint was worn at night
¢ Monitoring of patients: not reported
l Group B: exercise intervention: manual jaw-opening exercises performed
by the participants as follows: as a warm-up, the individual placed their
fingertips on the edge of the mandibular anterior teeth and slowly pulled
the mandible down until pain occurred on the TMJ-affected side. This
mouth-opening position was held for 30 seconds. Three cycles of this
stretching movement were defined as a single set. The participants
performed four sets per day, one after each meal and one after bathing
Duration of treatment: 8 weeks
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Outcomes Assessed at 4 and 8 weeks: we used the 8-week data for our 0–3 month
analysis
Primary:
l Pain – current maximum daily pain intensity using a 0 (no pain) to
100 (worst pain) mm VAS (no description of how measured)
l Harms/adverse effects – reported narratively (‘No significant adverse
effect was reported resulting from either treatment’)
Secondary:
l Change in restricted mouth-opening – maximum mouth-opening range
(distance between the incisal edges of the upper and lower central
incisors in mm) was reported separately with and without pain (we
used opening without pain)
l Quality of life (including physical and emotional function) – pain-related
limitation of daily functions assessed using the ‘Limitation of Daily
Functions for the TMD Questionnaire’ – 10 questions scored using a
5-level NRS from (1) no problem at all to (5) extremely difficult. The
summary score of the 10 questions ranges from 10 to 50 (data not
used – median and IQR)
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘The assignment was made by a table of random sampling numbers’ and
‘a clinician drew a sealed envelope from a series of envelopes, each
containing a card indicating either of two treatments for that individual’
l Comment: appropriate method
Allocation concealment (selection bias):
l Low risk of bias
l ‘a clinician drew a sealed envelope from a series of envelopes, each
containing a card indicating either of two treatments for that
individual’ and ‘One examiner who was completely independent of the
treatment of participants prepared this procedure’
l Comment: these methods should ensure that the next assignment was
adequately concealed from the person randomising patients
Blinding of participants and personnel
(performance bias):
l High risk of bias
Unable to blind patients
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessment by patients (except for ‘change in restricted
mouth-opening’ which was objective and measured by a blinded assessor)
Incomplete outcome data (attrition bias):
l Low risk of bias
Overall attrition was 22% (group A: 11%; group B: 21%) – probably not
sufficient to cause serious bias
Selective reporting (reporting bias):
l Low risk of bias
No evidence of selective reporting
Other bias:
l Low risk of bias
No apparent other bias
Hasanoglu 201752
Characteristics
Study details Trial design: parallel (two arms)
Location: Department of Oral Surgery, Gazi University, Turkey
Number of centres: one
DOI: 10.3310/hta24070 Health Technology Assessment 2020 Vol. 24 No. 7
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Riley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
145
Attribute Study details
Recruitment period: January to June 2014
Sample size calculation: yes (met)
Funding: ‘The authors have no support or funding to report’
Declarations/conflicts of interest: ‘The authors have stated explicitly that
there are no conflict of interests in connection with this article’
Participants Diagnosis: myofascial pain (RDC/TMD Group I: pain or ache in the jaw,
temples, face, pre-auricular area or inside the ear at rest or during
function and pain in response to palpation of ≥ 3 of the specified
20 muscle sites. In addition, at least one site must be ipsilateral to
the site of pain complaint)
Duration since presenting condition began: group A – mean 3.49 years
(SD 2.75 years); group B – mean 1.16 years (SD 1.36 years)
Age at baseline (years): (inclusion was ≥ 18 years) group A – mean
24.6 years (SD 9.2 years); group B – mean 32.25 years (SD 11.97 years)
Sex: group A – 20% male; group B – 15% male
Number randomised: 40 (group A: 20; group B: 20)
Number evaluated: 40 (group A: 20; group B: 20)
Interventions Comparison: splint vs. no splint for TMD
Both groups received first line therapy for facial pain: guidance, assurance,
counselling and behavioural changes (no further description given)
l Group A
¢ Splint type: custom NTI-tss
¢ Upper jaw/lower jaw: not reported
¢ Material: (hard) ‘For its adjustment, the thermoplastic material
provided in the box with the splint is melted in hot water, filled into
the concave region of the splint and adapted to lower or upper
incisor teeth. The material re-polymerises again, becomes rigid, fits
to the anterior teeth and avoids contact of canines and molars’
¢ Teeth coverage: partial
¢ Details of impression-taking: not reported
¢ Instructions to patients: wear device overnight
¢ Monitoring of patients: not reported
l Group B: no other treatment
Duration of treatment: 6 weeks
Outcomes Assessed at 3 and 6 weeks: we used the 6-week data for our 0–3 month
analysis
Primary:
l Pain – current pain intensity 0 (no pain) to 100 (worst pain) mm VAS
Secondary:
l Change in restricted mouth-opening – self-assessment of functional
limitation of jaw using 0 (no limitation) to 100 (severe limitation) mm VAS
Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
l ‘Patients were randomly divided into two groups’
l Comment: insufficient information
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Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Patients were randomly divided into two groups’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Unable to blind patients
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessment by patients
Incomplete outcome data (attrition bias):
l Low risk of bias
All randomised patients were included in the analyses
Selective reporting (reporting bias):
l Low risk of bias
No evidence of selective reporting
Other bias:
l Low risk of bias
No apparent other bias
Johansson 199137
Characteristics
Study details Trial design: parallel (three arms)
Location: Department of Stomatognathic Physiology, University of
Gothenberg, Sweden
Number of centres: one
Recruitment period: not reported
Sample size calculation: not reported
Funding: not reported
Declarations/conflicts of interest: not reported
Participants Diagnosis: CMD – a history including signs and symptoms of CMD;
complaints of headache and/or facial pain; clinical examination
demonstrating tenderness to palpation in the masticatory muscles;
exclusion of individuals with psychologic/psychogenic factors, trauma,
surgery, or systemic joint, muscle, or skin diseases influencing the
symptoms; exclusion of pathologic conditions in TMJs, facial skeleton,
or teeth using radiographs
Duration since presenting condition began: not reported
Age at baseline (years): not reported
Sex: not reported
Number randomised: 30 (group A: 15; group B: 15)
Number evaluated: 30 (group A: 15; group B: 15)
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Interventions Comparison: splint vs. no splint for TMD
l Group A
¢ Splint type: custom occlusal splint
¢ Upper jaw
¢ Material: hard (acrylic)
¢ Teeth coverage: full
¢ Details of impression-taking: not reported
¢ Instructions to patients: not reported
¢ Monitoring of patients: additional adjustments to splints were made
after 2 weeks
l Group B: no treatment
l Group C: acupuncture (not eligible for this review)
Duration of treatment: splint group were examined at ‘3 months after
treatment’, but it is unclear if the treatment period lasted 3 months
Outcomes Group A assessed at 3 months, group B assessed at 2 months
Primary:
l Pain –
¢ 0 (no pain) to 100 (worst pain) mm VAS (presented graphically with
no SD – unable to use data)
¢ subjective dysfunction score on five-point scale: 1 = no pain;
2=mild pain; 3=moderate pain; 4= severe pain; 5 = very severe
pain (no usable data – reported as incidence of different
score changes)
¢ changes in facial pain and headache: reported as incidence of
impaired, unchanged, improved, symptom free (we dichotomised the
data to report the incidence of improved and symptom free)
Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
l ‘Patients meeting the above criteria were randomly divided into
three groups’
l Comment: insufficient information
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Patients meeting the above criteria were randomly divided into
three groups’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Unable to blind patients
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessment by patients
Incomplete outcome data (attrition bias):
l Low risk of bias
All randomised patients were included in the analyses
Selective reporting (reporting bias):
l Low risk of bias
Poor reporting but probably not done selectively
Other bias:
l High risk of bias
Outcomes were assessed at 3 months for the splint group but at 2 months
for the control group
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Karakis 201453
Characteristics
Study details Trial design: parallel (two arms)
Location: Department of Prosthodontics, Gazi University, Ankara, Turkey
Number of centres: one
Recruitment period: not reported
Sample size calculation: not reported
Funding: public (Cumhuriyet University, Foundation of Scientific Research
Projection)
Declarations/conflicts of interest: not reported
Participants Diagnosis: sleep bruxism according to the following criteria – history of
frequent tooth grinding occurring at least 3 nights per week for the
preceding 6 months, as confirmed by a sleep partner; clinical presence of
tooth wear; masseter muscle hypertrophy; report of jaw muscle fatigue or
tenderness in the morning
Duration since presenting condition began: at least 6 months
Age at baseline (years): ranging from 18 to 27 (not reported by treatment
group)
Sex: not reported
Number randomised: 12 (group A: 6; group B: 6)
Number evaluated: not reported
Interventions Comparison: custom-made splint vs. prefabricated splint for bruxism
Group A
l Splint type: custom occlusal stabilisation splint
l Upper jaw
l Material: hard (acrylic)
l Teeth coverage: full
l Details of impression-taking: not reported
l Instructions to patients: not to take any medications, such as muscle
relaxants, sleeping pills, tranquilizers and antidepressants during
treatment; to be worn during sleep (at least 8 hours)
l Monitoring of patients: not reported
Group B
l Splint type: prefabricated occlusal splint (Bruxogard)
l Upper jaw
l Material: soft
l Teeth coverage: full
l Details of impression-taking: no impression. Placed in boiling water for
30 seconds, fitted to patient’s mouth, removed and placed in cold water
for 20 seconds
l Instructions to patients: as above
l Monitoring of patients: as above
Duration of treatment: 6 weeks
Outcomes The outcomes assessed at 3 and 6 weeks (Craniomandibular Index and
occlusal force) were not outcomes of this review; therefore, there were no
usable data in this study
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Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
l ‘Participants were randomly assigned to either of two splint groups’
l Comment: insufficient information
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Participants were randomly assigned to either of two splint groups’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Unable to blind patients
Blinding of outcome assessment
(detection bias):
l Low risk of bias
Irrelevant as there are no outcomes of use for this review
Incomplete outcome data (attrition bias):
l Unclear risk of bias
Numbers of participants analysed is not reported
Selective reporting (reporting bias):
l High risk of bias
There are no useful bruxism outcomes
Other bias:
l Low risk of bias
No apparent other bias
Katyayan 201456
Characteristics
Study details Trial design: parallel (two arms)
Location: Department of Prosthetic Dentistry, Government Dental College
and Hospital, Ahmedabad, India
Number of centres: one
Recruitment period: not reported (‘over a period of one year’)
Sample size calculation: not reported
Funding: not reported
Declarations/conflicts of interest: not reported
Participants Diagnosis: TMD (RDC/TMD axis I)
Duration since presenting condition began: at least 6 months
Age at baseline (years): mean 34.4 (range 20–56) – not reported by group
Sex: 22.5% male – not reported by group
Number randomised: 80 (group A: 40; group B: 40)
Number evaluated: 80 (group A: 40; group B: 40)
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Interventions Comparison: splint vs. no splint for TMD
All patients received counselling and masticatory muscle exercises:
mandible held in the maximal position for a few seconds on each
movement (laterotrusive and protrusive), then with resistance from
the patient’s fingers. After jaw exercised, the patients were suggested
to open the jaw wide stretching it with their fingers a few times for
10–20 seconds. Movements were repeated 7–10 times per training
session and sessions were performed two or three times per day. Patients
received written instructions and the movements were demonstrated
by the dentist before treatment and after, if necessary
l Group A
¢ Splint type: custom occlusal stabilisation splint
¢ Upper jaw
¢ Material: hard (acrylic)
¢ Teeth coverage: full
¢ Details of impression-taking: not reported
¢ Instructions to patients: wear at night while sleeping for a minimum
of 12 hours. The appliance was adjusted at regular intervals and,
after 10 weeks, the patients were advised to gradually reduce wear
of the appliance to a minimum of 8 hours per day
¢ Monitoring of patients: adjustments at 1-, 7-, 15-, 30-, 90-, 150- and
180-day intervals for follow-up
l Group B: no other treatment
Duration of treatment: 6 months
Outcomes Assessed at 6 months: grouped under 3 to 6 months analysis
Primary:
l Pain –
¢ current pain intensity on 0 (no pain) to 100 (worst pain) mm VAS
(authors confirmed that these scores were accidentally reported in
cm – we converted them to mm)
¢ number of painful muscle sites on palpation (out of 20 sites); 2 lb of
pressure for extraoral muscles, 1 lb of pressure on the joints and
intraoral muscles
Secondary:
l Change in restricted mouth-opening – maximum mouth-opening in mm –
the sum of unassisted maximal interincisal opening and the vertical
incisal overlap
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘The assignment was made by a table of random sampling numbers’
l Comment: appropriate method
Allocation concealment (selection bias):
l Low risk of bias
l ‘a clinician drew a sealed envelope from a series of envelopes, each
containing a card indicating either of two treatments for that
individual’ and ‘This allocation was done by a clinician who was
independent of the trial and unaware of patient diagnosis, and was not
involved at any stage in the clinical treatment phase’
l Comment: these methods should ensure that the next assignment was
adequately concealed from the person randomising patients
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Blinding of participants and personnel
(performance bias):
l High risk of bias
Unable to blind patients
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessment by patients (except for ‘change in
restricted mouth-opening’, which was objective and measured by a blinded
assessor)
Incomplete outcome data (attrition bias):
l Low risk of bias
All randomised patients were included in the analyses
Selective reporting (reporting bias):
l Low risk of bias
No evidence of selective reporting
Other bias:
l Low risk of bias
No apparent other bias
Leeson 200763
Characteristics
Study details Trial design: parallel (four arms)
Location: Eastman Dental Hospital, London, UK
Number of centres: one
Recruitment period: unclear but appears to be 1995–97
Sample size calculation: yes (met)
Funding: public and pharmaceutical (medication donated by Lilly
Pharmaceutical Company and the project was funded by a Department of
Health and Social Care grant and locally organised research funding)
Declarations/conflicts of interest: not reported
Participants Diagnosis: chronic TMD of recent onset (of > 3 months duration, hence
exposed to minimal treatment intervention) – pain in one or both TMJs with
or without (1) clicking, (2) limited mouth-opening, (3) muscle tenderness
Duration since presenting condition began: at least 3 months
Age at baseline (years): group A – mean 34.1 (SD 9.99), range 16–55;
group B – mean 29.8 (SD 7.99), range 16–55
Sex: group A – 21.0% male; group B – 23.8% male
Number randomised: 125 (group A: 62; group B: 63)
Number evaluated: 125 (group A: 62; group B: 63) imputational analysis
used (last score brought forward)
Interventions Comparison: splint vs. no splint for TMD
All patients in groups A and B received medication: SSRI fluoxetine,
Prozac. Initial 20 mg daily, then doubled to 40 mg at the 2-month review.
After 3 months, patients who improved on medical therapy and wished to
continue on treatment, remained on medication, usually at the 40mg
dosage. If pain had failed to respond, or worsened, patients were
reassessed and, in some cases, withdrawn from continuation in the study.
Further data were collected from these patients to include in the ITT
analysis. All patients requested to only embark on minimal essential dental
treatment and refrain from alternative pain therapies during treatment
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l Group A
¢ Splint type: custom occlusal stabilisation splint (Michigan splint)
¢ Upper jaw
¢ Material: hard (acrylic)
¢ Teeth coverage: full
¢ Details of impression-taking: an appointment was arranged for
impressions, wax bite and face bow recordings with the restorative
lecturer. The work was then sent to Kurban Dental Laboratory
(London, UK) for construction of splint
¢ Instructions to patients: not reported
¢ Monitoring of patients: reviewed after 2 weeks for further
adjustment and then minor alterations at monthly intervals up to
3 months
l Group B: no other treatment
l Group C*: splint alone (no medication)
l Group D*: placebo medication
*Groups C and D are excluded from this review as it was not possible to
make any eligible pairwise comparisons using them
Duration of treatment: 3 months
Outcomes Assessed at 1, 2 and 3 months: we used the 3-month data for our
0–3 month analysis
Primary:
l Pain –
¢ current pain intensity on 0 (no pain) to 10 (worst pain) cm VAS
(we converted this to mm in order to combine with data from other
studies); this was also reported as incidence of both 25% and 50%
reduction in VAS pain score at 3 months (we used the 50%
reduction data as this enabled pooling with other data)
¢ current pain intensity reported categorically as follows: none, mild,
moderate, severe (we used only the VAS data)
¢ pain frequency reported categorically as follows: never, occasionally,
often, always (we used only the VAS data)
¢ pain response reported categorically as follows: worse, in pain,
improved, pain free (we used only the VAS data)
¢ pain interference with life reported as yes or no (we used only the
VAS data)
Secondary:
l Change in restricted mouth-opening – maximum unassisted pain-free
mouth-opening in mm (interincisal)
l Quality of life (including physical and emotional function) –
(1) Multidimensional Pain Inventory severity; (2) McGill Short Pain
Questionnaire; (3) Kellner Illness Attitude Scale; (4) BDI scores
(no usable data – median and IQR)
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘Patients were randomly allocated to one of four groups, using the
method of block randomisation’
l Comment: probably done
Allocation concealment (selection bias):
l Low risk of bias
l ‘Randomisation was undertaken by a third party, namely a member
of the administration or dental nursing staff. A sealed envelope was
opened indicating group participation and recorded in a locked register’
l Comment: these methods should ensure that the next assignment was
adequately concealed from the person randomising patients
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Blinding of participants and personnel
(performance bias):
l High risk of bias
Unable to blind patients
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessment by patients (except for ‘change in
restricted mouth-opening’, which was objective but unclear whether or
not it was measured by a blinded assessor)
Incomplete outcome data (attrition bias):
l Low risk of bias
lnputational analysis used (last score brought forward) so that all
randomised patients were included in the analyses
Selective reporting (reporting bias):
l Low risk of bias
No evidence of selective reporting
Other bias:
l Low risk of bias
No apparent other bias
List 199238
Characteristics
Study details Trial design: parallel (three arms)
Location: Department of Stomatognathic Physiology, University of
Gothenberg, Sweden
Number of centres: one
Recruitment period: April 1987 to March 1989
Sample size calculation: not reported
Funding: public (Jonkoping County Council and Swedish Medical Research
Council, project 55)
Declarations/conflicts of interest: not reported
Participants Diagnosis: craniomandibular disorder (CMD): signs and symptoms of CMD
of primarily muscular origin; pain for > 6 months; clinical dysfunction
index of Di II or more according to Helkimo74
Duration since presenting condition began: pain for > 6 months – median
duration in years (range) – group A: 3.0 (14.5); group B: 4.3 (24.5)
Age at baseline (years): group A – mean 39 (SD 11); group B – mean 48
(SD 13)
Sex: group A – 35% male; group B – 3% male
Number randomised: 70 (group A: 40; group B: 30)
Number evaluated: 56 (group A: 34; group B: 22)
Interventions Comparison: splint vs. no splint for TMD
l Group A
¢ Splint type: custom occlusal stabilisation splints
¢ Upper jaw (only applied in the mandible area for patients with loss
of molar support; n = 3)
¢ Material: hard (acrylic)
¢ Teeth coverage: full
¢ Details of impression-taking: not reported
¢ Instructions to patients: used at night until evaluation 7–8
weeks later
¢ Monitoring of patients: splints were checked and adjusted after 1 week
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Group B: no treatment (3-month wait list)
Group C: acupuncture (not eligible for this review)
Duration of treatment: group A – 6–8 weeks (but preceded by 1-month
pre-treatment period); group B – on waiting list for 3 months
Outcomes Group A assessed at 2 months, group B assessed at 3 months: grouped
under 0–3 months’ analysis There were also 6-month and 12-month
assessments but they are not reported
Primary:
l Pain –
¢ 0 (no pain) to 100 (worst pain) mm VAS; recorded three times daily
(morning, noon, evening) in a pain diary, with the average calculated
on a weekly basis (appears to be presented in the study report as
cm – we converted this to a mm scale)
¢ frequency of pain: number of occasions during a week with a VAS pain
score of > 0, so the number of recordings during the week (3 × 7) could
vary in the range 0–21 (we used only the VAS data above)
Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
l ‘Randomly assigned’
l Comment: insufficient information
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Randomly assigned’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Unable to blind patients
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessment by patients
Incomplete outcome data (attrition bias):
l Low risk of bias
Overall attrition 20% (group A: 15%; group B: 27%). There were no
dropouts in the study but only pain diaries in which > 70% of the required
recordings had been completed were included in the analysis. Unlikely to
change the results much
Selective reporting (reporting bias):
l High risk of bias
The assessments at 6 and 12 months are reported in a separate study
report, but only for groups A and C
Other bias:
l High risk of bias
l (1) Outcomes were assessed at 6–8 weeks for the splint group but at
3 months for the control group
l (2) Substantial sex imbalance between groups (potentially indicating
that the randomisation process was inadequate or did not work)
Lundh 198539
Characteristics
Study details Trial design: parallel (three arms)
Location: Department of Stomatology, University of Lund, Sweden
Number of centres: one
Recruitment period: January 1982 to March 1984
Sample size calculation: not reported
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Funding: public and industry, that is private health-care company (financial
support from University of Lund, and Praktikertjanst AB, Sweden; study
supported by Magnus Bergvalls Foundation, Torsten and Ragnar
Soderbergs Foundations, and Swedish Medical Research Council)
Declarations/conflicts of interest: not reported
Participants Diagnosis: ‘1704 patients referred for pain and dysfunction of the
masticatory system’, every third patient given an appointment (n= 568).
These were then subdivided into those with reciprocal clicking (clicking on
opening and closing) (n= 88) these were then subdivided again into those
that could eliminate clicking by beginning mandibular movements in a
position anterior to intercuspal position (centric occlusion), but not as far as
edge to edge incisal potion and only these added to the trial (n= 78). Those
that could not eliminate clicking unless mandibular movements were started
from edge to edge incisal position, these were excluded from the trial (n= 10)
Duration since presenting condition began: not reported
Age at baseline (years): median 30, range 10–69 (not reported by group)
Sex: 31% male (not reported by group)
Number randomised: 70 (group A: 24; group B: 23; group C: 23)
Number evaluated: 70 (group A: 24; group B: 23; group C: 23)
Interventions Comparison: splint vs. no splint for TMD
Group A
l Splint type: custom anterior repositioning splint
l Upper jaw
l Material: hard
l Teeth coverage: full
l Details of impression-taking: not reported
l Instructions to patients: wear 24 hours per day for 6 weeks then
reduce over following 2 weeks starting with taking it out for 2 hours
between meals
l Monitoring of patients: 6, 17 and 52 weeks
Group B
l Splint type: custom flat occlusal splint
l Upper jaw
l Material: hard
l Teeth coverage: full
l Details of impression-taking: not reported
l Instructions to patients: wear only at night for 6 weeks then reduce
over following 2 weeks
l Monitoring of patients: as above
Group C
l No treatment
Duration of treatment: 6 weeks (but followed by 2 weeks of reduction in
use and unclear thereafter)
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Outcomes Assessed at 6, 17 and 52 weeks: we used these in our 0–3 month,
3–6 month and 6–12 month analyses, respectively
Primary:
l Pain –
¢ pain at rest, chewing and on protrusion assessed separately on
0–10 cm worsening VAS at each follow-up examination (if bilateral
click then only the most painful side was scored) (no usable data –
no means or SD)
¢ palpation pain of muscles of mastication (data not used – incidence
reported separately for four different sites but was not equal at
baseline)
Secondary:
l TMJ clicking: reciprocal clicking assessed using a stethoscope
Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
l ‘Randomly assigned’
l Comment: insufficient information
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Randomly assigned’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding not possible
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessed by patient (except for clicking – but blinding
was not mentioned)
Incomplete outcome data (attrition bias):
l Low risk of bias
There did not appear to be any dropouts
Selective reporting (reporting bias):
l High risk of bias
No data reported for the VAS pain outcomes
Other bias:
l Low risk of bias
No other bias apparent
Lundh 198840
Characteristics
Study details Trial design: parallel (three arms)
Location: (1) Department of Stomatology, School of Dentistry, Malmö,
Sweden and (2) Department of Oral Surgery, University Hospital, Lund,
Sweden
Number of centres: two
Recruitment period: not reported
Sample size calculation: not reported
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Funding: public and industry, that is both private health-care company and
pharmaceutical company (supported by Magnus Bergvalls Foundation,
University of Lund, Praktikertjanst AB, Sweden, Swedish Medical Research
Council, Torsten and Ragnar Soderbergs Foundations, and the Ake Wiberg
Foundation; Nycomed AB, Sweden provided contrast medium used for
arthrography)
Declarations/conflicts of interest: not reported
Participants Diagnosis: disk displacement with reduction:
902 consecutive patients referred for treatment of masticatory muscle or
temporomandibular joint pain and dysfunction were clinically examined.
212 patients demonstrated temporomandibular joint reciprocal clicking
defined as clicking during opening that did not occur unless it was preceded
by clicking during closing. 149 of the 212 patients were excluded from the
study. 105 of these had minor subjective complaints (graded as less than 5
on a visual analog scale with 0 and 10 as end points), 27 patients were not
willing to participate in a scientific study, 11 patients needed mandibular
protrusion anterior to the edge-to-edge incisal relationship to eliminate the
clicking, 5 patients showed arthrographic evidence of disk displacement
without reduction, and 1 patient was arthrographically normal. The study
was therefore based on the remaining 63 patients
– confirmed by arthrography
Duration since presenting condition began: not reported
Age at baseline (years): median 24, range 13–74 (not reported by group)
Sex: 14% male (not reported by group)
Number randomised: 43 (group A: 21; group B: 22)
Number evaluated: 43 (group A: 21; group B: 22)
Interventions Comparison: splint vs. no splint for TMD
All patients were informed about basic anatomy and function of the TMJ,
the mechanisms of clicking and locking, and the possible caused of pain
l Group A
¢ Splint type: flat occlusal splint
¢ Upper jaw
¢ Material: hard
¢ Teeth coverage: full
¢ Details of impression-taking: no information
¢ Instructions to patients: wear at night
¢ Monitoring of patients: not reported
l Group B: no other treatment
l Group C: disk-repositioning onlays (not eligible for this review)
Duration of treatment: 6 months
Outcomes Assessed at 6 months: grouped under 3–6 month analysis
Primary:
l Pain –
¢ pain at rest, chewing and on protrusion assessed separately on 0 to
10 cm worsening VAS at each follow-up examination (if bilateral
click then only the most painful side was scored) (no usable data –
no means or SD)
¢ palpation pain of muscles of mastication as described by
Krogh-Poulsen 1979 (data not used – incidence reported
separately for five sites but was not equal at baseline)
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Secondary:
l TMJ clicking: reciprocal clicking assessed using a stethoscope
and/or palpation
Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
l ‘Randomly assigned’
l Comment: insufficient information
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Randomly assigned’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding not possible
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessed by patient (except for clicking – but blinding
was only done for around half of the assessments)
Incomplete outcome data (attrition bias):
l Low risk of bias
There did not appear to be any dropouts
Selective reporting (reporting bias):
l High risk of bias
Pain at rest was not reported
Other bias:
l Low risk of bias
No other bias apparent
Lundh 199241
Characteristics
Study details Trial design: parallel (two arms)
Location: Department of Stomatology, University of Lund, Malmö, Sweden
Number of centres: one
Recruitment period: not reported
Sample size calculation: not reported
Funding: public and industry, that is private health-care company
(supported by grants from Praktikertjanst AB, Sweden and by the Torsten
and Ragnar Soderbergs Foundations)
Declarations/conflicts of interest: not reported
Participants Diagnosis: pain on chewing (> 50 on a 0–100mm VAS) with
arthographically documented disc displacement without reduction in one
or both TMJs
Duration since presenting condition began: not reported
Age at baseline (years): mean 29, range 14–61 (not reported by group)
Sex: 10% male (not reported by group)
Number randomised: 51 (group A: 25; group B: 26)
Number evaluated: 51 (group A: 25; group B: 26)
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Interventions Comparison: splint vs. no splint for TMD
l Group A
¢ Splint type: flat occlusal splint
¢ Upper jaw
¢ Material: hard
¢ Teeth coverage: full
¢ Details of impression-taking: not reported
¢ Instructions to patients: wear at night
¢ Monitoring of patients: 1 week for further adjustments and then
follow-up at 6 and 12 months
l Group B: no treatment
Duration of treatment: 12 months
Outcomes Assessed at 12 months: grouped under 6–12 month analysis
Primary:
l Pain –
¢ pain at rest, during chewing and on protrusion assessed using
a 0–100 mm worsening VAS; reported categorically as pain
free, improved (at least 50% reduction), unchanged or worse
(we dichotomised the data as incidence of pain free and improved vs.
unchanged and worse)
¢ changes in palpatory tenderness of masseter muscle reported as
better vs. unchanged or worse (data not used – those with no
tenderness at start and end of study were not included)
Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
l ‘Randomised’
l Comment: insufficient information
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Randomised’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding not possible
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessed by patient
Incomplete outcome data (attrition bias):
l Low risk of bias
There did not appear to be any dropouts
Selective reporting (reporting bias):
l High risk of bias
Only outcomes with statistically significant differences were reported
Other bias:
l Low risk of bias
No other bias apparent
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Magnusson 199942
Characteristics
Study details Trial design: parallel (two arms)
Location: Department of Stomatognathic Physiology, The Institute for
Postgraduate Dental Education, Jonkoping, Sweden
Number of centres: one
Recruitment period: November 1993 to September 1996
Sample size calculation: not reported
Funding: not reported
Declarations/conflicts of interest: not reported
Participants Diagnosis: TMD of mainly muscular origin: patients referred to specialist
clinic with main subjective symptom of tension-type headache and/
orofacial pain of non-neurogenic or non-dental origin
Duration since presenting condition began: pain history of at least 1 year
Age at baseline (years): group A – mean 32 (range 17–49); group B –
mean 37 (range 16–67)
Sex: not reported
Number randomised: 26 (group A: 14; group B: 12)
Number evaluated: 18 (group A: 9; group B: 9)
Interventions Comparison: splint vs. minimal treatment for TMD
Group A
l Splint type: interocclusal stabilisation splint (Michigan style)
l Upper jaw
l Material: hard
l Teeth coverage: full
l Details of impression-taking: not reported
l Instructions to patients: wear at night
l Monitoring of patients: only reports that adjustments and follow-ups
were made by a dentist
Group B
l Jaw exercise programme – based on different jaw movements to
achieve reciprocal inhibition, proprioceptive neuromuscular facilitation,
and stretching – performed at least three times per day with each
session lasting at least 2–3 minutes; dental assistant delivered the
instructions to patients and also decided on length of time between,
as well as number of, follow-ups (she also modified patients’ individual
programmes when necessary by adding or removing specific exercises)
Patients with significant symptoms after 3 months of treatment were
offered complementary treatment with the other treatment modality.
Those receiving combined treatment were analysed separately (group not
included in this review)
Duration of treatment: 6 months
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Outcomes Assessed at 3 and 6 months: we used these in our 0–3 month and
3–6 month analyses, respectively
Primary:
l Pain –
¢ categorised as none, mild and severe; reported separately for TMJ
pain, muscle pain and pain on movement as part of clinical dysfunction
index Di (Helkim74) (we dichotmised as incidence of being pain free)
¢ incidence of both pain when opening the mouth and pain in the
face or jaws as part of a ‘subjective’ anamnestic dysfunction index
Ai (Helkimo74) (not used as too similar to other pain outcomes)
¢ Behaviour Rating scale for pain 1 (no pain) to 6 (very strong pain, totally
handicapped, cannot do anything) (no usable data – graphs with no SD)
Secondary:
l TMJ clicking: incidence of joint sounds during functional examination
l Change in restricted mouth-opening: maximum jaw opening in mm
(no usable data – no SD); also reported as incidence of having difficulty
in opening the mouth wide
Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
l ‘Randomly assigned’
l Comment: insufficient information
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Randomly assigned’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding not possible
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessed by patient (except for clicking – but the
outcome assessor was not blinded)
Incomplete outcome data (attrition bias):
l Low risk of bias
Overall attrition 31% (group A: 36%; group B: 25%) – reasons mostly
the same
Selective reporting (reporting bias):
l Low risk of bias
No evidence of selective reporting
Other bias:
l Low risk of bias
No other bias apparent
Michelotti 201264
Characteristics
Study details Trial design: parallel (two arms)
Location: Clinic for Temporomandibular Disorders and Orofacial Pain,
University of Naples Federico II, Italy
Number of centres: one
Recruitment period: 9 months (dates not reported)
Sample size calculation: no (post hoc only)
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
162
Attribute Study details
Funding: not reported
Declarations/conflicts of interest: ‘None of the authors reported any
disclosures’
Participants Diagnosis: myogenous pain according to RDC/TMD categories Ia and Ib;
also objective evidence of joint pathology or dysfunction; spontaneous
muscle pain > 30 mm on 100mm VAS
Duration since presenting condition began: recurrent or constant
myogenous pain for > 3 months
Age at baseline (years): group A – mean 30 (range 20–53); group B –
mean 30 (range 18–49)
Sex: group A – 29% male; group B – 17% male
Number randomised: 44 (group A: 21; group B: 23)
Number evaluated: 41 (group A: 18; group B: 23)
Interventions Comparison: splint vs. minimal treatment for TMD
Group A
l Splint type: custom occlusal stabilisation splint (Michigan)
l Upper jaw
l Material: hard
l Teeth coverage: full
l Details of impression-taking: alginate impressions of both arches and
an interocclusal record with a wax wafer
l Instructions to patients: wear only while sleeping
l Monitoring of patients: both groups seen every 3 weeks for 15 minutes
(assessments carried out, motivation reinforced, and splint group had
any necessary adjustments)
Group B
l Education – explanation of the aetiology and of the good prognosis for
TMD, as well as information about self-care for the jaw musculature
Duration of treatment: 3 months
Outcomes Assessed at 3 months: grouped under 0–3 month analysis
Primary:
l Pain – current pain intensity (spontaneous muscle pain) using 0 mm
(no pain) to 100 mm (worst pain) VAS; reported as change from baseline
score (unable to combine change score in primary meta-analysis using
SMD; used in sensitivity analyses of studies reporting current pain
intensity on VAS/NRS at 0 to 3 months)
Secondary:
l Change in restricted mouth-opening: maximal unassisted pain-free
opening (mm) – distance between the maxillary and mandibular incisal
edges and added the overbite measurement. ‘Pain free’ defined as the
maximum distance the participant could open their mouth without
experiencing any additional pain and discomfort; reported as
change score
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Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘We assigned the patients to two treatment groups by means of a
balanced block randomization’
l Comment: probably done
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘We assigned the patients to two treatment groups by means of a
balanced block randomization’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding not possible
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessment by patients (except for ‘change in restricted
mouth-opening’ which was objective and measured by a blinded assessor)
Incomplete outcome data (attrition bias):
l Low risk of bias
Overall attrition 7% (group A: 14%; group B: 0%) – only 3 participants
dropped out in group A so probably not enough to bias the results in a
meaningful way
Selective reporting (reporting bias):
l Low risk of bias
Outcomes fully reported
Other bias:
l Low risk of bias
No other bias apparent
Nagata 201567
Characteristics
Study details Trial design: parallel (two arms)
Location: Nippon Dental University, Niigata Hospital, Niigata, Japan
Number of centres: one
Recruitment period: June 2009 to July 2013
Sample size calculation: yes (met)
Funding: none
Declarations/conflicts of interest: ‘None of the authors received support
from a corporation or any funding for this study’
Participants Diagnosis: TMD (RDC/TMD axis I); RDC/TMD axis II was excluded
Duration since presenting condition began (months): group A – median 24
(range 3–360); group B – median 24 (range 4–72)
Age at baseline (years): group A – mean 41 (SD 19); group B – mean 43 (SD 18)
Sex: group A – 31% male; group B – 39% male
Number randomised: 201 (group A: 103; group B: 98)
Number evaluated: 181 (group A: 96; group B: 85)
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Interventions Comparison: splint vs. no treatment for TMD
All patients in both groups received multimodal therapy: self-exercise of
the jaw (pulled down on bilateral lower last molars with secondary fingers
while opening jaw to the greatest possible extent – performed with 20
repetitions three times per day), CBT (guidance about clenching control
during waking hours and coping with pain and stress) and received
education about TMD self-management (i.e. a diet of soft foods, avoiding
gum chewing and correcting bad posture). Participants with mouth-
opening of < 35 mm also underwent jaw manipulation
l Group A:
¢ Splint type: custom stabilisation splint
¢ Upper jaw
¢ Material: hard (acrylic)
¢ Teeth coverage: full
¢ Details of impression-taking: not reported
¢ Instructions to patients: wear while sleeping, but daytime use was
not required
¢ Monitoring of patients: if no change of symptoms was achieved by
this treatment, the splint was altered to the bruxism-controlled type
to disturb the eccentric movements of the mandible with a steep
obstacle located at the anterior teeth
l Group B: no other treatment
Duration of treatment: 10 weeks
Outcomes Assessed at 2, 4, 6, 8 and 10 weeks: we used the 10-week data for our
0–3 month analysis
Primary:
l Pain – current orofacial pain using a 0–10 worsening NRS
(we converted to a 0 –100 scale)
Secondary:
l TMJ clicking – measured using a 0–10 worsening NRS
l Change in restricted mouth-opening – between upper and lower teeth
in mm (not reported which teeth); asked to open mouth as wide as
possible unassisted, even if they felt pain
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘Participants were randomly assigned to the non-splint multimodal
therapy group (NS) or to the multimodal therapy plus splint group
(NS+S) with block randomisation’
l Comment: probably done
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Participants were randomly assigned to the non-splint multimodal
therapy group (NS) or to the multimodal therapy plus splint group
(NS+S) with block randomisation’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding not possible
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective pain outcome assessment by patients (except for ‘change in
restricted mouth-opening’ and clicking which were objective – described
as single blind so probably the assessors for these outcomes)
Incomplete outcome data (attrition bias):
l Low risk of bias
Overall attrition 10% (group A: 7%; group B: 13%) – low attrition and
similar reasons stated
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Selective reporting (reporting bias):
l Low risk of bias
No evidence of selective reporting
Other bias:
l Low risk of bias
No other bias apparent
Niemelä 201271
Characteristics
Study details Trial design: parallel (two arms)
Location: Oral and Maxillofacial Department, Oulu University Hospital,
Finland
Number of centres: one
Recruitment period: March 2008 to September 2009
Sample size calculation: yes (not met)
Funding: public (supported by the Finnish Dental Society, Apollonia and
the Academy of Finland)
Declarations/conflicts of interest: ‘No conflict of interests are declared’
Participants Diagnosis: TMD (RDC/TMD) – the patients were referred to the Oral and
Maxillofacial Department, Oulu University Hospital, for treatment of TMD
and had thus been suffering from relatively chronic and severe TMD
Duration since presenting condition began: not reported
Age at baseline (years): (inclusion= at least 20) group A – mean 43
(SD 13); group B – mean 44 (SD 13)
Sex: group A – 18% male; group B – 27% male
Number randomised: 80 (group A: 39; group B: 41)
Number evaluated: 1 month: 76 (group A: 39; group B: 37); 1 year: 78
(group A: 37; group B: 41) – ITT
(Two patients dropped out of the trial from the splint group; one did not
attend any of the check-ups and the other was offered other treatment, that
is orthognathic surgery. In addition, during the 1-year follow-up, altogether
16 patients interrupted their attendance to the trial or did not show up for
their appointed follow-up. Sixteen controls were transferred from the control
group to the splint group because of their symptoms and need of treatment.
Thirteen patients (10 patients in the splint group and three in the control
group) were treated with arthrocentesis of the TMJ during the study. All the
patients in the total sample were defined as belonging to the ‘intention-
to-treat’ (ITT) population except for the two who were excluded at the
beginning of the trial. Thus, the ITT also included those who switched
groups or those who in whichever group received other treatment than
initially planned based on the group criteria)
Interventions Comparison: splint vs. no treatment for TMD
All patients in both groups received counselling and instructions for
masticatory muscle exercises – at the beginning of the training
programme, active mouth-openings, laterotrusive movements and
protrusive movements were performed. The mandible was held in the
maximal positions for a few seconds on each movement. Thereafter, these
movements were made towards resistance (using patient’s own fingers).
After jaw exercises, the patients were suggested to open the jaw wide,
stretching it with fingers a few times for 10–20 seconds. These
movements were repeated 7–10 times per training sessions, and the
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sessions were performed two or three times per day. The patients
received written instructions, and the movements were also demonstrated
by the dentist before the treatment and reprised if necessary
l Group A:
¢ Splint type: custom occlusal stabilisation splint
¢ Upper jaw/lower jaw: not reported
¢ Material: hard (acrylic)
¢ Teeth coverage: full
¢ Details of impression-taking: ‘occlusion of the splint was defined in
the centric relation occlusion using wax’
¢ Instructions to patients: use every night during study
¢ Monitoring of patients: not reported
l Group B: no other treatment
Duration of treatment: 1 year
Outcomes Assessed at 1, 3, 6 months and 1 year (mouth-opening only assessed at
1 month) VAS pain only reported as median at 3 and 6 months so data
not used
Primary:
l Pain –
¢ current facial pain intensity using 0 (no pain) to 10 (worse pain) cm
VAS (we converted this to mm in order to combine with data from
other studies)
¢ number of painful masticatory muscle sites on palpation (out of
20 sites) (only VAS data used – baseline scores for this outcome
were not comparable)
¢ incidence of TMJ pain on lateral or posterior palpation of one or
both TMJs (only VAS data used – baseline scores for this outcome
were not comparable)
Secondary:
l Change in restricted mouth-opening: unassisted maximal opening
(exact location not reported; whether with/without/until pain
not reported)
l Quality of life (including physical and emotional function): 14-item
Oral Health Impact Profile (OHIP-14) – responses were as follows:
0= never, 1= hardly ever, 2 = occasionally, 3 = fairly often and 4= very
often. The OHIP severity score was calculated by summing the ordinal
values for 14 items (range 0 to 56)
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘Patients were assigned randomly using computer generated
random number’
l Comment: appropriate method
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Patients were assigned randomly using computer generated
random number’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding not possible
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective pain outcomes assessed by patients (except for ‘change in
restricted mouth-opening’, which was objective and measured by a blinded
assessor)
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Incomplete outcome data (attrition bias):
l Low risk of bias
Low attrition and ITT was used at 1 year for pain on VAS (but quality-of-
life data have very high attrition at all assessment points and should be
considered at high risk of bias)
Selective reporting (reporting bias):
l Low risk of bias
Outcomes fully reported
Other bias:
l Low risk of bias
No other apparent bias
Nilner 200873
Characteristics
Study details Trial design: parallel (two arms)
Location: (1) Department of Stomatognathic Physiology, Malmö University,
Sweden; (2) Department of Stomatognathic Physiology, Turku University,
Finland
Number of centres: two
Recruitment period: study performed from February 2005 to August 2007
Sample size calculation: yes (met) – equivalence
Funding: public (supported by the Finnish Dental Society, Apollonia and
Finska Lakaresallskapet)
Declarations/conflicts of interest: ‘The authors report no conflicts of interest’
E-mailed authors for data but none provided so far
Participants Diagnosis: pain of muscular origin with or without limited opening,
according to the RDC/TMD; myofascial pain of at least 4 on a 0–10 NRS
Duration since presenting condition began (months): myofascial pain –
group A: median 36 (range 6–240); group B: median 36 (range 3–480)
Age at baseline (years): (inclusion= at least 18) group A – mean 36
(range 18–71); group B – mean 37 (range 20–63)
Sex: group A – 6% male; group B – 16% male
Number randomised: 65 (group A: 33; group B: 32)
Number evaluated: 10 weeks: 65 (group A: 33; group B: 32); 6 months: 52
(group A: 24; group B: 28); 12 months: 49 (group A: 22; group B: 27)
Interventions Comparison: custom-made splint vs. prefabricated splint for TMD
All patients in both groups were informed about the lack of a clear-cut
cause of their myofascial pain and about contributing factors. They were
reassured and informed about the nature of TMD and the relationship
between muscle fatigue, muscle pain, the psychophysiologic aspects of
stress and how to self-monitor TMD symptoms
Group A
l Splint type: custom occlusal stabilisation splint
l Upper jaw
l Material: hard (methylmethacrylate)
l Teeth coverage: full
l Details of impression-taking: not reported
l Instructions to patients: use at night
l Monitoring of patients: comfort, patient acceptance and function of both
appliances were checked within 2 weeks, by the general practitioner, and
the same procedure was repeated at all follow-up points
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Group B
l Splint type: prefabricated occlusal splint (Relax)
l Upper jaw
l Material: hard (‘made of polymethylmetacrylate . . . The appliance is
individually fitted with a silicon self-curing material, polyvinylsiloxane’)
l Teeth coverage: partial
l Details of impression-taking: not done
l Instructions to patients: as above
l Monitoring of patients: as above
Duration of treatment: 12 months
Outcomes Assessed at 6 and 10 weeks, 6 months and 12 months: we used the
10-week, 6-month and 12-month data for our 0–3 month, 3–6 month,
and 6–12 month analyses, respectively
Primary:
l Pain –
¢ daily pain intensity at rest, on mouth-opening and during chewing
using a 0–100 VAS (higher =more pain) in the week prior to each
assessment point; reported graphically as mean (only at 6 and
10 weeks) and reported as both 30% and 50% reduction in worst
reported pain at all follow-up points (no usable data for VAS means –
e-mailed authors for VAS means and SDs)
¢ frequency of myofascial pain on a nine-point scale: 0= never;
1= rarely; 2= once a month; 3= once every second week; 4= once
a week; 5 = twice a week; 6 = three to four times a week; 7= daily;
8= constantly; reported only at 6 and 10 weeks (data not reported)
¢ GCPS reported by incidence of grades 0 to IV, which is included
in the RDC/TMD Axis II questionnaire. Divided into two parts:
(1) assessment of pain intensity (0–100 worsening scale) and
(2) assessment of pain-related disability/limitations in physical
functioning (0–6 worsening scale). GCPS grade 0: no TMD pain in
past 6 months; grade I: low disability (< 3) and low-intensity pain
(< 50); grade II: low disability (< 3) and high-intensity pain (> 50);
grade III: high disability that was moderately limiting (3 to 4
regardless of pain score); grade IV: high disability that was severely
limiting (5 to 6 regardless of pain score) (we dichotomised as
incidence of grade III or IV)
l Harms/adverse effects – reported as changes in the occlusion – vertical
overbite assessed to nearest 0.5 mm (only reported at 6 and 12 months)
Secondary:
l Change in restricted mouth-opening: mentioned in separate paper
(Doepel 2011124 – linked under this study ID) – maximum opening without
pain, both unassisted and assisted but not fully reported (no usable data)
l Frequency of headaches (secondary to pain-related TMD): during the
preceding 6 months on a verbal scale, as follows: no headache; rarely;
once a month; once a week; at least 15 times a month; continuous
(we dichotomised this as once per week or more)
l Quality of life (including physical and emotional function): SCL-90-R
instrument in the RDC/TMD Axis II questionnaire – 20 questions for
depression and 12 questions for non-specific physical symptoms (NSPhS).
The total score was calculated (0–4); reported at 6 and 12 months
l Adherence to treatment: reported as incidence of use of appliance every
night, several nights per week or when necessary (we dichotomised as
use of appliance for several nights per week or more – data only
available at 10 weeks)
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Attribute Study details
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘One independent person (D2) at each clinic carried out the
randomization by using 10 series of consecutively numbered, sealed,
opaque envelopes. Each envelope contained a treatment specification.
The last series included 6 envelopes (3 for each treatment modality).
This randomization procedure was repeated until 66 patients were
included in the study’
l Comment: method of sequence generation not described but
probably done
Allocation concealment (selection bias):
l Low risk of bias
l ‘Treatment assignment was concealed from the examiner in
sealed envelopes’
l Comment: the next assignment was adequately concealed from the
person randomising patients
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding not possible
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessment by patients (except for ‘harms/adverse
effects’ – vertical overbite)
Incomplete outcome data (attrition bias):
l High risk of bias
20% attrition (group A: 27%; group B: 13%) at 6 months; this rose to
25% (group A: 33%; group B: 16%) at 6 months and 36% (group A: 30%;
group B: 43%) at 12 months; unequal between groups
Selective reporting (reporting bias):
l High risk of bias
Some outcomes measured but not reported fully (i.e. with SDs or p-values
for between-group differences), or not reported at all at some time points
(e.g. VAS pain)
Other bias:
l Low risk of bias
No other apparent bias
Nilsson 200943
Characteristics
Study details Trial design: parallel (two arms)
Location: Department of Stomatognathic Physiology, University of Malmö,
Sweden
Number of centres: one
Recruitment period: April 2000 to April 2003
Sample size calculation: yes (met at 10 weeks but not 6 or 12 months)
Funding: public (study was supported by the Swedish Dental Society and
Malmö University)
Declarations/conflicts of interest: not reported
Participants Diagnosis: mixed TMDs according to RDC/TMD; worst self-assessed TMD
pain at least 40 mm on 100mm VAS
Duration since presenting condition began (months): group A – median 24
(range 3–360); group B – median 24 (range 4–72)
Age at baseline (years): group A – mean 35 (range 14–67); group B –
mean 33 (range 13–68)
Sex: group A – 25% male; group B – 11% male
Number randomised: 80 (group A: 40; group B: 40)
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Number evaluated: 68 (group A: 35; group B: 33) at 10 weeks but ITT results
reported for outcome of 30% reduction in worst pain; 57 (group A: 32;
group B: 25) at 6 months; 51 (group A: 28; group B: 23) at 12 months
Interventions Comparison: splint vs. control splint for TMD
Group A:
l Splint type: custom occlusal splint
l Upper jaw
l Material: soft [4-mm-thick Bioplast® (Scheu Dental GmbH, Iserlohn,
Germany) clear-transparent film]
l Teeth coverage: full
l Details of impression-taking: not reported
l Instructions to patients: wear at night
l Monitoring of patients: checked within 2 weeks and adjusted if
necessary; no further adjustments made in the following 4 weeks
except for comfort reasons; thereafter ‘Another TMD specialist who
was not involved in the evaluation delivered, adjusted and checked the
use, wear and durability of appliances’
Group B:
l Splint type: custom non-occlusal palatal splint
l Upper jaw
l Material: hard
l Teeth coverage: palatal coverage with clasps to attach to one molar on
each side (appliance did not cover occlusal surfaces)
l Details of impression-taking: not reported
l Instructions to patients: as above
l Monitoring of patients: as above
Duration of treatment: 12 months
Outcomes Assessed at 6 and 10 weeks, 6 and 12 months: we used the 10-week,
6-month and 12-month data for our 0–3 month, 3–6 month, and
6–12 month analyses, respectively
Primary:
l Pain –
¢ worst pain on 0 mm (no pain) to 100mm (worst pain) VAS (10-week
data not usable – no SD/p-value); also reported as incidence of 30%
reduction (only for 10 weeks and 12 months)
¢ characteristic pain intensity 0 to 100 worsening scale: mean of
three scales – current pain, worst and average in previous 6 months
(10-week data not usable – presented graphically but unclear what
error bars represent); also reported as incidence of 30% reduction
(only for 10 weeks and 12 months)
¢ frequency of pain reported categorically: we dichotomised the data
as incidence of recurrent or persistent (vs. never/one-time
experience)
Secondary:
l Frequency of headaches (secondary to pain-related TMD): reported
categorically at 6 and 12 months: we dichotomised the data as
incidence of recurrent or persistent (vs. never/one-time experience)
l Quality of life (including physical and emotional function): depression
(20 questions) and somatisation (12 questions) from subscales of the
SCL-90-R – each reported as incidence of normal, moderate or severe;
we dichotmised as incidence of moderate to severe (reported only for
6 and 12 months)
l Adherence to treatment: splint wear reported categorically
(dichotomised as every night/most nights vs. when needed/not at all)
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Attribute Study details
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘patients were randomized to treatment . . . in blocks of 10’
l Comment: probably done
Allocation concealment (selection bias):
l Low risk of bias
l ‘independent dental assistant . . . allocated the patients . . . Each block
included five concealed sheets with the text ‘resilient appliance’ and
five with the text ‘control appliance’
l Comment: probably done
Blinding of participants and personnel
(performance bias):
l Unclear risk of bias
A TMD specialist not involved in the study fitted and made all
adjustments. However, not clear if the patients were aware of their group
assignment. If they were aware, this might affect behaviours and
introduce performance bias
Blinding of outcome assessment
(detection bias):
l Unclear risk of bias
l ‘Both examiners were blinded to group assignment’
l Comment: however, the outcomes were patient-reported and it was
not clear if the patients were aware of their group assignment
Incomplete outcome data (attrition bias):
l High risk of bias
15% attrition (group A: 13%; group B: 18%) at 10 weeks but this rose to
29% (group A: 20%; group B: 38%) at 6 months and 36% (group A: 30%;
group B: 43%) at 12 months
Selective reporting (reporting bias):
l Low risk of bias
TMD pain VAS at 10 weeks reported with no SD or a p-value for the
difference between the groups. However, this was reported fully for the
longer-term outcomes at 6 and 12 months
Other bias:
l Low risk of bias
No other apparent bias
Nitecka-Buchta 201470
Characteristics
Study details Trial design: parallel (two arms)
Location: Department of Orthodontics and TMJ Dysfunction, Medical
University of Silesia Katowice, Zabrze, Poland
Number of centres: one
Recruitment period: not reported
Sample size calculation: not reported
Funding: public (study was funded by the Medical University of Silesia
Katowice, Poland)
Declarations/conflicts of interest: ‘The authors have no conflict of interest
regarding this commentary’
Participants Diagnosis: RDC/TMD examination for group Ia (myofascial pain) and Ib
(myofascial pain with limited opening)
Duration since presenting condition began: not reported
Age at baseline (years): overall mean 47 (range 44–70)
Sex: group A – 29% male; group B – 30% male
Number randomised: 72 (group A: 36; group B: 36)
Number evaluated: 65 (group A: 35; group B: 30)
Interventions Comparison: splint vs. no splint for TMD
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l Group A
¢ Splint type: custom occlusal splint
¢ Upper jaw/lower jaw: not reported
¢ Material: not reported
¢ Teeth coverage: not reported
¢ Details of impression-taking: not reported
¢ Instructions to patients: not reported
¢ Monitoring of patients: not reported
l Group B: no treatment
Duration of treatment: 30 days
Outcomes Assessed at 30 days: grouped under 0–3 month analysis
Primary:
l Pain – current pain intensity on 0 (no pain) to 10 (worst pain) cm VAS
(we converted this to mm)
l Harms/adverse effects – reported narratively (‘no complications or any
unintended effects in either group’)
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘Randomised . . . allocated into one of two groups (by picking a colour
card from an envelope)’
l Comment: probably done
Allocation concealment (selection bias):
l Low risk of bias
l ‘One person enrolled participants in the study, and another dental
practitioner assigned them to the interventions’
l Comment: attempted to conceal allocation
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding not possible
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective pain outcome assessment by patients
Incomplete outcome data (attrition bias):
l High risk of bias
10% attrition (group A: 3%; group B: 17%), which differed by group and
may feasibly have biased results
Selective reporting (reporting bias):
l Low risk of bias
Pain reported clearly
Other bias:
l Low risk of bias
No other apparent bias
Pierce 198846
Characteristics
Study details Trial design: parallel (five arms)
Location: School of Dental Medicine, State University of New York,
Buffalo, USA
Number of centres: one
Recruitment period: not reported
Sample size calculation: not reported
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Attribute Study details
Funding: public (study was supported in part by research grants DE-05344
and DE-04358 from the National Institutes of Health, USA)
Declarations/conflicts of interest: not reported
Participants Diagnosis: (1) self-reported history of bruxism; or (2) currently bruxing
and someone else had heard them bruxing; or (3) tooth wear indicating
bruxism. This was then confirmed by EMG activity and patients were
included only if they had a baseline of mean bruxing episodes per hour
of > 1.0
Duration since presenting condition began: not reported
Age at baseline (years): overall mean 38 (range 18–72)
Sex: 35% male
Number randomised: 40 (group A: 20; group B: 20)
Number evaluated: not reported
Interventions Comparison: splint vs. no splint for bruxism
l Group A
¢ Splint type: flat-plane occlusal splint with cuspid rise
¢ Upper jaw
¢ Material: hard (acrylic)
¢ Teeth coverage: full
¢ Details of impression-taking: not reported
¢ Instructions to patients: wear at night
¢ Monitoring of patients: asked to return during first week of
treatment for splint adjustment, or any other time if discomfort or
lack of fit was experienced
l Group B: no treatment
l Group C: ‘massed negative practice’: individually tailored; six blocks of
clenching per day consisting of five clench/relax cycles varying between
5 seconds and 1 minute; each clench continued to the point of
discomfort, not pain, and then discontinued (not used due to more
appropriate control group consisting of no treatment)
l Group D: nocturnal biofeedback (not eligible for this review)
l Group E: diurnal biofeedback (not eligible for this review)
EMG monitoring of all patients while sleeping (at their home i.e. not in a
sleep clinic); use of EMG monitored at regular appointments
Duration of treatment: 2 weeks
Outcomes Outcomes assessed at 2 weeks (for 2-week treatment phase) and at
6 months (EMG monitoring carried out for a 2-week period and to
calculate the means for the bruxism outcomes)
Primary:
l Tooth wear (bruxism only): not reported
Secondary:
l Bruxism severity: duration of bruxing per hour (no usable data – no
SD/SE/CI or p-values)
l Bruxism frequency: episodes per hour (no usable data – no SD/SE/CI or
p-values)
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Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
l ‘each subject was randomly assigned to one of the five
experimental groups’
l Comment: insufficient information
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘each subject was randomly assigned to one of the five
experimental groups’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Not possible to blind
Blinding of outcome assessment
(detection bias):
l Low risk of bias
Objective assessment using EMG monitoring while participants were
asleep
Incomplete outcome data (attrition bias):
l Unclear risk of bias
The numbers analysed per group at each assessment were not reported
Selective reporting (reporting bias):
l High risk of bias
Poor reporting of outcomes
Other bias:
l Low risk of bias
No other apparent bias
Rampello 201365
Characteristics
Study details Trial design: parallel (two arms)
Location: Clinical Gnathology Service, Umberto I Polyclinic, Sapienza
University, Rome, Italy
Number of centres: one
Recruitment period: January to May 2011
Sample size calculation: not reported
Funding: not reported
Declarations/conflicts of interest: ‘all authors report no conflict of interest
relevant to this article’ – however, one of the authors designed and
patented the splint [Universal Neuromuscular Immediate Relaxing
Appliance (UNIRA)] used in the study
E-mailed authors for information and data but none provided so far
Participants Diagnosis: muscular, articular and headache/migraine VAS scores all > 30;
non-reducing dislocations of the articular disc in acute cases of miocene;
parafunctions associated with muscular and/or articular pain; limited
mouth-opening of muscular origin; abstract mentions ‘according to the
RDC-TMD (SPEC) criteria’
Duration since presenting condition began: not reported
Age at baseline (years): group A – mean 30.9, SD 7.9 (range 20–46);
group B – mean 30.2, SD 7.3 (range 20–45)
Sex: group A – 20% male; group B – 12% male
Number randomised: 50 (group A: 25; group B: 25)
Number evaluated: 50 (group A: 25; group B: 25)
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Interventions Comparison: splint vs. no splint for TMD
Group A
l Splint type: UNIRA (Universal Neuromuscular Immediate Relaxing
Appliance) ‘ready-to-use’ occlusal splint
l Upper jaw/lower jaw: not reported
l Material: (soft) polyvinyl (polypropylene)
l Teeth coverage: not reported
l Details of impression-taking: not reported
l Instructions to patients: ‘applied for a minimum of 1 night, followed by
rest to a maximum of 12 h/day (including night and rest) for patients
with intense pain’; no other form of therapy permitted
l Monitoring of patients: not reported
Group B
l No treatment
Duration of treatment: maximum of 3 months
Outcomes Assessed at 3 months for splint group but 4 months for control: we would
have grouped under 0–3 month analysis
Primary:
l Pain – 0 to 100 VAS, separate ratings for (1) muscular, (2) migraine,
(3) cervical, (4) TMJ, reported only graphically with mean and SE but
unable to accurately use; also reported for numbers cured/improved of
above pains 1 to 4 (however, only some of the patients in each group
had the specified pain type at baseline, and very poorly reported –
not usable)
Secondary:
l Change in restricted mouth-opening: only reported for splint group and
for those who started with restricted mouth-opening (data not usable)
Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
l ‘Divided randomly’
l Comment: insufficient information
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Divided randomly’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding not possible
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective pain outcome assessment by patients
Incomplete outcome data (attrition bias):
l Low risk of bias
Does not appear to have been any attrition
Selective reporting (reporting bias):
l Low risk of bias
Although there are no usable data, this is not related to selective
reporting
Other bias:
l High risk of bias
The splint group outcomes were assessed at 3 months (end of treatment)
whereas the ‘no treatment’ control group were assessed at 4 months
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Raphael 200147
Characteristics
Study details Trial design: parallel (two arms)
Location: Oral Medicine Clinic, University of Medicine and Dentistry of
New Jersey, USA
Number of centres: one
Recruitment period: not reported
Sample size calculation: not reported
Funding: public (study supported by National Institute of Dental and
Craniofacial Research grants DE11714 and DE13486)
Declarations/conflicts of interest: not reported
Author provided some clarification regarding measurement of pain and
quality of life
Participants Diagnosis: myofascial face pain according to RDC/TMD (facial pain
complaint was associated with localised tenderness in response to
palpation at 3 or more of 20 muscle sites); patients meeting criteria for
other TMDs (e.g. TMJ osteoarthritis) also included but only if primary
complaint was pain (rather than clicking or restricted mouth-opening)
Duration since presenting condition began: mean duration of pain=
5 years (30% reported duration of ≤ 1 year; 19% reported duration of
≥ 10 years)
Age at baseline (years): mean 33.7 (SD 10.9)
Sex: all female
Number randomised: 68 (group A: 35; group B: 33)
Number evaluated: 63 (group A: 32; group B: 31)
Interventions Comparison: splint vs. control splint for TMD
Group A
l Splint type: flat-plane ‘active splint’
l Upper jaw
l Material: hard (acrylic)
l Teeth coverage: full (‘covered the hard palate’; also covered the
occlusal surfaces)
l Details of impression-taking: not reported
l Instructions to patients: at baseline patients were instructed to eat a
soft diet; at 2-week appointment patients were instructed to add moist
heat/massage; at 4-week appointment patients were instructed to
add exercises
l Monitoring of patients: after fitting the splints there were assessments
at 2 and 4 weeks during which adjustments were made to the splints if
needed
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Group B
l Splint type: palatal-only splint that did not interfere with occlusion
l Upper jaw
l Material: hard (acrylic)
l Teeth coverage: partial (‘did not cover the occlusal surfaces or interfere
with occlusion in any way’ and ‘the palatal splint was designed to only
partially cover the palate’)
l Details of impression-taking: not reported
l Instructions to patients: as above
l Monitoring of patients: as above
Duration of treatment: 6 weeks
Outcomes Some outcomes measured at 2, 4 and 6 weeks – in all cases, we used only
the 6-week data, which were grouped under 0–3 month analysis
Primary:
l Pain –
¢ mean pain and mean value of worst pain, both assessed using 0
(no pain) to 10 (worst pain) NRS; we used the mean pain score in the
main meta-analysis (we converted to a 0–100 scale) and recorded
the mean value of worst pain in the additional table (author informed
us error bars in graphs are probably SE, and that pain was probably
recorded daily and these measurements represent 2-week
retrospective measures of average and worst pain)
¢ pain on palpation using 2 lb of pressure: mean number of painful
facial muscles (unclear how many were muscles were palpated)
Secondary:
l Quality of life (including physical and emotional function) –
¢ average mood assessed using a 0 (best possible mood) to
10 (worst possible mood) scale
¢ psychological distress assessed using self-reported depression
symptom scale from the SCL-90 (higher score =worse depression)
(length of scale not reported but is 0 to 4 in other included studies)
¢ how much the facial pain interfered with daily activities in the last
2 weeks on 0 (no interference) to 10 (unable to carry on any
activities) scale (mentioned in methods but not actually reported)
l Adherence to treatment: dichotomised as every night/more than half
the time vs. less than half the time/not at all
Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
l ‘Randomly assigned to treatment’
l Comment: insufficient information
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Randomly assigned to treatment’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l Unclear risk of bias
Unclear if the personnel fitting and adjusting the splints were involved in the
study. Also unclear if the patients were aware of their group assignment.
If they were aware, this might affect behaviours and introduce performance
bias
Blinding of outcome assessment
(detection bias):
l Unclear risk of bias
Personnel carrying out the RDC examinations were blinded. However,
other outcomes were patient-reported and it was not clear if the patients
were aware of their group assignment
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Incomplete outcome data (attrition bias):
l Low risk of bias
7% attrition (group A: 9%; group B: 6%): low attrition, similar between
groups and reasons stated
Selective reporting (reporting bias):
l Low risk of bias
Although details around some outcomes are poorly reported, there is no
evidence of selective reporting
Other bias:
l Low risk of bias
No other apparent bias
Rubinoff 198748
Characteristics
Study details Trial design: parallel (two arms)
Location: School of Dental Medicine, State University of New York,
Buffalo, NY, USA
Number of centres: one
Recruitment period: not reported
Sample size calculation: not reported
Funding: not reported
Declarations/conflicts of interest: not reported
Participants Diagnosis: myofascial pain dysfunction based on complaint of facial pain
plus one or more of the following: limited opening, joint sounds, deviation
on opening, tenderness to muscle palpation. Also required to have
absence of organic pathologic condition of the TMJ assessed clinically and
radiographically
Duration since presenting condition began: not reported
Age at baseline (years): mean 33.7 (range 18–62)
Sex: group A – 20% male; group B – 8% male
Number randomised: 28 (group A: 15; group B: 13)
Number evaluated: 25 (group A: 14; group B: 11) for patient-reported
pain; 26 (group A: 15; group B: 11) for all other outcomes
Interventions Comparison: splint vs. control splint for TMD
Group A
l Splint type: custom ‘conventional’ occlusal stabilisation splint
l Upper jaw
l Material: hard (acrylic)
l Teeth coverage: full
l Details of impression-taking: upper and lower alginate impressions
made for all patients and master casts poured from these impressions
l Instructions to patients: wear splints 24 hours per day, removed only for
cleaning and eating; advised to apply moist heat to painful areas of face/
neck; instructed to place lips together with teeth apart and keep jaws
relaxed as a 2-minute daily home exercise, and to repeat whenever possible
l Monitoring of patients: examined and appliances adjusted weekly (or
until no further alterations required at two consecutive appointments)
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Group B
l Splint type: ‘experimental’ non-occluding stabilisation splint
l Upper jaw
l Material: hard (acrylic)
l Teeth coverage: partial (palatal)
l Details of impression-taking: as above
l Instructions to patients: as above
l Monitoring of patients: as above (with mock adjustments)
Duration of treatment: 6 weeks
Outcomes Assessed at 6 weeks: grouped under 0–3 month analysis
Primary:
l Pain –
¢ patient-reported pain assessed three times daily in pain diary using
0 (no pain) to 5 (worst pain; incapacitating; unable to carry on with
normal activities) ordinal categorical scale (individual patient data
reported – not used as would not contribute to main meta-analysis)
¢ tenderness on palpation scored 0 (no response) to 3 (retreat of
head in anticipation and report of considerable pain upon contact)
on multiple regions and scores summed to obtain a palpation score
(length of scale unclear) – we used change scores presented in the
text of the study report
Secondary:
l TMJ clicking: presence of joint sounds
l Change in restricted mouth-opening: maximal interincisal distance in
mm – we used change scores presented in the text of the study report
Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
l ‘Randomly assigned’
l Comment: insufficient information
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Randomly assigned’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l Unclear risk of bias
‘Two dentists participated in this study, one as an examiner and one as
a therapist. Neither the examiner nor the patient knew which type of
appliance the patient wore. Moreover, the therapist was unaware of the
data collected by the examiner during the six weeks of active treatment’
Comment: unclear if therapist was aware of the purpose of the study.
Patients did not know which type of splint they had
Blinding of outcome assessment
(detection bias):
l Low risk of bias
See above quote
Comment: patients and outcome assessors did not know which type of
splint they had
Incomplete outcome data (attrition bias):
l Low risk of bias
Only one patient missing from group A and two from group B for
patient-reported pain
Selective reporting (reporting bias):
l Low risk of bias
Individual patient data all reported
Other bias:
l Low risk of bias
No other bias apparent
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Sharma 201649
Characteristics
Study details Trial design: parallel (three arms)
Location: School of Dental Medicine, State University of New York,
Buffalo, USA
Number of centres: one
Recruitment period: not reported
Sample size calculation: no (post hoc only)
Funding: not reported
Declarations/conflicts of interest: not reported
Participants Diagnosis: bilateral masseter myalgia according Diagnostic Criteria for
TMDs (DC/TMD); pain intensity of 5 or more on a 0 (no pain) to 10
(worst pain) scale; morning symptoms of jaw pain and stiffness
Duration since presenting condition began: not reported
Age at baseline (years): (overall range 24 to 62) group A: mean 42.6
(SD 9.6); group B: mean 35 (SD 9.5)
Sex: group A – 0% male; group B – 17% male
Number randomised: 13 (group A: 7; group B: 6)
Number evaluated: 13 (group A: 7; group B: 6) – two dropouts but not
reported by group A, B or C, and not clear if ITT used
Interventions Comparison: splint vs. no splint for TMD
In groups A and B, if indicated, ethyl chloride vapocoolant spray was used
during spray and stretch physical therapy sessions once per week for a
total of four treatment sessions
l Group A:
¢ Splint type: custom occlusal flat plane splint
¢ Upper jaw
¢ Material: hard/soft dual laminate material [a compound material
made up of hard polycarbonate (PC) base material and a soft
thermoplastic (TPU) material]; a translucent 2.5 mm (1.2 mm
PC/1.3 mm TPU) dura-soft sheet was used
¢ Teeth coverage: full
¢ Details of impression-taking: not reported
¢ Instructions to patients: not reported
¢ Monitoring of patients: patients see weekly and splint checked and
polished (followed by spray and stretch, as described above, if indicated)
l Group B: no other treatment
l Group C: above splint alone (this group was not included in the review
as it was not possible to include it in an eligible pairwise comparison)
Duration of treatment: 5 weeks
Outcomes Assessed at 5 weeks: grouped under 0–3 month analysis
Primary:
l Pain – CPI – patients scored: (1) current pain, (2) worst pain, (3) average
pain each on 0 (no pain) to 10 (worst pain) scale – scores 1 to 3 were
summed together, divided by 3 and then multiplied by 100 to get a
score on a 0–100 scale; reported as change score
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Secondary:
l Change in restricted mouth-opening – (1) pain-free opening (mm);
(2) maximum unassisted opening (mm); (3) maximum assisted opening
(mm) (we used pain-free opening data); reported as change score
l Quality of life (including physical and emotional function) – assessed
using Axis II questionnaires: (1) Patient Health Questionnaire-9;
(2) Patient Health Questionnaire-15; (3) Generalised Anxiety Disorder-7
scale (scales not described – unclear direction of benefit – data not used)
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘A computer generated spreadsheet was utilized to randomly assign
each subject before recruiting any subjects, a block randomization
process was performed to evenly distribute every participant into one
of the three treatment arms’
l Comment: probably done
Allocation concealment (selection bias):
l Unclear risk of bias
No mention of allocation concealment
Blinding of participants and personnel
(performance bias):
l High risk of bias
Not possible to blind patients
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessment by patients (except for ‘change in
restricted mouth-opening’ which was objective and measured by a blinded
assessor)
Incomplete outcome data (attrition bias):
l Unclear risk of bias
Two dropouts but not reported which group and not clear if ITT used in
analyses
Selective reporting (reporting bias):
l Low risk of bias
Outcomes fully reported
Other bias:
l Low risk of bias
No other bias apparent
Tatli 201754
Characteristics
Study details Trial design: parallel (three arms)
Location: TMD clinic, Cukurova University Dental Hospital, Adana, Turkey
Number of centres: one
Recruitment period: not reported
Sample size calculation: yes (achieved)
Funding: none
Declarations/conflicts of interest: ‘nothing to declare’
Participants Diagnosis: unilateral TMJ disc displacement without reduction diagnosis
based on clinical DC/TMD (history of reduction in mouth-opening, TMJ
pain during palpation and/or function, TMJ clicking) and MRI
Duration since presenting condition began: not reported
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Age at baseline (years): group A – mean 38.9 (SD 11.3); group B – mean
35.2 (SD 9.4)
Sex: group A – 2.5% male; group B – 12.5% male
Number randomised: 80 (group A: 40; group B: 40)
Number evaluated: 80 (group A: 40; group B: 40)
Interventions Comparison: splint vs. no splint for TMD
All patients in groups A and B were treated with arthrocentesis plus
sodium hyaluronate at the start of the study
l Group A:
¢ Splint type: occlusal stabilisation splint
¢ Upper jaw/lower jaw: not reported
¢ Material: hard (acrylic)
¢ Teeth coverage: full
¢ Details of impression-taking: not reported
¢ Instructions to patients: wear at night and also for 1 or 2 hours
during the day; patients in all groups instructed to use ibuprofen
(600 mg) when needed
¢ Monitoring of patients: not reported
l Group B: no other treatment
l Group C: stabilisation splint alone (i.e. no arthrocentesis and sodium
hyaluronate) – excluded from the review as not comparable with other
groups
Duration of treatment: 6 months
Outcomes Assessed as 1, 3 and 6 months: we used the 3- and 6-month data in our
0–3 month and 3–6 month analyses, respectively
Primary:
l Pain –
¢ current pain intensity 0 to 10 cm VAS (we converted this to mm in
order to combine with data from other studies)
¢ CPI – patients scored: (1) current pain, (2) worst pain, (3) average
pain each on 0 (no pain) to 10 (worst pain) scale – scores 1 to 3
were summed together, divided by 3 and then multiplied by 100 to
get a score on a 0–100 scale
l Harms/adverse effects – reported but they were all due to
arthrocentesis
Secondary:
l Change in restricted mouth-opening: maximum mouth-opening
measured between the edges of the upper and lower central incisors in
mm (unclear if with/without pain or assisted/unassisted)
l Quality of life (including physical and emotional function): pain-related
disability (0 to 100 worsening scale) and psychological status (0 to 4
worsening scale) both separately assessed using RDC/TMD Axis II
biobehavioural questionnaire
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Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘Assigned randomly to the treatment groups using
randomization software’
l Comment: appropriate method
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Assigned randomly to the treatment groups using
randomization software’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding not possible
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessment by patients (except for ‘change in
restricted mouth-opening’, which was objective and measured by a blinded
assessor)
Incomplete outcome data (attrition bias):
l Low risk of bias
All randomised patients were included in the analyses
Selective reporting (reporting bias):
l Low risk of bias
Outcomes fully reported
Other bias:
l Low risk of bias
No other bias apparent
Tavera 201223
Characteristics
Study details Trial design: parallel (three arms)
Location: Mexican Institute for Clinical Research, Mexico
Number of centres: one
Recruitment period: May to September 2008
Trials registry ID: NCT00815776
Sample size calculation: not reported
Funding: not reported
Declarations/conflicts of interest: not reported
We e-mailed authors for data but none provided so far
Participants Diagnosis: RDC/TMD diagnosis of myofascial pain, arthralgia, and/or
disc displacement with reduction, and a VAS pain score of > 4 (0–10
worsening scale)
Duration since presenting condition began: not reported
Age at baseline (years): group A – mean 38 (SD 11); group B – mean 36.3
(SD 13)
Sex: group A – 17% male; group B – 11% male
Number randomised: 108 (group A: 71; group B: 37)
Number evaluated: 78 (group A: 56; group B: 22)
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Interventions Comparison: splint vs. minimal treatment for TMD
Group A:
l Splint type: flat-planed occlusal stabilisation splint
l Upper jaw/lower jaw (not reported)
l Material: hard (plastic)
l Teeth coverage: full (‘full coverage’ and ‘fits over the occlusal one-third
surfaces of the dentition’)
l Details of impression-taking: not reported
l Instructions to patients: wear at night
l Monitoring of patients: not reported
Group B
l Jaw exercise: patients instructed to open jaw as wide as possible
without pain and hold the position for 5 seconds. Patients then closed
their jaw and rested for 10 seconds. This was performed 10 times in a
row. Also advised to apply warm compress to the jaw area after the
exercises for 10 minutes
Group C
l TMDes (a novel, non-invasive and reversible custom-fit ear insert worn
in the outer third of both ear canals; small, hollow and constructed
from rigid, medical grade plastics used in hearing devices) (not used
because more appropriate control group consisting of jaw exercise)
Duration of treatment: 3 months
Outcomes Assessed at 1, 2 and 3 months: we would have used the 3-month data in
our 0–3 month analyses
Primary:
l Pain – 0 (no pain) to 10 (worst pain) VAS (mean and SD not reported
for each group – data not usable)
l Harms/adverse effects: incidence of the following treatment-related
adverse events: discomfort or pain, increased TMD symptoms,
diminished hearing acuity, headache, dizziness or nausea, other
(jaw muscle/gum-related for group A)
Secondary:
l Patient satisfaction: only reported for groups A and C so not usable
l Adherence to treatment: assessed using a daily diary and average usage
reported as hours per day for group A and C, and average exercise
repetitions for group B; therefore, data not comparable and not used
Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
l ‘Randomly assigned’
l Comment: insufficient information
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Randomly assigned’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding was not possible
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Blinding of outcome assessment
(detection bias):
l High risk of bias
Neither patients nor study personnel were blinded
Incomplete outcome data (attrition bias):
l High risk of bias
Overall attrition was 28% (group A: 20%; group B: 43% at 2 months;
very similar at 3 months). Attrition was notably higher in group B
Selective reporting (reporting bias):
l High risk of bias
Very poor reporting of outcomes – focuses on TMDes group (group C)
Other bias:
l Low risk of bias
No other bias apparent
Truelove 200650
Characteristics
Study details Trial design: parallel (two arms)
Location: Orofacial Pain Clinic, Department of Oral Medicine, University
of Washington, Seattle, USA
Number of centres: one
Recruitment period: not reported
Sample size calculation: yes (not met)
Funding: public (study supported by National Institute of Dental and
Craniofacial Research grant P01 DE-08773)
Declarations/conflicts of interest: not reported
Participants Diagnosis: RDC/TMD Axis I diagnosis of myofascial pain (group Ia or Ib)
with or without a concurrent diagnosis of arthralgia (Group IIIa) or disk
displacement with reduction (Group IIa), as well as a RDC/TMD Axis II
Graded Chronic Pain score of grade I (low pain) or grade II (high pain),
both of which had no or minimal pain-related psychosocial interference.
Any other RDC/TMD Axis I diagnosis (e.g. arthritis, disk displacement
without reduction) was excluded
Duration since presenting condition began: years with facial pain: group A –
mean 6 (SD 9); group B – mean 5 (SD 6); group C – mean 5 (SD 5)
Age at baseline (years): group A – mean 36 (SD 11); group B – mean 35
(SD 12); group C – mean 36 (SD 11)
Sex: group A – 13% male; group B – 10% male; group C – 19% male
Number randomised: 200 (group A: 68; group B: 68; group C: 64)
Number evaluated: 3 months: 164 (group A: 54; group B: 56)
Interventions Comparison: (1) splint vs. no splint for TMD; (2) custom-made splint vs.
prefabricated splint for TMD
All groups received usual treatment: dentist-prescribed, conservative
and reversible self-care strategies that required the dentist to follow
a standardised treatment checklist that identifies all treatment
recommendations (jaw relaxation, reduction of parafunction, thermal
packs, NSAIDs, passive opening stretches and suggestions about stress
reduction); treatments such as narcotic analgesics, antidepressant
medications and use of a non-study prescribed splint were discouraged
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Group A
l Splint type: custom flat-plane hard splint adjusted to centric occlusion
l Upper jaw
l Material: hard (acrylic)
l Teeth coverage: full
l Details of impression-taking: not reported
l Instructions to patients: wear at night plus 2 hours during the day;
discontinue if problems developed
l Monitoring of patients: patients in all three groups followed up at 3, 6
and 12 months (nothing mentioned regarding adjustment/monitoring of
the actual splints)
Group B:
l Splint type: (prefabricated) soft thermoplastic athletic mouthguard
splint (with the dentist supervising and directing the patient in
splint fabrication)
l Upper jaw
l Material: soft (vinyl)
l Teeth coverage: full
l Details of impression-taking: ‘we took a bite registration using dental
wax to provide an oral procedure of comparable duration’
l Instructions to patients: as above
l Monitoring of patients: as above
Group C
l No other treatment
Duration of treatment: 12 months
Outcomes Assessments at 3, 6* and 12 months: we used the 3- and 12-month data
in our 0–3 month and 6–12 months analyses, respectively
*Data at 6 months not reported because ‘we typically found six-month
data to be intermediate or equivalent to 12-month data’
Primary:
l Pain –
¢ CPI 0–10 scale (the mean of present, average and worst TMD-
related pain in the previous 2 months) (we converted to 0–100
scale; range of SDs reported – we used median value; unclear which
group the single SD in the graph belongs to)
¢ pain duration (both hours/day and days/month) (no usable data –
reported narratively)
¢ pain on palpation assessed as number of extraoral muscle sites
(0–16), intraoral muscle sites (0–4) and TMJ sites (0–4)
l Harms/adverse effects – ‘no subjects reported an adverse effect with
any of the treatments’
Secondary:
l TMJ clicking – on opening, closing or both; patient-assessed and
clinician-assessed, reported as incidence (we used clinician-assessed in
line with other studies, and also because they were blinded)
l Change in restricted mouth-opening – vertical jaw opening in mm,
reported both as unassisted without pain and assisted (no usable data –
no SD reported)
l Adherence to treatment – reported for custom-made splint vs.
prefabricated splint (not clear what level of compliance e.g. using splint
all the time/majority of the time, etc)
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Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘We generated randomization assignments using randomly selected
block sizes of six, nine or 12 and stratified them by provider’
l Comment: probably done
Allocation concealment (selection bias):
l Low risk of bias
l ‘We concealed randomization to all study personnel until after we
obtained the subjects’ consent’
l Comment: randomly permuted block size, probably done adequately
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding was not possible
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessment by patients (except for ‘change in
restricted mouth-opening’ and ‘TMJ clicking’, which were objective and
measured by a blinded assessor)
Incomplete outcome data (attrition bias):
l High risk of bias
Overall attrition 18% (group A: 21%; group B: 18%; group C: 16%) at
3 months; overall attrition 16% (group A: 4%; group B: 19%; group C: 25%)
at 12 months. There was a large difference between group A and the other
groups at 12 months
Selective reporting (reporting bias):
l Low risk of bias
Although we were unable to use some of the data, this does not appear to
be because of selective reporting
Other bias:
l Low risk of bias
No other bias apparent
van der Zaag 200569
Characteristics
Study details Trial design: parallel (two arms)
Location: Clinic for Oral Kinesiology at Academic Centre for Dentistry
Amsterdam (ACTA), the Netherlands
Number of centres: one
Recruitment period: not reported
Sample size calculation: not reported
Funding: public (study supported by The Netherlands Institute of Dental
Sciences)
Declarations/conflicts of interest: not reported
Participants Diagnosis: recent history of tooth-grinding sounds for at least 3 nights per
week during the previous 6 months, confirmed by patient or their partner;
tooth wear to at least the degree of exposed dentine (grade 2); presence of
bruxism was clinically established by means of an inspection of the soft and
hard intraoral tissues; patients with a TMD pain diagnosis were excluded (this
was examined using the RDC/TMD); if the participant was eligible to enrol in
the study protocol, they underwent a first polysomnographic recording at the
hospital’s sleep laboratory (i.e. does not seem to be part of eligibility/diagnosis)
Duration since presenting condition began: at least 6 months
Age at baseline (years): (had to be aged ≥ 18 years as part of eligibility)
group A – mean 34.2 (SD 13.1; range 21–68); group B – mean 34.9
(SD 11.2; range 18–55)
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Sex: group A – 36% male; group B – 10% male
Number randomised: 27 (not reported by group)
Number evaluated: 21 (group A: 11; group B: 10)
Interventions Comparison: splint vs. control splint for bruxism
Group A
l Splint type: occlusal stabilisation splint
l Upper jaw
l Material: hard (acrylic)
l Teeth coverage: full coverage of the occlusal surfaces
l Details of impression-taking: not reported
l Instructions to patients: wear 24 hours per day, except during eating
l Monitoring of patients: not reported (probably none as a result of short
treatment time)
Group B
l Splint type: palatal splint
l Upper jaw
l Material: hard (same acrylic as above)
l Teeth coverage: partial (palatal coverage only)
l Details of impression-taking: not reported
l Instructions to patients: as above
l Monitoring of patients: as above
l Polysomnographic recording was carried out at the end of treatment at
the hospital’s sleep laboratory (quiet, dark, single room) using a Biosaca
sleep-recording unit (Ortivus AB, Danderyd, Sweden)
Duration of treatment: 4 weeks
Outcomes Assessed at 4 weeks: grouped under 0–3 month analysis
Primary:
l Tooth wear (bruxism only) – not reported
Secondary:
l Bruxism severity – reported as bruxism time index (percentage of total
sleep time spent bruxing)
l Bruxism frequency – reported as both episodes per hour and bursts
per hour (we used episodes per hour because bursts per hour was not
properly described)
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘Participants were randomly assigned using the block
randomization method’
l Comment: probably done
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Participants were randomly assigned using the block
randomization method’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
l ‘A second experienced dentist (FL) inserted the splints, without
mentioning the type of splint and its expected mechanism’
l Comment: although attempts were made to blind patients to splint
type, the clinician giving the treatment could not be blinded (and was
involved in the study)
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Blinding of outcome assessment
(detection bias):
l Low risk of bias
Objective measurements carried out by a machine. Furthermore, the data
were analysed by an investigator blinded to the patients’ allocated splint
Incomplete outcome data (attrition bias):
l Low risk of bias
Although overall attrition was 22% (not reported by group), none of the
reasons were linked to treatment allocation or outcomes
Selective reporting (reporting bias):
l Low risk of bias
Data fully reported
Other bias:
l Low risk of bias
No other apparent bias
Wahlund 200344
Characteristics
Study details Trial design: parallel (three arms)
Location: TMD Unit, Specialist Centre for Oral Rehabilitation, Linkoping,
Sweden
Number of centres: one
Recruitment period: 1996–2000
Sample size calculation: not reported
Funding: public (study was supported by the Public Dental Service of
Ostergotland – County Council)
Declarations/conflicts of interest: not reported
Participants Diagnosis: TMD pain according to RDC/TMD
Duration since presenting condition began: at least 3 months
Age at baseline (years): overall range 12–18; group A – mean 15.7 (SD 2.1);
group B – mean 14.8 (SD 1.9)
Sex: group A – 26% male; group B – 31% male
Number randomised: 81 (group A: 42; group B: 39)
Number evaluated: 76 (group A: 37; group B: 39)
Interventions Comparison: splint vs. no splint for TMD
All patients received an individual 30-minute session in which TMD-related
anatomy, pain epidemiology, parafunction and stress were discussed
l Group A
¢ Splint type: occlusal stabilisation splint
¢ Upper jaw
¢ Material: not reported
¢ Teeth coverage: full
¢ Details of impression-taking: not reported
¢ Instructions to patients: wear every night during treatment phase
and then whenever needed until 6-month follow-up point
¢ Monitoring of patients: four visits at 2-week intervals (first: brief
information described above; second: impression-taking; third: splint
fitted and adjusted; fourth: splint checked and readjusted)
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l Group B: no other treatment
l Group C: relaxation training – this was not considered to be minimal
treatment owing to multiple individual sessions and was therefore
excluded from this review
Duration of treatment: not clear from the text of the study report. There
was a treatment period that seems to have been 2 or 4 weeks long, but
then there was follow-up at 6 months. From the end of the treatment
period to the 6-month follow-up, patients were instructed to wear their
splint whenever needed
Outcomes All outcomes are reported at the end of treatment period (unclear how
many weeks), which we included in our 0–3 month analysis, and at
6 months’ follow-up, which we included in our 3–6 month analysis
Primary:
l Pain (not clear if all measures were recorded in the daily pain diary or
at the two assessment time points) –
¢ pain intensity on 0 (no pain) to 10 (worst pain imaginable) cm VAS
(unable to use data – not possible to read SDs from graph)
¢ pain frequency on five-point scale (never, one or two times a month,
once per week, several times per week, daily) (unable to use –
reported as median and quartiles)
¢ pain index on a 0–50 worsening scale (pain intensity (VAS)
multiplied by frequency of pain) (unable to use data – not possible
to read SDs from graph)
¢ incidence of 50% reduction in pain index (unable to use data – unclear
whether data are for the end of treatment or 6-month follow-up)
¢ pressure pain threshold measured using a pressure algometer that
applied pressure on the skin surface over the TMJ and masticatory
muscles (scale/units of measurement not stated but higher
score= better outcome)
l Harms/adverse effects: ‘None of the patients in any of the treatment
modes reported any major adverse effects’
Secondary:
l TMJ clicking – measured but not reported
l Change in restricted mouth-opening – reported as maximum assisted
mandibular opening (mm) without pain
l Adherence to treatment – reported for splint group but not control group
Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
l Quote: ‘randomly assigned’
l Comment: insufficient information
Allocation concealment (selection bias):
l Unclear risk of bias
l Quote: ‘randomly assigned’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding not possible
Blinding of outcome assessment
(detection bias):
l High risk of bias
Subjective outcomes assessment by patients (except for ‘change in restricted
mouth-opening’, which was objective and measured by a blinded assessor)
Incomplete outcome data (attrition bias):
l High risk of bias
Overall attrition 6% (group A: 12; group B: 0%); ‘subjects who dropped out
had lower pain scores and less motivation to participate in treatment’ – this
may have biased the results
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Selective reporting (reporting bias):
l High risk of bias
Outcomes poorly reported and mostly unusable
Other bias:
l Low risk of bias
No other bias apparent
Wassell 200422
Characteristics
Study details Trial design: parallel (two arms) – non-responders from the control group
were allowed to cross over after 6 weeks; therefore, we report data up to
6 weeks
Location: general dental practices in and around Newcastle, UK
Number of centres: 11 (two of these centres did not return their data)
Recruitment period: February 1994 to end of July 1996
Sample size calculation: not reported
Funding: public (sponsored by British Dental Association Research
Foundation through the Shirley Glasstone Hughes Memorial Prize)
Declarations/conflicts of interest: not reported
Participants Diagnosis: pain in TMJ or muscles or both plus one or more of the
following: joint sounds; history of jaw locking or limited opening; TMJ or
muscle tenderness on palpation
Subdiagnosis later assigned using criteria developed in collaboration
between the International Headache Society and the American Academy
of Craniomandibular Disorders
Duration since presenting condition began: > 4 weeks
Age at baseline (years): (had to be aged ≥ 18 years) group A – mean 37.9
(SD 12.6); group B – mean 35.9 (SD 10.3)
Sex: 12% male (of 78 patients who started treatment – not reported by group)
Number randomised: 93 (not reported by group)
Number evaluated: 72 (group A: 38; group B: 34)
Interventions Comparison: splint vs. control splint for TMD
Group A
l Splint type: occlusal stabilising splint
l Lower jaw
l Material: hard (acrylic)
l Teeth coverage: full
l Details of impression-taking: ‘Alginate maxillary and mandibular
impressions were recorded along with a wax retruded record at a
vertical separation approximating to the thickness of a stabilising splint.
Patients’ mandibles were manipulated bimanually in an attempt to
achieve centric relation. A facebow facilitated mounting on a semi-
adjustable articulator. Major undercuts were blocked out before the
splints were waxed. To ensure consistency, this approach was used for
both the stabilising and the nonoccluding control’
l Instructions to patients: wear all the time except meal times
l Monitoring of patients: every 3 weeks
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Group B
l Splint type: non-occluding control splint
l Upper jaw/lower jaw: not reported
l Material: hard (acrylic)
l Teeth coverage: (unclear) ‘essentially a lingual flange of acrylic
extending from the occlusal or incisal surfaces into the lingual sulcus’
l Details of impression-taking: as above
l Instructions to patients: as above
l Monitoring of patients: as above
Duration of treatment: 6 weeks (treatment continued for longer but
non–responders crossed over after 6 weeks)
Outcomes Assessed at 3 and 6 weeks: we used the 6-week data for our 0–3 month
analysis (TMJ-clicking only)
Primary:
l Pain –
¢ 0 (no pain) to 10 (unbearable pain) VAS assessed in waiting room
prior to follow-up appointments (no usable data – no SD/SE/p-value
reported)
¢ number of tender muscles on palpation (masticatory and cervical)
out of a total of 24 regions (no usable data – no SD/SE/p-value
reported)
¢ aggregate joint tenderness (determined by giving a score of one
for tenderness laterally or in the external auditory meatus or on
movement and adding the scores for both TMJs to give a maximum
total of 6) (no usable data – no SD/SE/p-value reported)
Secondary:
l TMJ clicking – incidence read from graph
l Change in restricted mouth-opening: maximum interincisal opening
with pain (mm) (no usable data – no SD/SE/p-value reported)
l Frequency of headaches (secondary to pain-related TMD) – number
per week (no usable data – no SD/SE/p-value reported)
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘random allocation of splints was predetermined for each GDP using a
permuted block of ten’
l Comment: probably done
Allocation concealment (selection bias):
l Low risk of bias
l ‘All dentists were blind to the allocation until the patient was registered
into the trial’
l Comment: probably done
Blinding of participants and personnel
(performance bias):
l High risk of bias
The authors state that it was not a blinded study
Blinding of outcome assessment
(detection bias):
l High risk of bias
Outcome assessment was not blinded
Incomplete outcome data (attrition bias):
l Low risk of bias
Overall attrition 23%, but mostly due to general dental practice
withdrawal
Selective reporting (reporting bias):
l High risk of bias
Very poorly reported with no measures of variability around the means
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Other bias:
l Low risk of bias
No other bias apparent
Wright 199551
Characteristics
Study details Trial design: parallel (three arms)
Location: TMJ and Craniofacial Pain Clinic, University of Minnesota, MN, USA
Number of centres: one
Recruitment period: not reported
Sample size calculation: not reported
Funding: not reported
Declarations/conflicts of interest: not reported
Participants Diagnosis: orofacial pain with clinical evidence of a masticatory muscle
origin (medical history and clinical examination used to rule out other
sources of pain such as dental, metabolic and neurological disorders);
inclusion criteria included (1) patient’s pain aggravated by jaw function
(e.g. talking/eating) or parafunctional habits (e.g. clenching or grinding
teeth) – based on patient history and (2) pain aggravated/duplicated by
palpation of the muscles of mastication – based on clinical examination;
TMJ intra-articular sources of pain ruled out by exclusion criteria: (1) pain
aggravated by clinical loading of TMJ – based on clinical examination,
(2) pain aggravated by TMJ clicking or catching or both – based on patient
history and clinical examination
Duration since presenting condition began: not reported
Age at baseline (years): (overall range 19–51): group A – mean 34;
group B – mean 31
Sex: not reported
Number randomised: 20 (group A: 10; group B: 10)
Number evaluated: 20 (group A: 10; group B: 10)
Interventions Comparison: splint vs. no splint for TMD
l Group A
¢ Splint type: custom soft splint
¢ Lower jaw
¢ Material: soft [3.8-mm-thick resilient mouth guard material –
Dentiform (JDE Interstate, Amityville, New York, NY, USA)]
¢ Teeth coverage: full
¢ Details of impression-taking: not reported
¢ Instructions to patients: wear all day except when eating meals
¢ Monitoring of patients: not reported
l Group B: no treatment
l Group C: palliative treatment (verbal and written instructions on
self-care: applying moist heat or ice, eating soft diet, decreasing oral
parafunctional habits, decreasing caffeine, modifying sleeping posture,
using over-the-counter medication) (not used because more
appropriate control group consisting of no treatment)
Duration of treatment (weeks): group A – mean 6.3; group B – mean 6.7
(range 4–11)
Outcomes Assessed at end of treatment (roughly 6 weeks): grouped under
0–3 month analysis
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Primary:
l Pain – muscle pain threshold assessed with a pressure algometer on
the anterior temporal muscle and on the superior and inferior areas of
the masseter muscle (psi)
l Harms/adverse effects – occlusal contact changes
Secondary:
l Change in restricted mouth-opening – maximum pain-free opening
(from incisor to incisor in mm)
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l (1) ‘Randomization was made in blocks to maintain equal group sizes’
and (2) ‘two additional subjects were sequentially added to the study
and assigned to the groups in the order that the dropouts were
originally assigned’
l Comments: (1) probably done, (2) unlikely to affect the results in any
meaningful way
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Randomization was made in blocks to maintain equal group sizes’
l Comments: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding not possible
Blinding of outcome assessment
(detection bias):
l High risk of bias
l ‘Final evaluations were with the same independent, blinded examiner
who performed the initial evaluation’
l Comment: although a blinded examiner carried out the pain assessment
procedure, the patient was not blinded and this could introduce bias
Incomplete outcome data (attrition bias):
l Low risk of bias
Two dropouts but they were replaced (see above)
Selective reporting (reporting bias):
l Low risk of bias
Outcomes fully reported
Other bias:
l Low risk of bias
No other apparent bias
Yu 201659
Characteristics
Study details Trial design: parallel (four arms)
Location: Department of Prosthodontics, Shanghai Ninth People’s Hospital,
Shanghai, China
Number of centres: one
Recruitment period: February 2013 to March 2015
Sample size calculation: not reported
Funding: unclear if public or other (Fund of Construction of Shanghai Key
Subject, T0202)
Declarations/conflicts of interest: not reported
Participants Diagnosis: TMJ disc displacement without reduction (RDC/TMD)
Duration since presenting condition began: unclear
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Age at baseline (years): mean 32.5 (SD 9.8) (only overall data available)
Sex: 11.3% male (only overall data available)
Number randomised: 168 (group A: 42; group B: 42; group C: 42;
group D: 42)
Number evaluated: 168 (group A: 42; group B: 42; group C: 42; group D: 42)
Interventions Comparison: splint vs. no/minimal treatment for TMD
We split the four groups/arms into two pairwise comparisons of A vs. D
and C vs. B
l Group A
¢ Splint type: custom stabilised (Michigan) splint
¢ Upper jaw
¢ Material: transparent base resin
¢ Teeth coverage: full
¢ Details of impression-taking: alginate was used to take the
impression of both upper and lower dentitions, wax and the ‘chin
point guided CR position’ method were used to record patients’
centric relation position
¢ Instructions to patients: 20 hours per day usage
¢ Monitoring of patients: not reported
l Group B: MPT
¢ Manipulative therapy: application of the proprioception
neuromuscular promoting technique and joint mobilisation
¢ Physical therapy: ultra-short wave therapy and ultrasonic therapy
l Group C: stabilised splint therapy plus MPT (see the above)
l Group D: control (TMJ related health instructions)
Duration of treatment: 3 months
Outcomes Assessed at 3 months: grouped under 0–3 month analysis
Primary:
l Pain – current pain intensity – spontaneous masseter pain, palpation
pain and chewing pain were separately measured, using a 0 to 10 VAS
card made by the Chinese Medical Association (we used spontaneous
masseter pain as it is most comparable with other included studies; we
converted the scale to 0 to 100)
Secondary:
l Change in restricted mouth-opening – pain-free unassisted maximum
mouth-opening
Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
l ‘Patients were randomly allocated to four groups’
l Comment: insufficient information
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘Patients were randomly allocated to four groups’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding not possible
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Blinding of outcome assessment
(detection bias):
l High risk of bias
Pain assessed by patients, who were not blinded
Incomplete outcome data (attrition bias):
l Low risk of bias
No dropouts
Selective reporting (reporting bias):
l Low risk of bias
Outcomes fully reported
Other bias:
l Low risk of bias
No other apparent bias
Zhang 201360
Characteristics
Study details Trial design: parallel (two arms)
Location: Department of Stomatology, AnZhen Hospital, Capital Medical
University, Beijing, China
Number of centres: one
Recruitment period: not reported
Sample size calculation: ‘The sample size for this study was calculated’ –
no further details (apparently met)
Funding: not reported
Declarations/conflicts of interest: not reported
Participants Diagnosis: RDC/TMD Axis 1 (myofascial pain)
Duration since presenting condition began: as part of eligibility criteria,
patients had to have chronic TMD pain for > 6 months (longest reported
duration was 3 years): group A – mean 8.3 months (SD 6.4); group B –
mean 6.5 months (SD 6.4)
Age at baseline (years): (overall range 16–57) group A – mean 31.4 (SD 9);
group B – mean 31.3 (SD 8.3)
Sex: 33% male (not reported by group)
Number randomised: 36 (group A: 18; group B: 18)
Number evaluated: 36 (group A: 18; group B: 18)
Interventions Comparison: splint vs. control splint for TMD
Group A
l Splint type: occlusal stabilisation splint
l Upper jaw/lower jaw (not reported)
l Material: hard (acrylic)
l Teeth coverage: full
l Details of impression-taking: full-mouth impression
l Instructions to patients: wear all day
l Monitoring of patients: not reported
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Group B
l Splint type: placebo (non-occluding palatal) splint
l Upper jaw (palatal)
l Material: hard (acrylic)
l Teeth coverage: full
l Details of impression-taking: full-mouth impression
l Instructions to patients: wear all day
l Monitoring of patients: not reported
Duration of treatment: 1 month
Outcomes Assessed at 1 month: grouped under 0–3 month analysis
Primary:
l Pain – current pain intensity 0 to 100 mm VAS (higher =worse pain)
Risk of bias
Random sequence generation
(selection bias):
l Low risk of bias
l ‘A random digit table is used to separate the selected patients into
two groups’
l Comment: adequate method
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘A random digit table is used to separate the selected patients into
two groups’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l Unclear risk of bias
‘double-blind’
Comment: only blinding of the examiner was specified
Blinding of outcome assessment
(detection bias):
l Unclear risk of bias
‘double-blind’ and ‘The second examiner . . . performed the clinical
examination . . . This examiner was blinded to the type of treatment the
patient received’
Comment: blinding of the examiner is not relevant to the outcome of pain,
and it is not clear if the patients were properly blinded to their treatment
Incomplete outcome data (attrition bias):
l Low risk of bias
All randomised patients were included in the analyses
Selective reporting (reporting bias):
l High risk of bias
Very poorly reported outcomes. Pain outcome not mentioned in the
methods section and the description of the results is vague and does not
appear to match the results reported in the table
Other bias:
l Low risk of bias
No other apparent bias
Zuim 200634
Characteristics
Study details Trial design: parallel (four arms)
Location: Temporomandibular Disorders Diagnostic and Treatment Centre,
Aracatuba Dental School, São Paulo State University, Brazil
Number of centres: one
Recruitment period: not reported
Sample size calculation: not reported
Funding: not reported
Declarations/conflicts of interest: not reported
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Participants Diagnosis: TMD patients with chronic pain, muscle pain on palpation
Duration since presenting condition began: at least 6 months
Age at baseline (years): 13–47 (not reported by group)
Sex: 10% male (not reported by group)
Number randomised: 20 (group A: 5; group B: 5; group C: 5; group D: 5)
Number evaluated: 20 (group A: 5; group B: 5; group C: 5; group D: 5)
Interventions Comparison: splint vs. no splint for TMD
We split the four groups/arms into two pairwise comparisons of A vs. B
and C vs. D:
l Groups A and B had MENS on affected muscles using conductive pads
or probes; eight applications of 10 minutes each (twice per week over
4 weeks)
l Groups C and D had placebo MENS (apparatus was turned off)
Group A
l Splint type: occlusal splint
l Upper jaw
l Material: hard (heat cured acrylic resin)
l Teeth coverage: full
l Details of impression-taking: maxillary and mandibular alginate
impressions taken; impressions were poured using special gypsum
type IV and the casts were mounted in semi-adjustable articulator
l Instructions to patients: not reported
l Monitoring of patients: evaluated at weekly intervals for necessary
adjustments
Group B
l No other treatment
Group C
l Same splint as group A
Group D
l No other treatment
Duration of treatment: 1 month
Outcomes Assessed at 1 month: we would have grouped under 0–3 month analysis
Primary:
l Pain – 0 (no pain) to 10 (worst pain) cm VAS (not clear if current/
worst/average) (no usable data – individual patient data but only
five patients per group)
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Risk of bias
Random sequence generation
(selection bias):
l Unclear risk of bias
l ‘The patients were randomly placed in one of four treatment modalities’
l Comment: insufficient information
Allocation concealment (selection bias):
l Unclear risk of bias
l ‘The patients were randomly placed in one of four treatment modalities’
l Comment: insufficient information
Blinding of participants and personnel
(performance bias):
l High risk of bias
Blinding not possible
Blinding of outcome assessment
(detection bias):
l High risk of bias
Pain assessed by patients, who were not blinded
Incomplete outcome data (attrition bias):
l Low risk of bias
All randomised patients were included in the analyses
Selective reporting (reporting bias):
l Low risk of bias
Individual patient data reported
Other bias:
l Low risk of bias
No other apparent bias
BDI, Beck Depression Inventory; CAPES, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Coordination
for the Improvement of Higher Education Personnel); CBT, cognitive–behavioural therapy; CMD, craniomandibular
disorder; EMG, electromyographic; EVA, ethylene-vinyl acetate; HADS, Hospital Anxiety and Depression Scale;
IQR, interquartile range; ITT, intention to treat; MENS, microcurrent electrical nerve stimulation; Mod-SSI, Modified
Symptom Severity Index; MPT, manipulative and physical therapies; NSAID, non-steroidal anti-inflammatory drug;
SE, standard error; SF-36, Short Form questionnaire-36 items; TMJ, temporomandibular joint.
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Appendix 4 Forest plots of comparisons for
the systematic review
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FIGURE 15 Forest plot of comparison: TMD, splint vs. no/minimal treatment; outcome – pain: any combinable scale (higher =more pain), 3–6 months. Risk of bias: A, random sequence
generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment (detection bias);
E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias. a, Current pain intensity 0 to 100 mm VAS (authors confirmed that scores were
accidentally reported in cm – we converted them to mm); b, current pain intensity 0 to 10 cm VAS (we converted this to mm).
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FIGURE 16 Forest plot of comparison: TMD, splint vs. no/minimal treatment; outcome – pain: any combinable scale (higher =more pain), 6–12 months. Risk of bias: A, random
sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment
(detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias. a, Current facial pain intensity 0 to 10 cm VAS (we converted this
to mm); b, CPI 0 to 10 converted to 0 to 100 scale – SD is median value from range of SDs reported in paper; c, CPI 0 to 10 converted to 0 to 100 scale – SD is median value from
range of SDs reported in paper (custom-made splint vs. control).
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FIGURE 19 Forest plot of comparison: TMD, splint vs. no/minimal treatment; outcome – CPI 0–100 worsening scale, 0–3 months. Risk of bias: A, random sequence generation
(selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment (detection bias); E, incomplete
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FIGURE 20 Forest plot of comparison: TMD, splint vs. no/minimal treatment; outcome – CPI 0–100 worsening scale, 3–6 months. Risk of bias: A, random sequence generation
(selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment (detection bias); E, incomplete
outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias.
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FIGURE 21 Forest plot of comparison: TMD, splint vs. control splint; outcome – pain: any combinable scale (higher =more pain), 3–6 months. Risk of bias: A, random sequence
generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment (detection bias);
E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias.
Mean difference
IV, random (95% CI)Weight (%)
Splint
Study or subgroup
3.00 (– 14.31 to 20.31)
3.00 (– 14.31 to 20.31)
100.0
100.0
aNilsson 200943
Total (95% CI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (p = 0.73)
A B C D E GF
Risk of biasControl splint
SD TotalMean
30 23
23
3733 28
28
40
SD TotalMean
? ? – +++ +
– 10 – 5 0 5 10
Favours splint Favours control splint
FIGURE 22 Forest plot of comparison: TMD, splint vs. control splint; outcome – pain: any combinable scale (higher =more pain), 6–12 months. Risk of bias: A, random sequence
generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment (detection bias);
E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias. a, Worst pain on 0 to 100 VAS.
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Test for overall effect: Z = 0.60 (p = 0.55)
2
23
3
28
29
85
24
23
9
54
56
166
10
11
2
13
14
50
11
12
9
27
27
86
10.1
30.5
8.3
25.3
25.9
100.0
0.09 (0.02 to 0.35)
1.11 (0.90 to 1.36)
1.50 (0.32 to 6.94)
1.08 (0.67 to 1.72)
1.00 (0.64 to 1.55)
0.85 (0.51 to 1.43)
Risk of bias
Study or subgroup Events Total Weight (%)
Risk ratio
M–H, random (95% CI)
Splint
Events Total
Control
FIGURE 23 Forest plot of comparison: TMD, splint vs. no/minimal treatment; outcome –TMJ clicking: presence of joint noises (detected during TMJ palpation/opening/closing), 0–3 months.
M–H, Mantel–Haenszel. Risk of bias: A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias);
D, blinding of outcome assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias. a, Anterior repositioning splint; b, flat
occlusal splint; c, custom; d, prefabricated.
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FIGURE 24 Forest plot of comparison: TMD, splint vs. no/minimal treatment; outcome –TMJ clicking: presence of joint noises (detected during TMJ palpation/opening/closing), 3–6 months.
M–H, Mantel–Haenszel. Risk of bias: A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias);
D, blinding of outcome assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias. a, Flat occlusal splint; b, anterior
repositioning splint.
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FIGURE 25 Forest plot of comparison: TMD, splint vs. no/minimal treatment; outcome –TMJ clicking: presence of joint noises (detected during TMJ palpation/opening/closing), 6–12 months.
M–H, Mantel–Haenszel. Risk of bias: A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias);
D, blinding of outcome assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias. a, Flat occlusal splint; b, anterior
repositioning splint; c, custom; d, prefabricated.
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FIGURE 26 Forest plot of comparison: TMD, splint vs. no/minimal treatment; outcome – change in restricted mouth-opening: maximum mouth-opening (mm), 0–3 months. Risk of bias:
A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome
assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias. a, Custom NTI-tss (unassisted opening until pain felt);
b, custom anterior repositioning (unassisted opening until pain felt); c, unclear if with/without/until pain or assisted/unassisted; d, custom splint (unassisted opening without pain);
e, prefabricated splint (unassisted opening without pain); f, opening without pain; g, unassisted pain-free opening; h, unassisted pain-free opening (reported as change score); i, asked to
open mouth as wide as possible, even if they felt pain; j, unassisted (with/without/until pain not reported); k, pain-free opening (reported as change score); l, unclear if with/without/
until pain or assisted/unassisted; m, assisted opening without pain; n, pain-free opening; o, pain-free unassisted opening (splint vs. control); p, pain-free unassisted opening (splint +
manipulative and physical therapies vs. manipulative and physical therapies).
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FIGURE 27 Forest plot of comparison: TMD, splint vs. no/minimal treatment; outcome – change in restricted mouth-opening: maximum mouth-opening (mm), 3–6 months. Risk of bias:
A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome
assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias. a, The sum of unassisted maximal interincisal opening
and the vertical incisal overlap; b, unclear if with/without pain or assisted/unassisted; c, assisted opening without pain.
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FIGURE 28 Forest plot of comparison: TMD, splint vs. no/minimal treatment; outcome – quality of life: OHIP-14, 0–56 worsening scale, 0–3 months. Risk of bias: A, random sequence
generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment (detection bias);
E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias. a, Change score reported; b, end score reported.
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FIGURE 29 Forest plot of comparison: TMD, splint vs. no/minimal treatment; outcome – quality of life: OHIP-14, 0–56 worsening scale, 3–6 months. Risk of bias: A, random sequence
generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment (detection bias);
E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias. a, Change score reported; b, end score reported.
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FIGURE 30 Forest plot of comparison: TMD, splint vs. no/minimal treatment; outcome – quality of life: OHIP-14, 0–56 worsening scale, 6–12 months. Risk of bias: A, random sequence
generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment (detection bias);
E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias.
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FIGURE 31 Forest plot of comparison: TMD, splint vs. control splint; outcome – TMJ clicking: presence of joint sounds during palpation, 0–3 months. M–H, Mantel–Haenszel. Risk of
bias: A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome
assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias.
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Heterogeneity: τ2 = 1.62; χ2  = 2.43, df = 1 (p = 0.12); I 2 = 59%
Test for overall effect: Z = 0.84 (p = 0.40)
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FIGURE 32 Forest plot of comparison: TMD, splint vs. control splint; outcome – change in restricted mouth-opening: opening < 40mm. M–H, Mantel–Haenszel. Risk of bias: A, random
sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment
(detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias.
D
O
I:
1
0
.3
3
1
0
/h
ta2
4
0
7
0
H
ealth
T
ech
n
o
lo
gy
A
ssessm
en
t
2
0
2
0
V
o
l.2
4
N
o
.7
©
Q
u
een
’s
P
rin
ter
an
d
C
o
n
tro
ller
o
f
H
M
SO
2
0
2
0
.T
h
is
w
o
rk
w
as
pro
d
u
ced
b
y
R
iley
et
al.
u
n
d
er
th
e
term
s
o
f
a
co
m
m
issio
n
in
g
co
n
tract
issu
ed
b
y
th
e
Secretary
o
f
State
fo
r
H
ealth
an
d
So
cial
C
are.T
h
is
issu
e
m
ay
b
e
freely
repro
d
u
ced
fo
r
th
e
pu
rpo
ses
o
f
private
research
an
d
stu
d
y
an
d
extracts
(o
r
in
d
eed
,
th
e
fu
ll
repo
rt)
m
ay
b
e
in
clu
d
ed
in
pro
fessio
n
al
jo
u
rn
als
pro
vid
ed
th
at
su
itab
le
ackn
o
w
led
gem
en
t
is
m
ad
e
an
d
th
e
repro
d
u
ctio
n
is
n
o
t
asso
ciated
w
ith
an
y
fo
rm
o
f
ad
vertisin
g.
A
pplicatio
n
s
fo
r
co
m
m
ercial
repro
d
u
ctio
n
sh
o
u
ld
b
e
ad
d
ressed
to
:
N
IH
R
Jo
u
rn
als
Lib
rary,
N
atio
n
al
In
stitu
te
fo
r
H
ealth
R
esearch
,
E
valu
atio
n
,
Trials
an
d
Stu
d
ies
C
o
o
rd
in
atin
g
C
en
tre,
A
lph
a
H
o
u
se,
U
n
iversity
o
f
So
u
th
am
pto
n
Scien
ce
P
ark,So
u
th
am
pto
n
SO
1
6
7
N
S,U
K
.
2
1
1
0.2 0.5 1 2 5
Favours control splint Favours splint
Study or subgroup Events Total Events Total Weight (%) A B C D E GF
?– –
? ? ? ?
? ? –
+ + ++
++ ++
+++
Risk ratio
M–H, random (95% CI)
Ekberg 200336
Nilsson 200943
Raphael 200147
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 1.27, df = 2 (p = 0.53); I 2 = 0%
Test for overall effect: Z = 0.66 (p = 0.51)
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1.07 (0.94 to 1.22)
1.03 (0.94 to 1.12)
Risk of biasSplint Control splint
FIGURE 33 Forest plot of comparison: TMD, splint vs. control splint; outcome – compliance: splint worn every night or most nights, 0–3 months. M–H, Mantel–Haenszel. Risk of bias:
A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome
assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias.
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Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (p = 0.80) 2 5 10
Favours control splint Favours splint
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Risk of bias
TotalEvents
Control splint
FIGURE 34 Forest plot of comparison: TMD, splint vs. control splint; outcome – compliance: splint worn every night or most nights, 3–6 months. M–H, Mantel–Haenszel. Risk of bias:
A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome
assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias.
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Test for overall effect: Z = 0.21 (p = 0.83)
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Risk of biasSplint Control splint
FIGURE 35 Forest plot of comparison: TMD, splint vs. control splint; outcome – compliance: splint worn every night or most nights, 6–12 months. M–H, Mantel–Haenszel. Risk of bias:
A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome
assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias.
Mean difference
IV, random (95% CI)Weight (%)
Custom splint
Study or subgroup
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aChristidis 201472
Total (95% CI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (p = 0.89)
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SD TotalMean
14.839 20
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SD TotalMean
? ––– +++
– 100 – 50 0 50 100
Favours custom splint Favours prefabricated splint
FIGURE 36 Forest plot of comparison: TMD, custom splint vs. prefabricated splint; outcome – pain: any combinable scale (higher =more pain), 3–6 months. Risk of bias: A, random
sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment
(detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias. a, Assessed daily in a 1-week pain diary for the week prior to each
assessment point using 0 to 100 VAS (pain at rest).
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Heterogeneity: τ2 = 0.00; χ2 = 0.63, df = 1 (p = 0.43); I 2 = 0%
Test for overall effect: Z = 1.12 (p = 0.26)
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Study or subgroup
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– 0.18 (– 0.50 to 0.14)
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Favours custom splint Favours prefabricated splint
FIGURE 37 Forest plot of comparison: TMD, custom splint vs. prefabricated splint; outcome – pain: any combinable scale (higher =more pain), 6–12 months. Risk of bias: A, random
sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment
(detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias. a, Assessed daily in a 1-week pain diary for the week prior to each
assessment point using 0 to 100 VAS (pain at rest); b, CPI 0 to 10 converted to 0 to 100 scale – SD is median value from range of SDs reported in the paper.
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Christidis 201472
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Total events
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (p = 0.56) 2 5 10
Favours control Favours prefabricated
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Risk of bias
TotalEvents
FIGURE 38 Forest plot of comparison: TMD, custom splint vs. prefabricated splint; outcome – pain: GCPS (incidence of grade III or IV), 0–3 months. Risk of bias: A, random sequence
generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment (detection bias);
E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias.
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Test for overall effect: Z = 0.47 (p = 0.64)
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Custom splint Prefabricated splint
+
FIGURE 39 Forest plot of comparison: TMD, custom splint vs. prefabricated splint; outcome – pain: GCPS (incidence of grade III or IV), 3–6 months. M–H, Mantel–Haenszel. Risk of
bias: A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome
assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias.
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Total events
Heterogeneity: τ2 = 4.17; χ2 = 2.86, df = 1 (p = 0.09); I 2 = 65%
Test for overall effect: Z = 0.00 (p = 1.00)
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Custom splint Prefabricated splint
FIGURE 40 Forest plot of comparison: TMD, custom splint vs. prefabricated splint; outcome – pain: GCPS (incidence of grade III or IV), 6–12 months. M–H, Mantel–Haenszel. Risk of
bias: A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome
assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias.
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bGiannakopoulos 201662
Total (95% CI)
Heterogeneity: τ2 = 41.12; χ2 = 3.32, df = 1 (p = 0.07); I 2 = 70%
Test for overall effect: Z = 0.83 (p = 0.41)
Mean difference
IV, random (95% CI)Weight (%)
Custom splint
Study or subgroup
– 9.50 (– 16.69 to – 2.31)
1.35 (– 7.85 to 10.55)
– 4.47 (– 15.07 to 6.13)
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Risk of biasPrefabricated splint
SD TotalMean
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8.66
21
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33
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SD TotalMean
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Favours prefabricated splint Favours custom splint
FIGURE 41 Forest plot of comparison: TMD, custom splint vs. prefabricated splint; outcome – change in restricted mouth-opening: maximum opening (mm), 0–3 months. Risk of bias:
A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment
(detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias. a, Maximum voluntary mouth-opening; b, unassisted opening without
pain.
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IV, random (95% CI)Weight (%)
Custom splint
Study or subgroup
– 1.00 (– 6.74 to 4.74)
– 1.00 (– 6.74 to 4.74)
100.0
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aChristidis 201472
Total (95% CI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (p = 0.73)
A B C D E GF
Risk of biasPrefabricated splint
SD TotalMean
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SD TotalMean
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Favours prefabricated splint Favours custom splint
FIGURE 42 Forest plot of comparison: TMD, custom splint vs. prefabricated splint; outcome – change in restricted mouth-opening: maximum opening (mm), 3–6 months. Risk of bias:
A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment
(detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias. a, Maximum voluntary mouth-opening.
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Test for overall effect: Z = 0.29 (p = 0.77)
A B C D E GF
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SD TotalMean
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Favours prefabricated splint Favours custom splint
FIGURE 43 Forest plot of comparison: TMD, custom splint vs. prefabricated splint; outcome – change in restricted mouth-opening: maximum opening (mm), 6–12 months. Risk of bias:
A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome
assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias.
Christidis 201472
Total (95% CI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (p = 0.89)
Mean difference
IV, random (95% CI)Weight (%)
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Study or subgroup
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SD TotalMean
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SD TotalMean
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Favours custom splint Favours prefabricated splint
FIGURE 44 Forest plot of comparison: TMD, custom splint vs. prefabricated splint; outcome – quality of life: SCL-90-R – depression 0–4 (higher =worse), 0–3 months. Risk of bias:
A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment
(detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias.
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Total (95% CI)
Heterogeneity: τ2 = 0.02; χ2 = 1.53, df = 1 (p = 0.22); I 2 = 35%
Test for overall effect: Z = 0.22 (p = 0.83)
Mean difference
IV, random (95% CI)Weight (%)
Custom splint
Study or subgroup
– 0.21 (– 0.72 to 0.30)
0.17 (– 0.14 to 0.48)
0.04 (– 0.31 to 0.39)
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Favours custom splint Favours prefabricated splint
FIGURE 45 Forest plot of comparison: TMD, custom splint vs. prefabricated splint; outcome – quality of life: SCL-90-R – depression 0–4 (higher =worse), 3–6 months. Risk of bias:
A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment
(detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias.
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Total (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.00, df = 1 (p = 0.95); I 2 = 0%
Test for overall effect: Z = 0.32 (p = 0.75)
Mean difference
IV, random (95% CI)Weight (%)
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0.10 (– 0.58 to 0.78)
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Favours custom splint Favours prefabricated splint
FIGURE 46 Forest plot of comparison: TMD, custom splint vs. prefabricated splint; outcome – quality of life: SCL-90-R – depression 0–4 (higher =worse), 6–12 months. Risk of bias:
A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment
(detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias.
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Christidis 201472
Total (95% CI)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (p = 0.93)
Mean difference
IV, random (95% CI)Weight (%)
Custom splint
Study or subgroup
– 0.02 (– 0.50 to 0.46)
– 0.02 (– 0.50 to 0.46)
100.0
100.0
A B C D E GF
Risk of biasPrefabricated splint
SD TotalMean
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SD TotalMean
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Favours custom splint Favours prefabricated splint
FIGURE 47 Forest plot of comparison: TMD, custom splint vs. prefabricated splint; outcome – quality of life: SCL-90-R – non-specific physical symptoms 0–4 (higher =worse), 0–3 months.
Risk of bias: A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome
assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias.
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FIGURE 48 Forest plot of comparison: TMD, custom splint vs. prefabricated splint; outcome – quality of life: SCL-90-R – non-specific physical symptoms 0–4 (higher =worse), 3–6 months.
Risk of bias: A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome
assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias.
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FIGURE 49 Forest plot of comparison: TMD, custom splint vs. prefabricated splint; outcome – quality of life: SCL-90-R – non-specific physical symptoms 0–4 (higher=worse), 6–12 months.
Risk of bias: A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome
assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias.
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FIGURE 51 Forest plot of comparison: TMD, custom splint vs. prefabricated splint; outcome – adherence to treatment: use of appliance for several nights per week or more, 3–6 months.
M–H, Mantel–Haenszel. Risk of bias: A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance
bias); D, blinding of outcome assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias.
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FIGURE 52 Forest plot of comparison: TMD, custom splint vs. prefabricated splint; outcome – adherence to treatment: use of appliance for several nights per week or more, 6–12 months.
M–H, Mantel–Haenszel. Risk of bias: A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance
bias); D, blinding of outcome assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); and G, other bias.
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Appendix 5 Draft structure of bruxism model
The proposed model structure in Figure 53 is based on the severity of tooth wear (defined in Adultand Dental Health Survey Report 2009125). Tooth wear was identified as the primary outcome for
bruxism patients according to clinical expert opinion (Stephen Davies, School of Dentistry, Manchester,
2018, personal communication).
Death
4
Moderate tooth wear
2
Mild tooth wear
1
Severe tooth wear
3
FIGURE 53 Transition state diagram for bruxism.
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